<SEC-DOCUMENT>0001125345-23-000076.txt : 20230509
<SEC-HEADER>0001125345-23-000076.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509160458
ACCESSION NUMBER:		0001125345-23-000076
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		23901869

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:4c965add-b010-4624-ba75-b98f8d64a55e,g:758eb5bc-71ca-48c1-8a86-febd43fa4ed1,d:9a03e40e8f4f4b699bd9595d0d3ddca2--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mgnx="http://macrogenics.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGFibGU6YzYyODJkNDQwZWFkNDA5OWE2YjlmMGM0NmE5MzYyMmIvdGFibGVyYW5nZTpjNjI4MmQ0NDBlYWQ0MDk5YTZiOWYwYzQ2YTkzNjIyYl8yLTEtMS0xLTczNDI3_2495f99c-21ee-45d6-9c43-712e3e7bd9cc">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGFibGU6YzYyODJkNDQwZWFkNDA5OWE2YjlmMGM0NmE5MzYyMmIvdGFibGVyYW5nZTpjNjI4MmQ0NDBlYWQ0MDk5YTZiOWYwYzQ2YTkzNjIyYl80LTEtMS0xLTczNDI3_2ffbf323-179c-4faa-b5df-c259a0498941">2023</ix:nonNumeric><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGFibGU6YzYyODJkNDQwZWFkNDA5OWE2YjlmMGM0NmE5MzYyMmIvdGFibGVyYW5nZTpjNjI4MmQ0NDBlYWQ0MDk5YTZiOWYwYzQ2YTkzNjIyYl81LTEtMS0xLTczNDI3_61caa675-f573-4c66-ad77-ae632c98e271">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGV4dHJlZ2lvbjo4YzQ1OTE0ZTliOGY0ZWJmOWIyYzEzMTU0M2Q4NjRmMF8xMjk_691684b8-cb25-4a79-868a-1e26a9a12845">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGV4dHJlZ2lvbjo4YzQ1OTE0ZTliOGY0ZWJmOWIyYzEzMTU0M2Q4NjRmMF8xMzA_54dc2353-bac2-4db9-9e58-32491f4d9de0">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d79286ab6a47cfacb994e1f0f15d94_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i03d2ebaff189455d9264808a3a02d4ce_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic4f0f1e8de514b11931ce86e1ce9c0ee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a98792199545d0b1e0ce65290c98a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2696e59aade645e6a31de5ce306ad24e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66bdc4231fb4465bb7766711b27e85fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0dc21a4b854d46b133215409b5edaf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6cdb2f256d447d2b9f7754d52c55373_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948a349b6ef34738bd4d665ba4bfee46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i718ca217b2c94e7faf44f187ecac2ab6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e0feec85c148ad8d5f82bfac85f208_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c12373f1db407a9b6f037cab5d3651_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92410bd27764e678b82f7b1d39f6a03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i553278606eff41f39a304b10b3fbc2b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie232f14bbd714187ba2bfd7b2e021484_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1954c9399f4d6a8e5a2d1a10e70b32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e7c5864d42448aaf643c7bb82ddeba_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68bcba7d3ffe49fe849dfa82a6c68caa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5a90075d424a33b6caf03ea64c1fe6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d72584774b4de49861a1a693f96eaa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ffdb2f49280412891db80c368a3b88d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39c37d66f564a8191cf294376ecc067_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f22b26d7b774c3c8a78ab4bca00737c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief28b87fc8be4092a7fb1df32ca29e1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33d36c0ce38b4033be7b52fdc3f1139b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie24b857dee5b4a5b835b0e031ba00304_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id066d12821a94a4da435f27478529262_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225ebb75186c4e83acb6a1f0a73da7ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0dcaaeed8124d08ad0445d456f82fb0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39aa1c5f5b9f4d4caba6633baf8cb5a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549e08742d14433d91f8b2d470a14ae3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090e20f1694842edaabcb0092ed0ebfe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8b7cbe2f8041ab946f4daf94549f23_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d893440bf04325a0c84a2fc57bc8ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i301a3cb5a7284b718c396f6fbad527ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b294fc0b3654d22a51d4b9b63e8fc3d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea8b4c0cee9423cb8076b969da02716_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3d2b649df941eb8fa3c1e7cc8c023f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb01d2775284756822f388b6d2e16a3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacdb818e9174a62a35cd37cde8493fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d1469f54904ec9974d404f50d6b074_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i346fa1f03c994f03af0d92e026a3ec33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3379a8d83154bc7a2f3dfcf35bf0466_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7897989264334daca83be8205e1f9066_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia862e744faeb4ae98a11485e9fc56db7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7781c40faa9749489c6481063c576abe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980ce273d57d43e180d24954e57132ed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e168dd44f5c4d8590a34135fb61acb0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59f34ccbd0974b3fa3aedac0a0794404_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232dd89d03094cb0b9b34b4c2be81444_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a81484002646ca86c7980bdcde7f36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia556b2d5cb5245a1893a8a5f302714c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75e544fa68641f8940ee5f29bc524c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b5e32b9dcb4adfbcbcbfb2e6c5bcb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i931c2e63969e41f787594bffd508c45e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b5beeee5f64179b2145f46e3032766_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1a641b6ade4b1197580a782d03ccff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24dc0ddf9a849be8ab92812afd2d286_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a5923cf7e84a8bbedc65e244cd7791_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6f07e499e8471bb13f4992e6f93740_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d80c05867546299ae2cae022aee461_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1914dd9539bd46cd9d50436b60dae7d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8430871688c24161b99e79ce00cc373a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0595b4044d4e48a4b54395ad62ddc89c_I20230308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iab71ac1d87d8415a9550205dc1aa8b3b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8125884812c4401b8b311bdffc16d974_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9309ea0208184fa4b37705ea22d3a556_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d36e822023b4273a9509235bd8c6acd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a1a46d9b1045c9b6ee53abe05a7ead_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef59164d9804d038bd3cc080e152e53_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e1ac7059204d649fe5363543d08fd8_D20180101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe7647445614121a80a6be8d87248c3_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a1a941fe6dc4e42b16747db51f11bd9_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd6332acd224939b6e64d01df3361e7_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="i2682097a1f3e4a89a96cab41f8cbd4ea_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b07faa5b7d643d883cf0c135e8f3d80_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1857d4cd8f7406fa5bbf069c7a857d6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc0cdb960994c118fa8a5cfd0f2a280_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if334a8dd8b764a01a900c1c6d7f9b363_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbbd06906d6345b2afe1b89f2851967a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374c14d1f7814bd99693ece7e091f00d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6896341f33cd4b08985cd9e24146387e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06dd337e669d44fda86ff6918e8c7999_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5999119dfc294e80ad0713a177c361f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98612cc5ba1468d888c8629fe2b15bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40b3c7658dd4cf3af7b29395be88093_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe661497ec1436ea3ea36041dec66b1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55a0f9ecd9b4ceda005b981bf2f7d8e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1057cf41b349daa7c0fc063798c809_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02aba6ee80e4485593c6ef2dd3196270_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16b1ce65ef4498e985806621089d540_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dee982850e549a68b6a81eb6c007052_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf999f4a23674de6901577a7a2e0e94d_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fbed9f54de04d85a3e8c55feabc0565_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7079bd55b0684e16805a5c2352089fd5_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4475f726644746db8a9d6f1b092abe4c_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee007f50b7b54e878349b22a7469557d_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8b4fcaac5140cca18c505dac7f2417_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b508f7b0c74f06858ab827b8a99958_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae198fa14cb849eba1d6619f7acc0b25_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831ccd6f3347498497b72f53753edd5e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7f5ae7b36f40efb495d731d6421605_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b2edd43ee5f4027854eb6a336bdca71_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97eb432defc54b6ea97bda7a332c90f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d8b24b3b4c46df987acd17c19050e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieddfecbe8ad14ef7a8ff835b12b95d4a_D20220101-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17159c2a9e9f40a68a48e3051433e894_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7595340e36ea4d09bf2116e33b8641f3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa3eccd028da467f83bd22324f391a17_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3306c0844c488aa3ac28c64699528b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800a7e6440dc4197a9837d73a114cba7_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="iabee161e88cd43838204d199c20da652_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a1d67968a747cca217bd0b0428cf02_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56231c20b15840d1afa950fe878367de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cbab60f55fa402c96d89e18f0e3beb9_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14822659c7d4a8e9cf7fcec3ee0ae7f_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58506024e45456592bc19755da226d2_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa174cd3914f4d469152f496ac824c06_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie45d01decd32435a8498c793207f66fd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39a7a5272cb4b76897f3e799b70f9ab_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aa16b089d85451b96f0b9061c2797e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e4cfb9ea29453487b8acb62f27c309_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0c52ec53274fdba3171ff3170db6a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1660944dc73f45fea86496b594fce178_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb09aa6ccd548e5b5a67339e277f132_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6a705742804457a4eb1b0d964ea1e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf39a1c94944731b2514e5c45e8ecee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5317a874bbfc4ef6baca4f516aa0f218_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921b7f549052407f832cadb468c93a6c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799a33353e9a49a4b78a98bda1c4c308_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica024959f8ab45b2aee0bf2b8219b68e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036d859b9f664d9d82dd693c3f33d537_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214d7afe999940ae898ec280e17de7a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c83b9d58eb41a8a4f5d2bbc203e254_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91e3da1af4b4728802be58d315b3279_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae7da4578181431996ca6f580a7f5d94_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV84Mg_0126c285-e5d7-4f1e-997c-1e8d3d8466de">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDNjNjVhOTRhNjk4NDQ0MmEwM2RjMzlkODgyNDEzMTUvdGFibGVyYW5nZTpkM2M2NWE5NGE2OTg0NDQyYTAzZGMzOWQ4ODI0MTMxNV8wLTAtMS0xLTczNDI3_534666f3-6b67-4d1c-abe1-c14fabadac06">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xMTc_092c810e-bcc4-4b3e-a888-f9a706916c3a">March 31, 2023</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NmU1MGRiMDdhYjUwNDJmMThkOTNiZTFhMGExNjgwNGUvdGFibGVyYW5nZTo2ZTUwZGIwN2FiNTA0MmYxOGQ5M2JlMWEwYTE2ODA0ZV8wLTAtMS0xLTczNDI3_2be8aa9a-0c7d-466e-b8d8-4f5f04a36d43">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yMDg_f228ee0c-5f7a-45fb-97e5-ffc087ddcf3d">001-36112</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yMTE_d05a2a1c-1681-4254-bdc1-b6cdf0c9d39a">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8wLTAtMS0xLTczNDI3_18357a96-2894-4c44-9152-c8414c1c44a8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8wLTEtMS0xLTczNDI3_4b169c8e-2304-40df-af20-8b52e95e5ccd">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTAtMS0xLTczNDI3L3RleHRyZWdpb246NDU1MDY2ODA0N2FmNGM5YzllZWM0NTY2MDRkODgzYTBfNQ_be30d4b9-bcf1-4186-9755-06bb472f01e4">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTAtMS0xLTczNDI3L3RleHRyZWdpb246NDU1MDY2ODA0N2FmNGM5YzllZWM0NTY2MDRkODgzYTBfOA_e2e1582b-5033-4e92-9988-d344f1c76a70">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTAtMS0xLTczNDI3L3RleHRyZWdpb246NDU1MDY2ODA0N2FmNGM5YzllZWM0NTY2MDRkODgzYTBfMTI_611d0fc3-a241-4740-b084-ff667c3dd486">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTEtMS0xLTczNDI3_990241b5-dcf0-4536-a466-4cc43db15e87">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yNzA_9225a555-46da-4b88-8134-989d997a309e">301</ix:nonNumeric>-<ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yNzM_22adba2f-6a05-4742-9c1e-cd3285c1c3ce">251-5172</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDEyYTg0YTgwYTYxNDZiODk0NjMwY2NkNjA5ODdjMmMvdGFibGVyYW5nZTpkMTJhODRhODBhNjE0NmI4OTQ2MzBjY2Q2MDk4N2MyY18xLTAtMS0xLTczNDI3_5f5e2eb0-1dd5-42f2-b39b-aecdde1da83d">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDEyYTg0YTgwYTYxNDZiODk0NjMwY2NkNjA5ODdjMmMvdGFibGVyYW5nZTpkMTJhODRhODBhNjE0NmI4OTQ2MzBjY2Q2MDk4N2MyY18xLTEtMS0xLTczNDI3_eccf166b-3d9c-4d9e-a048-8888b313d868">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDEyYTg0YTgwYTYxNDZiODk0NjMwY2NkNjA5ODdjMmMvdGFibGVyYW5nZTpkMTJhODRhODBhNjE0NmI4OTQ2MzBjY2Q2MDk4N2MyY18xLTItMS0xLTczNDI3_031cf641-801a-4517-9830-846e2f3ef655">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xOTE1_773f7e61-1000-4db3-ac9b-11699dc50142">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xOTE2_c4405986-6862-4ac7-8aa1-a5ab39a2a632">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDY4NTM1ZTRjMzAxNDA1YjgwMWM0NmYxZmI4Y2ZhMWQvdGFibGVyYW5nZTpkNjg1MzVlNGMzMDE0MDViODAxYzQ2ZjFmYjhjZmExZF8yLTAtMS0xLTgxNTA1_429a301c-1450-41f0-8a98-450b28725060">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDY4NTM1ZTRjMzAxNDA1YjgwMWM0NmYxZmI4Y2ZhMWQvdGFibGVyYW5nZTpkNjg1MzVlNGMzMDE0MDViODAxYzQ2ZjFmYjhjZmExZF8yLTMtMS0xLTczNDI3_dccda90e-57ac-4aa6-8221-dcd0e2381dbf">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDY4NTM1ZTRjMzAxNDA1YjgwMWM0NmYxZmI4Y2ZhMWQvdGFibGVyYW5nZTpkNjg1MzVlNGMzMDE0MDViODAxYzQ2ZjFmYjhjZmExZF80LTEtMS0xLTczNDI3_6366be9c-369b-46b7-8c78-f8db3a49bef3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xOTE3_8ca051b9-4b42-49b1-b5f2-c988d2d5a319">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;5, 2023, <ix:nonFraction unitRef="shares" contextRef="if1d79286ab6a47cfacb994e1f0f15d94_I20230505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xODI4_553dfde2-ef73-493b-ad8f-5ff7dcef59ff">61,838,893</ix:nonFraction> shares of the registrant's common stock, par value $0.01 per share, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_16">Financial Statements</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_19">Consolidated Balance Sheets at</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_19"> March&#160;31, 2023 (unaudited) and December&#160;31, 2022 </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_22">Consolidated Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2023 and March&#160;31, 2022 (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_25">Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2023 and March 31, 2022 (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_28">Consolidated Statements of Cash Flows for the three months ended March&#160;31, 2023 and March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_28">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_28">31, 2022 (unaudited)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_28"> </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_31">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_67">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_85">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_88">Controls and Procedures</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_91">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_94">Legal Proceedings</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_97">Risk Factors</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_100">Exhibits</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9a03e40e8f4f4b699bd9595d0d3ddca2_103">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_10"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2022 and "Part II, Item 1A. Risk Factors" of this Quarterly Report on Form 10-Q), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, enrollment of trials, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls; and</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of a global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_16"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNC0xLTEtMS03MzQyNw_4ec5a410-0d7b-45ce-bfbb-df9b84d73055">224,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNC0zLTEtMS03MzQyNw_73d0eca3-48f6-46eb-ba8b-7635effe7491">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNS0xLTEtMS03MzQyNw_387e3fbb-54ab-414f-b000-b730822c88cd">17,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNS0zLTEtMS03MzQyNw_167f2bfc-2817-48e5-ad33-9b96f28ec4da">45,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNi0xLTEtMS03MzQyNw_0125296b-46b8-4421-80d0-8ac938aab1a8">36,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNi0zLTEtMS03MzQyNw_ee31647f-c3d3-44bc-9823-01d8afecfa6c">56,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNy0xLTEtMS03MzQyNw_d9f98ba2-af09-4372-bf61-cc27e8af8035">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNy0zLTEtMS03MzQyNw_8529c992-55ee-475d-820d-3e90e0274cba">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfOC0xLTEtMS03MzQyNw_ee3d41d1-e69e-4f58-90c1-a356d7e1aa8b">9,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfOC0zLTEtMS03MzQyNw_95d983f4-dbcb-442a-bce7-c2ad99b25da9">10,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTAtMS0xLTEtNzM0Mjc_64d8c47c-83bd-4358-8ad2-06e4f97891ca">288,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTAtMy0xLTEtNzM0Mjc_b31640f0-1774-4576-af88-5ddaba67660a">222,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTEtMS0xLTEtNzM0Mjc_2edd41b7-6f04-470c-91d6-782f71a5a6c1">26,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTEtMy0xLTEtNzM0Mjc_c342a2a7-7ddc-4320-8f72-fa39adf0eb74">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTItMS0xLTEtNzM0Mjc_3e636d02-4a3f-4cdc-aba1-8161215af778">26,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTItMy0xLTEtNzM0Mjc_1ee446d4-b3a9-4649-b481-ae6e07f173b2">27,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTMtMS0xLTEtNzM0Mjc_71c5acb1-7bb7-408a-982a-c3cb0b2b7d29">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTMtMy0xLTEtNzM0Mjc_95a54a56-5749-4e1d-ab70-6c4bed510c9a">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTQtMS0xLTEtNzM0Mjc_3c83517d-6459-480d-88e7-672b31dbe3fc">343,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTQtMy0xLTEtNzM0Mjc_c69f4317-b8a0-48bf-9bf4-014ec7a7f688">280,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTgtMS0xLTEtNzM0Mjc_33fc34fd-07ec-46c1-b29a-6162140a3dcb">3,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTgtMy0xLTEtNzM0Mjc_e155452c-65c7-4a6a-98d0-0ef800bd610c">4,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTktMS0xLTEtNzM0Mjc_4a711703-cd33-4ba3-af4d-6b77abe2fe04">28,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTktMy0xLTEtNzM0Mjc_6cc66929-8854-4e26-ba81-afb47931b14f">28,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjAtMS0xLTEtNzM0Mjc_84db1b18-6908-4df5-8838-4931cc93b66d">9,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjAtMy0xLTEtNzM0Mjc_0698582f-fa56-4022-9768-c058f93ffba3">9,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjEtMS0xLTEtNzM0Mjc_c011ea48-11e3-4f2c-968f-56a7642253e0">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjEtMy0xLTEtNzM0Mjc_4a5d39a0-ed98-4dd3-a145-8452fcd68d52">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjMtMS0xLTEtNzM0Mjc_3c6e10f7-985d-4a76-933a-c1456591dbe6">45,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjMtMy0xLTEtNzM0Mjc_268c74ed-104a-4695-803b-1379e1b26538">48,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="mgnx:LiabilityRelatedToFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMS0xLTEtNzY0Mzc_a3320024-e2b5-470f-8591-7d1c2c6a087c">100,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="mgnx:LiabilityRelatedToFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMy0xLTEtNzY0NDU_4dd60fe3-c3e7-45b8-80b3-0324d5c959fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjQtMS0xLTEtNzM0Mjc_ec29f168-6182-4a6e-8633-c3f4ce65fbdb">58,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjQtMy0xLTEtNzM0Mjc_a6b05251-0242-490a-ab05-e66cd7572f07">59,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMS0xLTEtNzM0Mjc_f0d715f5-b5bd-4193-9ffb-79a2bf126a5b">30,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMy0xLTEtNzM0Mjc_9e1d565d-71ad-4efd-baaa-897be188395f">30,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjYtMS0xLTEtNzM0Mjc_371f1765-f166-4f5f-a0a4-acbc4a033b95">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjYtMy0xLTEtNzM0Mjc_8856e998-1482-4851-ad70-2f793bb23018">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjctMS0xLTEtNzM0Mjc_efa66add-d698-445a-bbfd-2f4cfb8c9691">234,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjctMy0xLTEtNzM0Mjc_a545f132-cd67-4105-845f-a643c0a2fa23">138,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8xOA_e24eb610-c6a5-400f-aa42-0653fda5a1e7"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8xOA_e2ffebc8-eff5-4611-8cb9-1825366a7dfa">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8zNA_9ed3223d-ae5d-44ca-83ee-8044d5220411"><ix:nonFraction unitRef="shares" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8zNA_ad783e86-0fd0-4b85-8be6-dde4d45d1ff6">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl81Ng_006b2682-32fd-4d35-8cb0-801419614948">61,838,565</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl82Mw_c6d12b26-ad6e-4577-a3f5-aea3d0833c0f">61,701,467</ix:nonFraction> shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMS0xLTEtNzM0Mjc_23311034-d991-4a47-b8d9-aa051e83a976">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMy0xLTEtNzM0Mjc_bf971965-5c5b-4998-b67b-102f0ae7c612">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzAtMS0xLTEtNzM0Mjc_1402bd2e-1154-4dcc-bb13-4fedcc3e5379">1,240,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzAtMy0xLTEtNzM0Mjc_4c63b9c0-c272-4088-ab14-3e525a071ae3">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzEtMS0xLTEtNzM0Mjc_aa27815e-f2fc-4b51-872d-f5316b0bec8d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzEtMy0xLTEtNzM0Mjc_0a4477b8-90d2-4b32-ae4f-b1b0e54f015b">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzItMS0xLTEtNzM0Mjc_41c70819-16ec-444c-996c-8c43626ac6a8">1,131,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzItMy0xLTEtNzM0Mjc_630dc626-7e17-44ff-a886-a85cc03857af">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzMtMS0xLTEtNzM0Mjc_a3cc145d-fca2-4a27-8273-ba90ac2e442d">109,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzMtMy0xLTEtNzM0Mjc_eb034d53-33e2-4c5d-9407-0b507a71ad35">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzQtMS0xLTEtNzM0Mjc_4bbbff10-f735-489a-923c-de17ada031c7">343,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzQtMy0xLTEtNzM0Mjc_f8d36d5e-0f2f-46bf-b5ac-d4fce47c48db">280,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"><tr><td style="width:1.0%"></td><td style="width:62.521%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f0f1e8de514b11931ce86e1ce9c0ee_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMy01LTEtMS03MzQyNw_a8c2511d-da07-4988-bfb1-a5d0b6839e44">16,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4a98792199545d0b1e0ce65290c98a7_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMy03LTEtMS03MzQyNw_e9632f5b-8492-45fb-b1c3-04979c2ab6cc">7,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2696e59aade645e6a31de5ce306ad24e_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNC01LTEtMS03MzQyNw_e207de16-777f-4ae1-8f80-3df5df53fbe2">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66bdc4231fb4465bb7766711b27e85fe_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNC03LTEtMS03MzQyNw_bb36171a-abf9-4fc7-987b-c40550bf59e3">3,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0dc21a4b854d46b133215409b5edaf_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNS01LTEtMS03MzQyNw_f335d889-890f-4b5c-a6ab-ae6b22fc802c">3,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6cdb2f256d447d2b9f7754d52c55373_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNS03LTEtMS03MzQyNw_e09fecb8-deb4-44da-aa51-44bf31d680d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948a349b6ef34738bd4d665ba4bfee46_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi01LTEtMS03ODczMg_f294b183-b6a6-4be7-83c1-f6df8ab61d92">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718ca217b2c94e7faf44f187ecac2ab6_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi03LTEtMS03ODczMg_83a862ec-0f7f-4e87-9a30-22f01dc84ee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e0feec85c148ad8d5f82bfac85f208_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi01LTEtMS03MzQyNw_171a4109-d718-4b02-bddf-e5a3baf48968">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c12373f1db407a9b6f037cab5d3651_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi03LTEtMS03MzQyNw_69308411-0fd7-4f9e-af39-70e32f9ff93c">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNy01LTEtMS03MzQyNw_c0051920-779e-4587-9429-3be488277c96">24,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNy03LTEtMS03MzQyNw_05e3840b-9776-45ef-9cb5-5a5b91bb4587">11,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfOS01LTEtMS03MzQyNw_b5d9ead6-f7f5-4614-9208-f41ab408fcb6">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfOS03LTEtMS03MzQyNw_63927aec-6506-48b5-9860-2ff05672a626">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTAtNS0xLTEtNzM0Mjc_1ee20d75-3666-47f7-a37d-638624699f6c">3,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTAtNy0xLTEtNzM0Mjc_d30166a2-9bfa-4f88-93a3-1ebcf8089466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTEtNS0xLTEtNzM0Mjc_733ee195-5a55-4b01-b242-6b18156a77a9">45,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTEtNy0xLTEtNzM0Mjc_7cf95b71-2617-4266-ac9a-f4d84c25874d">61,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTItNS0xLTEtNzM0Mjc_b4b275d6-be46-497c-9ddd-e1b5c410dea0">13,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTItNy0xLTEtNzM0Mjc_1cb81bff-8134-4a2b-9ea5-bac26f10d95d">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTMtNS0xLTEtNzM0Mjc_1bd630d6-031d-4c7a-97f0-161338375daa">62,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTMtNy0xLTEtNzM0Mjc_c9c0a48c-2cb9-46ee-b8db-c499d5a5d2f7">77,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTQtNS0xLTEtNzM0Mjc_e67e1e68-036d-4fd2-8f2b-bab09ab66d2c">38,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTQtNy0xLTEtNzM0Mjc_b8c3d34e-6ae8-4a88-b8c9-8e18139b5583">66,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTUtNS0xLTEtNzM0Mjc_0b91e762-3d44-49c0-950e-9efe784a7620">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTUtNy0xLTEtNzM0Mjc_87448bf2-aee3-436c-ab69-ec13b290b444">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTctNS0xLTEtNzkxODY_7c872ef7-231d-45cd-b52e-aa6c348d0331">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTctNy0xLTEtNzkxODY_6101af6e-a083-4765-aedf-6912765b1806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTYtNS0xLTEtNzM0Mjc_9de77551-a03d-4e9f-bd60-f967ab1c7723">38,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTYtNy0xLTEtNzM0Mjc_79772213-1f8a-440b-8792-535fedde5f73">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTgtNS0xLTEtNzM0Mjc_523a0be2-e420-4a05-a20f-d9beeb5fe1eb">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTgtNy0xLTEtNzM0Mjc_bac45067-abef-4b32-aef6-966c8be380d0">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTktNS0xLTEtNzM0Mjc_65627bc6-92c3-46e9-b359-810285d40272">37,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTktNy0xLTEtNzM0Mjc_ac2d42d9-0ebc-4aa7-ba7d-ac800f26a3bb">66,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNS0xLTEtNzM0Mjc_174f8203-3507-4cb6-9e0a-493692189b82"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNS0xLTEtNzM0Mjc_ec8cf3c8-d6e7-42ab-9bcc-bd84892b942b">0.61</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNy0xLTEtNzM0Mjc_6d83e6b6-1181-4029-9b97-07f8b1b8b7ac"><ix:nonFraction unitRef="usdPerShare" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNy0xLTEtNzM0Mjc_ae5bcf27-855f-499b-941d-84065d6a07f7">1.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNS0xLTEtNzM0Mjc_78a2b207-a9b1-4494-b292-e9a339791464"><ix:nonFraction unitRef="shares" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNS0xLTEtNzM0Mjc_9a2610b4-2475-4f8f-a74a-588e8db0c98c">61,809,817</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNy0xLTEtNzM0Mjc_2b4a5627-2971-49ab-ab22-0ddd88cb25ca"><ix:nonFraction unitRef="shares" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNy0xLTEtNzM0Mjc_9f030a2d-65a3-45b1-a247-72e3cc2219e5">61,324,163</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:30.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if92410bd27764e678b82f7b1d39f6a03_I20221231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xLTEtMS03MzQyNw_7b4871a0-2666-4c00-bd4f-64a90800fb84">61,701,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92410bd27764e678b82f7b1d39f6a03_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0zLTEtMS03MzQyNw_4140591a-432f-415b-8b72-efb38abe96b6">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i553278606eff41f39a304b10b3fbc2b9_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi05LTEtMS03MzQyNw_98bc5270-2934-4108-9150-8dfb9a5491ce">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie232f14bbd714187ba2bfd7b2e021484_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xMS0xLTEtNzM0Mjc_1d377f4d-2777-4bd9-a1aa-2eea39ed6e2a">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d1954c9399f4d6a8e5a2d1a10e70b32_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xMy0xLTEtNzM0Mjc_966c40bd-32e6-49e3-8119-4044ae90808f">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xNS0xLTEtNzM0Mjc_a008cdd9-14a0-4cbb-b6f0-0e9c418f7177">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMy05LTEtMS03MzQyNw_789fb6f4-2bd5-4fe3-b65a-c68108891031">4,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMy0xNS0xLTEtNzM0Mjc_c1670a18-e5a9-4f65-bba4-519298922ce9">4,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC0xLTEtMS03MzQyNw_659491c1-a643-4778-8b60-8df42a12c798">95,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC0zLTEtMS03MzQyNw_f0bff172-379d-4e7a-867e-c40687009761">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC05LTEtMS03MzQyNw_95f4fdb2-2f47-4893-9ad6-3c5bfbba3bcf">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC0xNS0xLTEtNzM0Mjc_57de98bf-d24a-4679-b05f-1eda8b340e73">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNS0xLTEtMS03MzQyNw_4e1c49ca-8d66-41b8-b7b6-50fe29a2cbe0">42,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331" decimals="-3" sign="-" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNS05LTEtMS03MzQyNw_99e6a29b-a65d-4d7f-be4b-22c1f32a5242">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNS0xNS0xLTEtNzM0Mjc_704f6d7d-e2b1-4b9b-b219-e9cbc2df98f4">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e7c5864d42448aaf643c7bb82ddeba_D20230101-20230331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNi0xMy0xLTEtNzM0Mjc_53a1b2b4-b126-48d4-b343-d590db2120fa">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNi0xNS0xLTEtNzM0Mjc_68f2da0c-299e-4fdc-80a6-ef6857dfd0b2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68bcba7d3ffe49fe849dfa82a6c68caa_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNy0xMS0xLTEtNzM0Mjc_8c6c5c70-684b-460b-ac62-14b05e28c3d9">38,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNy0xNS0xLTEtNzM0Mjc_6ec78708-be90-4c1b-b23c-ab47b2891b58">38,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc5a90075d424a33b6caf03ea64c1fe6_I20230331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xLTEtMS03MzQyNw_f967ca0c-fb5c-4c68-b95b-d1d652c9c5c6">61,838,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5a90075d424a33b6caf03ea64c1fe6_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0zLTEtMS03MzQyNw_fa821c69-2f65-45d9-85d8-a866169e847f">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d72584774b4de49861a1a693f96eaa_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC05LTEtMS03MzQyNw_54f23a5b-4e55-41a1-90d4-5fa00b3e370c">1,240,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ffdb2f49280412891db80c368a3b88d_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xMS0xLTEtNzM0Mjc_52264ead-0156-4439-b28c-5f7f6df7db8c">1,131,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39c37d66f564a8191cf294376ecc067_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xMy0xLTEtNzM0Mjc_fa74d8c5-f36d-4ee8-97a7-d45c93dc52ac">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xNS0xLTEtNzM0Mjc_9ba5eebe-dff0-4650-8136-7ee4f876a951">109,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.981%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f22b26d7b774c3c8a78ab4bca00737c_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xLTEtMS03MzQyNw_e5c10b85-bb15-41b4-8096-0465464fa3a3">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f22b26d7b774c3c8a78ab4bca00737c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0zLTEtMS03MzQyNw_d8203dbb-fac3-4d95-be1a-c17851c1e2ef">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief28b87fc8be4092a7fb1df32ca29e1e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi05LTEtMS03MzQyNw_efd22c33-7e7c-4159-8e0d-d204fc33e36a">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33d36c0ce38b4033be7b52fdc3f1139b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xMS0xLTEtNzM0Mjc_4250afc0-aaa2-45e6-b0aa-0b96135d8589">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie24b857dee5b4a5b835b0e031ba00304_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xMy0xLTEtNzM0Mjc_69dc36a2-747c-414e-a499-94fd86bd613f">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id066d12821a94a4da435f27478529262_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xNS0xLTEtNzM0Mjc_9dd1e643-3b5e-4046-bf50-7a8561d30df8">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225ebb75186c4e83acb6a1f0a73da7ed_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMy05LTEtMS03MzQyNw_6be7886b-a1d6-423a-9a72-222e5705ca11">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMy0xNS0xLTEtNzM0Mjc_c28c6cf4-985f-47be-8b35-8bc0c6fbca67">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0dcaaeed8124d08ad0445d456f82fb0_D20220101-20220331" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNS0xLTEtMS03MzQyNw_a8b798fe-c299-4b5b-a35c-72e93db1742a">25,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225ebb75186c4e83acb6a1f0a73da7ed_D20220101-20220331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNS05LTEtMS03MzQyNw_f4cf46c5-46d8-44f3-a5d5-53370c4c29b5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNS0xNS0xLTEtNzM0Mjc_1f373f35-7262-42e6-8eb7-f82727eaea05">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39aa1c5f5b9f4d4caba6633baf8cb5a0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNi0xMy0xLTEtNzM0Mjc_0c8889fc-e666-4fec-9680-36ac2936d17e">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNi0xNS0xLTEtNzM0Mjc_5c89ade2-ced5-45c2-8599-f3a02d9cdd4d">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i549e08742d14433d91f8b2d470a14ae3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNy0xMS0xLTEtNzM0Mjc_53f40e59-065f-41a6-a4bf-e20fbdd7a10e">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNy0xNS0xLTEtNzM0Mjc_15dff939-bae5-4e83-9159-62b225f6f00a">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090e20f1694842edaabcb0092ed0ebfe_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xLTEtMS03MzQyNw_7967c1b8-0088-49eb-9aaf-1b6e8fb7efcd">61,333,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090e20f1694842edaabcb0092ed0ebfe_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0zLTEtMS03MzQyNw_a47f41ee-a318-476e-9464-d652ad7e7594">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8b7cbe2f8041ab946f4daf94549f23_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC05LTEtMS03MzQyNw_95d1d00d-502f-42ba-9cce-a9408c357826">1,218,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4d893440bf04325a0c84a2fc57bc8ef_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xMS0xLTEtNzM0Mjc_b984117e-2a6c-4f99-b2bb-39689ece71d8">1,040,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i301a3cb5a7284b718c396f6fbad527ef_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xMy0xLTEtNzM0Mjc_ec5e244a-d0a8-4a29-88fe-7bc8ffc2f806">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b294fc0b3654d22a51d4b9b63e8fc3d_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xNS0xLTEtNzM0Mjc_0352cf0b-2841-4f61-8b70-84ef38522895">178,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMy0xLTEtMS03MzQyNw_eb7f8f03-15e7-478a-b508-89419f1872f3">38,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMy0zLTEtMS03MzQyNw_91b0901c-92a5-4d09-bf9d-90a58b951787">66,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNS0xLTEtMS03MzQyNw_1b207949-6d55-48ec-acdf-d329c218a43c">2,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNS0zLTEtMS03MzQyNw_8fbbb717-c8ca-41ff-aadf-d99ae7198bc3">2,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNi0xLTEtMS03MzQyNw_23d48823-cae1-4681-b872-d5628fd64f5d">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNi0zLTEtMS03MzQyNw_8127cae4-72ba-411f-a156-99dc9f62caf1">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNy0xLTEtMS03MzQyNw_7c9f20c0-e855-4013-8a87-bad3ab7048cb">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNy0zLTEtMS03MzQyNw_ca27e354-da15-4f01-b5cc-d7e931c91f7b">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:NonCashRoyaltyRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOC0xLTEtMS03MzQyNw_2262cf16-354d-4b7e-8427-9761e6bd7e5d">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:NonCashRoyaltyRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOC0zLTEtMS03MzQyNw_52d5ae8d-aff5-47c1-ad3d-6a9a2ada122a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOS0xLTEtMS03MzQyNw_845ed1c6-fc81-4dad-8a1d-d4bc0d4a2a0c">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOS0zLTEtMS03MzQyNw_4a6fe726-33b9-4c8b-8058-1bd2e736719e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTEtMS0xLTEtNzM0Mjc_14717272-08f8-4552-ae5d-5ce74fcc78c4">20,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTEtMy0xLTEtNzM0Mjc_8cd822c7-9147-4d6f-8bb5-6e6a985ad1d4">4,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTItMS0xLTEtNzM0Mjc_b50a892a-f80f-46ef-84ff-122a455d1c14">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTItMy0xLTEtNzM0Mjc_ac79dc25-b628-4d94-841a-b50e99ac2adc">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTMtMS0xLTEtNzM0Mjc_3bbe14fb-fb87-49df-89e8-ad5e62a33e31">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTMtMy0xLTEtNzM0Mjc_6e386460-799b-4b43-bf56-aa8163a123e3">6,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMS0xLTEtNzk5OTI_8ba9bb7f-e9a5-4a13-a22f-d75479bc70d5">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMy0xLTEtNzk5OTI_59745249-a90f-4bf5-8c34-fa6132b71ad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMS0xLTEtNzM0Mjc_83494aab-fd1b-46b8-a5f8-a3545e1b06b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMy0xLTEtNzM0Mjc_ee78b4fb-4a01-4e82-b334-18544fa78e7a">801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTUtMS0xLTEtNzM0Mjc_11638a6a-7751-4a49-a91d-144c712284ea">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTUtMy0xLTEtNzM0Mjc_f58fedb0-978e-4799-a7b8-fe167a88531c">11,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTYtMS0xLTEtNzM0Mjc_617df105-a058-4e58-9a52-4fa9dacbe420">677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTYtMy0xLTEtNzM0Mjc_06f7f83a-c9ad-444e-a172-d21c15cf102c">543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTctMS0xLTEtNzM0Mjc_3184018b-766b-44de-b014-b0a10038e64c">284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTctMy0xLTEtNzM0Mjc_c191596d-cc31-4ef7-bd19-3dd937d5e45c">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTgtMS0xLTEtNzM0Mjc_7ed207de-96e3-4517-bacc-6e5a9a58d39c">2,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTgtMy0xLTEtNzM0Mjc_ee86d865-5a0a-401c-8222-cf1d74ebf754">11,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjAtMS0xLTEtNzM0Mjc_94b26c9c-1da6-4399-b79c-c055cde27d6d">12,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjAtMy0xLTEtNzM0Mjc_50ddfd79-4190-4ed2-9324-ca0d473c3544">57,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjItMS0xLTEtNzM0Mjc_dd38ed9a-ee30-4759-8a63-f90b93034654">17,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjItMy0xLTEtNzM0Mjc_2537fca5-2b81-4e9f-90ce-df00c4d7e02d">54,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjMtMS0xLTEtNzM0Mjc_614f3e06-d3f4-4f2b-a14c-de539220bc1f">45,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjMtMy0xLTEtNzM0Mjc_912b2926-ba48-42d3-bfc9-5edad738f937">37,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjQtMS0xLTEtNzM0Mjc_66b9a1c5-c88f-45a7-a429-fdedd6019bb6">359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjQtMy0xLTEtNzM0Mjc_53e40d97-296b-4fed-8d24-e951cd3b3299">1,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjUtMS0xLTEtNzM0Mjc_1bb277a0-9171-4656-8314-93487433b5ab">28,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjUtMy0xLTEtNzM0Mjc_4c6660db-c19c-4753-b760-3a6a22b3c98f">18,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjctMS0xLTEtNzM0Mjc_474a7c72-9262-4478-8971-9298d0a0c807">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjctMy0xLTEtNzM0Mjc_74202fb3-b568-4955-b972-b805df733e06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjgtMS0xLTEtNzM0Mjc_aa7d94fb-cb4b-4143-b7e5-59bab9f239fa">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjgtMy0xLTEtNzM0Mjc_85176b94-2dbb-4fc1-908d-ebebe0354794">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjktMS0xLTEtNzM0Mjc_eb4d4c22-a76c-447f-b7d2-ed067a908ab9">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjktMy0xLTEtNzM0Mjc_21cb7605-ab99-457b-b010-9bd16d3c8714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMS0xLTEtNzc2ODM_e27929e6-99fc-4ed8-ad5c-af68fddc10f3">99,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMy0xLTEtNzc2ODM_1b6eea49-61c3-4ec0-a3d3-d7cf932a97aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMS0xLTEtNzM0Mjc_bfab234f-2736-445b-9b39-01ee3092f936">100,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMy0xLTEtNzM0Mjc_b6e495f4-b613-4502-8bee-e73b1887e51e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzEtMS0xLTEtNzM0Mjc_7679704c-12c4-4f9e-8392-81c04548e164">115,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzEtMy0xLTEtNzM0Mjc_3c0105c2-2e3f-4769-9d63-c57a7b8abec5">76,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzItMS0xLTEtNzM0Mjc_371d2477-dd03-4779-bc3b-bc679edcc041">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id066d12821a94a4da435f27478529262_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzItMy0xLTEtNzM0Mjc_b3b96105-4079-4aff-8f69-c86c500300f9">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzMtMS0xLTEtNzM0Mjc_2e9067af-b910-48f2-821f-f34927194dd7">224,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b294fc0b3654d22a51d4b9b63e8fc3d_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzMtMy0xLTEtNzM0Mjc_bfad0e16-a95f-413c-9201-7b78cdef5d3c">47,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software included in accounts payable or accruals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzYtMS0xLTEtNzM0Mjc_8add7f99-5877-40a5-85dd-f676ce6535bf">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzYtMy0xLTEtNzM0Mjc_291d4d98-5c3c-4b0e-92f4-ab026660ec5d">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_34"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNC9mcmFnOjZkZWJmM2QzNmE1ZDRkMGM4MGMzOGY4MWIyNTAwYzU3L3RleHRyZWdpb246NmRlYmYzZDM2YTVkNGQwYzgwYzM4ZjgxYjI1MDBjNTdfNTY4Ng_da4a21de-9327-45a8-97e7-2d0cfe46ee1e" continuedAt="i9a9185a8be874842871dd647c8628b07" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i9a9185a8be874842871dd647c8628b07" continuedAt="i0c1e2581d8404a4a87be2e06a1d90125"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.  The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, product sales and royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates, adverse events involving financial institutions or the financial services industry and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNC9mcmFnOjZkZWJmM2QzNmE1ZDRkMGM4MGMzOGY4MWIyNTAwYzU3L3RleHRyZWdpb246NmRlYmYzZDM2YTVkNGQwYzgwYzM4ZjgxYjI1MDBjNTdfNTY4NQ_dd2c803a-3b5f-432b-9ec1-ef7046bfc05d" continuedAt="i2044a44d7d354e7e85697b148f0c97af" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c1e2581d8404a4a87be2e06a1d90125"><ix:continuation id="i2044a44d7d354e7e85697b148f0c97af">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</ix:continuation></ix:continuation></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_37"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNy9mcmFnOmZkOGZkMTVjMGQ1OTRhZTE4N2M0ZTgwZjUwMjljOGU3L3RleHRyZWdpb246ZmQ4ZmQxNWMwZDU5NGFlMTg3YzRlODBmNTAyOWM4ZTdfNTQx_10627b43-68c8-4a49-b88c-0f5cdb64c0bd" continuedAt="ia69be22b34114b72815d5b3547ea418b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia69be22b34114b72815d5b3547ea418b"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company adopted the following significant accounting policies in addition to those disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="mgnx:LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNy9mcmFnOmZkOGZkMTVjMGQ1OTRhZTE4N2M0ZTgwZjUwMjljOGU3L3RleHRyZWdpb246ZmQ4ZmQxNWMwZDU5NGFlMTg3YzRlODBmNTAyOWM4ZTdfNTQ5NzU1ODI0OTMw_f3366100-35bd-4265-b27f-c12790cc1d4c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the relevant accounting criteria under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#8217;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNy9mcmFnOmZkOGZkMTVjMGQ1OTRhZTE4N2M0ZTgwZjUwMjljOGU3L3RleHRyZWdpb246ZmQ4ZmQxNWMwZDU5NGFlMTg3YzRlODBmNTAyOWM4ZTdfNTQy_fa0a2125-cc5e-467d-8dce-28c65c877b99" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjgzNg_59a8a871-e83d-4627-a16c-5367dd4bdfea" continuedAt="i2214ccf83b5646d1850da2e20097b5ea" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i2214ccf83b5646d1850da2e20097b5ea" continuedAt="ie7a052f1a9b542f5befb490afdbd807a"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjgzNw_e6a4c759-e371-4fdc-aff5-4f83957d5c9b" continuedAt="ibf6bb69a845d470cacee0c412a7bffb0" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf6bb69a845d470cacee0c412a7bffb0" continuedAt="i7cd105da0e394ca7892d8feb85b49a9f">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </ix:continuation></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7cd105da0e394ca7892d8feb85b49a9f">There were no transfers between levels during the periods presented.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie7a052f1a9b542f5befb490afdbd807a"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjgzOQ_e3af0081-9ad5-4097-918a-f367f70b1e50" escape="true"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea8b4c0cee9423cb8076b969da02716_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfMy0xLTEtMS03MzQyNw_62815ae3-1503-4265-989e-7ce94c2b4620">52,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3d2b649df941eb8fa3c1e7cc8c023f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfMy0zLTEtMS03MzQyNw_3b8b3d6b-656e-42a5-a2ec-ed557d7aa945">52,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb01d2775284756822f388b6d2e16a3_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfMy01LTEtMS03MzQyNw_a65926b2-f9b0-43c6-b29a-a99541c4a317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacdb818e9174a62a35cd37cde8493fe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNS0xLTEtMS03MzQyNw_46c47444-2f7d-452c-b9db-52099a2c6dc1">28,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d1469f54904ec9974d404f50d6b074_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNS0zLTEtMS03MzQyNw_5aa6fe6e-90a2-4ceb-a7e4-c1c4a90b314f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346fa1f03c994f03af0d92e026a3ec33_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNS01LTEtMS03MzQyNw_65cb21c3-dc1f-4116-bf4b-bd65ff9a8d7f">28,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3379a8d83154bc7a2f3dfcf35bf0466_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNi0xLTEtMS03MzQyNw_d7f4b70e-d905-4de4-a1e4-fa2a6ab15742">11,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7897989264334daca83be8205e1f9066_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNi0zLTEtMS03MzQyNw_967e55a9-9307-4a3e-af49-bda0ace4ba49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia862e744faeb4ae98a11485e9fc56db7_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNi01LTEtMS03MzQyNw_d2a0d521-3b32-45cc-b4d1-eae264da76a2">11,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7781c40faa9749489c6481063c576abe_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfOC0xLTEtMS03MzQyNw_0cf00357-97bf-47ef-8266-76926c8accbd">92,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980ce273d57d43e180d24954e57132ed_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfOC0zLTEtMS03MzQyNw_ebb2be73-faad-4685-9da0-6877fc582cc7">52,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e168dd44f5c4d8590a34135fb61acb0_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfOC01LTEtMS03MzQyNw_437275f7-1e2b-408e-a17a-5a9caa6e8c67">40,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f34ccbd0974b3fa3aedac0a0794404_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfMy0xLTEtMS03MzQyNw_cc48a1fd-c235-4b9c-810e-401e99f9f391">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232dd89d03094cb0b9b34b4c2be81444_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfMy0zLTEtMS03MzQyNw_35d40c1c-ce8a-4efa-abb5-9bd32630ef5c">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a81484002646ca86c7980bdcde7f36_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfMy01LTEtMS03MzQyNw_d780dcb6-94cb-4e06-a59a-e8b4f180bb61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia556b2d5cb5245a1893a8a5f302714c5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNS0xLTEtMS03MzQyNw_0ed0723c-9ffc-4024-a2f5-c9eec071bf7d">32,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e544fa68641f8940ee5f29bc524c2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNS0zLTEtMS03MzQyNw_6f58a9d3-1739-40af-a7ef-aa9ed6a0e9ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b5e32b9dcb4adfbcbcbfb2e6c5bcb8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNS01LTEtMS03MzQyNw_6ff09bfc-b57a-446d-bf40-006e047dde76">32,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i931c2e63969e41f787594bffd508c45e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNi0xLTEtMS03MzQyNw_d5f9cc06-d41c-43cd-a554-9774457963ec">17,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b5beeee5f64179b2145f46e3032766_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNi0zLTEtMS03MzQyNw_8426c6d3-447e-4522-9a7a-e2f1cbaa35a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1a641b6ade4b1197580a782d03ccff_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNi01LTEtMS03MzQyNw_a191befc-27cd-47d6-aaa7-b8209513d485">17,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24dc0ddf9a849be8ab92812afd2d286_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfOC0xLTEtMS03MzQyNw_2168b50b-b1cf-4160-a72d-d45d0cdbc777">92,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a5923cf7e84a8bbedc65e244cd7791_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfOC0zLTEtMS03MzQyNw_795799e8-e01c-41dd-b95b-3728ac811011">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6f07e499e8471bb13f4992e6f93740_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfOC01LTEtMS03MzQyNw_cbedfab8-c57f-4661-89fc-25091fff2cfc">50,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at March&#160;31, 2023 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i7781c40faa9749489c6481063c576abe_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjYxNg_a7f1a219-63e2-42a1-86d6-6d8452489512">75.5</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ib24dc0ddf9a849be8ab92812afd2d286_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjc2MQ_8d229d1e-0ae5-4228-ad24-e1996dbdfe45">46.5</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div></ix:nonNumeric></ix:continuation><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_43"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfMTAzMQ_da9d7d22-0cd0-4de0-9d77-219f89db51c3" continuedAt="ic35ab86fbaba4012a170cdd985a73a25" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ic35ab86fbaba4012a170cdd985a73a25" continuedAt="ibfe22fd3518d4532a7e4080f52f28fd5"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfMTAzMg_4e87ea7e-d336-47f5-94f6-8c3344817b5a" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy0xLTEtMS03MzQyNw_763bac69-0728-4fce-8a2e-dec5ab98bbef">13,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy0zLTEtMS03MzQyNw_c30ee4a7-e32e-4327-bbdb-26046d6e7e36">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy01LTEtMS03MzQyNw_61c6b885-7ed9-4f7b-9d59-4c57e957f713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy03LTEtMS03MzQyNw_5e240378-d397-45f5-add3-c7cc0316aa05">13,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d80c05867546299ae2cae022aee461_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC0xLTEtMS03MzQyNw_f79323d9-d71b-49dc-a11d-dd1c494b0016">4,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d80c05867546299ae2cae022aee461_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC0zLTEtMS03MzQyNw_9d0cfb39-1b07-484e-8c6f-3af0376f3648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d80c05867546299ae2cae022aee461_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC01LTEtMS03MzQyNw_6a5b8c4d-ebc9-4dd2-ac0b-2af0dee3ade3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d80c05867546299ae2cae022aee461_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC03LTEtMS03MzQyNw_d7ae1538-8b07-4190-a077-751f748c5288">4,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS0xLTEtMS03MzQyNw_0097fe24-4719-4f2d-b4b4-b45b88d5234c">17,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS0zLTEtMS03MzQyNw_654e7bdc-0217-4d9e-a3de-504822d95504">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS01LTEtMS03MzQyNw_e8033a7a-61d9-42c3-ac56-bffaf50c4490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS03LTEtMS03MzQyNw_5b4c12d6-492d-45c1-b114-f1151af0ec8b">17,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy0xLTEtMS03MzQyNw_18137495-0c69-4e24-a99a-e73e86dfad1f">32,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy0zLTEtMS03MzQyNw_432e2dfe-1f00-46f2-9dee-f3dd80f805d3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy01LTEtMS03MzQyNw_20ab68a9-7f46-4263-97be-818e8c003b43">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy03LTEtMS03MzQyNw_dcbb37eb-6346-4675-b866-83046954f7cc">32,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8430871688c24161b99e79ce00cc373a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC0xLTEtMS03MzQyNw_c29cb443-b72d-4596-b96e-5049b58c0700">12,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8430871688c24161b99e79ce00cc373a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC0zLTEtMS03MzQyNw_20d740ec-1c73-4a56-9f32-c6a4a76fcbf3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8430871688c24161b99e79ce00cc373a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC01LTEtMS03MzQyNw_d7c82141-5390-4f68-a10b-55effc127163">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8430871688c24161b99e79ce00cc373a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC03LTEtMS03MzQyNw_225dd646-11ed-4496-a806-7fdf3d8ceafe">12,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS0xLTEtMS03MzQyNw_52d23c21-7896-49ea-af34-463c862c62a8">45,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS0zLTEtMS03MzQyNw_04d32eef-76e0-46a1-9b92-bb2d60529160">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS01LTEtMS03MzQyNw_a59df274-9f66-42bd-88d9-3a4a2e727fea">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS03LTEtMS03MzQyNw_f1058c2c-c7e8-4c75-85c4-13f0f30592e0">45,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibfe22fd3518d4532a7e4080f52f28fd5">All available-for-sale marketable debt securities held as of March&#160;31, 2023 and December&#160;31, 2022 had contractual maturities of less than one year. All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of  December&#160;31, 2022 were in a loss position for less than twelve months. Unrealized losses on available-for-sale debt securities as of  December&#160;31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, <ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfNjgw_8479362e-47bf-4c1c-92f8-e41ad892fdf0"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfNjgw_c1e16cc2-b41f-4408-828b-8105c66ac80e">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNjky_e7022fb6-0f65-4b0c-8567-21ccef028ad8" continuedAt="i1ea4cad9a59b407690a601654477eb91" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="i1ea4cad9a59b407690a601654477eb91" continuedAt="icb660a0d8acc41d9b045abe46075b943"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNjkz_cc0bf09d-3e8a-42bd-9692-17a61b94137f" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMi0xLTEtMS03MzQyNw_0f8115fb-bb98-4dd1-8680-08f8efe23a25">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMi0zLTEtMS03MzQyNw_1f7a3817-bf8a-4398-9c73-3e24289d46ea">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMy0xLTEtMS03MzQyNw_c445dc0a-8a16-4901-a7c7-eaafc96a25c3">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMy0zLTEtMS03MzQyNw_e939c674-f76a-49bc-a69e-4569476b8de3">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfNC0xLTEtMS03MzQyNw_1a4c3ffb-3b84-4a30-a8e4-771405219479">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfNC0zLTEtMS03MzQyNw_b2b1f3ca-00c6-4f9d-93a2-1da7ab6f38a8">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb660a0d8acc41d9b045abe46075b943">Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March&#160;31, 2023 and December&#160;31, 2022 is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNTQ4_772b9d06-9f69-40b9-95ba-f29338550c12"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNTQ4_beeb7cc9-1a86-4e8f-8336-24a071b9be3e">4.9</ix:nonFraction></ix:nonFraction>&#160;million for unsaleable inventory.  These reserves are reflected in cost of product sales during the period they are recorded.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_481"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTkyOA_41931acb-47f3-486a-a457-d5a8226c2411" continuedAt="i6ac3594824444d99b105f471418b17ed" escape="true">Royalty Monetization Arrangement </ix:nonNumeric></span></div><ix:continuation id="i6ac3594824444d99b105f471418b17ed"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company&#8217;s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) (the DRI Transaction) under the Company&#8217;s Asset Purchase Agreement dated May 7, 2018, as amended (the Asset Purchase Agreement), with Provention Bio, Inc. (Provention). The Company retains its other economic interests related to TZIELD, including future potential development, regulatory, and commercial milestones.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Royalty Purchase Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="i0595b4044d4e48a4b54395ad62ddc89c_I20230308" decimals="-5" name="mgnx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk0NA_0f7be5c9-b0a3-4f85-87a8-4dd063245ea5">100.0</ix:nonFraction>&#160;million from DRI for its single-digit royalty interest on global net sales of TZIELD under the Asset Purchase Agreement. The Company will have the right to receive a <ix:nonFraction unitRef="number" contextRef="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk1NA_ac20e140-4103-4c39-9a50-953f29f9ecb9">50</ix:nonFraction>% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $<ix:nonFraction unitRef="usd" contextRef="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308" decimals="-5" name="mgnx:FutureRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk3MA_2844b3ee-92fb-43cb-a6ff-ce3693d6e861">50.0</ix:nonFraction>&#160;million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. The Company may also receive an additional $<ix:nonFraction unitRef="usd" contextRef="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308" decimals="-5" name="mgnx:FutureRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk5MQ_7a3cdcc8-b638-46b9-bc77-cb551fbe96ec">50.0</ix:nonFraction>&#160;million milestone from DRI if TZIELD achieves a certain level of net sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i0595b4044d4e48a4b54395ad62ddc89c_I20230308" decimals="-5" name="mgnx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMjAxMQ_8e2d84a5-4d24-4688-9755-02b1282f720c">100.0</ix:nonFraction>&#160;million proceeds received from DRI under the Royalty Purchase Agreement were recorded as a liability for future royalties, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i0595b4044d4e48a4b54395ad62ddc89c_I20230308" decimals="-5" name="mgnx:TransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMjAyOQ_a166ace8-fc93-4b97-a849-16b83e4c4e50">0.3</ix:nonFraction>&#160;million, which will be amortized over the term of the arrangement using the effective interest rate method. The Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company has significant continuing involvement in the delivery of future royalty payments to DRI and other existing obligations under the Asset Purchase Agreement. Royalty revenue will be recognized as earned on net sales of TZIELD, and the Company will record the royalty payments to DRI as a reduction of the liability when paid. The aggregate future estimated payments, less the $<ix:nonFraction unitRef="usd" contextRef="iab71ac1d87d8415a9550205dc1aa8b3b_D20230101-20230331" decimals="-5" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyNzg0Mg_af381487-574b-493b-a006-f2ac42ab9ab1">99.7</ix:nonFraction>&#160;million of net proceeds, will be recorded as interest expense over the term of the arrangement. As such payments are made to DRI, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement. The Company will estimate the payments to be made to DRI over the term of the Royalty Purchase Agreement based on forecasted royalties and will calculate the effective interest rate required to discount such payments back to the liability balance. Over the course of the Royalty Purchase Agreement, the actual effective interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as necessary.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzE2NDkyNjc0NTA0MjQ_058ef93e-573f-43aa-b3e8-020884ef234f" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the liability related to future royalties were as follows for the three months ended March 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:66.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="-3" name="mgnx:LiabilityRelatedToFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzAtMS0xLTEtNzk0NDI_4acc6dac-c97d-407e-a767-77346402e11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzEtMS0xLTEtNzk0NDI_4b601b33-e9e2-42d6-989c-725ee1dd904d">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" sign="-" name="mgnx:DeferredTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzItMS0xLTEtNzk0NDI_7578f881-b1bb-48db-aad1-f1eeff308c03">344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue payable to DRI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:NonCashRoyaltyRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzMtMS0xLTEtNzk0NDI_0a6d53f6-06d5-4733-a92d-1c7a7c2208e0">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzQtMS0xLTEtNzk0NDI_e4689ff6-9b15-4776-aefd-7707dda6b5c0">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="mgnx:LiabilityRelatedToFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzUtMS0xLTEtNzk0NDI_81e0b33e-96c6-4254-87b6-a98d5700f3a6">100,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_49"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                              7. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTcyOA_e3f5d656-09f8-4d3d-bd54-dcada8066ca9" continuedAt="i6ec4612a9fcf40259bb7e7f2cb18cb35" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ec4612a9fcf40259bb7e7f2cb18cb35">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMjE4_ba788eef-54ad-4a8f-a520-4b3d5c10df34">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The Company sold <ix:nonFraction unitRef="shares" contextRef="i8125884812c4401b8b311bdffc16d974_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfNTQ5NzU1ODE3NDI5_16be229b-6989-4e38-9f57-27d150b88db5">3,622,186</ix:nonFraction> shares of common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8125884812c4401b8b311bdffc16d974_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfNTQ5NzU1ODE3NDQ2_4ea0dd8b-5d70-4567-83ee-e6403829e489">98.2</ix:nonFraction>&#160;million through December 31, 2021 under the Sales Agreement. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increased the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTAwOQ_a67012e7-7e7d-4e76-9a3d-d8439424174b">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i9309ea0208184fa4b37705ea22d3a556_D20210401-20210430" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTA1Mg_41a58934-6432-4db7-b024-908daa849c6e">300.0</ix:nonFraction>&#160;million. In March 2023, the Company terminated the Sales Agreement and entered into a new sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0ODA0NA_41ec4d97-53d6-47d5-a6c4-b274caba679e">100.0</ix:nonFraction>&#160;million through an ATM Offering. During the three months ended March 31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="i6d36e822023b4273a9509235bd8c6acd_D20220101-20220331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0Mzc2Mg_c39d1257-034f-48d0-8da4-453e4e5c2ec1">95,000</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if5a1a46d9b1045c9b6ee53abe05a7ead_I20220331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0MzgzMA_e94c0908-5290-4d8c-8a84-253d80175b39">6.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i6d36e822023b4273a9509235bd8c6acd_D20220101-20220331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0Mzg3OA_bc21a35b-822e-495b-a722-84af990be73b">0.6</ix:nonFraction> million, net of offering expenses.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQ0Nzc_a0c86dfd-e28f-4cc0-a455-a5b18a3d671f" continuedAt="i374b13761b3f49c78feb1b6b255b5b6f" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="i374b13761b3f49c78feb1b6b255b5b6f" continuedAt="i1e28c0e7782b4e1db12063a1d3b8ed80"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte), which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ieef59164d9804d038bd3cc080e152e53_D20180101-20180630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNzM5_fde8f90b-c21f-4e8c-bc5f-8c65a3662e62">150.0</ix:nonFraction> million in 2017. MacroGenics will manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte in multiple indications, the Company could receive up to a total of $<ix:nonFraction unitRef="usd" contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjY2NQ_534d37dc-90be-4c19-ace0-5d47f1ac5a1f">435.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjcxOQ_2cd067d4-3096-4bbc-8efa-75397b93d828">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="id2e1ac7059204d649fe5363543d08fd8_D20180101-20230331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjgzOA_db1c0265-9305-4916-a36e-8f88adfa42b3">115.0</ix:nonFraction> million in development milestones under the Incyte License Agreement, including $<ix:nonFraction unitRef="usd" contextRef="iafe7647445614121a80a6be8d87248c3_D20230301-20230331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc0OTc2_b26430d9-d33e-4bc2-841f-841a681b263a">15.0</ix:nonFraction> million received following the FDA approval of ZYNYZ. The Company is also eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i2a1a941fe6dc4e42b16747db51f11bd9_D20180101-20180630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzAxMg_2c5aaa05-881e-4e7a-9c1f-cec6f454adbf">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1cd6332acd224939b6e64d01df3361e7_D20180101-20180630" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzAxOA_76ecf3f7-2915-4f60-9dfb-724b5447196e">24</ix:nonFraction>% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606) at inception and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231" decimals="INF" name="mgnx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzY3Nw_1a061c84-5c1a-46d5-b899-86c595daf1c5">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNDQ2Mw_8605df75-be65-4a45-b9f2-aca28f3b796c">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i1e28c0e7782b4e1db12063a1d3b8ed80" continuedAt="if15ccc8b1de848158068b10035ac30f5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="id2e1ac7059204d649fe5363543d08fd8_D20180101-20230331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjA0Mw_db1c0265-9305-4916-a36e-8f88adfa42b3">115.0</ix:nonFraction> million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and regulatory activities related to the further advancement of retifanlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i2682097a1f3e4a89a96cab41f8cbd4ea_D20180101-20180630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjM0OQ_8e60fbb6-2ece-4b0f-83ee-2e2fc3ebc58f">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="i6b07faa5b7d643d883cf0c135e8f3d80_D20170101-20181231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjQ3Mw_80b26973-7974-47af-95b3-527da0790ca6">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ic1857d4cd8f7406fa5bbf069c7a857d6_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjYwOA_20ceb27b-41c7-493d-b5fa-2e1a0b9f8156"><ix:nonFraction unitRef="usd" contextRef="ic1857d4cd8f7406fa5bbf069c7a857d6_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjYwOA_5c906f63-d058-4061-9308-34197be5b06e">15.0</ix:nonFraction></ix:nonFraction>&#160;million ZYNYZ approval milestone as revenue under the Incyte License Agreement during the three months ended March 31, 2023. During the three months ended March 31, 2022, <ix:nonFraction unitRef="usd" contextRef="iafc0cdb960994c118fa8a5cfd0f2a280_D20220101-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjc5NA_5ab44606-41a0-4498-bb1e-6f3353d8b2ba">no</ix:nonFraction> revenue was recognized under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="if334a8dd8b764a01a900c1c6d7f9b363_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfODEwMQ_059226ca-5ff6-4585-be36-ea33e3e350f8">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibbbd06906d6345b2afe1b89f2851967a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfODEwOA_7fc89d6b-dc35-4fa3-92b6-04bc4145f4a3">0.3</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODQ5Njky_e526d17f-3059-42fe-9a24-93159f1a5124">60.0</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014" decimals="-5" name="mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNDg5NTg_167e4c2d-4170-424d-8bd0-0696542a195a">1.7</ix:nonFraction>&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="if15ccc8b1de848158068b10035ac30f5" continuedAt="i8e8eb4977516410b95f6b67e8438b977"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNDEzNjU_e526d17f-3059-42fe-9a24-93159f1a5124">60.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will reassess the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODUyNTYx_e526d17f-3059-42fe-9a24-93159f1a5124">60.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company will defer revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i374c14d1f7814bd99693ece7e091f00d_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODUzOTMz_7bc2f130-fe90-4e16-944b-d84ae60b2cf5">0.4</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Gilead Agreement. As of March&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6896341f33cd4b08985cd9e24146387e_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODUzOTk1_d9124ad1-7195-4761-b801-cd6d26e7d083">59.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6896341f33cd4b08985cd9e24146387e_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODU0MDQ1_9a9738ad-cb30-4cdd-8cc2-677b4eeca3a5">2.1</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i06dd337e669d44fda86ff6918e8c7999_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODU0MDc0_180e4465-a60a-4e6d-ae0e-d5e289d76c9a">57.4</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current. As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i5999119dfc294e80ad0713a177c361f0_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzUxNDg3Mw_d1295790-b997-427d-827a-1a03cff60a0e">59.8</ix:nonFraction>&#160;million in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5999119dfc294e80ad0713a177c361f0_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzUxNDg3Nw_81173e57-b4f4-46f6-b077-facefdb70765">1.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5999119dfc294e80ad0713a177c361f0_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzUxNDg4MQ_84d41465-5aa7-4cb3-9341-91f4641aec20">58.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#174; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA3MjY_f24b612f-5933-4e6a-aff6-b43fe0e81df5">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA3MzA_8a41972b-33f1-4a6c-91c9-406c6b02639b">22.5</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930" decimals="-5" name="mgnx:NonrefundablePaymentTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA3Nzk_624c8cbd-f870-420c-ab04-a0c2ee47e9d4">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="ic98612cc5ba1468d888c8629fe2b15bb_I20210930" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA5MjU_7fdc8859-3421-4e7a-9826-fef7b0b1bca3">140.0</ix:nonFraction> million in development and regulatory milestones, of which the Company has earned $<ix:nonFraction unitRef="usd" contextRef="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTEwMDI_49d4ff32-aae5-4179-83dc-43c25517ad63">9.0</ix:nonFraction> million through March&#160;31, 2023. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="if40b3c7658dd4cf3af7b29395be88093_D20190101-20190930" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTExMTM_be074028-eb9b-43c0-9cb5-8015cf8161f7">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="i3fe661497ec1436ea3ea36041dec66b1_D20190101-20190930" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTEyMzY_3d7cc8c8-78a6-43af-87e7-64111964577b">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab: (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i8e8eb4977516410b95f6b67e8438b977" continuedAt="i2361f808a88b41e0b8d889df20a3139a"><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTI1NDA_8a41972b-33f1-4a6c-91c9-406c6b02639b">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTM5MTY_49d4ff32-aae5-4179-83dc-43c25517ad63">9.0</ix:nonFraction> million. Therefore, the associated consideration, $<ix:nonFraction unitRef="usd" contextRef="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930" decimals="-5" name="mgnx:MilestonesValueAddedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTM5NjE_87e0c846-58b0-4e91-8140-eb4f143a1ff4">8.1</ix:nonFraction>&#160;million net of value-added tax withholdings, was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the three months ended March 31, 2023, <ix:nonFraction unitRef="usd" contextRef="ic55a0f9ecd9b4ceda005b981bf2f7d8e_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTQxNjE_42afe166-6f1c-4b37-b799-b2aa46fd8131">no</ix:nonFraction> revenue was recognized, and during the three months ended March 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ief1057cf41b349daa7c0fc063798c809_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTQxOTk_04da8ec1-411c-47a0-a24e-9bbefd178089"><ix:nonFraction unitRef="usd" contextRef="ief1057cf41b349daa7c0fc063798c809_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTQxOTk_96220393-c3b3-447a-bc55-8f8b07a0e052">5.0</ix:nonFraction></ix:nonFraction>&#160;million in revenue was recognized under the 2018 Zai Lab Agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company. In August 2022, the Company and Zai Lab agreed to discontinue research and development of the Lead Program. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTcxNjU_984181da-b76c-4d87-9958-546fd746bfb9">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a stock purchase agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTczOTM_8cac8f8b-e617-49c9-8431-69ca825a1d79">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc0NTY_424644ce-d8cf-4a10-9b6a-e18d8f08ecf0">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc0ODA_da30726f-39b8-4621-842b-92a78d736f80">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="i02aba6ee80e4485593c6ef2dd3196270_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc1MDM_9d135127-e88d-48d0-a710-e1e92fd59883">10.4</ix:nonFraction> million premium over the share price on the stock purchase agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the remaining Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc3MDE_5df5b82f-0d94-4464-afa2-2707923f9049">680.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc3NDk_c7402184-1475-4eda-9d35-977b816f670b">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i2361f808a88b41e0b8d889df20a3139a" continuedAt="ia7f2764cba0e488fa6debce6ce7ce0e5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk0MDY_3ad5258e-a6fb-4561-a2a9-500ef126dbd9">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk0Mjg_c28b0c0a-654f-4bd4-bf68-7e038d49afac">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="i02aba6ee80e4485593c6ef2dd3196270_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk0NTI_d5a4debc-a436-4b84-83f8-2923882d10ed">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the $<ix:nonFraction unitRef="usd" contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk1MjY_eb8f934e-3c43-44b8-8e77-0ae5caee6928">5.0</ix:nonFraction> million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjAzOTg_d36dc21f-3fdf-4a92-9e66-d0da17922921">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in 2021. During the three months ended March 31, 2023 the Company recognized no revenue under the 2021 Zai Lab Agreement, and the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie16b1ce65ef4498e985806621089d540_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjE5OTAyMzMxNTA5Mg_80a5668a-4c8b-45cd-b9cf-b91bff4bdcf1">0.3</ix:nonFraction>&#160;million during the three months ended March 31, 2022 under the 2021 Zai Lab Agreement.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3dee982850e549a68b6a81eb6c007052_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NTUwMQ_c23ac013-bb68-469b-9017-80f4aa239e66">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ibf999f4a23674de6901577a7a2e0e94d_I20180531" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NTY2MQ_40f4e9e9-6a56-4bb0-9801-8a25b9f43d07">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="ibf999f4a23674de6901577a7a2e0e94d_I20180531" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NTcxNg_787f0e57-227e-4e95-93a2-1ef008c1c6e9">225.0</ix:nonFraction> million in commercial milestones. As of March&#160;31, 2023, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into the Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5fbed9f54de04d85a3e8c55feabc0565_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NjczNg_8cedd32b-c779-4364-80fb-6936f2b99bbf">2.50</ix:nonFraction> per share. Under the Asset Purchase Agreement, Provention is obligated to pay the Company contingent milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="i7079bd55b0684e16805a5c2352089fd5_I20180531" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4Njg3MA_ba694d37-cd70-440d-93ed-b14c45b7767e">170.0</ix:nonFraction> million upon the achievement of certain regulatory milestones. In addition, Provention is obligated to make contingent milestone payments to the Company totaling $<ix:nonFraction unitRef="usd" contextRef="i7079bd55b0684e16805a5c2352089fd5_I20180531" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NzAyOQ_0539868e-7a0a-41ee-9727-8b75343d6850">225.0</ix:nonFraction> million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. In March 2023, the Company entered into a Royalty Purchase Agreement with DRI; see Note 6, Liability Related to Future Royalties, for additional information. The FDA approved the BLA for TZIELD (teplizumab-mzwv) in November 2022, and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i4475f726644746db8a9d6f1b092abe4c_D20221101-20221130" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NzIzNQ_cd5e489f-4c44-42ea-b2a8-c1165a1ee537">60.0</ix:nonFraction> million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amended the Asset Purchase Agreement. Under this amendment, the milestone for first approval was split into four equal payments, the first two of which were received prior to March 31, 2023. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i7079bd55b0684e16805a5c2352089fd5_I20180531" decimals="-5" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4Nzg2NA_3aef1bd7-8f8a-4be0-8e61-68f9fc7332af">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia7f2764cba0e488fa6debce6ce7ce0e5" continuedAt="i4d079295ddd14066b1a2de441a2ec561"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="iee007f50b7b54e878349b22a7469557d_I20180531" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4ODYzNA_5992ceeb-5baf-46d9-9287-7e13de2d7534">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="iee007f50b7b54e878349b22a7469557d_I20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4ODcxNQ_1a918806-6080-461a-bc93-d1757047b0b6">2,432,688</ix:nonFraction> shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ied8b4fcaac5140cca18c505dac7f2417_D20180501-20180531" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4OTY1NQ_61158fc3-49a0-4ce3-8a9e-11875b6f85fe">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4475f726644746db8a9d6f1b092abe4c_D20221101-20221130" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ5MDE4OQ_cd5e489f-4c44-42ea-b2a8-c1165a1ee537">60.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i83b508f7b0c74f06858ab827b8a99958_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc1MjYz_64ea04e9-75ae-4fa1-80a3-90e241bbec7e">0.4</ix:nonFraction> million in royalty revenue under these agreements based on the sales of TZIELD, and no revenue under these agreements during the three months ended March 31, 2022. As of March&#160;31, 2023, Provention owed the Company $<ix:nonFraction unitRef="usd" contextRef="iae198fa14cb849eba1d6619f7acc0b25_I20230331" decimals="-5" name="mgnx:ReceivableFromCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ5MDQ5Mw_d363b5e9-e9cb-46c9-80eb-16cfd1216bec">30.0</ix:nonFraction> million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet. This receivable was due to be paid on June 1, 2023 and September 1, 2023 under the amended Asset Purchase Agreement. Provention was acquired by Sanofi in April 2023. Sanofi accelerated the payment schedule and paid the Company the balance due subsequent to March 31, 2023. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. In August 2022, I-Mab notified the Company of its intention to terminate the I-Mab License Agreement effective February 25, 2023. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjY4NDA_74509b57-5621-4048-bafb-6a6ccc9a7c67">15.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjY4NDk_41e92f41-b9f1-4e7a-acba-3f4911a31717">5.0</ix:nonFraction>&#160;million of milestone revenue has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjc3MTU_74509b57-5621-4048-bafb-6a6ccc9a7c67">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630" decimals="-5" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjgxMzA_6754ee88-e69e-47f1-b63c-09dc8605b89f">1.0</ix:nonFraction> million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of <ix:nonFraction unitRef="number" contextRef="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331" decimals="2" name="mgnx:CollaborationArrangementOneTimeCreditPaidPercent" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA5OTUxMTcwMTAwNg_30c9d605-7658-4f9f-aeb3-e2370ea42156">eighty</ix:nonFraction> percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $<ix:nonFraction unitRef="usd" contextRef="i831ccd6f3347498497b72f53753edd5e_D20220101-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjg0ODM_63f9f3eb-eb23-43c9-a160-1e36807834ff">5.0</ix:nonFraction>&#160;million milestone ($<ix:nonFraction unitRef="usd" contextRef="i6b7f5ae7b36f40efb495d731d6421605_I20221231" decimals="-5" name="mgnx:OneTimeMillstoneCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjg0OTc_33ca8409-d860-4e67-bcf4-5cd991890248">4.5</ix:nonFraction>&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement was recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i4d079295ddd14066b1a2de441a2ec561" continuedAt="ifc6c612ed7834ce1b7e273ad32493ba3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment, was the best measure of progress towards satisfying the performance obligations. During the three months ended March 31, 2023 the Company recognized <ix:nonFraction unitRef="usd" contextRef="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjkyMjk_512b44a0-8efc-42d2-b799-a87a20ccaee7">no</ix:nonFraction> revenue under the I-Mab License Agreement, and during the three months ended March 31, 2022 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i6b2edd43ee5f4027854eb6a336bdca71_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODY3MzIy_0bf967dc-3407-4e50-afc6-d987fa2d4646">0.2</ix:nonFraction> million under the I-Mab License Agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023, the Company recognized <ix:nonFraction unitRef="usd" contextRef="i97eb432defc54b6ea97bda7a332c90f5_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODY3NDE5_20f1ac17-b490-4055-8a5d-4fe9c3eb113b">no</ix:nonFraction> revenue for research and development activities performed under the I-Mab Clinical Supply Agreement. During the three months ended March 31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i50d8b24b3b4c46df987acd17c19050e2_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc0OTMz_8e67d0fd-beb4-44db-8235-1142d82e8102">0.9</ix:nonFraction>&#160;million under the agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ieddfecbe8ad14ef7a8ff835b12b95d4a_D20220101-20220731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzEwOTU_0ee7238c-bde9-4e8f-8f94-931773382453">10.0</ix:nonFraction>&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $<ix:nonFraction unitRef="usd" contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzEyMDE_43a6ce16-48c9-4017-8b7e-b442b79e5dc8">14.4</ix:nonFraction>&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $<ix:nonFraction unitRef="usd" contextRef="i7595340e36ea4d09bf2116e33b8641f3_I20230331" decimals="-5" name="mgnx:AdditionalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzE1NTk_e73538c3-9bb8-42ff-b7db-dc04aa37329c">5.1</ix:nonFraction>&#160;million (July 2022 Incyte Amendment). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $<ix:nonFraction unitRef="usd" contextRef="ieddfecbe8ad14ef7a8ff835b12b95d4a_D20220101-20220731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzIwMjU_0c4b2568-4d46-4022-9018-0c3fbf9a6322">10.0</ix:nonFraction>&#160;million and the annual fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="i7595340e36ea4d09bf2116e33b8641f3_I20230331" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzIwNjc_acd40a74-7f03-439a-b58b-f8cc9fecf50c">19.5</ix:nonFraction>&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur. Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iaa3eccd028da467f83bd22324f391a17_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzI5NjI_899ee857-77fa-42de-9f4b-fa17dbb238f6">3.6</ix:nonFraction>&#160;million under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e3306c0844c488aa3ac28c64699528b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc0OTg1_20f42c7a-0421-4352-b35f-b8fe5ac5f31c">no</ix:nonFraction></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue during</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three months ended March 31, 2022. As of March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzMwODg_f1e43aed-c481-4c2b-9e2d-41be3764c41e">7.8</ix:nonFraction>&#160;million in revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzMxMzc_4d2ba97a-9070-4be9-b40b-73704ca8572e">7.1</ix:nonFraction>&#160;million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzMxNjU_3f2e94bd-6a86-4c2a-921e-9bdc10ddefa9">0.7</ix:nonFraction>&#160;million of which was non-current.  </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i800a7e6440dc4197a9837d73a114cba7_D20150915-20150915" decimals="INF" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzM0MjQ_6fc7a507-7415-4c0b-9d9e-0853ab20e22f">two</ix:nonFraction> DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc6c612ed7834ce1b7e273ad32493ba3">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="iabee161e88cd43838204d199c20da652_D20230101-20230331" decimals="-5" name="mgnx:TotalPotentialValueUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQxMzY_ebdc4d4c-b701-4538-a216-cfc911216208">25.1</ix:nonFraction>&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended March 31, 2023 and 2022, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="ic4a1d67968a747cca217bd0b0428cf02_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQ0NTA_b90e0d93-7c8f-4299-b709-a3c206960f57">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56231c20b15840d1afa950fe878367de_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQ0NTc_068a0489-4e6c-4ab3-99cc-3eaced69679b">0.4</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_58"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyNQ_a597db41-ec47-4e5e-a736-65d8167d7eb0" continuedAt="i11a94c09622b4bfbb5e0cd7a085874f4" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i11a94c09622b4bfbb5e0cd7a085874f4" continuedAt="i927588806f7f49e593234317629f870d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved <ix:nonFraction unitRef="shares" contextRef="i1cbab60f55fa402c96d89e18f0e3beb9_I20170531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDI3_432b6bc5-bec2-4ca7-880c-2116f9f0f84f">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="ie14822659c7d4a8e9cf7fcec3ee0ae7f_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNjI2_b52d4277-57f3-4f94-94f8-4935d947e836">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <ix:nonNumeric contextRef="ie58506024e45456592bc19755da226d2_D20170501-20170531" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIzMg_748af8d0-3eb4-4f09-ab84-0b7212c841ff">six-month</ix:nonNumeric> offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="ie14822659c7d4a8e9cf7fcec3ee0ae7f_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfODcy_f898d4b1-e3c4-4a8f-a834-95c2ab31f75c">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the three months ended March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="ifa174cd3914f4d469152f496ac824c06_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMTAwMg_b6ea393f-0f30-49b9-af43-c86b7df990d5">no</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Equity Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of March&#160;31, 2023, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie45d01decd32435a8498c793207f66fd_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMTkyNA_793f260a-fae7-43cd-b64e-a3baf812e315">61,572</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="ie39a7a5272cb4b76897f3e799b70f9ab_I20131031" decimals="INF" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMjM2MQ_da71c223-65d0-4092-8afc-8e616991812c">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i7aa16b089d85451b96f0b9061c2797e3_D20230101-20230331" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMjM3Ng_acc4b49f-c6b0-4c85-9996-c47f84191ad9">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the three months ended March&#160;31, 2023, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="ib6e4cfb9ea29453487b8acb62f27c309_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMjcyOA_a0ed29cf-d64e-45ee-8217-7dd7808daf3c">15,816,949</ix:nonFraction>.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of March&#160;31, 2023, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib6e4cfb9ea29453487b8acb62f27c309_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzMwNA_515a322b-c022-4880-a946-2df3d985260c">12,778,040</ix:nonFraction> shares of common stock outstanding.</span></div><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIzNA_00d263d7-5493-4eb3-8cde-f2eabb656531" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0c52ec53274fdba3171ff3170db6a3_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMi01LTEtMS03MzQyNw_398d67af-6e80-4695-9d9b-7724760e9e62">2,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1660944dc73f45fea86496b594fce178_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMi03LTEtMS03MzQyNw_88cf437c-9311-48a4-8752-bb86d217caaf">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb09aa6ccd548e5b5a67339e277f132_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMy01LTEtMS03MzQyNw_da56d134-d9aa-4651-9576-8627942279be">2,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6a705742804457a4eb1b0d964ea1e0_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMy03LTEtMS03MzQyNw_a0289387-5919-4ee8-9691-a7c0d69d1d78">2,882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfNC01LTEtMS03MzQyNw_427c83fb-3b1d-4a30-a97b-ac7240534fb9">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfNC03LTEtMS03MzQyNw_edc89341-f96b-40fa-af9a-6de35ca3ad54">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee stock options</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyNg_6ef6e146-68d4-44b8-826e-6990983029ca" continuedAt="i50fc18dfac6448fe84be15319031c3b7" escape="true">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i927588806f7f49e593234317629f870d"><div style="margin-bottom:9pt;margin-top:15pt"><ix:continuation id="i50fc18dfac6448fe84be15319031c3b7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMi0xLTEtMS03MzQyNw_dd31f4f2-e623-458a-84bb-2eb4a0face69">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMi0zLTEtMS03MzQyNw_7a480c5d-23fe-42ae-8fc7-da9f2911320c">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icaf39a1c94944731b2514e5c45e8ecee_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmE2MzlhMjk0ZjAwZjQ3OTBiZjZhOTA5YTJiODQ3NGVkXzQ_cf51e8c0-7a8a-428a-9d0c-c3c31a3b4287">92.6</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i5317a874bbfc4ef6baca4f516aa0f218_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmE2MzlhMjk0ZjAwZjQ3OTBiZjZhOTA5YTJiODQ3NGVkXzg_baee93f5-8233-4d2b-98a5-56ccc3274114">94.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i921b7f549052407f832cadb468c93a6c_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjU0NDY3Yzc2MWQ2OTQzZWViYTEzY2MwNTA3MDE0YWQ3XzQ_ed4de384-eefc-4c84-ac35-bc6320d219c8">87.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i799a33353e9a49a4b78a98bda1c4c308_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjU0NDY3Yzc2MWQ2OTQzZWViYTEzY2MwNTA3MDE0YWQ3Xzk_c468b12a-119c-4b0d-ba23-22fdfe1a0a5d">88.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icaf39a1c94944731b2514e5c45e8ecee_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmQyNDdmNDE1ZTAwZjRiMjNiM2FmNzBlZmM0ODk3ZmNhXzQ_78974185-c0b7-4c7f-9f60-a10fd0648a9a">3.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i5317a874bbfc4ef6baca4f516aa0f218_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmQyNDdmNDE1ZTAwZjRiMjNiM2FmNzBlZmM0ODk3ZmNhXzk_6cb3fef2-3f09-4021-8f28-60cac47e1696">4.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i921b7f549052407f832cadb468c93a6c_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjAzY2Q0MzhmNmUzYTRhNWVhMDEzNjA1MWJhOTkxMWNiXzQ_c8fda62d-7a32-4844-a138-f3aad9fdc5d4">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i799a33353e9a49a4b78a98bda1c4c308_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjAzY2Q0MzhmNmUzYTRhNWVhMDEzNjA1MWJhOTkxMWNiXzk_223d7596-ea8b-4c00-a74c-1ab231e06a72">2.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNS0xLTEtMS03MzQyNw_817e3475-9878-4ff0-b314-e08fa6492ea9">5.88</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNS0zLTEtMS03MzQyNw_bb0d6cf9-f976-4583-a25b-82d67d9635b4">5.95</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyNw_63021d7e-3b57-42a0-b151-703cefd543be" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMS0xLTEtMS03MzQyNw_cae87d6b-ee00-4f30-b07b-77f76344d6e7">10,098,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMS0zLTEtMS03MzQyNw_4359e322-8d1d-439a-9477-2f42aaafd0db">18.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica024959f8ab45b2aee0bf2b8219b68e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMS01LTEtMS03MzQyNw_4ad03425-c9a8-46af-b27c-a4a96d2687bd">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMi0xLTEtMS03MzQyNw_6bf8e4ee-0958-4d53-a2e3-2d018bb5138a">2,914,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMi0zLTEtMS03MzQyNw_b8f525a1-b75d-4756-a6dd-7129fcca813d">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMy0xLTEtMS03MzQyNw_d0950368-594c-4e5e-b858-82ec136f2ec4">3,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMy0zLTEtMS03MzQyNw_26dfd769-886d-422f-a5a1-a08fc4a7ddc0">1.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNC0xLTEtMS03MzQyNw_53dba7f7-4c02-47ab-831f-85423820fe14">87,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNC0zLTEtMS03MzQyNw_792facaf-d5d8-4ad1-b635-84a937e522cd">11.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNS0xLTEtMS03MzQyNw_41204806-0a42-4687-85cb-a2a9fb0aa3ff">82,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNS0zLTEtMS03MzQyNw_a0b78216-6825-4838-83d2-cc388a367218">22.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi0xLTEtMS03MzQyNw_112c951d-5d00-402f-a6c8-1bf59c8a1b84">12,839,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi0zLTEtMS03MzQyNw_9cb75f4b-bf57-47c9-9565-451e69b12c54">15.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi01LTEtMS03MzQyNw_7a2714a4-f88d-4987-889e-f6468da9c660">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi03LTEtMS03MzQyNw_3e0a8866-0a73-405b-9c4c-2a731efd60a9">7,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC0xLTEtMS03MzQyNw_b4f3d9e3-0242-482f-84d8-c3746dda2397">7,048,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC0zLTEtMS03MzQyNw_86297494-5f8d-4ba8-bfa6-33c012af4d10">20.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC01LTEtMS03MzQyNw_833aa6cc-ac13-486d-a0a7-227445424028">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC03LTEtMS03MzQyNw_3b487b6c-cbe2-405d-89cc-895fdee3b9e6">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS0xLTEtMS03MzQyNw_299a6d1d-4304-4b38-848e-0e0f8aa1a156">11,763,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS0zLTEtMS03MzQyNw_b5f5af19-7bb5-49fe-b739-96da95b01742">16.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS01LTEtMS03MzQyNw_e23553f3-03f0-45b1-bfee-94c06c92eea7">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS03LTEtMS03MzQyNw_24fd53e2-3e69-413e-ae25-7ab283e19108">6,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzg0OA_bf1c27cd-a121-4db4-b47d-89dbab660368">3.77</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzg1NQ_88d8fb45-d19d-4f12-a7e0-92611a790620">7.48</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the three months ended March&#160;31, 2023 was de minimis and the total intrinsic value of options exercised during the three months ended 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzk4Mg_3689bdb1-568d-4653-8430-b6cb477242b2">0.3</ix:nonFraction> million. The total cash received for options exercised during the three months ended March&#160;31, 2023 and 2022 was de minimis. The total fair value of shares vested in the three months ended March&#160;31, 2023 and 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDIwMg_c812a3fd-6a5d-4f95-91de-17a20680b9b8">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTQ5NzU1ODE5MjQ3_c94351cf-5444-491a-81c2-85681b65c155">5.4</ix:nonFraction> million, respectively. As of March&#160;31, 2023, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDM3MQ_c4bf8e71-06b4-48da-9bd6-a5bd4bd6e7bf">29.2</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDQ2Mg_8482dbaa-1899-4548-b3a7-e1ce91e48990">1.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company awards restricted stock units (RSUs) to employees. RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIzMA_3b378631-eb0e-457d-afd2-4a25d33f9ec6" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i036d859b9f664d9d82dd693c3f33d537_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMS0xLTEtMS03MzQyNw_7a4b4f9b-af3f-402b-9d9d-04d862bc4473">415,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i036d859b9f664d9d82dd693c3f33d537_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMS0zLTEtMS03MzQyNw_daee6706-3b07-4e26-a7a2-cf0845b27b08">8.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMi0xLTEtMS03MzQyNw_3e535d39-dacd-405c-96a1-6a627924336a">656,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMi0zLTEtMS03MzQyNw_d44b535c-c165-459f-a705-66c35612518d">4.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMy0xLTEtMS03MzQyNw_e3ff4917-36e7-4a2f-8c5f-6b5c7f55e576">62,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMy0zLTEtMS03MzQyNw_5c07efc0-d16b-4e38-b791-2d916777aac4">10.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNC0xLTEtMS03MzQyNw_fed7dc7a-466b-4389-85a2-54bb442559fd">27,657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNC0zLTEtMS03MzQyNw_76253cec-c83f-4032-b7fa-08cd3bde63a1">6.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214d7afe999940ae898ec280e17de7a4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNS0xLTEtMS03MzQyNw_5a65016c-ae57-4bb6-b4f7-4ba9a988f3da">980,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i214d7afe999940ae898ec280e17de7a4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNS0zLTEtMS03MzQyNw_b3f986c5-5c1d-4814-9fb0-5b7f70b60b41">6.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i214d7afe999940ae898ec280e17de7a4_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTA1Nw_d242b728-71b4-48f8-9934-d91af75aee1e">4.9</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately <ix:nonNumeric contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyMw_ece77096-1cdb-482b-b634-b5bcb5dc6447">1.6</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_61"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 10. <ix:nonNumeric contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfMTI5Mw_c17f8e00-df50-48d8-8132-5d7097404df2" continuedAt="i3df89a1049834a6aa35b5549a3af6aa7" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i3df89a1049834a6aa35b5549a3af6aa7" continuedAt="i07ede8bdbe8f4b7093fda2f33e503c68">In-licensing arrangement</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i07ede8bdbe8f4b7093fda2f33e503c68"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V. (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="i91c83b9d58eb41a8a4f5d2bbc203e254_I20220331" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfNTQ5NzU1ODIwOTgx_5cdf8380-aee6-4765-84cc-83f0051606ee">2.8</ix:nonFraction>&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ib91e3da1af4b4728802be58d315b3279_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfNTQ5NzU1ODIwOTk1_7321ef5f-9b64-4f76-9dcd-e0953a3e775b">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae7da4578181431996ca6f580a7f5d94_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfNTQ5NzU1ODIxMDA5_0a793117-f9ff-4ff8-9905-be3629ab3b20">1.0</ix:nonFraction>&#160;million under this agreement during the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserted a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal in the Fourth Circuit. The Company did not accrue any liability associated with this action as of December 31, 2022. The 4th Circuit affirmed the District Court&#8217;s dismissal in a decision published on March 2, 2023.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators in addition to several molecules in preclinical development. Our clinical product candidates include multiple oncology programs, many of which were created using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, three products originating from our pipeline of proprietary or partnered product candidates have received U,S. Food and Drug Administration (FDA) approval. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2022, the FDA approved TZIELD&#8482; (teplizumab-mzwv) to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Teplizumab was acquired from us by Provention Bio, Inc. (Provention) in 2018, pursuant to an asset purchase agreement. In March 2023, the FDA approved ZYNYZ&#8482; (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). Retifanlimab was previously developed by us and licensed to Incyte Corporation (Incyte) pursuant to an exclusive global collaboration and license agreement in October 2017.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have concentrated on staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of March&#160;31, 2023, combined with anticipated and potential collaboration payments, product revenues and royalties, should enable us to fund our operations through 2025. Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial of vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC), our planned Phase 2 study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2023, we had an accumulated deficit of $1.1 billion. We expect that over the next several years this deficit will increase as we continue to incur research and development expense in connection with our ongoing activities and several clinical studies.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, credit markets and financial markets have and may continue to experience significant volatility as a result of significant worldwide events, including adverse events involving financial institutions or the financial services industry, inflation and rising interest rates and geopolitical upheaval, such as Russia&#8217;s incursion into Ukraine (collectively, the Macroeconomic Conditions). These Macroeconomic Conditions have and may continue to create supply chain disruptions, inventory disruptions, and fluctuations in economic growth, including fluctuations in employment rates, inflation, energy prices and consumer sentiment. It remains difficult to assess or predict the ultimate duration and economic impact of the Macroeconomic Conditions. Prolonged uncertainty with respect to Macroeconomic Conditions could cause further economic slowdown or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition. </span></div><div><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Under this agreement, as amended, Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. We received an upfront payment of $150.0 million and milestone payments totaling $115.0 million from Incyte through March&#160;31, 2023, including $15.0&#160;million upon the FDA approval of ZYNYZ (retifanlimab-dlwr) in March 2023. We are eligible to receive an additional $320.0 million in development and regulatory milestones and $330.0 million in commercial milestones. We are also eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement). </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2022, we and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and create bispecific cancer antibodies using our DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Gilead Agreement, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0&#160;million and we will be eligible to receive up to $1.7&#160;billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option,successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and products result from the two additional research programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming exercise of the CD123 Option, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or other CD123 products developed under the agreement) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. Zai Lab has informed us that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have earned $9.0 million through March&#160;31, 2023. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us.  In August 2022, we and Zai Lab agreed to discontinue research and development of the Lead Program. </span></div><div style="padding-left:54pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the remaining Programs under the 2021 Zai Lab Agreement, we could receive up to $1.3 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Provention</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into an asset purchase agreement (APA) with Provention pursuant to which Provention acquired our interest in teplizumab. Under the APA, if Provention successfully develops, obtains regulatory approval for, and commercializes teplizumab, we will be eligible to receive up to $170.0 million in regulatory milestones, and up to $225.0 million in commercial milestones. In November 2022, the FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with Stage 2 T1D, and we recognized $60.0 million in milestone revenue during the year ended December 31, 2022. In November 2022 we and Provention amended the APA. Under the amended APA, the $60.0 million milestone for a first approval was split into four $15 million payments, the first two of which were received prior to March 31, 2023. We are also eligible to receive single-digit royalties on net sales of TZIELD. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to us, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the APA. Further, Provention is required to pay us a low double-digit percentage of certain consideration to the extent it is received in connection with a grant of rights by Provention to a third party. </span></div><div style="margin-bottom:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we sold our royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust (DRI). We retain our other economic interests related to TZIELD, including future potential regulatory and commercial milestones. We received a $100.0 million upfront payment from DRI for the sale of our single-digit royalty on global net sales of TZIELD. We retain the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, we are eligible to receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed T1D and may also receive an additional $50.0 million if TZIELD achieves a certain level of net sales.</span></div><div style="margin-bottom:6pt;padding-left:54pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting estimates are policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting estimates is presented in Part II, Item&#160;7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended December&#160;31, 2022. The following accounting policies and estimates were deemed critical during the three months ended March 31, 2023: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:39pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability related to future royalties is presented net of unamortized issuance costs on our consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on our current estimates of future royalties expected to be received over the life of the arrangement, which we determine by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. We periodically assess the expected payments and to the extent our estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, we will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:39pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the three months ended March&#160;31, 2023 and 2022 (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:63.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue of $13.4 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $15.0 million in milestone payments under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte License Agreement during the three months ended March 31, 2023; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.6 million recognized under the Incyte Manufacturing and Clinical Supply Agreement.</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by a decrease of $5.0 million in revenue recognized under the 2018 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other agreements may vary substantially from period to period depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved under current agreements, and whether we enter into additional collaboration agreements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for all periods presented consists primarily of product royalties and fill finish costs. Product sold during these periods consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin. We expect cost of product sales to continue to be positively impacted as we sell through this drug product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain Incyte bulk drug substance under the Incyte Manufacturing and Clinical Supply Agreement. We did not begin the manufacturing services until the second quarter of 2022, therefore there are no such costs during the three months ended March 31, 2022.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the three months ended March&#160;31, 2023 and 2022 (dollars in millions):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.426%"><tr><td style="width:1.0%"></td><td style="width:52.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.440%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody-drug conjugates (ADCs) (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  Includes research and discovery projects, as well as early preclinical molecules and molecules not advanced to clinical development.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the three months ended March 31, 2023 decreased by $15.5 million compared to the three months ended March 31, 2022 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased vobra duo development costs; </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to enoblituzumab;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased SOPHIA-related clinical trial costs related to margetuximab; </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to flotetuzumab (due to discontinuance of our company-sponsored trial); and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to tebotelimab.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These decreases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of a non-disclosed ADC Investigational New Drug candidate; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development costs related to lorigerlimab.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are uncertainties associated with our research and development expenses for future quarters which are impacted by multiple variables, including timing of wind down activities for recently closed studies and current and expected expenditures associated with our vobra duo TAMARACK study.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased by $2.7 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to decreased consulting expenses, legal fees and other professional services.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities consists of our net loss adjusted for non-cash items such as depreciation and amortization expense and stock-based compensation and changes in working capital. Net cash used in operating activities for the three months ended March&#160;31, 2023 benefited from the $15.0 million in milestones received from Incyte under the Incyte License Agreement and $15.0 million received from Provention related to the TZIELD approval milestone. Net cash used in operating activities for the three months ended March 31, 2022 benefited from the $11.2 million received from Incyte under the Incyte Manufacturing and Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the three months ended March 31, 2023 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities. Net cash used in investing activities during the three months ended March 31, 2022 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2023 includes net cash proceeds from our Royalty Purchase Agreement with DRI of $99.7 million.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. Our future success is dependent on our ability to identify and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital, and accordingly, our ability to execute our future operating plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of March&#160;31, 2023 combined with anticipated and potential collaboration payments, product revenues and royalties, should enable us to fund our operations through 2025. Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial of vobra duo in mCRPC, our planned Phase 2 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there were no significant changes to our material cash requirements, including contractual and other obligations, as presented in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_85"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company," we are not required to provide the information required by this item in this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_88"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended March 31, 2023 that materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.</span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_91"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_94"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, Commitments and Contingencies, to the consolidated financial statements of this Quarterly Report on Form 10-Q for more information.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_97"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:7.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101driredactedagree.htm">Purchase and Sale Agreement by and between the Company and DRI Healthcare Acquisitions LP, dated M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101driredactedagree.htm">arch</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101driredactedagree.htm"> 8, 2023.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1q12023.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2q12023.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1q12023.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2q12023.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ &#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that MacroGenics, Inc. treats as private and confidential.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;Furnished herewith</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9a03e40e8f4f4b699bd9595d0d3ddca2_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 9, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101driredactedagree.htm
<DESCRIPTION>DRI HEALTHCARE PURCHASE AND SALE AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i52aeb7fb128d497892d38c6b6a2df8a4_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-right:14.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:29.25pt;padding-right:29.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:74.15pt;padding-right:74.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURCHASE AND SALE AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.15pt;padding-right:74.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">dated as of March 8, 2023</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.1pt;padding-right:74.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">between</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.12pt;padding-right:74.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MACROGENICS, INC.</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.1pt;padding-right:74.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:74.2pt;padding-right:74.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DRI HEALTHCARE ACQUISITIONS LP</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:74.17pt;padding-right:74.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:20.65pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Page</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1&#160;&#160;&#160;&#160;Defined Terms&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2&#160;&#160;&#160;&#160;Rules of Construction&#160;&#160;&#160;&#160;8</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II PURCHASE AND SALE OF THE PURCHASED ROYALTY INTEREST&#160;&#160;&#160;&#160;9</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.1&#160;&#160;&#160;&#160;Purchase and Sale.&#160;&#160;&#160;&#160;9</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.2&#160;&#160;&#160;&#160;Purchase Price&#160;&#160;&#160;&#160;11</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.3&#160;&#160;&#160;&#160;No Assumed Obligations&#160;&#160;&#160;&#160;11</font></div><div style="margin-top:5.95pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.4&#160;&#160;&#160;&#160;Excluded Assets&#160;&#160;&#160;&#160;11</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.5&#160;&#160;&#160;&#160;Milestone Payments&#160;&#160;&#160;&#160;11</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER&#160;&#160;&#160;&#160;13</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.1&#160;&#160;&#160;&#160;Existence&#59; Organization&#160;&#160;&#160;&#160;13</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.2&#160;&#160;&#160;&#160;No Conflicts&#160;&#160;&#160;&#160;13</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.3&#160;&#160;&#160;&#160;Authorization&#59; Enforceability&#160;&#160;&#160;&#160;13</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.4&#160;&#160;&#160;&#160;Ownership&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.5&#160;&#160;&#160;&#160;Governmental and Third Party Authorizations&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.6&#160;&#160;&#160;&#160;No Litigation&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.7&#160;&#160;&#160;&#160;No Brokers&#8217; Fees&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.8&#160;&#160;&#160;&#160;Compliance with Laws&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.9&#160;&#160;&#160;&#160;Intellectual Property Matters&#160;&#160;&#160;&#160;15</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.10&#160;&#160;&#160;&#160;Asset Purchase Agreement&#160;&#160;&#160;&#160;16</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.11&#160;&#160;&#160;&#160;UCC Matters&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.12&#160;&#160;&#160;&#160;Taxes&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.13&#160;&#160;&#160;&#160;Solvency&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE PURCHASER&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.1&#160;&#160;&#160;&#160;Organization&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.2&#160;&#160;&#160;&#160;No Conflicts&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.3&#160;&#160;&#160;&#160;Authorization&#59; Enforceability&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.4&#160;&#160;&#160;&#160;Governmental and Third Party Authorizations&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.5&#160;&#160;&#160;&#160;No Litigation&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.6&#160;&#160;&#160;&#160;Funds Available&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:6.05pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V COVENANTS&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:7.4pt;padding-left:74.15pt;padding-right:74.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-i-</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i52aeb7fb128d497892d38c6b6a2df8a4_4"></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:203.25pt;padding-right:203.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS CONTINUED</font></div><div style="margin-top:12pt;padding-right:20.65pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Page</font></div><div style="margin-top:10.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.1&#160;&#160;&#160;&#160;Public Announcement&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.2&#160;&#160;&#160;&#160;Further Assurances.&#160;&#160;&#160;&#160;20</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.3&#160;&#160;&#160;&#160;Royalty Reports&#59; Notices and Correspondence&#160;&#160;&#160;&#160;20</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.4&#160;&#160;&#160;&#160;Misdirected Payments&#59; Late Fee.&#160;&#160;&#160;&#160;21</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.5&#160;&#160;&#160;&#160;Set-Offs&#160;&#160;&#160;&#160;22</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.6&#160;&#160;&#160;&#160;Maintenance of Asset Purchase Agreement.&#160;&#160;&#160;&#160;22</font></div><div style="margin-top:5.9pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.7&#160;&#160;&#160;&#160;Enforcement of Asset Purchase Agreement&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.8&#160;&#160;&#160;&#160;No Assignment&#59; No Liens&#160;&#160;&#160;&#160;25</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.9&#160;&#160;&#160;&#160;Audits&#160;&#160;&#160;&#160;25</font></div><div style="margin-top:6.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.10&#160;&#160;&#160;&#160;Tax Matters.&#160;&#160;&#160;&#160;25</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.11&#160;&#160;&#160;&#160;Change of Name, Jurisdiction, Etc&#160;&#160;&#160;&#160;27</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.12&#160;&#160;&#160;&#160;Provention Directions&#160;&#160;&#160;&#160;27</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VI THE CLOSING&#160;&#160;&#160;&#160;27</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.1&#160;&#160;&#160;&#160;Closing&#160;&#160;&#160;&#160;27</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.2&#160;&#160;&#160;&#160;Payment of Initial Purchase Price&#160;&#160;&#160;&#160;27</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.3&#160;&#160;&#160;&#160;Closing Deliverables&#160;&#160;&#160;&#160;28</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VII INDEMNIFICATION&#160;&#160;&#160;&#160;28</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.1&#160;&#160;&#160;&#160;Indemnification by the Seller&#160;&#160;&#160;&#160;28</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.2&#160;&#160;&#160;&#160;Indemnification by the Purchaser&#160;&#160;&#160;&#160;29</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.3&#160;&#160;&#160;&#160;Procedures for Third Party Claims&#160;&#160;&#160;&#160;29</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.4&#160;&#160;&#160;&#160;Other Claims&#160;&#160;&#160;&#160;31</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.5&#160;&#160;&#160;&#160;Limitations on Liability&#160;&#160;&#160;&#160;31</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.6&#160;&#160;&#160;&#160;Exclusive Remedy&#59; Set-Offs&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VIII CONFIDENTIALITY&#160;&#160;&#160;&#160;33</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.1&#160;&#160;&#160;&#160;Confidentiality&#160;&#160;&#160;&#160;33</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.2&#160;&#160;&#160;&#160;Termination of Existing Confidentiality Agreement&#160;&#160;&#160;&#160;34</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.3&#160;&#160;&#160;&#160;Required Disclosure&#160;&#160;&#160;&#160;34</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.4&#160;&#160;&#160;&#160;Permitted Disclosure.&#160;&#160;&#160;&#160;35</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.5&#160;&#160;&#160;&#160;Certificates.&#160;&#160;&#160;&#160;35</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IX TERMINATION&#160;&#160;&#160;&#160;37</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.1&#160;&#160;&#160;&#160;Termination of Agreement&#160;&#160;&#160;&#160;37</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-ii-</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i52aeb7fb128d497892d38c6b6a2df8a4_7"></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:203.25pt;padding-right:203.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS CONTINUED</font></div><div style="margin-top:12pt;padding-right:20.65pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Page</font></div><div style="margin-top:10.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.2&#160;&#160;&#160;&#160;Effect of Termination&#160;&#160;&#160;&#160;37</font></div><div style="margin-top:6pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE X MISCELLANEOUS&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.1&#160;&#160;&#160;&#160;Specific Performance&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.2&#160;&#160;&#160;&#160;Notices&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.3&#160;&#160;&#160;&#160;Successors and Assigns&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.4&#160;&#160;&#160;&#160;Independent Nature of Relationship&#160;&#160;&#160;&#160;40</font></div><div style="margin-top:5.9pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.5&#160;&#160;&#160;&#160;Entire Agreement&#160;&#160;&#160;&#160;40</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.6&#160;&#160;&#160;&#160;No Third Party Beneficiaries&#160;&#160;&#160;&#160;40</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.7&#160;&#160;&#160;&#160;Governing Law&#59; Jurisdiction&#59; Venue&#59; Consent to Service.&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:6.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.8&#160;&#160;&#160;&#160;Waiver of Jury Trial&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.9&#160;&#160;&#160;&#160;Severability&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.10 Counterparts&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.11 Amendments&#59; No Waivers&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.12 Cumulative Remedies&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:6pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.13 Table of Contents and Headings&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:6pt;padding-left:61pt;padding-right:279.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A Asset Purchase Agreement Exhibit B Bill of Sale</font></div><div style="padding-left:61pt;padding-right:279.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit C Initial Provention Instruction Exhibit D Purchaser Account</font></div><div style="padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit E  Seller Account</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-iii-</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i52aeb7fb128d497892d38c6b6a2df8a4_10"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:74.15pt;padding-right:74.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURCHASE AND SALE AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This PURCHASE AND SALE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) dated as of March 8, 2023 is between MacroGenics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and DRI Healthcare Acquisitions LP, a Delaware limited partnership (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Seller and the Purchaser are referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.17pt;padding-right:74.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">E S S E T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, pursuant to the Asset Purchase Agreement, Provention agreed to pay to the Seller, and the Seller has the right to receive, the Royalty&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Seller desires to sell to the Purchaser, and the Purchaser desires to purchase from the Seller, the Purchased Royalty Interest, upon and subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties set forth herein and of other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto covenant and agree as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:77.05pt;padding-right:77.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE I</font></div><div style="padding-left:69.65pt;padding-right:69.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DEFINED TERMS AND RULES OF CONSTRUCTION</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following terms, as used herein, shall have the following respective meanings&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any designated Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such designated Person. For purposes of this definition, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise, and the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have meanings correlative to the foregoing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:121.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Agreed Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in the preamble. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Applicable Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 8.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">.</font></div><div style="padding-left:61pt;padding-right:14.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Asset Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Asset Purchase Agreement, dated May 7, 2018, by and between the Seller and Provention, as amended by that certain Amendment No. 1 to Asset Purchase Agreement dated as of November 30, 2022.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Audit Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain bill of sale, dated as of the Closing Date, executed by the Seller and the Purchaser, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day that is not a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by applicable Law to remain closed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:175.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">.</font></div><div style="padding-left:61pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:101.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Confidentiality Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">.</font></div><div style="padding-left:61pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosure Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Disclosure Schedules delivered by the Seller to the Purchaser concurrently with the execution and delivery of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Earn-Out Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning ascribed to such term in the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Escrow Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the segregated account established pursuant to the Paying Agent Agreement, into which (a) until the &#91;***&#93;, or if the &#91;***&#93; and does not provide for &#91;***&#93;, all payments by Provention under the Asset Purchase Agreement, including the Purchased Royalty Interest and the Retained Interest, are to be remitted pursuant to the Initial Provention Instruction and (b) following &#91;***&#93;, if the &#91;***&#93; provides for &#91;***&#93;, all payments by Provention in respect of the Royalty, and &#91;***&#93;.</font></div><div style="margin-top:0.3pt;padding-left:97pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Existing Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Section 10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">. </font></div><div style="margin-top:0.3pt;padding-left:97pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.3pt;padding-left:97pt;padding-right:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means the U.S. Food and Drug Administration or any successor agency thereto. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means the government of the United States, any other nation</font></div><div style="margin-top:0.3pt;padding-left:61pt;padding-right:14.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any political subdivision thereof, whether state or local, and any agency, authority (including supranational authority), commission, instrumentality, regulatory body, court, central bank or</font></div><div style="margin-top:3pt;padding-left:60.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Provention Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the direction letter to Provention in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:101.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Initial Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 2.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">IRS Withholding Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 5.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Judgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any judgment, order, stipulation, consent order, ruling, injunction, assessment, award, writ or decree.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Seller, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any law, statute, rule, regulation or ordinance issued or promulgated by a Governmental Authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property or other priority or preferential arrangement of any kind or nature whatsoever.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any loss, assessment, award, cause of action, claim, charge, cost, damage, expense (including expenses of investigation and attorneys&#8217; fees), fine, Judgment, liability, obligation, penalty.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) a material adverse effect on the legality, validity or enforceability of any of the Transaction Documents or the Asset Purchase Agreement, (b) a material adverse effect on the ability of the Seller to perform its obligations under any of the Transaction Documents or under the Asset Purchase Agreement, (c) a material adverse effect on the rights or remedies of the Purchaser under any of the Transaction Documents to which it is a party, (d) a material adverse effect on the rights of the Seller under the Asset Purchase Agreement that relate to, or involve or otherwise affect, the Purchased Royalty Interest, (e) an adverse effect in any material respect on the timing, amount or duration of the Purchased Royalty Interest or (f) an adverse effect in any respect on the right of the Purchaser to receive the Purchased Royalty Interest.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Non-Sales Milestone Payment and the Sales-Based Milestone Payment (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning ascribed to such term in the Asset Purchase Agreement.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Permitted Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) any set-off, counterclaim, downward adjustment, credit, reduction or deduction, by contract or otherwise, exercised by Provention against the Purchased Royalty Interest (other than any Permitted Reduction) in respect of a claim against the Seller, including any amounts actually or allegedly owed by the Seller to Provention and &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">If the &#91;***&#93; is achieved and the &#91;***&#93; has not previously been achieved, &#91;***&#93;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">If the &#91;***&#93; is achieved &#91;***&#93; and the &#91;***&#93; has not previously been achieved or is achieved &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">If the &#91;***&#93; is achieved on &#91;***&#93; and the &#91;***&#93; has not previously been achieved, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Wilmington Trust, N.A., as escrow agent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Paying Agent Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an escrow agreement, in a form reasonably acceptable to the Seller and the Purchaser, by and among the Seller, the Purchaser, and the Paying Agent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following&#58; (a) any adjustments, modifications, credits, offsets, reductions or deductions to payments of the Purchased Royalty Interest made </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to Section 3.3(b) of the Asset Purchase Agreement, (b) any adjustments, modifications, credits, offsets, reductions or deductions to payments of the Purchased Royalty Interest made pursuant to Section 3.3(c) of the Asset Purchase Agreement or &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any natural person, firm, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity, including public bodies, whether acting in an individual, fiduciary or other capacity.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;&#91;***&#93;&#8221; means the &#91;***&#93;&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">(i) the issue of a public press release or current or periodic report filed with the SEC under the U.S. Securities Exchange Act of 1934, as amended, by &#91;***&#93; or any Third Party acting on behalf of &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (ii) the issue of other public disclosure by &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or any Third Party acting on behalf of &#91;***&#93; in a presentation at a &#91;***&#93;, such as the &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (iii) the publication of an &#91;***&#93;, stating, in each case (i)- (iii), (1) that the &#91;***&#93; (which, for the avoidance of doubt, shall mean the &#91;***&#93; as of the date of this Agreement, i.e., the &#91;***&#93; and (2) that such &#91;***&#93;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:133pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">(i) the announcement that &#91;***&#93;, on the one hand, and &#91;***&#93;, on the other hand, have &#91;***&#93; or (ii) the announcement that &#91;***&#93;or an Affiliate of &#91;***&#93; that &#91;***&#93;, on the one hand, and a &#91;***&#93;, on the other hand, have entered into a definitive agreement for a &#91;***&#93; of the type described in clause (a) or clause (b) of the &#91;***&#93;, and solely if &#91;***&#93;, in each case (i) and (ii) via a public press release or other public disclosure made in a current or periodic report filed with the SEC under the U.S. Securities Exchange Act of 1934, as amended, by &#91;***&#93; or such Affiliate, as applicable, or the &#91;***&#93; that is party to such &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, the events set forth in clauses (a) and (b) &#91;***&#93; so long as &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all amounts actually recovered by the Seller as a result of any settlement or resolution of any actions, suits, proceedings, claims or disputes related to the Purchased Royalty Interest or enforcement of the Asset Purchase Agreement pursuant to this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:57pt;padding-right:57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Provention Bio, Inc. and its successors and assigns.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provention Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Confidential Information (as defined in the Asset Purchase Agreement) disclosed by Provention or its Affiliates (as defined in the Asset Purchase Agreement) under the Asset Purchase Agreement and Confidential Information (as defined in the Asset Purchase Agreement) deemed to be the Confidential Information (as defined in the Asset Purchase Agreement) of Provention as provided in the last sentence of the definition of &#8220;Confidential Information&#8221;.</font></div><div style="margin-top:11.6pt;padding-left:97pt;padding-right:131.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#91;***&#93;</font></div><div style="margin-top:11.6pt;padding-left:97pt;padding-right:131.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 2.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">.</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchased Royalty Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all of the Seller&#8217;s right, title and interest in and to (a) &#91;***&#93; of the Royalty payable in respect of the &#91;***&#93; of worldwide annual Net Sales of the Royalty Product in a given calendar year during the Earn-Out Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) fifty percent (50%) of the Royalty payable in respect of worldwide annual Net Sales of the Royalty Product in such </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year &#91;***&#93; of worldwide annual Net Sales of the Royalty Product referenced in clause (a) for such calendar year.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchaser Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the account set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or such other account as may be designated by the Purchaser in writing from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchaser Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 2.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">.</font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retained Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) the excess, if any, of the Royalty paid, owed, accrued or otherwise payable by Provention under the Asset Purchase Agreement over the Purchased Royalty Interest and (ii) the amounts paid, owed, accrued or otherwise payable by Provention under Section 3.2, Section 3.4 and Section 3.5, respectively, of the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) all amounts paid or payable to the Seller by Provention under Section 3.3(a) of the Asset Purchase Agreement in respect of worldwide annual Net Sales of the Royalty Product &#91;***&#93;, (b) all interest payments paid or payable by Provention under Section 3.8 of the Asset Purchase Agreement in respect of the amounts described in clause (a), and (c) all other amounts paid or payable to the Seller by Provention under the Asset Purchase Agreement in lieu of the amounts described in clauses (a) and (b), including any payments made to the Seller by Provention pursuant to Section 9.3 of the Asset Purchase Agreement subject to the terms of Article 9 of the Asset Purchase Agreement in respect of payments of the amounts described in clauses (a) and (b) that are late or which Provention has failed to make.</font></div><div style="margin-top:0.3pt;padding-left:97pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Royalty Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means the Product (as defined in the Asset Purchase Agreement). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Royalty Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means the Product Patents (as defined in the Asset Purchase</font></div><div style="margin-top:0.3pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the quarterly royalty reports required to be prepared and delivered by Provention to the Seller pursuant to Section 3.6 of the Asset Purchase Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sales-Based Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence, &#91;***&#93; on or after &#91;***&#93; equaling, in the &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:175.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Sales-Based Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; means $50,000,000. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in the preamble.</font></div><div style="padding-left:61pt;padding-right:17.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the account set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto or such other account as may be designated by the Seller in writing from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.65pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person on any date of determination, that on such date (a) the fair value of the assets of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (b) the present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person&#8217;s ability to pay such debts and liabilities as they mature, (d) such Person is not engaged in business or a transaction, and is not about to engage in business or a transaction, for which such Person&#8217;s property would constitute an unreasonably small capital and (e) such Person is able to pay its debts and liabilities, contingent obligations and other commitments as they mature in the ordinary course of business. The amount of contingent obligations or contingent liabilities, as applicable, at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability or obligation, as applicable.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person that is not the Purchaser, an Affiliate of the Purchaser, the Seller or an Affiliate of the Seller.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Agreement, the Bill of Sale (when executed and delivered), the &#91;***&#93; (if and when executed and delivered), the Paying Agent Agreement (when executed and delivered) and the Initial Provention Instruction.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Uniform Commercial Code as in effect from time to time in the State of New York&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, if, with respect to any financing statement or by reason of any provisions of applicable Law, the perfection or the effect of perfection or non-perfection of the back-up security interest or any portion thereof granted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of New York, then &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States of America, each territory thereof and the District of Columbia.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rules of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless the context otherwise requires, in this Agreement&#58;</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">unless otherwise defined, all terms that are defined in the UCC shall have the meanings stated in the UCC&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders&#59;</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">the definitions of terms shall apply equally to the singular and plural forms of the terms defined&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">the terms &#8220;include&#8221;, &#8220;including&#8221; and similar terms shall be construed as if followed by the phrase &#8220;without limitation&#8221;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:14.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restated, reformed, supplemented or otherwise modified in accordance with the terms thereof (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth herein) and include any annexes, exhibits and schedules attached thereto&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.08pt">references to any Law shall include such Law as from time to time in effect, including any amendment, modification, codification, replacement or reenactment thereof or any substitution therefor&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">references to any Person shall be construed to include such Person&#8217;s successors and permitted assigns (subject to any restrictions on assignment, transfer or delegation set forth herein or in any of the other Transaction Documents), and any reference to a Person in a particular capacity excludes such Person in other capacities&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.74pt">the words &#8220;hereof&#8221;, &#8220;herein&#8221;, &#8220;hereunder&#8221; and similar terms when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein are references to Articles and Sections of, and Exhibits to, this Agreement unless otherwise specified&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.74pt">the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other thing extends and such phrase shall not mean simply &#8220;if,&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">the word &#8220;or&#8221; is not exclusive and shall mean &#8220;and&#47;or&#8221;, unless the context otherwise requires&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.74pt">any reference to a Law shall include any rules and regulations promulgated thereunder, and any reference to any Law shall mean such Law as from time to time amended, modified or supplemented&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.74pt">in the computation of a period of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including&#8221; and each of the words &#8220;to&#8221; and &#8220;until&#8221; means &#8220;to but excluding&#8221;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">where any payment is to be made, any funds are to be applied or any calculation is to be made under this Agreement on a day that is not a Business Day, unless this Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly&#59;</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">in determining whether any action by the Seller would constitute &#8220;commercially reasonable efforts&#8221;, the Seller shall make such determination as if it had not sold the Purchased Royalty Interest to the Purchaser pursuant to this Agreement (such that the Seller had continued to own the Purchased Royalty Interest).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77.67pt;padding-right:77.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II</font></div><div style="padding-left:102.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PURCHASE AND SALE OF THE PURCHASED ROYALTY INTEREST</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase and Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">Upon the terms and subject to the conditions of this Agreement, at the Closing, the Seller shall sell to the Purchaser, and the Purchaser shall purchase from the Seller, all of the Seller&#8217;s right, title and interest in and to the Purchased Royalty Interest, free and clear </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any and all Liens, other than those Liens created in favor of the Purchaser by the Transaction Documents.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">It is the intention of the parties hereto that the sale contemplated by this Agreement shall be, and is, a true, complete, absolute and irrevocable sale by the Seller to the Purchaser of all of the Seller&#8217;s right, title and interest in and to the Purchased Royalty Interest and that such sale shall provide the Purchaser with the full benefits of ownership of the Purchased Royalty Interest from and after the effectiveness of this Agreement. Neither the Seller nor the Purchaser intends the transactions contemplated by this Agreement to be, or for any purpose characterized as, a loan from the Purchaser to the Seller or a pledge, a financing transaction or a borrowing. Each of the Seller and the Purchaser hereby waives, to the maximum extent permitted by applicable Law, any right to contest or otherwise assert that this Agreement does not constitute a true, complete, absolute and irrevocable sale by the Seller to the Purchaser of all of the Seller&#8217;s right, title and interest in and to the Purchased Royalty Interest under applicable Law, which waiver shall, to the maximum extent permitted by applicable Law, be enforceable against the Seller in any bankruptcy or insolvency proceeding relating to the Seller. Each of the Seller and the Purchaser agrees to account for the transaction contemplated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as a true sale as described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (except to the extent generally accepted accounting principles in the United States require such transaction to be accounted for as a liability or a derivative in the Seller&#8217;s consolidated financial statements). In addition, until the &#91;***&#93; is obtained and &#91;***&#93; the Royalty, and no other payments under the Asset Purchase Agreement, into the Escrow Account, the Seller grants to the Purchaser a security interest in the Escrow Account to the extent such Escrow Account contains proceeds of the Purchased Royalty Interest. To perfect the Purchaser&#8217;s purchase of the Purchased Royalty Interest and security interest in the Escrow Account, the Purchaser may file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Seller as the seller or debtor and the Purchaser as the buyer or secured party in respect of the Purchased Royalty Interest&#59; provided, in each case, that such financing statements shall not describe as collateral anything other than the Purchased Royalty Interest, any &#8220;proceeds&#8221; thereof (as defined in the UCC) and the Escrow Account and shall not contain an &#8220;all asset&#8221; (or words of similar effect) collateral description.  Notwithstanding the</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intention of the parties hereto and solely as a precaution to protect the Purchaser&#8217;s interests hereunder in the event the transactions contemplated by this Agreement and the other Transaction Documents are alleged or determined not to constitute a true sale of the Purchased Royalty Interest by the Seller to the Purchaser, or if such transactions shall for any reason be found ineffective or unenforceable, this Agreement shall also be deemed to constitute a security agreement under the UCC and the Seller hereby grants to the Purchaser as of the date of this Agreement, and the Purchaser shall have at all times on and after the date of this Agreement, a security interest in and to all right, title and interest of the Seller, in, to and under the Purchased Royalty Interest any &#8220;proceeds&#8221; (as such term is defined in the UCC) thereof and, until the &#91;***&#93; is obtained and &#91;***&#93; the Royalty, and no other payments under the Asset Purchase Agreement, into the Escrow Account, the Escrow Account, to secure the Seller&#8217;s due and timely payment and performance of all of the Seller&#8217;s liabilities and obligations to the Purchaser under this Agreement and any of the other Transaction Documents (whether such liabilities and obligations are direct, indirect, absolute, contingent or otherwise), including the payments of amounts to the Purchaser equal to the Purchased Royalty Interest as they become due and payable. In furtherance of the foregoing, the Seller hereby authorizes the Purchaser to take such actions as the Purchaser may elect to cause the security interest described above to be perfected by filing one or more UCC financing statements (and any amendments thereto from time to time) with respect to such security interest&#59; provided that such financing statements shall not describe as collateral anything other than the Purchased Royalty Interest, any &#8220;proceeds&#8221; thereof (as defined in the UCC) and the Escrow Account and shall not contain an &#8220;all asset&#8221; (or words of similar effect) collateral description.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">The purchase price to be paid as the full consideration for the sale of the Purchased Royalty Interest comprises (i) $100,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) the Non-Sales Milestone Payment, to the extent the same becomes due and payable and (iii) the Sales-Based Milestone Payment, to the extent the same becomes due and payable (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">The Purchaser shall pay the Initial Purchase Price to the Seller at the Closing in immediately available funds by wire transfer to the Seller Account.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Assumed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any provision in this Agreement or any other writing to the contrary, the Purchaser is purchasing, acquiring and accepting only the Purchased Royalty Interest and is not assuming any liability or obligation of the Seller or any of the Seller&#8217;s Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter (including any liability or obligation of the Seller under the Asset Purchase Agreement). All such liabilities and obligations shall be retained by and remain liabilities and obligations of the Seller or the Seller&#8217;s Affiliates, as the case may be.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchaser does not, by purchase, acquisition or acceptance of the right, title or interest granted hereunder or otherwise pursuant to any of the Transaction Documents, purchase, acquire or accept any assets or contract rights of the Seller, including the Retained Interest, other than the Purchased Royalty Interest as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:3pt;padding-left:101.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:169pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Non-Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.74pt">If the &#91;***&#93; is achieved and the &#91;***&#93; has not previously been achieved or is achieved &#91;***&#93;, the Seller shall deliver written notice of such achievement to the Purchaser &#91;***&#93;, together with reasonable supporting documentation thereof. The Purchaser shall pay the &#91;***&#93; to the Seller &#91;***&#93; by the Purchaser of such written notice and supporting documentation in &#91;***&#93; by wire transfer to the Seller Account&#59; provided, that in the case of a &#91;***&#93; involving a &#91;***&#93; that has not been &#91;***&#93; as of such date, the &#91;***&#93; shall become payable if and only if such &#91;***&#93; is in fact &#91;***&#93; of the definitive agreement for such &#91;***&#93;. In such event, (i) upon the announcement that &#91;***&#93; or the applicable Affiliate of &#91;***&#93;, on the one hand, and the applicable &#91;***&#93;, on the other hand, &#91;***&#93; via a public press release or other public disclosure made in a current or periodic report filed with the SEC under the U.S Securities Exchange Act of 1934, as amended or other applicable stock exchange filing (by &#91;***&#93; or such Affiliate, as applicable, or the &#91;***&#93; that is party to the &#91;***&#93;), the Seller shall deliver written notice of &#91;***&#93; to the Purchaser &#91;***&#93;, together with reasonable supporting documentation thereof and (ii) the Purchaser shall then pay the &#91;***&#93; to the Seller &#91;***&#93; by the Purchaser of such written notice and supporting documentation in &#91;***&#93; by wire transfer to the Seller Account. For the avoidance of doubt, (A) if the events in clauses (a) and (b) of the definition of &#91;***&#93; take place &#91;***&#93;, but the &#91;***&#93;, then such &#91;***&#93; at a later date, but the &#91;***&#93; shall become payable if and only if such &#91;***&#93; is in fact subsequently &#91;***&#93; and (B) if such &#91;***&#93; is not &#91;***&#93; within the &#91;***&#93;, the Purchaser shall have no further liability or obligation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.36pt">If the &#91;***&#93; is achieved &#91;***&#93; and the &#91;***&#93; has not previously been achieved, the Seller shall deliver written notice of such achievement to the Purchaser &#91;***&#93;, together with reasonable supporting evidence thereof, consisting of a public press release &#91;***&#93; with respect to achievement of the &#91;***&#93; or the public &#91;***&#93; reflecting achievement of the &#91;***&#93; on the &#91;***&#93;. The Purchaser shall pay the &#91;***&#93; to the Seller &#91;***&#93; by the Purchaser of such written notice and supporting documentation in &#91;***&#93; by wire transfer to the Seller Account.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.03pt">If the &#91;***&#93; is achieved &#91;***&#93; and the &#91;***&#93; has not previously been achieved, the Seller shall deliver written notice of such achievement to the Purchaser &#91;***&#93;, </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together with reasonable supporting evidence thereof, consisting of a public press release &#91;***&#93; with respect to achievement of the &#91;***&#93; or the public &#91;***&#93; reflecting achievement of the &#91;***&#93; on the &#91;***&#93; at &#91;***&#93;. The Purchaser shall pay the &#91;***&#93; to the Seller &#91;***&#93; receipt by the Purchaser of such written notice and supporting documentation in &#91;***&#93; by wire transfer to the Seller Account.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.69pt">For the avoidance of doubt, the &#91;***&#93; shall be &#91;***&#93;. For example, if the &#91;***&#93;, and &#91;***&#93;, the &#91;***&#93; shall be &#91;***&#93;, in respect of achievement of the &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.02pt">Sales-Based Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Sales-Based Milestone Event is achieved, the Seller shall deliver written notice of such achievement to the Purchaser &#91;***&#93; by &#91;***&#93; of the Royalty Report in respect of the &#91;***&#93; contained in the &#91;***&#93;, together with a certificate, executed by the &#91;***&#93; of the Seller, certifying that the Sales-Based Milestone Event has been achieved and that the Seller has received Royalty Reports from Provention in respect of the &#91;***&#93; contained in the &#91;***&#93; evidencing achievement of the Sales-Based Milestone Event&#59; provided that no such &#91;***&#93; shall be required if the &#91;***&#93; has been &#91;***&#93;, permits the &#91;***&#93; to the Purchaser of at least all Royalty Reports and Audit Reports, and is in effect. The Purchaser shall pay the Sales-Based Milestone Payment to the Seller within &#91;***&#93; receipt by the Purchaser of such written notice and certificate in &#91;***&#93; by wire transfer to the Seller Account.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:64.87pt;padding-right:64.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III</font></div><div style="padding-left:73.87pt;padding-right:73.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as set forth on the Disclosure Schedules, the Seller hereby represents and warrants to the Purchaser as of the date hereof as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existence&#59; Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller is a corporation duly organized, validly existing and in good standing under the Laws of Delaware. The Seller has all requisite corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business as presently conducted. The Seller possesses all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities required to own or lease, as the case may be, and to operate its properties and conduct its business as presently conducted, except where the failure to possess such license, permit, franchise, authorization, consent or approval has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. The Seller is duly qualified as a</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted or property owned or leased by it makes such qualification necessary, other than those in which the failure so to qualify or be in good standing would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The execution, delivery and performance by Seller of the Transaction Documents and the consummation of the transactions contemplated hereby and thereby do not&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:169pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">violate any provision of the certificate of incorporation or bylaws of the</font></div><div style="padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:169pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">violate any provision of any Judgment applicable to the Seller, to which it</font></div><div style="padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is a party, or by which it or any of its properties or assets are bound&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">violate any provision of any Law applicable to the Seller, except for such violations that, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect&#59; nor</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">violate, breach, conflict with, constitute a default (or an event which with notice or lapse of time or both would become a default), or require consent under any </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provision of, or give to any Person any rights of termination, amendment, acceleration or cancellation of (i) the Asset Purchase Agreement or (ii) any other material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Seller is a party, except for such violations, breaches, conflicts or defaults that, individually or in the aggregate and with or without the passage of time, would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authorization&#59; Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has all necessary corporate power and authority to execute, deliver and perform the Transaction Documents and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance of the Transaction Documents, and the consummation of the transactions contemplated hereby and thereby, have been duly authorized by all necessary corporate action and no further consent or authorization of the Seller, its board of directors and its stockholders is required. Each of the Transaction Documents has been duly executed and delivered by the Seller and constitutes the legal, valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms, except as may be limited by general principles of equity (regardless of whether considered in a proceeding at Law or in equity) and by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&#8217; rights generally, general equitable principles and principles of public policy.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has good and valid title to the Purchased Royalty Interest, free and clear of all Liens (other than those contemplated to be granted by the Seller to the Purchaser in respect of the Purchased Royalty Interest pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and is exclusively entitled to the payments that comprise the Purchased Royalty Interest. Upon payment of the Initial Purchase Price by the Purchaser, the Purchaser will have acquired, subject to the terms and conditions set forth in this Agreement, good and valid title to the Purchased Royalty</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interest, free and clear of all Liens (other than those contemplated to be granted by the Seller to the Purchaser in respect of the Purchased Royalty Interest pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). Upon the filing of the financing statement referred to in the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with the Secretary of State of the State of Delaware and to the extent that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance of the Purchased Royalty Interest by the Seller to the Purchaser pursuant to this Agreement is hereafter held not to be a sale, the Purchaser will have a valid and perfected first priority security interest in and to the Purchased Royalty Interest.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.5  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental and Third Party Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The execution, delivery and performance by the Seller of the Transaction Documents, the consummation of any of the transactions contemplated hereby and thereby do not require any consent, waiver, approval, license, order, authorization or declaration from, notice to, action or registration by or filing with any Governmental Authority or any other Person, except for (a) a Current Report on Form 8-K by the Seller with the U.S. Securities and Exchange Commission and (b) the UCC financing statements contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No action, suit, proceeding or investigation before any Governmental Authority, court or arbitrator is pending, or, to the Knowledge of the Seller, threatened, against the Seller (i) by Provention, (ii) challenging the validity or enforceability of the Asset Purchase Agreement, (iii) relating to the Royalty Product, the Royalty Product Patents or the Royalty, or (iv) relating to any other matter that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.7  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Brokers&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There is no investment banker, broker, finder, financial advisor or other Person who has been retained by or is authorized to act on behalf of the Seller who is entitled to any fee or commission from the Purchaser in connection with the transactions contemplated by this Agreement, including any fee or commission payable on the Purchased Royalty Interest.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.8  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller (a) has not violated, is not in violation of, has not been given any notice of Seller&#8217;s violation of, and, to the Knowledge of the Seller, is not under investigation with respect to, nor has it been threatened to be charged with, any violation of, any applicable Law or any Judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority and</font></div><div style="padding-left:60.95pt;padding-right:14.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) is not subject to any Judgment, order, writ, decree, injunction, stipulation or consent order issued or entered by any Governmental Authority&#59; in each case of clauses (a) and (b), that involves the Royalty Product, the Royalty Product Patents or the Royalty.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3pt;padding-left:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The representations and warranties contained in Section 5.7 of the Asset Purchase Agreement were true and correct in all respects as of the date of the Asset Purchase Agreement. Since May 7, 2018, Seller has not received written notice from Provention or any other Person of any, there is no pending or threatened opposition, interference, reexamination, injunction, claim, suit, action, citation, summon, subpoena, hearing, inquiry, investigation (by the International Trade Commission or otherwise), complaint, arbitration, mediation, demand, decreeor other dispute, disagreement, proceeding or claim challenging the validity, enforceability or ownership of any of the Royalty Product Patents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt;text-decoration:underline">Schedule 3.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is a true, correct and complete copy of Exhibit 2 to the Asset Purchase Agreement as of the date of the Asset Purchase Agreement. Since May 7, 2018, the Seller has not received any written notice from Provention or any other Person relating to the lapse, expiration or other termination of any of the Royalty Product Patents, or any written legal opinion that alleges that any of the issued Royalty Product patents are invalid or unenforceable.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">Since May 7, 2018, the Seller has not received from Provention or any Person any written notice of any claim by any Person challenging inventorship or ownership of, the rights of the Seller or Provention, as applicable, in and to, or the patentability, validity or enforceability of, any Royalty Product Patent, or asserting that the development, manufacture, importation, sale, offer for sale or use of the Royalty Product infringes any patent or other intellectual property rights of such Person.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">To the Knowledge of the Seller, there is no pending or threatened action, suit or proceeding that claims that the manufacture, use, marketing, sale, offer for sale, importation or distribution of the Royalty Product does or will infringe on any patent or other intellectual property rights of any other Person or constitute misappropriation of any other Person&#8217;s trade secrets or other intellectual property rights.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">To the Knowledge of the Seller, the discovery and development of the Royalty Product did not and has not infringed, violated or misused any patent or other intellectual property rights owned by any third party. To the Knowledge of the Seller, except as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.9(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Provention has not in-licensed any intellectual property right covering the development, manufacture, use, sale, offer for sale or import of the Royalty Product.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">To the Knowledge of the Seller, the manufacture, use, marketing, sale, offer for sale, importation or distribution of the Royalty Product by Provention does not and will not constitute an infringement of any valid patent or other intellectual property rights of any other Person or constitute misappropriation of any other Person&#8217;s trade secrets or other intellectual property rights.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.08pt">To the Knowledge of the Seller, no third party has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any of the Royalty Product Patents or any other patent right claiming the composition of matter of, or the method of making or using, the Royalty Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Asset Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.7pt">True, Correct and Complete Copy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A true, correct and complete copy of the Asset Purchase Agreement is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.02pt">No Other Agreements&#59; No Amendments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and other than the Asset Purchase Agreement, there is no contract, agreement or other arrangement (whether written or oral) between the Seller, on the one hand, and Provention, on the other hand. Other than the Asset Purchase Agreement, there is no contract, agreement or</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other arrangement (whether written or oral) between the Seller, on the one hand, and a Third Party, on the other hand, that relates to the Royalty Product, the Royalty Product Patents, the Asset Purchase Agreement or the Royalty. The Seller has not granted any written waiver under the Asset Purchase Agreement or released Provention, in whole or in part, from any of its obligations under the Asset Purchase Agreement. The Seller has not received from Provention any written proposal, and has not made any written proposal to Provention, to amend or waive any provision of the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.7pt">No Royalty Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no portion of the Purchased Royalty Interest has been nor, to the Knowledge of the Seller, is subject to any claim against the Seller pursuant to any right of set-off, counterclaim, downward adjustment, credit, reduction or deduction, by contract or otherwise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including pursuant to a Permitted Reduction. No event or condition exists that, upon notice or passage of time or both, would reasonably be expected to permit Provention to make, or have the right to make, a Royalty Reduction, other than a Permitted Reduction, against the Royalty. The representations and warranties of the Seller contained in Section 5.14 of the Asset Purchase Agreement were true and correct as of the date of the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.02pt">Validity and Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Asset Purchase Agreement is in full force and effect and is the legal, valid and binding obligation of the Seller and Provention, enforceable against the Seller and Provention in accordance with its terms, except as may be limited by general principles of equity (regardless of whether considered in a proceeding at Law or in equity) and by applicable bankruptcy, insolvency, moratorium and other similar Laws of general application relating to or affecting creditors&#8217; rights generally. The Seller has not received any written notice challenging the validity or enforceability of, or alleging any dispute with respect to, any provision of the Asset Purchase Agreement, the obligation of Provention to pay the Purchased Royalty Interest thereunder, or the Royalty Product Patents.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.7pt">No Breaches or Defaults. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Seller has not breached, violated or defaulted under, nor is it in breach or violation of or in default under, the Asset Purchase Agreement, and, to the Knowledge of Seller, Provention has not breached, violated or defaulted under, nor is it in breach or violation of or in default under, the Asset Purchase Agreement and there is no event that upon notice or the passage of time, or both, would reasonably be expected to give rise to any breach or default either by the Seller or, to the Knowledge of the Seller, by Provention.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:35.03pt">No Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the Knowledge of the Seller, no event has occurred that would give the Seller or Provention the right to terminate the Asset Purchase Agreement or cease paying the Purchased Royalty Interest. The Seller has not received any written notice of an intention by Provention to terminate, breach or default under the Asset Purchase Agreement, in whole or in part, or challenge the validity or enforceability of the Asset Purchase Agreement or the obligation to pay the Purchased Royalty Interest thereunder, or that the Seller or Provention is in default of its obligations under the Asset Purchase Agreement. The Seller has not delivered </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any written notice of an intention by the Seller to terminate, breach or default under the Asset Purchase Agreement, in whole or in part, or challenge the validity or enforceability of or alleging any dispute with respect to the Asset Purchase Agreement, or that the Seller or Provention is in default of its obligations under the Asset Purchase Agreement. The Seller has no</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intention of terminating the Asset Purchase Agreement and has not given Provention any notice of termination of the Asset Purchase Agreement, in whole or in part.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:15.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.07pt">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the Knowledge of the Seller, there are no licenses or sublicenses entered into by Provention or any other Person under the Royalty Product Patents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.07pt">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not exercised its rights to conduct an audit or any inspection of books or records under Section 3.10 of the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:35.69pt">Payments Made. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.10(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Seller has received the full amount of each payment payable to it under the Asset Purchase Agreement, to the extent such payments have come due.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:35.74pt">No Indemnification Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not notified Provention or any other Person of any claims for indemnification under the Asset Purchase Agreement nor has the Seller received any claims for indemnification under the Asset Purchase Agreement, whether pursuant to Article 9 thereof or otherwise. The Seller is not aware of any event that would give rise to a claim for indemnification under the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33.02pt">No Liens or Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not, except as contemplated hereby, conveyed, assigned or in any other way transferred or granted any Liens (other than Liens for taxes not yet due and payable) upon or with respect to all or any portion of its right, title and interest in and to the Royalty or the Asset Purchase Agreement, nor has the Seller consented to any such assignment, transfer or Lien, and, to the Seller&#8217;s Knowledge, except as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.10(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Provention has not assigned or otherwise transferred or granted any Liens upon or with respect to any of its rights or obligations under the Asset Purchase Agreement or any portion of its right, title and interest in and to the Product Patents or the Royalty Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:35.69pt">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. TZIELD&#8482; (teplizumab-mzwv) is a Product (as defined in the Asset Purchase Agreement).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UCC Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller&#8217;s exact legal name is, and for the ten (10) years immediately preceding the Closing Date has at all times been, &#8220;MacroGenics, Inc.&#8221; The Seller&#8217;s principal place of business is, and for the ten (10) years immediately preceding the Closing Date has at all times been, located in the State of Maryland. The Seller&#8217;s address is 9704 Medical Center Drive, Rockville, Maryland 20850. The Seller&#8217;s jurisdiction of organization is, and for the ten (10) years immediately preceding the Closing Date has at all times been, the State of Delaware.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No deduction or withholding for or on account of any tax has been made from any payment by Provention to the Seller under the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.13  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller is, individually and together with its subsidiaries on a consolidated basis, Solvent.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:56.15pt;padding-right:56.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV</font></div><div style="padding-left:53.9pt;padding-right:53.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE PURCHASER</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Purchaser hereby represents and warrants to the Seller as of the date hereof as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchaser is a limited partnership duly organized, validly existing and in good standing under the Laws of Delaware and has all powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business as presently conducted.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. None of the execution and delivery by the Purchaser of any of the Transaction Documents to which the Purchaser is party, the performance by the Purchaser of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated hereby or thereby will contravene, conflict with, result in a breach, violation, cancellation or termination of, constitute a default (with or without notice or lapse of time, or both) under, require prepayment under, give any Person the right to exercise any remedy or obtain any additional rights under, or accelerate the maturity or performance of or payment under, in any respect, (i) any applicable Law or any Judgment, permit or license of any Governmental Authority to which the Purchaser or any of its assets or properties may be subject or bound, (ii) any term or provision of any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which the Purchaser is a party or by which the Purchaser or any of its assets or properties is bound or committed or (iii) any term or provision of any of the organizational documents of the Purchaser.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authorization&#59; Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchaser has all powers and authority to execute and deliver, and perform its obligations under, the Transaction Documents to which it is party and to consummate the transactions contemplated hereby and thereby. The execution and delivery of each of the Transaction Documents to which the Purchaser is party and the performance by the Purchaser of its obligations hereunder and thereunder have been duly authorized by the Purchaser. Each of the Transaction Documents to which the Purchaser is party has been duly executed and delivered by the Purchaser. Each of the Transaction Documents to which the Purchaser is party constitutes the legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar applicable Laws affecting creditors&#8217; rights generally, general equitable principles and principles of public policy.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.4  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental and Third Party Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The execution and delivery by the Purchaser of the Transaction Documents to which the Purchaser is party, the performance by the Purchaser of its obligations hereunder and thereunder and the consummation of any of the transactions contemplated hereunder and thereunder do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by or filing with any Governmental Authority or any other Person, except as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3pt;padding-left:63pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There is no (a) action, suit, arbitration proceeding, claim, demand, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal) pending or, to the knowledge of the Purchaser, threatened by or against the Purchaser, at Law or in equity, or (b) inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative or informal) by or before a Governmental Authority pending or, to the knowledge of the Purchaser, threatened against the Purchaser, that, in each case, challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents to which the Purchaser is party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Funds Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchaser has sufficient cash on hand to satisfy its obligation to pay the Initial Purchase Price at the Closing and will have sufficient cash on hand to satisfy its obligation to pay each Milestone Payment if and when it becomes due and payable in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchaser acknowledges and agrees that its obligations under this Agreement are not contingent on obtaining financing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:207.75pt;padding-right:207.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COVENANTS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Public Announcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except (a) for a press release previously approved in form and substance by the Seller and the Purchaser or any other public announcement using substantially the same text as such press release and (b) subject to the second sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any disclosure required by applicable Law, by the rules and regulations of any securities exchange or market on which any security of such party hereto may be listed or traded or by any Governmental Authority of competent jurisdiction, neither the Purchaser nor the Seller shall, and each party hereto shall cause its Affiliates not to, without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld, delayed or conditioned), issue any press release or make any other public disclosure with respect to this Agreement or any of the other Transaction Documents or any of the transactions contemplated hereby or thereby. The Purchaser acknowledges that it will be necessary for the Seller to file this Agreement with the SEC and to make other public disclosures regarding the terms of this Agreement in its reports filed with the SEC, and the Seller agrees that it will provide the Purchaser a reasonable opportunity to review and comment on any proposed redactions to the copy of this Agreement to be filed with the SEC, as well as on such other public disclosures made by the Seller relating to the Purchaser or this Agreement or the transactions contemplated thereby (e.g., press releases or Current Report on Form 8-K), which comments the Seller shall consider in good faith, provided that the Seller shall not be required to provide the Purchaser the opportunity to review and comment on (i) any disclosure substantively identical to any disclosure previously reviewed and commented upon by the Purchaser, (ii) any disclosure required by applicable Law or stock exchange rule to the extent solely related to the accounting or tax treatment of the transactions contemplated hereby or (iii) any disclosure to the extent such disclosure is limited to the announcement of the Seller&#8217;s receipt of a Milestone Payment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">Subject to the terms and conditions of this Agreement, each party hereto shall execute and deliver such other documents, certificates, instruments, agreements and other writings, take such other actions and perform such additional acts under applicable Law as may be reasonably requested by the other party hereto and necessary or reasonably desirable to implement expeditiously the transactions contemplated by, and to carry out the purposes and intent of the provisions of, this Agreement and the other Transaction Documents, including to (i) perfect the sale, contribution, assignment, transfer, conveyance and granting of the Purchased</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty Interest to the Purchaser pursuant to this Agreement, (ii) perfect, protect, more fully evidence, vest and maintain in the Purchaser good and valid title in and to the Purchased Royalty Interest free and clear of all Liens (other than those Liens created in favor of the Purchaser by the Transaction Documents) and (iii) create, evidence and perfect the Purchaser&#8217;s back-up security interest granted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">Without limiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for a period of &#91;***&#93; following the date hereof, the Seller shall use its commercially reasonable efforts to obtain from Provention &#91;***&#93;, in a form acceptable to the Purchaser and duly executed by each of the Seller and Provention, pursuant to which Provention (i) &#91;***&#93; providing the Purchaser and any assignee of Purchaser with &#91;***&#93;, and other &#91;***&#93; which would &#91;***&#93; by the Seller to the Purchaser under this Agreement but for the &#91;***&#93; by the Seller to Provention as of the date hereof under the Asset Purchase Agreement and (ii) agrees to &#91;***&#93; under the Asset Purchase Agreement so that &#91;***&#93; unless and until Provention &#91;***&#93; otherwise in writing, and all other payments under the Asset Purchase Agreement are made into an account designated by the Seller, &#91;***&#93;, and acknowledges and agrees that the Initial Provention Instruction &#91;***&#93;. In the exercise by the Seller of such commercially reasonable efforts, the Seller shall act without regard to &#91;***&#93; outside of the Asset Purchase Agreement. Prior to the execution by each of the Seller and Provention &#91;***&#93; is not obtained, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reports&#59; Notices and Correspondence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, promptly (and in any event no later than &#91;***&#93;) following the receipt by the Seller from Provention of (i) a Royalty Report or (ii) any notice, report, or other material written correspondence delivered to the Seller by Provention under the Asset Purchase Agreement that relates to, or involves, directly or indirectly, the Purchased Royalty Interest, Royalty Product, or the Royalty Product Patents, the Seller shall deliver a true, correct and complete copy of the same to the Purchaser, provided that in the case of a Royalty Report, any information included in such Royalty Report related solely to the &#91;***&#93; may be redacted.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">The Seller shall consult with the Purchaser prior to the Seller sending any material written notice or correspondence to Provention that relates to, or involves, directly or indirectly, the Purchased Royalty Interest or would be expected to, directly or indirectly and with or without the passage of time, impact the Purchased Royalty Interest or otherwise have a Material Adverse Effect. The Seller shall not send any such material written notice or correspondence without the prior written consent of the Purchaser (which consent shall not be unreasonably withheld, conditioned or delayed)&#59; provided that such consent shall not be required with respect to any notice or correspondence that relates solely to Provention&#8217;s obligations under any of Section 3.2, Section 3.4, Section 3.5, Section 3.7 (solely as it relates to Section 3.2, Section 3.4 or Section 3.5) or Section 3.8 of the Asset Purchase Agreement (solely as it relates to Section 3.2, Section 3.4 or Section 3.5 of the Asset Purchase Agreement) and that would not otherwise be expected to have a Material Adverse Effect, with or without the passage of time&#59;</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and provided further that if the Seller has sent a request for the Purchaser&#8217;s consent to the Purchaser via FedEx or electronic mail, and delivery of such request has been confirmed (whether by FedEx or electronic mail), and the Purchaser does not respond to such request from the Seller within &#91;***&#93; following such delivery, Purchaser&#8217;s consent to the Seller sending such material written notice or correspondence to Provention shall be deemed to have been given. The Seller shall send to Provention such notices or correspondence related to the Purchased Royalty Interest and&#47;or Provention&#8217;s obligations under Section 7.8 of the Asset Purchase Agreement as the Purchaser shall reasonably request, as long as such notice or correspondence would not reasonably be expected to have an adverse effect in any material respect on the value of the Retained Interest. The Seller shall, promptly (and in any event &#91;***&#93;) following the delivery thereof by the Seller to Provention, furnish a copy of any material written notice or material written correspondence sent by the Seller to Provention relating to, or involving, directly or indirectly, the Purchased Royalty Interest, the Royalty Product, or the Royalty Product Patents, subject in each case to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if and to the extent applicable.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Misdirected Payments&#59; Late Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">Notwithstanding the terms of the Initial Provention Instruction &#91;***&#93;, commencing upon the Closing and at all times thereafter during the term of this Agreement, if any portion of the Purchased Royalty Interest is paid to the Seller, then (i) the Seller shall hold such amount in trust for the benefit of the Purchaser in a segregated account, (ii) the Seller shall have no right, title or interest whatsoever in such amount and shall not create or suffer to exist any Lien thereon and (iii) the Seller promptly, and in any event &#91;***&#93; following the receipt by the Seller of such amount, shall remit such amount in full, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the Purchaser Account. The Seller shall notify the Purchaser of such wire transfer and provide reasonable details regarding the Purchased Royalty Interest payment so received by the Seller.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">Notwithstanding the terms of the Initial Provention Instruction &#91;***&#93;, commencing upon the Closing and at all times thereafter, if any amount due under the Asset Purchase Agreement that does not constitute the Purchased Royalty Interest is paid to the Purchaser, then (i) the Purchaser shall hold such amount in trust for the benefit of the Seller in a </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">segregated account, (ii) the Purchaser shall have no right, title or interest whatsoever in such amount and shall not create or suffer to exist any Lien thereon and (iii) the Purchaser promptly, and in any event &#91;***&#93; following the receipt by the Purchaser of such amount, shall remit such amount in full to the Seller Account. The Purchaser shall notify the Seller of such wire transfer and provide reasonable details regarding the erroneous payment so received by the Purchaser.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">A late fee of &#91;***&#93; published by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from time to time as the prime rate shall accrue on all unpaid amounts on an annualized basis with respect to any sum payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93; after the Seller, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or the Purchaser, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, receives such erroneous payment, or with respect to a Milestone Payment, &#91;***&#93; after the applicable written notice and supporting documentation is received by the Purchaser from the Seller in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Set-Offs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Provention exercises a Non-Permitted Reduction against any payment of the Purchased Royalty Interest, such Non-Permitted Reduction shall not be deemed to reduce any payment of the Purchased Royalty Interest otherwise payable to the Purchaser, and if such Non-Permitted Reduction has the effect of reducing any payment of the Purchased Royalty Interest to less than the full amount of the payment of the Purchased Royalty Interest that would otherwise have been payable to the Purchaser, then the Seller shall promptly (and in any event within thirty (30) calendar days following the payment of the Purchased Royalty Interest affected by such set-off) make a true-up payment to the Purchaser such that the Purchaser receives the full amount of such Purchased Royalty Interest payment that would have been payable to the Purchaser had such Non-Permitted Reduction not occurred. Notwithstanding anything to the contrary herein, to the extent the Seller shall have made a true-up payment to the Purchaser pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in respect of any Non-Permitted Reduction, any subsequent payment received from Provention in respect, and to the extent, of such Non- Permitted Reduction shall not be included in the Purchased Royalty Interest, such that the subsequent payment is included in the Retained Interest. For all purposes hereunder, any true-up payment made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will be treated as paid with respect to the Purchased Royalty Interest for U.S. federal income tax purposes to the fullest extent permitted by applicable Law. For the avoidance of doubt, withholding taxes shall not be treated as a Non-Permitted Reduction and shall be governed by the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of Asset Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">The Seller shall perform and comply with all of its obligations under the Asset Purchase Agreement, and shall not take any action or forego any action that would reasonably be expected to constitute a breach of or default under any provision of the Asset Purchase Agreement or that would reasonably be expected to result in a Material Adverse Effect. The Seller shall not amend, modify, supplement, restate, waive, assign, transfer, delegate, cancel or terminate (or consent to any cancellation, termination, assignment, transfer or delegation of), in whole or in part, any provision of or right under the Asset Purchase Agreement that relates to the Royalty or the Royalty Product (including any consent or agreement by the Seller that the Seller to &#91;***&#93; to be allocated between the Seller and &#91;***&#93;) or that would reasonably be expected to result in a Material Adverse Effect without the prior written consent of the Purchaser, provided that the assignment of the Asset Purchase Agreement in its entirety to any Third Party that acquires all or substantially all of the Seller&#8217;s business, whether by merger, sale of assets or otherwise, shall not require the prior written consent of the Purchaser so long as such assignment of the Asset Purchase Agreement is made together with an assignment of this Agreement permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof. Subject to the foregoing, promptly, and in any event &#91;***&#93;, (i) &#91;***&#93; by the Seller of any proposed amendment, modification, supplement, restatement, waiver, cancellation or termination of the Asset Purchase Agreement to which the &#91;***&#93; pursuant to the foregoing sentence, the Seller shall, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;***&#93; and (ii) following receipt by the Seller of any final amendment, modification, supplement, restatement, waiver, cancellation or termination of the Asset Purchase Agreement, the Seller shall, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;***&#93;.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">The Seller shall not terminate or agree with Provention to terminate, or take any action that would reasonably be expected to give Provention the right to terminate, the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">The Seller shall not, without the prior written consent of the Purchaser, grant or withhold any consent, exercise or waive any right, obligation or option or fail to exercise any right or option in respect of, affecting or relating to the Purchased Royalty Interest.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">&#91;***&#93; from Provention alleging any breach of or default under the Asset Purchase Agreement by the Seller (including any threat of litigation, demand, proceeding, or other action), the Seller shall give written notice thereof to the Purchaser. Such notice shall (i) state that a breach, default or termination event, as applicable, has occurred, (ii) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;***&#93; breach, default or termination event, and (ii) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;***&#93;. The Seller shall use its commercially reasonable efforts to promptly cure any such breach or default by it under the Asset Purchase Agreement, and, in any case, shall give written notice to the Purchaser upon curing such breach or default. The Seller shall consult with the Purchaser as to any action the Seller proposes to take to dispute or cure any alleged breach or default under the Asset Purchase Agreement. In connection with any dispute regarding an alleged breach or default that is related to the Purchased Royalty Interest or would reasonably be expected to have a Material Adverse Effect, the Seller shall employ such counsel, reasonably acceptable to the Seller, as the Purchaser may select. The Seller shall not forgive, release or compromise any amount or waive any obligation of, or grant any consent to, Provention under, in respect of or related to the Purchased Royalty Interest without the prior written consent of the Purchaser.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement of Asset Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">Promptly (but in any event &#91;***&#93;) after the Seller obtains Knowledge of any breach by Provention of &#91;***&#93; the Asset Purchase Agreement or any other breach of or default under the Asset Purchase Agreement by Provention related to the Purchased Royalty Interest, the Royalty Product or the Royalty Product Patents or of the existence of any facts, circumstances or events that, alone or together with other facts, circumstances or events, would reasonably be expected (with or without the giving of notice or passage of time, or both) to give rise to any such breach or default, the Seller shall promptly, but in any event &#91;***&#93; the Seller &#91;***&#93;, give written notice to the Purchaser (i) stating that the relevant breach or default that has occurred and (ii) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;***&#93; the relevant breach or default. In addition, the Seller shall provide to the Purchaser &#91;***&#93; breach or alleged breach of the Asset Purchase Agreement &#91;***&#93; Provention as soon as practicable and in any event &#91;***&#93; following such delivery.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">In the case of any breach by Provention referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Seller shall consult with the Purchaser regarding the timing, manner and conduct of any enforcement of Provention&#8217;s obligations under the Asset Purchase Agreement, shall use commercially reasonable efforts to enforce the Seller&#8217;s rights and remedies (whether under the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asset Purchase Agreement or by operation of Law) and Provention&#8217;s obligations under the Asset Purchase Agreement and shall keep the Purchaser reasonably updated, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as to any material developments relating to any such breach&#59; provided that in the case of any breach by Provention referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> relating solely to the failure to pay any portion of the Purchased Royalty Interest (other than pursuant to a Non-Permitted Reduction in respect of which the Seller has complied with its payment obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or any breach that would reasonably be expected to have a Material Adverse Effect, the Seller shall, at the Purchaser&#8217;s reasonable direction and at the Purchaser&#8217;s expense, (i) use commercially reasonable efforts to promptly and fully enforce the Seller&#8217;s rights and remedies (whether under the Asset Purchase Agreement or by operation of Law) and Provention&#8217;s obligations under Section 3.3 of the Asset Purchase Agreement, including, if reasonably requested by the Purchaser, instituting formal legal proceedings against Provention and (ii) employ such counsel, reasonably acceptable to the Seller, as the Purchaser may select.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">The Purchaser shall reimburse the Seller for &#91;***&#93; reasonable out-of-pocket costs and expenses (including the out-of-pocket fees and expenses of the Seller&#8217;s counsel) incurred by the Seller, as such costs and expenses are incurred, in connection with any actions taken or exercise of rights and remedies by the Seller at the direction of the Purchaser pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">All Proceeds resulting from any enforcement of Provention&#8217;s obligations under the Asset Purchase Agreement shall be applied (i) first to reimburse the Seller for any expenses incurred by it in connection with such enforcement to the extent not previously reimbursed to it by the Purchaser in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (ii) second, if such enforcement was undertaken at the direction of Purchaser pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the Purchaser for any expenses incurred by it in connection with such enforcement. The remainder of such Proceeds that are in respect of the Purchased Royalty Interest shall be allocated to the Purchaser, with any remaining Proceeds allocated to the Seller. The Seller hereby assigns and, if not presently assignable, agrees to assign to the Purchaser the amount of Proceeds due to the Purchaser in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For the avoidance of doubt, if such Proceeds are in respect of an unpaid portion of the Purchased Royalty Interest, and the amount of Proceeds remaining after application of the first sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is less than such unpaid portion of the Purchased Royalty Interest, the Seller shall have no obligation to reimburse or make whole the Purchaser for such differential amount.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">At the direction of the Purchaser, the Seller shall charge interest on any late payment of the Royalty pursuant to Section 3.8 of the Asset Purchase Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Assignment&#59; No Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall not dispose of, assign or otherwise transfer, or grant, incur or suffer to exist any Lien on the Purchased Royalty Interest&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if, notwithstanding the intention of the parties hereto, the transactions contemplated by this Agreement and the other Transaction Documents are determined by a court or tribunal of competent jurisdiction not to constitute a true sale of the Purchased Royalty Interest by the Seller to the Purchaser, then the foregoing provision shall not prohibit the Seller from assigning any rights it has in respect of the Purchased Royalty Interest in connection with a permitted assignment of this Agreement by the Seller in accordance with the provisions of</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to any other Person with which the Seller may merge or consolidate or to which the Seller may sell all or substantially all of its assets.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.9  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If requested in writing by the Purchaser, the Seller shall, to the extent permitted by Section 3.10 of the Asset Purchase Agreement, provide written notice to Provention to cause an inspection or audit in respect of payments of the Royalty under the Asset Purchase Agreement. All of the expenses of any such inspection or audit requested by the Purchaser that would otherwise be borne by the Seller pursuant to the Asset Purchase Agreement shall instead be borne by the Purchaser, including such fees and expenses of any public accounting firm engaged by the Seller in connection with such an inspection or audit, together with the Seller&#8217;s reasonable out-of-pocket costs incurred in connection with such inspection or audit. With respect to any inspection or audit requested by the Purchaser, the Seller shall select such public accounting firm as the Purchaser shall recommend for such purpose. The Seller will, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, furnish to the Purchaser a true, correct and complete copy of any inspection or audit report prepared in connection with such an inspection or audit (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If, following the completion of such inspection or audit, the Seller is required to reimburse Provention for overpayment of the Purchased Royalty Interest, then the Purchaser shall promptly upon request (and in any event &#91;***&#93; such request) reimburse the portion of such overpaid amount that was paid to the Purchaser to the Seller or, at the Seller&#8217;s request, to Provention on behalf of the Seller. If, following the completion of such inspection or audit conducted at the request of the Purchaser, Provention is required to reimburse the Seller for the cost of such audit or inspection as required by Section 2.11 of the Asset Purchase Agreement, then the Seller shall promptly upon receipt of such reimbursement (and in any event &#91;***&#93; such receipt) pay to the Purchaser the full amount of such reimbursement that was paid to the Seller. The Seller shall not initiate any inspection or audit under Section 3.10 of the Asset Purchase Agreement without</font></div><div style="padding-left:60.95pt;padding-right:14.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) consulting with the Purchaser in good faith regarding such inspection or audit and (ii) providing the Purchaser &#91;***&#93; and including in such inspection or audit an audit of Royalty payments, if requested by the Purchaser.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">The Purchaser and the Seller agree that as of the Closing, each of the Initial Purchase Price and each Milestone Payment and any payment made with respect to the Purchased Royalty Interest, assuming the parties deliver the applicable documentation contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, is not subject to deduction or withholding.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">If any applicable Law (as reasonably determined by the Purchaser in consultation with the Seller) requires the deduction or withholding of any tax by the Purchaser from the Purchase Price, the Purchaser shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Law. Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any such withheld or deducted amounts shall be treated for all purposes of the Transaction Documents as having been paid to the Seller.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">Notwithstanding the accounting treatment therefor and unless otherwise required by applicable Law, for all U.S. federal and applicable state and local tax purposes, the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller and the Purchaser shall treat (i) the Purchaser&#8217;s payment of the Initial Purchase Price (pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and the Purchaser&#8217;s payment of each Milestone Payment (pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) as received by the Seller in a taxable transaction and (ii) the Purchaser as the recipient of the payments made with respect to the Purchased Royalty Interest. If there is an inquiry by any Governmental Authority of the Seller or the Purchaser related to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties shall cooperate with each other in responding to such inquiry in a commercially reasonable manner consistent with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">On or prior to the Closing Date, and throughout the term of this Agreement whenever required by Law or requested by the Seller in order for the Seller to have on file an accurate and valid IRS Withholding Form, the Purchaser shall deliver to the Seller a duly completed and valid (i) IRS Form W-9, (ii) IRS Form W-8BEN-E claiming treaty benefits under a double taxation treaty in a manner qualifying for a zero percent (0%) withholding rate with respect to the payments made to the Purchaser under the Transaction Documents or Asset Purchase Agreement, (iii) IRS Form W-8IMY to which a form set forth in the preceding (i) or</font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) is attached, or (iv) other applicable IRS Form W-8 that indicates no withholding is required with respect to the payments made to the Purchaser under the Transaction Documents (or, in each case, any successor or other applicable form prescribed by the U.S. Internal Revenue Service) (in each case ((i) through (iv)), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IRS Withholding Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). On or prior to the Closing Date, and prior to any payment of a Milestone Payment if required by Law or requested by the Purchaser in order for the Purchaser to have on file an accurate and valid IRS Form W-9 prior to the payment of a Milestone Payment, the Seller shall deliver to the Purchaser a duly completed and valid IRS Form W-9.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">All payments to the Purchaser under the Transaction Documents shall be made without any deduction or withholding by the Seller for or on account of any tax, unless required by applicable Law. If any applicable Law (as reasonably determined by the Seller in consultation with the Purchaser) requires the deduction or withholding of any tax by the Seller or Provention (as applicable), then the Seller or Provention (as applicable) shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Law. Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any such withheld or deducted amounts shall be treated for all purposes of the Transaction Documents as having been paid to the Purchaser.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.08pt">Notwithstanding anything in this Agreement to the contrary, if an action (including but not limited to any assignment of rights or obligations under this Agreement or the Asset Purchase Agreement, or any failure to comply with applicable Law or filing or record retention requirements (including a party&#8217;s failure to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.3(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) by a party hereto leads to the imposition of withholding taxes on payments to the other party under the Transaction Documents or the Asset Purchase Agreement that would not have been imposed in the absence of such action or in an increase in such liability above the liability that would have been imposed in the absence of such action (any such action, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the sum payable by the party responsible for such Withholding Action shall be increased to the extent necessary to ensure that the other party receives a sum equal to the sum which it would have received had no such Withholding Action occurred. The Seller shall not agree with Provention to &#91;***&#93; of any taxes or withholding</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requirements to be allocated between the Seller and Provention under Section 3.9 of the Asset Purchase Agreement without the written consent of the Purchaser.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">Notwithstanding anything to the contrary in this Agreement, the party making payment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall use commercially reasonable efforts to give the other party notice and the opportunity, in good faith, to contest and prevent such withholding and deduction contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Payor shall use commercially reasonable efforts to give or cause to be given to the payee such assistance and such information concerning the reasons for withholding or deduction (including, in reasonable detail, the method of calculation for the deduction or withholding thereof) as may be reasonably requested by the payee and at the payee&#8217;s expense to enable the payee to claim exemption therefrom, or credit therefor, or relief (whether at source or by reclaim) therefrom, and, in each case, shall furnish the payee, with proper evidence of the taxes withheld and deducted and remitted to the relevant Governmental Authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Name, Jurisdiction, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Seller shall provide written notice to the Purchaser &#91;***&#93; (a) a change in the Seller&#8217;s legal name or type of organization or (b) a change of the Seller&#8217;s jurisdiction of organization. At the reasonable request of the Purchaser, the Seller shall promptly provide the Purchaser with certified copies of its organizational documents reflecting any of the changes described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provention Directions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. After the Closing, the Seller shall not, without the Purchaser&#8217;s prior written consent, deliver any directions to Provention regarding payment of the Purchased Royalty Interest or revoke, amend, waive or modify the Initial Provention Instruction or, following its execution and delivery, the &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:260.3pt;padding-right:205.1pt;text-indent:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VI </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">THE CLOSING</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The closing of the transactions contemplated hereby (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall take place on the &#91;***&#93; following date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) via the remote exchange of documents and signatures, or at such other time and location as the parties hereto mutually agree.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Initial Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the Closing, the Purchaser shall deliver to the Seller payment of the Initial Purchase Price by wire transfer of immediately available funds to the Seller Account, without any deduction for withholding or other taxes and without any other set-off or deduction of any kind.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">At the Closing, each of the Seller and the Purchaser shall deliver to the other party hereto a duly executed counterpart to the Bill of Sale, evidencing the sale and assignment to the Purchaser of the Purchased Royalty Interest.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">At the Closing, each of the Seller and the Purchaser shall deliver to the other party hereto, and to the Paying Agent, and shall receive from the Paying Agent, a duly executed counterpart to the Paying Agent Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">At the Closing, the Seller shall deliver to the Purchaser a certificate of an executive officer of the Seller, dated as of the Closing Date, certifying as to the (i) accuracy and completeness of attached copies of the organizational documents of the Seller and resolutions of the governing body of the Seller authorizing and approving the execution, delivery and performance by the Seller of the Transaction Documents and the transactions contemplated thereby and (ii) the incumbency of the officer or officers of the Seller who have executed and delivered the Transaction Documents, including therein a signature specimen of each such officer or officers.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">At the Closing, the Purchaser shall deliver to the Seller a certificate of an executive officer of the Purchaser, dated as of the Closing Date, certifying as to the (i) accuracy and completeness of attached copies of the organizational documents of the Purchaser and resolutions of the governing body of the Purchaser authorizing and approving the execution, delivery and performance by the Purchaser of the Transaction Documents to which it is a party and the transactions contemplated thereby and (ii) the incumbency of the officer or officers of the Purchaser who have executed and delivered the Transaction Documents, including therein a signature specimen of each such officer or officers.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">At the Closing, the Seller shall deliver to the Purchaser a duly completed and executed IRS Form W-9.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.03pt">At the Closing, the Purchaser shall deliver to the Seller an IRS Withholding Form.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">Promptly following the Closing, but in any event &#91;***&#93; thereafter, the Seller shall deliver to Provention a duly executed copy of the Initial Provention Instruction and shall provide evidence to Purchaser of such delivery.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">At the Closing, the Seller shall deliver to the Purchaser an electronic copy of the information and documents posted to the virtual data room hosted on behalf of the Seller in connection with the transactions contemplated by this Agreement, to which the Purchaser&#8217;s designees were granted access.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:239.7pt;padding-right:121.75pt;text-indent:14.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VII </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">INDEMNIFICATION</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by the Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller agrees to indemnify and hold harmless the Purchaser and its Affiliates and any or all of their respective partners, directors, officers, managers, employees, agents, successors and direct and indirect owners (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchaser Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against, and will pay to each Purchaser Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Purchaser Indemnified Party, whether or not involving a Third Party Claim, arising out of (a) any breach of any representation or warranty made by the Seller in any of the Transaction Documents, (b) any breach of or default under any covenant or agreement of the Seller in any of the Transaction Documents and (c) all liabilities and obligations of the Seller or any of its Affiliates that are retained by the Seller or any of its Affiliates as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the foregoing shall exclude any indemnification to any Purchaser</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnified Party (i) that results from the bad faith, gross negligence or willful misconduct of any Purchaser Indemnified Party, (ii) that results from the failure of Provention to perform any of its obligations under the Asset Purchase Agreement, unless resulting from the breach or default by the Seller of or under the Asset Purchase Agreement and except to the extent the Seller fails to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in enforcing such obligations of Provention, or (iii) to the extent resulting from acts or omissions of the Seller taken (or omitted to be taken) at the direction of any Purchaser Indemnified Party as set forth in any written instructions from any Purchaser Indemnified Party to the Seller. Any amounts due to any Purchaser Indemnified Party (as determined in accordance with and subject to the limitations, terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article</font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) hereunder shall be payable by the Seller to such Purchaser Indemnified Party &#91;***&#93; following written demand delivered to the Seller by such Purchaser Indemnified Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by the Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchaser agrees to indemnify and hold each of the Seller and its Affiliates and any or all of their respective partners, directors, officers, managers, members, employees, agents, successors and direct and indirect owners (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) harmless from and against, and will pay to each Seller Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Seller Indemnified Party, whether or not involving a Third Party Claim, arising out of (a) any breach of any representation or warranty made by the Purchaser in any of the Transaction Documents and (b) any breach of or default under any covenant or agreement of the Purchaser in any Transaction Document to which the Purchaser is party or in the Existing Confidentiality Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the foregoing shall exclude any indemnification to any Seller Indemnified Party (i) that results from the bad faith, gross negligence or willful misconduct of any Seller Indemnified Party, (ii) to the extent resulting from acts or omissions of the Seller that would entitle any Purchaser Indemnified Party to indemnification under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or (iii) to the extent resulting from acts or omissions of the Purchaser taken (or omitted to be taken) at the direction of any Seller Indemnified Party as set forth in any written instructions from any Seller Indemnified Party to the Purchaser. Any amounts due to any Seller Indemnified Party (as determined in accordance with and subject to the limitations, terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) shall be payable by the Purchaser to such Seller Indemnified Party &#91;***&#93; written demand by such Seller Indemnified Party. </font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Procedures for Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">If any claim or demand made by any Person other than the Purchaser or the Seller or their respective Affiliates against a Purchaser Indemnified Party or a Seller Indemnified Party, as applicable (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the indemnified party shall, promptly after receipt of notice of the commencement of such Third Party Claim, notify the indemnifying party in writing of the commencement thereof, enclosing a copy of all papers served, if any&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the failure to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless, and only to the extent that, the indemnifying party is actually prejudiced by such failure.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">In the event that any Third Party Claim is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the indemnifying party will be entitled, at the indemnifying party&#8217;s sole cost and expense, to participate therein and, to the extent that it may wish, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">In any such Third Party Claim, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the sole cost and expense of such indemnified party unless (a) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (b) the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such indemnified party or (c) the named parties to any such Third Party Claim (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of counsel to the indemnifying party. It is agreed that the indemnifying party shall not, in connection with any Third Party Claim or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such indemnified parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">The indemnifying party shall not be liable for any settlement of any Third Party Claim effected without its written consent, but, if settled with such consent or if there is a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any Loss by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or discharge of any pending or threatened Third Party Claim in respect of which any indemnified party is a party and indemnity could be sought hereunder by such indemnified party, unless such settlement, compromise or discharge, as the case may be, (i) includes an unconditional written release of such indemnified party, in form and substance reasonably satisfactory to the indemnified party, from all liability on claims that are the subject matter of such claim or proceeding, (ii) does not include any statement as to an admission of fault, culpability or failure to act or violation of Law by or on behalf of any indemnified party, and</font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) does not impose any continuing material obligation or restrictions on any indemnified party and provides that monetary damages are the sole relief for such Third Party Claim.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.4  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A claim by an indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for any matter not involving a Third Party Claim and in respect of which such indemnified party would be entitled to indemnification hereunder may be made by delivering, in good faith, a written notice of claim to the indemnifying party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which notice shall contain</font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) a description and the amount or estimated amount of any Losses incurred or suffered or reasonably expected to be incurred or suffered by the indemnified party, if known or reasonably capable of estimation, and the method of computation of such Losses, (b) a statement that the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indemnified party is entitled to indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for such Losses and a reasonable explanation of the basis therefor, and (c) a demand for payment in the amount of such Losses&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the failure to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless, and only to the extent that, the indemnifying party is actually prejudiced by such failure. &#91;***&#93; delivery of a Claim Notice, the indemnifying party shall deliver to the indemnified party a written response in which the indemnifying party shall either (i) agree that the indemnified party is entitled to receive the Claim Amount (in which case such response shall be accompanied by a payment to the indemnified party of the Claim Amount by the indemnifying party by wire transfer of immediately available funds), (ii) agree that the indemnified party is entitled to receive part, but not all, of the Claim Amount (the amount so agreed in (i) or (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreed Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (in which case such response shall be accompanied by a payment to the indemnified party of the Agreed Amount by the indemnifying party by wire transfer of immediately available funds) or</font></div><div style="padding-left:61pt;padding-right:14.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) contest that the indemnified party is entitled to receive any of the Claim Amount. If any such dispute is not resolved &#91;***&#93; the delivery by the indemnifying party of such response, the indemnifying party and the indemnified party shall each have the right to submit such dispute to a court of competent jurisdiction in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the indemnifying party does not notify the indemnified party &#91;***&#93; its receipt of a Claim Notice that the indemnifying party disputes its liability to the indemnified party under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in whole or in part, such claim specified by the indemnified party in such Claim Notice shall be conclusively deemed a liability of the indemnifying party under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the indemnifying party shall pay the amount of such liability to the indemnified party on demand or, in the case of any Claim Notice in which the amount of the claim (or any portion thereof) is estimated, on such later date when the amount of such claim (or such portion thereof) becomes finally determined. For all purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Seller shall be entitled to deliver such Claim Notice to the Purchaser on behalf of the Seller Indemnified Parties, and the Purchaser shall be entitled to deliver such Claim Notice to the Seller on behalf of the Purchaser Indemnified Parties.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">The Seller shall have liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to any breach of any representation or warranty made by the Seller in any of the Transaction Documents &#91;***&#93;, the Purchaser notifies the Seller of a claim in respect of such breach in accordance with &#91;***&#93;, as to which a claim may be made at any time &#91;***&#93; and (B) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as to which a claim may be made at any time &#91;***&#93;.</font></div><div style="margin-top:3pt;padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">The Purchaser shall have liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to any breach of any representation or warranty made by the Purchaser in any of the Transaction Documents, &#91;***&#93;, the Seller notifies the Purchaser of a claim in respect of such breach in accordance with &#91;***&#93;, as to which a claim may be made at any time &#91;***&#93;, and other than &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">No party hereto shall be liable for any consequential (including lost profits), punitive, special, indirect or incidental damages under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in or pursuant to this Agreement. Notwithstanding the foregoing, the Purchaser shall be entitled to make indemnification claims, in accordance with the procedures set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for Losses that include any portion of the Purchased Royalty Interest that the Purchaser was entitled to receive but did not receive timely or at all due to any indemnifiable events under this Agreement, and such portion of the Purchased Royalty Interest shall not be deemed consequential (including lost profits), punitive, special, indirect or incidental damages for any purpose of this Agreement. Notwithstanding the foregoing, other than with respect to any fraud, willful misconduct, or intentional misrepresentation, (i) in no event shall an indemnifying party&#8217;s </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">aggregate liability for Losses under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as the case may be, &#91;***&#93; and (ii) no indemnifying party shall have any liability for Losses under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as the case may be, unless and &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in which event the indemnifying party shall be liable for all Losses including such amount&#59; provided that the foregoing limitations shall not apply to any Losses arising from a failure by the Purchaser to pay any portion of the Purchase Price in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusive Remedy&#59; Set-Offs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">Except in the case of actual fraud and except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the failure by the Purchaser to pay any portion of the Purchase Price, the indemnification afforded by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be the sole and exclusive remedy for any and all Losses awarded against or incurred or suffered by a party in connection with the transactions contemplated by the Transaction Documents, including with respect to any breach of any representation or warranty made by a party in any of the Transaction Documents or any certificate delivered by a party to the other party in writing pursuant to this Agreement or any breach of or default under any covenant or agreement by a party pursuant to any Transaction Document.</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:63pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in this Agreement to the contrary, the parties acknowledge and agree that, in addition to any other right or remedy under this Agreement, the Purchaser shall have the right, but not the obligation, from time to time to set off against a Milestone Payment, to the extent the same becomes owed and has not yet been paid, any indemnification payments to which any Purchaser Indemnified Party is entitled pursuant to, andin accordance with, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement and any Losses in respect of claims for fraud, willful misconduct or intentional misrepresentation in bad faith (it being understood that nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be construed to limit or otherwise impair any right or remedy of any Purchaser Indemnified Party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">In addition, in the event that a court of competent jurisdiction makes a final and unappealable ruling in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Purchaser has breached this Agreement by failing to pay a Milestone Payment when due, the Seller shall have a right to recoup such Milestone Payment not paid by the Purchaser, together with any late fee in respect thereof in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, from the Purchased Royalty Interest. For the avoidance of doubt, this Agreement and the other Transaction Documents (including all agreements, schedules and exhibits hereto and thereto and the documents and instruments referred to herein that are to be delivered at the Closing Date) shall constitute a &#8220;single integrated agreement&#8221; and the transactions contemplated thereby shall constitute a &#8220;single integrated transaction&#8221; in each case for purposes of recoupment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:217.9pt;padding-right:217.9pt;text-align:center;text-indent:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VIII </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CONFIDENTIALITY</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during the term of this Agreement and until the &#91;***&#93; of the date of termination of this Agreement, each party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (i) shall keep confidential, and shall not publish or otherwise disclose to any Person (other than its Affiliates and its and its Affiliates&#8217; Representatives), and shall cause its Affiliates and its and its Affiliates&#8217; Representatives to keep confidential, not publish or otherwise disclose any Confidential Information (as defined below) and (ii) shall not, and shall cause its Affiliates and its and its Affiliates&#8217; Representatives not to, use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), the terms of this Agreement or any information (whether written or oral, or in electronic or other form) furnished to it by or on behalf of the other party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) pursuant to the Existing Confidentiality Agreement (as defined below) or this Agreement including Provention Confidential Information (such information, </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of the Disclosing Party, provided that the terms of this Agreement shall be Confidential Information of both parties and Provention Confidential Information shall at all times be Confidential Information of the Seller), except for that portion of such information that&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.69pt">was known by the Receiving Party prior to disclosure by the Disclosing Party, as evidenced by internal records or documentation of the Receiving Party&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.36pt">is in the public domain or subsequently enters the public domain through no fault of the Receiving Party&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.03pt">is received by the Receiving Party from an independent Third Party with the lawful right to disclose it&#59; or</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.69pt">was independently developed by the Receiving Party (or its Affiliates&#8217;) employees or contractors without the use of or reference to Confidential Information of the Disclosing Party, as evidenced by internal records or documentation of the Receiving Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each party hereby acknowledges that the United States federal and state securities laws prohibit any Person that has material, non-public information about a company from purchasing or selling securities of such a company or from communicating such information to any other Person under circumstances in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Existing Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective upon the date hereof, the Existing Confidentiality Agreement shall terminate and be of no further force or effect, and shall be superseded by the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Without limiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event that the Receiving Party or its Affiliates or any of its or its Affiliates&#8217; employees, officers, directors, representatives or agents (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) are requested by a Governmental Authority or required by applicable Law or legal process (including the regulations of a stock exchange or Governmental Authority or the order or ruling of a court, administrative agency or other government or regulatory body of competent jurisdiction) to disclose any Confidential Information, the Receiving Party shall promptly, to the extent practicable or permitted by Law, notify the Disclosing Party in writing of such request or requirement so that the Disclosing Party may seek (at the Disclosing Party&#8217;s sole expense) an appropriate protective order or other appropriate remedy (and if the Disclosing Party seeks such an order or other remedy, the Receiving Party will provide such cooperation, at the Disclosing Party&#8217;s sole expense, as the Disclosing Party shall reasonably request). If no such protective order or other remedy is sought or obtained and the Receiving Party or its Affiliates or its or its Affiliates&#8217; Representatives are, in the view of their respective counsel (which may include their respective internal counsel), legally required to disclose Confidential Information, the Receiving Party or its Affiliates or its or its Affiliates&#8217; Representatives, as the case may be, shall only disclose that portion of the Confidential Information that their respective counsel advises that the Receiving Party or its Affiliates or its or its Affiliates&#8217; Representatives, as the case may be, are required to disclose and will exercise commercially reasonable efforts, at the Disclosing Party&#8217;s sole expense, to obtain confidential treatment of that portion of the Confidential Information that is being disclosed. In any event, the Receiving Party will not oppose action by the Disclosing Party to obtain an appropriate protective order or confidential treatment of the Confidential Information. Notwithstanding the foregoing, notice to the Disclosing Party shall not be required where disclosure is made (i) in response to a request by a Governmental Authority having competent jurisdiction over the Receiving Party, its Affiliates or its or its Affiliates&#8217; Representatives, as the case may be, or (ii) in connection with a routine examination by a regulatory examiner, where in each case such request or examination does not expressly reference the Disclosing Party, its Affiliates, the Purchased Royalty Interest or this Agreement.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">Each party may disclose Confidential Information to the extent such disclosure is reasonably necessary in the following situations&#58;</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.69pt">in connection with the enforcement of its rights and remedies hereunder or prosecuting or defending any litigation&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:205pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">for regulatory, tax or customs purposes&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.08pt">for audit purposes, provided that each recipient of Confidential Information must be bound by contractual or professional obligations of confidentiality and non- use no less rigorous than those in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> prior to any such disclosure&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.69pt">disclosure to its Affiliates and its and its Affiliates&#8217; Representatives on a need-to-know basis, provided that each recipient of Confidential Information must be bound by contractual or professional obligations of confidentiality and non- use no less rigorous than those in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> prior to any such disclosure&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">disclosure to its actual or potential investors and co-investors, and other sources of financing, including debt financing, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment or financing transaction and that each recipient of Confidential Information must be bound by contractual or professional obligations of confidentiality and non-use no less rigorous than those in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> prior to any such disclosure&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:14.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.69pt">in connection with a merger, acquisition or change of control (including to fulfill due diligence inquiries related to a prospective merger, acquisition or change of control), provided that each recipient of Confidential Information must be bound by contractual or professional obligations of confidentiality and non-use no less rigorous than those in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> prior to any such disclosure&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:205pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#8217;s Confidential Information pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.4(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.4(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> it will comply with the obligations of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent applicable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if any Royalty Report, Audit Report, notice, notice, document, correspondence or other information &#91;***&#93;&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">&#91;***&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">In the case of an Audit Report, &#91;***&#93; (i) whether or not the Seller is required to reimburse Provention for overpayment of the Purchased Royalty Interest, and if so, in what amount, (ii) whether or not Provention is required to reimburse the Seller for underpayment of the Purchased Royalty Interest, and if so, in what amount, and (iii) whether or not Provention was required to reimburse the Seller for the cost of such audit or inspection, and the amount of any reimbursement received by the Seller.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:230.22pt;padding-right:230.22pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IX </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TERMINATION</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall continue in full force and effect until &#91;***&#93; after such time as Provention is no longer obligated to &#91;***&#93;, at which time this Agreement shall automatically terminate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon the termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, this Agreement shall become void and of no further force and effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (a) the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (with respect to portions of the Purchased Royalty Interest payable to the Purchaser pursuant to clause (b) below), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive such termination and shall remain in full force and effect, (b) if, upon the termination of this Agreement, any payments of the Purchased Royalty Interest are payable to the Purchaser hereunder, this Agreement shall remain in full force and effect until any and all such payments have been made in full, and (except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) solely for that purpose, and</font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">termination shall not relieve either Party of liability for any breach of this Agreement that occurs prior to termination.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:265.2pt;padding-right:121.75pt;text-indent:21.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE X </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the parties hereto acknowledges that the other party hereto may have no adequate remedy at Law if any of its obligations are breached, or, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are threatened to be breached. Accordingly, notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each of the parties hereto agrees that, without posting bond or other undertaking, the other party hereto shall be entitled to seek a temporary or permanent injunctive relief to prevent breaches, or, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, threatened breaches, of this Agreement and to seek specific performance of this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at Law or in equity. Such remedy shall not be deemed to be the exclusive remedy for breach of this Agreement but shall be in addition to all other rights and remedies available at Law or equity to the parties hereto.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices, consents, waivers and other communications hereunder shall be in writing and shall be effective (a) upon receipt when sent via certified mail, return receipt requested, postage prepaid, with such receipt to be effective the date of delivery indicated on the return receipt, (b) when sent via email, &#91;***&#93; the sending of such email, (c) upon receipt when sent by a national overnight courier, or (d) on the date personally delivered to an authorized officer of the party to which sent, in all cases of (a),</font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) and (d), with a copy emailed to the recipient at the applicable address, addressed to the recipient as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to the Seller, to&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:96.95pt;padding-right:279.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9704 Medical Center Drive Rockville, MD 20850</font></div><div style="padding-left:96.95pt;padding-right:175.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; President and Chief Executive Officer Attention&#58; Senior Vice President, General Counsel Email&#58; &#91;***&#93;</font></div><div style="padding-left:96.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="margin-top:0.3pt;padding-left:96.95pt;padding-right:205.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">with a copy, which shall not constitute notice, to&#58; Cooley LLP</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.3pt;padding-left:97pt;padding-right:279.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3 Embarcadero Center, 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor San Francisco, CA 94111 Attention&#58; &#91;***&#93; <br>Email&#58; &#91;***&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to the Purchaser, to&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;padding-right:279.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DRI Healthcare Acquisitions LP c&#47;o DRI Capital Inc.</font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">First Canadian Place</font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100 King St. West, Suite 7250</font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">P.O. Box 62</font></div><div style="padding-left:97pt;padding-right:287pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Toronto, ON M5x 1B1 Attention&#58; &#91;***&#93;</font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="margin-top:0.3pt;padding-left:97pt;padding-right:175.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">with a copy, which shall not constitute notice, to&#58; Goodwin Procter LLP</font></div><div style="margin-top:0.3pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100 Northern Avenue</font></div><div style="padding-left:97pt;padding-right:324.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, MA 02210 Attention&#58; &#91;***&#93;</font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each party hereto may, by notice given in accordance herewith to the other party hereto, designate any further or different address to which subsequent notices, consents, waivers and other communications shall be sent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">This Agreement, or any rights or obligations hereunder, may not be assigned by the Seller without the prior written consent of the Purchaser&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Seller may assign this Agreement in its entirety to any Person that acquires all or substantially all of the Seller&#8217;s business, whether by merger, sale of assets or otherwise so long as (i) the Seller promptly notifies the Purchaser of such assignment, (ii) such assignee expressly assumes all obligations of the Seller under the Transaction Documents (with any certifications required by officers of the Seller hereunder replaced by officers of such assignee having similar authority) and (iii) if such assignee is Provention, then Provention expressly agrees to continue performing its obligations set forth in the Asset Purchase Agreement in respect of and relating to the Purchased Royalty Interest as if such assignment had not occurred.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">This Agreement as a whole may not be assigned by the Purchaser without the prior written consent of the Seller&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Purchaser may assign its rights and obligations under this Agreement in its entirety to an Affiliate of the Purchaser or to any Person that acquires all or substantially all the Purchaser&#8217;s assets, whether by merger, sale of assets or otherwise, provided that (a) the Purchaser promptly notifies the Seller of such assignment, (b) such assignee complies with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (replacing &#8220;Purchaser&#8221; wherever it appears with such assignee and replacing &#8220;Closing Date&#8221; with the date of such assignment), and &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">Notwithstanding the foregoing, the Purchaser may assign its rights but not its obligations under this Agreement without the prior written consent of the Seller&#59; provided that</font></div><div style="padding-left:60.95pt;padding-right:14.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) the Purchaser promptly notifies the Seller of such assignment, (b) each such assignee complies with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (replacing &#8220;Purchaser&#8221; wherever it appears with such assignee and replacing &#8220;Closing Date&#8221; with the date that such assignee acquires an interest in the Purchaser&#8217;s rights hereunder), and (c) if the Purchaser assigns its right under this Agreement to more than one party, Provention shall not be requested or instructed to pay the Purchased Royalty Interest to more than one bank account.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.7pt">Any assignee of the rights of the Purchaser to receive Confidential Information of the Seller under this Agreement shall, as a condition to such assignment, agree in writing to be subject to confidentiality and non-use obligations no less rigorous than those set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to such Confidential Information.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:169pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Any purported assignment in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be null</font></div><div style="padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and void.</font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:3pt;padding-left:61pt;padding-right:14.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Nature of Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The relationship between the Seller and the Purchaser is solely that of seller and purchaser, and neither the Seller nor the Purchaser has any fiduciary or other special relationship with the other party hereto or any of its Affiliates. Nothing contained in this Agreement or in any other Transaction Document shall be deemed for any purpose (including tax purposes) to constitute the Seller and the Purchaser as a partnership, agency, an association, a joint venture or any other kind of entity or legal form. If there is an inquiry by any Governmental Authority of the Purchaser or the Seller related to the treatment described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Purchaser and the Seller shall cooperate with each other in responding to such inquiry in a reasonable manner which is consistent with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, together with the Exhibits and Schedules hereto and the other Transaction Documents constitute a complete and exclusive statement of the terms of agreement between the Parties, and supersede all prior agreements, understandings and negotiations, both written and oral, between the Parties (and, for this purpose, DRI Capital Inc.), with respect to the subject matter of this Agreement, including (a) that certain &#91;***&#93; and (b) that certain Mutual Confidential Disclosure Agreement, &#91;***&#93;, between the Seller and DRI Capital Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits or Schedules hereto or the other Transaction Documents) has been made or relied upon by either Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is for the sole benefit of the Seller and the Purchaser and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder&#59; except that the Purchaser Indemnified Parties and Seller Indemnified Parties shall be third party beneficiaries of the benefits provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.15pt;padding-right:1.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law&#59; Jurisdiction&#59; Venue&#59; Consent to Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.07pt">Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the Supreme Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any Judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State court or, to the extent permitted by applicable Law, in such federal court. Each of the parties hereto agrees that a final Judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the Judgment or in any other manner provided by applicable Law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.75pt">Each of the parties hereto hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any court referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.02pt">Each of the parties hereto irrevocably consents to service of process in the manner provided for notices in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable Law. Each of the parties hereto waives personal service of any summons, complaint or other process, which may be made by any other means permitted by New York law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS PURCHASE AND SALE AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS PURCHASE AND SALE AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION 10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If one or more provisions of this Agreement are held to be invalid, illegal or unenforceable by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, which shall remain in full force and effect, and the parties hereto shall replace such invalid, illegal or unenforceable provision with a new provision permitted by applicable Law and having an economic effect as close as possible to the invalid, illegal or unenforceable provision. Any provision of this Agreement held invalid, illegal or unenforceable only in part or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid, illegal or unenforceable.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other party hereto. Any </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61pt;padding-right:14.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">counterpart may be executed by facsimile or Adobe&#8482; Portable Document Format (PDF) sent by electronic mail or any electronic signature complying with the U.S. Federal ESIGN Act of 2000</font></div><div style="margin-top:3pt;padding-left:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will be deemed to be original signatures, will be valid and binding upon the parties, and, upon delivery, will constitute due execution of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments&#59; No Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither this Agreement nor any term or provision hereof may be amended, supplemented, restated, waived, changed or modified except with the written consent of the parties hereto. No failure or delay by either party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. No notice to or demand on either party hereto in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by applicable Law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The remedies herein provided are cumulative and not exclusive of any remedies provided by applicable Law. Without limiting the foregoing, the Seller hereby authorizes the Purchaser, at any time and from time to time, to the fullest extent permitted by applicable Law, to offset any amounts payable by the Purchaser to, or for the account of, the Seller against any obligations of the Seller to the Purchaser arising in connection with the Transaction Documents (including amounts payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) that are then due and payable.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:14.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Table of Contents and Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Table of Contents and headings of the Articles and Sections of this Agreement have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:208.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.072%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></td></tr></table></div></div></div><div id="i52aeb7fb128d497892d38c6b6a2df8a4_13"></div><hr style="page-break-after:always"><div style="min-height:5.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:6pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:17.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the parties hereto have caused this Agreement to be duly executed by its authorized representative as of the day and year first written above.</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:276.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MACROGENICS, INC.</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:295pt;padding-right:50.95pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Scott Koenig, M.D., Ph.D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:295pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:193.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Purchase and Sale Agreement&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i52aeb7fb128d497892d38c6b6a2df8a4_16"></div><hr style="page-break-after:always"><div style="min-height:5.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-left:5pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.45pt;padding-left:61pt;padding-right:17.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the parties hereto have caused this Agreement to be duly executed by its authorized representative as of the day and year first written above.</font></div><div><font><br></font></div><div style="margin-top:9.1pt;padding-left:277pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MACROGENICS, INC.</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:295pt;padding-right:48.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:295pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DRI HEALTHCARE ACQUISITIONS LP</font></div><div><font><br></font></div><div style="padding-left:286pt;padding-right:94.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; DRC Management III LLC 2, Its&#58; General Partner</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Grant Cellier&#160;&#160;&#160;&#160;</font></div><div style="padding-left:321.95pt;padding-right:101.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Grant Cellier Title&#58; Manager</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:196.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Royalty Purchase Agreement&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit31-1q12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i917ea4fc7dba4790a9dd66b349742196_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;9, 2023 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit31-2q12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6cccffbab7a648f7aebaa10c64e2f8e6_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;9, 2023 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit32-1q12023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic9e9fa16281245a8b61ae7db7bad06b7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;March&#160;31, 2023&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="padding-left:22pt;text-indent:-22pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2023 </font></div><div style="padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit32-2q12023.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9d656531aab9434eb56e6a295dcb36a4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;March&#160;31, 2023&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2023 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mgnx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4c965add-b010-4624-ba75-b98f8d64a55e,g:758eb5bc-71ca-48c1-8a86-febd43fa4ed1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://macrogenics.com/role/NatureofOperations">
        <link:definition>0000007 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>0000009 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>0000010 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNet" roleURI="http://macrogenics.com/role/InventoryNet">
        <link:definition>0000011 - Disclosure - Inventory, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangement" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangement">
        <link:definition>0000012 - Disclosure - Royalty Monetization Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>0000013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://macrogenics.com/role/Revenue">
        <link:definition>0000014 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>0000018 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>0000019 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>0000020 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangementTables" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementTables">
        <link:definition>0000021 - Disclosure - Royalty Monetization Arrangement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>0000022 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>0000023 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>0000024 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>0000025 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangementNarrativeDetails" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails">
        <link:definition>0000026 - Disclosure - Royalty Monetization Arrangement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangementRollforwardDetails" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails">
        <link:definition>0000027 - Disclosure - Royalty Monetization Arrangement - Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>0000028 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueIncyteCorporationDetails" roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails">
        <link:definition>0000029 - Disclosure - Revenue- Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueGileadScienceIncDetails" roleURI="http://macrogenics.com/role/RevenueGileadScienceIncDetails">
        <link:definition>0000030 - Disclosure - Revenue- Gilead Science Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueZaiLabDetails" roleURI="http://macrogenics.com/role/RevenueZaiLabDetails">
        <link:definition>0000031 - Disclosure - Revenue - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/RevenueIMabBiopharmaDetails">
        <link:definition>0000032 - Disclosure - Revenue - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNIAIDContractDetails" roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails">
        <link:definition>0000033 - Disclosure - Revenue - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueProventionDetails" roleURI="http://macrogenics.com/role/RevenueProventionDetails">
        <link:definition>0000034 - Disclosure - Revenue- Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>0000035 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>0000036 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>0000037 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>0000038 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentandContingenciesDetails">
        <link:definition>0000039 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_FutureRevenue" abstract="false" name="FutureRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonCashRoyaltyRevenue" abstract="false" name="NonCashRoyaltyRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" abstract="false" name="LiabilityRelatedToFutureRoyaltyTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_MilestonesValueAddedTax" abstract="false" name="MilestonesValueAddedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AdditionalAnnualFixedPayments" abstract="false" name="AdditionalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TransactionCost" abstract="false" name="TransactionCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_InLicensingArrangementLineItems" abstract="true" name="InLicensingArrangementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltyTable" abstract="true" name="LiabilityRelatedToFutureRoyaltyTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_OperatingLeaseNoncashExpense" abstract="false" name="OperatingLeaseNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2022GileadCollaborationAndLicenseAgreementMember" abstract="true" name="A2022GileadCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OneTimeMillstoneCredit" abstract="false" name="OneTimeMillstoneCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationArrangementOneTimeCreditPaidPercent" abstract="false" name="CollaborationArrangementOneTimeCreditPaidPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltyLineItems" abstract="true" name="LiabilityRelatedToFutureRoyaltyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CostOfManufacturingServices" abstract="false" name="CostOfManufacturingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromRoyalityAgreementsMemberMember" abstract="true" name="RevenueFromRoyalityAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_NetProceedsFromSaleOfFutureRoyalties" abstract="false" name="NetProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DeferredTransactionCosts" abstract="false" name="DeferredTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAgreementsMemberMember" abstract="true" name="RevenuesFromCMOAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ReceivableFromCollaborationPartner" abstract="false" name="ReceivableFromCollaborationPartner" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_TotalAnnualFixedPayments" abstract="false" name="TotalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_SynaffixBVMember" abstract="true" name="SynaffixBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyalties" abstract="false" name="LiabilityRelatedToFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAmendmentAgreementMember" abstract="true" name="RevenuesFromCMOAmendmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_InLicensingArrangementTable" abstract="true" name="InLicensingArrangementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_GileadMember" abstract="true" name="GileadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" abstract="false" name="PotentialTargetNominationOptionFeesAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonCashInterestExpenseRecognized" abstract="false" name="NonCashInterestExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" abstract="false" name="LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mgnx_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ContractManufacturingMember" abstract="true" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DRIHealthcareAcquisitionsLPDRIMember" abstract="true" name="DRIHealthcareAcquisitionsLPDRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mgnx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4c965add-b010-4624-ba75-b98f8d64a55e,g:758eb5bc-71ca-48c1-8a86-febd43fa4ed1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1fec086a-d229-4de6-80e0-d0e2b5b75ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e76e319c-848e-4fcf-ac92-20833a3753c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1fec086a-d229-4de6-80e0-d0e2b5b75ded" xlink:to="loc_us-gaap_Liabilities_e76e319c-848e-4fcf-ac92-20833a3753c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9f42c43a-215c-4f05-a831-bab1c5085b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1fec086a-d229-4de6-80e0-d0e2b5b75ded" xlink:to="loc_us-gaap_StockholdersEquity_9f42c43a-215c-4f05-a831-bab1c5085b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_feac0732-0b91-4bba-9a3b-d9bf1bf18853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c38b6fcf-b628-4704-9a33-f4ef75db9be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_feac0732-0b91-4bba-9a3b-d9bf1bf18853" xlink:to="loc_us-gaap_AccountsPayableCurrent_c38b6fcf-b628-4704-9a33-f4ef75db9be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_270a77db-12a4-4459-aed0-d2bf7a1f4239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_feac0732-0b91-4bba-9a3b-d9bf1bf18853" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_270a77db-12a4-4459-aed0-d2bf7a1f4239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f081d65-4797-4694-80f4-a8740425f965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_feac0732-0b91-4bba-9a3b-d9bf1bf18853" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f081d65-4797-4694-80f4-a8740425f965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a99be2bc-f06a-413f-b2e6-6ca19c53d523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_feac0732-0b91-4bba-9a3b-d9bf1bf18853" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a99be2bc-f06a-413f-b2e6-6ca19c53d523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5576535-afec-44fd-933a-d0a1be4d9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fcf07501-20b1-4e13-a8b9-10068d9751bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5576535-afec-44fd-933a-d0a1be4d9d3d" xlink:to="loc_us-gaap_CommonStockValue_fcf07501-20b1-4e13-a8b9-10068d9751bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3fbae7dc-5198-450e-8907-d660b2867e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5576535-afec-44fd-933a-d0a1be4d9d3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3fbae7dc-5198-450e-8907-d660b2867e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0cb1cffb-08e5-455a-ba6c-bc7783c9c1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5576535-afec-44fd-933a-d0a1be4d9d3d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0cb1cffb-08e5-455a-ba6c-bc7783c9c1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5abd9962-8e07-4192-a548-c2b3d597b763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5576535-afec-44fd-933a-d0a1be4d9d3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5abd9962-8e07-4192-a548-c2b3d597b763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_32c923e6-efdb-488d-bcee-9503fc91c55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cf82cdad-2815-4254-9a30-f1505a99a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32c923e6-efdb-488d-bcee-9503fc91c55c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cf82cdad-2815-4254-9a30-f1505a99a14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3fff06bf-1f11-4c55-bc91-6e0c8d2d9784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32c923e6-efdb-488d-bcee-9503fc91c55c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3fff06bf-1f11-4c55-bc91-6e0c8d2d9784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f4349dc9-705a-4c0a-bcae-dda4cc70d2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32c923e6-efdb-488d-bcee-9503fc91c55c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f4349dc9-705a-4c0a-bcae-dda4cc70d2a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5a097516-a49c-406b-9f35-4fc0004437d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_32c923e6-efdb-488d-bcee-9503fc91c55c" xlink:to="loc_us-gaap_AssetsCurrent_5a097516-a49c-406b-9f35-4fc0004437d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cfa7a8bc-5294-4564-95d8-ec7b526409cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_65962ed2-3240-4eb8-b87a-8ed99da29877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfa7a8bc-5294-4564-95d8-ec7b526409cb" xlink:to="loc_us-gaap_LiabilitiesCurrent_65962ed2-3240-4eb8-b87a-8ed99da29877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ec8dfd9a-ddfe-4b20-8b28-8fe1b70f757f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfa7a8bc-5294-4564-95d8-ec7b526409cb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ec8dfd9a-ddfe-4b20-8b28-8fe1b70f757f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_785dbd6b-6448-4208-a85c-2d2e93566499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfa7a8bc-5294-4564-95d8-ec7b526409cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_785dbd6b-6448-4208-a85c-2d2e93566499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_319f6a79-b305-4121-80df-fcc94988b85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfa7a8bc-5294-4564-95d8-ec7b526409cb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_319f6a79-b305-4121-80df-fcc94988b85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties_2df506fe-e90e-4dbb-823b-a3192a83eb2f" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfa7a8bc-5294-4564-95d8-ec7b526409cb" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyalties_2df506fe-e90e-4dbb-823b-a3192a83eb2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_846f0400-c5b8-486b-9a4a-a494c06c3794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_af870747-6f9f-4be1-b3cc-0e3219ff10f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_846f0400-c5b8-486b-9a4a-a494c06c3794" xlink:to="loc_us-gaap_Investments_af870747-6f9f-4be1-b3cc-0e3219ff10f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_66ef49c0-1c81-4938-b974-a82b5d596e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_846f0400-c5b8-486b-9a4a-a494c06c3794" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_66ef49c0-1c81-4938-b974-a82b5d596e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c0d53a39-a0db-4da8-91b0-a20a818477e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_846f0400-c5b8-486b-9a4a-a494c06c3794" xlink:to="loc_us-gaap_InventoryNet_c0d53a39-a0db-4da8-91b0-a20a818477e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c36dd027-a2af-4785-9610-6e83cf1613e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_846f0400-c5b8-486b-9a4a-a494c06c3794" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c36dd027-a2af-4785-9610-6e83cf1613e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54a80af5-97a3-4b66-b651-75f3d2858625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_846f0400-c5b8-486b-9a4a-a494c06c3794" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54a80af5-97a3-4b66-b651-75f3d2858625" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4fd08ef-b22b-48f6-ad3a-872d308c24d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e41bcdb-9dbc-4b09-909c-65e96bd892d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f4fd08ef-b22b-48f6-ad3a-872d308c24d0" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e41bcdb-9dbc-4b09-909c-65e96bd892d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_6c304d74-af5c-412e-ad02-287467caead0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f4fd08ef-b22b-48f6-ad3a-872d308c24d0" xlink:to="loc_us-gaap_OtherNonoperatingExpense_6c304d74-af5c-412e-ad02-287467caead0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_bf4057f4-3a86-48a8-aac7-2eb8aa79cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f4fd08ef-b22b-48f6-ad3a-872d308c24d0" xlink:to="loc_us-gaap_OtherNonoperatingIncome_bf4057f4-3a86-48a8-aac7-2eb8aa79cc55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6e03ef8d-fcc3-4521-baa2-c0da1e9b7f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e04932e7-2dde-42c9-b39e-856f56a0f715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e03ef8d-fcc3-4521-baa2-c0da1e9b7f36" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e04932e7-2dde-42c9-b39e-856f56a0f715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7f9f2907-e140-4bf4-9063-a3b12005e31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e03ef8d-fcc3-4521-baa2-c0da1e9b7f36" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7f9f2907-e140-4bf4-9063-a3b12005e31d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_3b49fe9e-1f5e-493d-b6b4-eb26a5865a11" xlink:href="mgnx-20230331.xsd#mgnx_CostOfManufacturingServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e03ef8d-fcc3-4521-baa2-c0da1e9b7f36" xlink:to="loc_mgnx_CostOfManufacturingServices_3b49fe9e-1f5e-493d-b6b4-eb26a5865a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9744bb94-7280-4f82-b6d9-1fc8a77ce3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e03ef8d-fcc3-4521-baa2-c0da1e9b7f36" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9744bb94-7280-4f82-b6d9-1fc8a77ce3d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e9a5c173-1f24-4810-8438-792823c3ad7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a8d66b26-b282-4a1a-838e-851b65d2b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e9a5c173-1f24-4810-8438-792823c3ad7a" xlink:to="loc_us-gaap_Revenues_a8d66b26-b282-4a1a-838e-851b65d2b85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d8c5b92f-0036-4a5e-9cd8-2e0a254c6881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e9a5c173-1f24-4810-8438-792823c3ad7a" xlink:to="loc_us-gaap_CostsAndExpenses_d8c5b92f-0036-4a5e-9cd8-2e0a254c6881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0783669f-64c2-4025-acf3-8bd158b12648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8dfeab8-e62b-4565-9f45-ceec01c35afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0783669f-64c2-4025-acf3-8bd158b12648" xlink:to="loc_us-gaap_NetIncomeLoss_a8dfeab8-e62b-4565-9f45-ceec01c35afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e230840c-87a5-463d-8f5b-a40b04ba8891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0783669f-64c2-4025-acf3-8bd158b12648" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e230840c-87a5-463d-8f5b-a40b04ba8891" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e71b0428-1ee5-4363-b65c-63135e13dbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_NetIncomeLoss_e71b0428-1ee5-4363-b65c-63135e13dbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e986992f-7d91-4cde-8ef8-fe33098095b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e986992f-7d91-4cde-8ef8-fe33098095b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_665a3c82-21f9-4820-bfa1-63106b1975bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_665a3c82-21f9-4820-bfa1-63106b1975bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9602fecb-c710-4c15-bc48-895910a902c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9602fecb-c710-4c15-bc48-895910a902c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_89390aee-f03e-49c0-9548-611acda51009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_89390aee-f03e-49c0-9548-611acda51009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1735aced-c800-47cd-be40-a47ee522ba8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1735aced-c800-47cd-be40-a47ee522ba8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_98ce5b17-64d3-47cd-969b-c807a3b6efc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_98ce5b17-64d3-47cd-969b-c807a3b6efc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_70f007a4-fc6d-4193-9b5d-fa1ba839640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_70f007a4-fc6d-4193-9b5d-fa1ba839640b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_86a13d7b-1066-4b41-87a7-974deee909df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_86a13d7b-1066-4b41-87a7-974deee909df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d4a526f8-54c9-43ea-9640-970e3f4302d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d4a526f8-54c9-43ea-9640-970e3f4302d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_f1eb17ec-0dab-4c16-a64a-571d44b57713" xlink:href="mgnx-20230331.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_f1eb17ec-0dab-4c16-a64a-571d44b57713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d589cc79-9c94-4b6f-995f-821c83656ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_ShareBasedCompensation_d589cc79-9c94-4b6f-995f-821c83656ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashRoyaltyRevenue_8d47e5bc-4c43-435d-af6e-12b4cba3f6d5" xlink:href="mgnx-20230331.xsd#mgnx_NonCashRoyaltyRevenue"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_mgnx_NonCashRoyaltyRevenue_8d47e5bc-4c43-435d-af6e-12b4cba3f6d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense_51029707-9c7f-4a1d-9a67-35ff675b225a" xlink:href="mgnx-20230331.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_mgnx_OperatingLeaseNoncashExpense_51029707-9c7f-4a1d-9a67-35ff675b225a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_057bf4f3-cf10-471d-91e0-cd7ff84819eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7db2205b-e95b-49d3-a456-5fdc2e69986f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_057bf4f3-cf10-471d-91e0-cd7ff84819eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59e23fd2-89ed-48dd-8548-63666dbb6963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_8f107ec7-b063-47cd-905a-7daa713cac72" xlink:href="mgnx-20230331.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59e23fd2-89ed-48dd-8548-63666dbb6963" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_8f107ec7-b063-47cd-905a-7daa713cac72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ba47db8c-7781-458f-836e-865059466dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59e23fd2-89ed-48dd-8548-63666dbb6963" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ba47db8c-7781-458f-836e-865059466dba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_840da910-4890-4514-99d8-2b2f244b368e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59e23fd2-89ed-48dd-8548-63666dbb6963" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_840da910-4890-4514-99d8-2b2f244b368e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_4a365e11-6dbd-4508-82b8-30a5504b6d6b" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59e23fd2-89ed-48dd-8548-63666dbb6963" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_4a365e11-6dbd-4508-82b8-30a5504b6d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a5a6063a-dfa9-487b-bf03-ce3fd2e42ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a27284f7-83a6-4daf-8a50-986e607145b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a5a6063a-dfa9-487b-bf03-ce3fd2e42ea7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a27284f7-83a6-4daf-8a50-986e607145b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ec2d9130-9a6e-477b-b556-d2dfe085d618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a5a6063a-dfa9-487b-bf03-ce3fd2e42ea7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ec2d9130-9a6e-477b-b556-d2dfe085d618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f85ba2cd-0e0f-4eec-93a7-630e987a9b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a5a6063a-dfa9-487b-bf03-ce3fd2e42ea7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f85ba2cd-0e0f-4eec-93a7-630e987a9b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea47d8df-4a9a-4c10-b923-ac83e88e13e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17a6def4-f560-43a5-8555-ae4b3999f397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea47d8df-4a9a-4c10-b923-ac83e88e13e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17a6def4-f560-43a5-8555-ae4b3999f397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4afd81a-545a-4825-b16e-80ad1402e481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea47d8df-4a9a-4c10-b923-ac83e88e13e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4afd81a-545a-4825-b16e-80ad1402e481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2b06eaa-0c33-4591-be83-2941bc7568ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea47d8df-4a9a-4c10-b923-ac83e88e13e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2b06eaa-0c33-4591-be83-2941bc7568ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9f3edbae-57db-4209-9552-af69482d9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b7d62be-d3ae-4b80-ba37-d1a9058f06b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9f3edbae-57db-4209-9552-af69482d9953" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b7d62be-d3ae-4b80-ba37-d1a9058f06b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71824a9b-a6e4-4827-a823-eb620a6cf572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9f3edbae-57db-4209-9552-af69482d9953" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71824a9b-a6e4-4827-a823-eb620a6cf572" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea7d024d-8f4a-47e3-bc58-ed6f09857995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23908c0a-603b-450a-be37-d09e27190a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea7d024d-8f4a-47e3-bc58-ed6f09857995" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23908c0a-603b-450a-be37-d09e27190a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c32509d6-c18d-43ad-9735-98b312814ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea7d024d-8f4a-47e3-bc58-ed6f09857995" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c32509d6-c18d-43ad-9735-98b312814ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d357e1a5-d21d-4903-8e3d-ecfa8b0d501b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea7d024d-8f4a-47e3-bc58-ed6f09857995" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d357e1a5-d21d-4903-8e3d-ecfa8b0d501b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#InventoryNetDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_21a9351e-c674-409a-843d-9dedf431a2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_7d5e8036-611f-4555-aeb4-f33a82203ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_21a9351e-c674-409a-843d-9dedf431a2b4" xlink:to="loc_us-gaap_InventoryWorkInProcess_7d5e8036-611f-4555-aeb4-f33a82203ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ad4eef60-3055-4803-a6b8-e1b5bc18f955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_21a9351e-c674-409a-843d-9dedf431a2b4" xlink:to="loc_us-gaap_InventoryFinishedGoods_ad4eef60-3055-4803-a6b8-e1b5bc18f955" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mgnx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4c965add-b010-4624-ba75-b98f8d64a55e,g:758eb5bc-71ca-48c1-8a86-febd43fa4ed1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i51830d2705d64af4804073361b076a21_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f3653a0-369d-42ae-9abf-e8fd815c4a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_RevenuesAbstract_3f3653a0-369d-42ae-9abf-e8fd815c4a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_467cae38-9384-4caa-b689-68f3be5d5c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3f3653a0-369d-42ae-9abf-e8fd815c4a79" xlink:to="loc_us-gaap_Revenues_467cae38-9384-4caa-b689-68f3be5d5c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_13596ce9-10cb-4b0c-b919-2b8d2877307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_13596ce9-10cb-4b0c-b919-2b8d2877307a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_d4911c70-1379-4d93-b5f3-c7ef6860c1a2" xlink:href="mgnx-20230331.xsd#mgnx_CostOfManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_mgnx_CostOfManufacturingServices_d4911c70-1379-4d93-b5f3-c7ef6860c1a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_36774ed7-e635-41cc-a044-7143eccde7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_36774ed7-e635-41cc-a044-7143eccde7fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ab764c47-da20-4f27-8edd-1aa5009af0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ab764c47-da20-4f27-8edd-1aa5009af0ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_91d9c058-a62b-4669-b12f-be0f548a4057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_CostsAndExpenses_91d9c058-a62b-4669-b12f-be0f548a4057" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6778411d-d81b-474a-9425-d78a6416f5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_OperatingIncomeLoss_6778411d-d81b-474a-9425-d78a6416f5bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_27b61011-28fe-4771-9dc2-9cd87e4c73dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_OtherNonoperatingIncome_27b61011-28fe-4771-9dc2-9cd87e4c73dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_6359e9fa-211a-494b-a1bb-3f708658f679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_OtherNonoperatingExpense_6359e9fa-211a-494b-a1bb-3f708658f679" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9669dc02-51d4-47f2-b1c3-c3364724b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_NetIncomeLoss_9669dc02-51d4-47f2-b1c3-c3364724b70c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb5cf332-b300-4f4a-958c-0a6217607d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb5cf332-b300-4f4a-958c-0a6217607d3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41bc38b9-4cc5-464e-9596-5f9a4b2bcc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb5cf332-b300-4f4a-958c-0a6217607d3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41bc38b9-4cc5-464e-9596-5f9a4b2bcc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd2df178-0578-44f8-b550-15bd18d2d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd2df178-0578-44f8-b550-15bd18d2d18b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_876d2a23-0742-4fd8-b921-47bb2d597835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_EarningsPerShareBasic_876d2a23-0742-4fd8-b921-47bb2d597835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b89c93c9-bb16-4132-b181-cf78e8ac2701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b89c93c9-bb16-4132-b181-cf78e8ac2701" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74d18b3f-a6c4-4eaa-aee9-61f42978ec42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74d18b3f-a6c4-4eaa-aee9-61f42978ec42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6c92e387-7fad-4da2-9620-74f0ce233b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6c92e387-7fad-4da2-9620-74f0ce233b8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:to="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec5eb785-0e95-492a-9f52-3399214741d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:to="loc_srt_ProductsAndServicesDomain_ec5eb785-0e95-492a-9f52-3399214741d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:to="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c21d7e95-9fac-4632-bd63-253d8f0bc1ed" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c21d7e95-9fac-4632-bd63-253d8f0bc1ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0f973848-6931-4af9-a1db-0aeb29dcf13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_us-gaap_ProductMember_0f973848-6931-4af9-a1db-0aeb29dcf13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_8dda60ab-cb53-4c85-bc30-f52802a898a8" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_8dda60ab-cb53-4c85-bc30-f52802a898a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_3b0bfdcb-5adf-490c-96c4-760353e2bc6b" xlink:href="mgnx-20230331.xsd#mgnx_ContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_ContractManufacturingMember_3b0bfdcb-5adf-490c-96c4-760353e2bc6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_72a02e3e-f56d-4248-89eb-24ddb0f556a6" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromRoyalityAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_72a02e3e-f56d-4248-89eb-24ddb0f556a6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i0639de90ecd64feab55e6fc00fdef36f_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b64c76c5-07b9-409b-a84f-a0aef44844a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b64c76c5-07b9-409b-a84f-a0aef44844a2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8e3536a6-dfad-42ee-89d9-fbd72f658d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_SharesIssued_8e3536a6-dfad-42ee-89d9-fbd72f658d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c63e26a8-8a66-4fc1-bdb5-5f73747bd013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c63e26a8-8a66-4fc1-bdb5-5f73747bd013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6d1ed942-5980-4e39-bb97-0fb5ca861ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6d1ed942-5980-4e39-bb97-0fb5ca861ea9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0949f38e-69da-4ace-b32e-f9b9b3558eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0949f38e-69da-4ace-b32e-f9b9b3558eb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_69d78367-abce-4571-bac2-a8582403f2e3" xlink:href="mgnx-20230331.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_69d78367-abce-4571-bac2-a8582403f2e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_0f23d760-f306-4304-8694-fb290807b898" xlink:href="mgnx-20230331.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_0f23d760-f306-4304-8694-fb290807b898" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3c5cc65-d0ee-4ad7-b893-8f434a6128b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3c5cc65-d0ee-4ad7-b893-8f434a6128b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_68feb96e-7f41-48b2-ad5d-40285fd7f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_68feb96e-7f41-48b2-ad5d-40285fd7f17d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_39fe1c61-b99d-4375-b111-e8dfd249e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_39fe1c61-b99d-4375-b111-e8dfd249e3a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_483e49a8-db66-4dbd-882b-46f348be0382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_NetIncomeLoss_483e49a8-db66-4dbd-882b-46f348be0382" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_bca75c8b-aa1f-4c77-85f1-cc49804486c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87687483-c6e7-4948-badc-36ff9fb830b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b64c76c5-07b9-409b-a84f-a0aef44844a2" xlink:to="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:to="loc_us-gaap_EquityComponentDomain_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:to="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3e3627a0-d435-4dfb-b3a8-2e6a61d841a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_CommonStockMember_3e3627a0-d435-4dfb-b3a8-2e6a61d841a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f2a1e2cb-537e-406c-a3bd-c7f6d4f936ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f2a1e2cb-537e-406c-a3bd-c7f6d4f936ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2cbcf12e-fe18-4a8c-86bb-19243664fb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_RetainedEarningsMember_2cbcf12e-fe18-4a8c-86bb-19243664fb37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_891cc99e-c239-43ca-a5f9-b9e8042fb6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_891cc99e-c239-43ca-a5f9-b9e8042fb6d7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ibac8b88593aa4f44908e3b8fe516b76b_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0970a99f-196c-4f33-bbd5-48006880d916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0970a99f-196c-4f33-bbd5-48006880d916" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7688956-89a0-4a03-adf9-c1120f08aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7688956-89a0-4a03-adf9-c1120f08aa6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6895b6fb-6089-494d-b252-c8aecdc0331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6895b6fb-6089-494d-b252-c8aecdc0331d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e676b9aa-943a-4e3b-81f5-1f8cbdd15634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e676b9aa-943a-4e3b-81f5-1f8cbdd15634" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0970a99f-196c-4f33-bbd5-48006880d916" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ab79f1e-bbe5-4010-8a21-d5987251c91a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ab79f1e-bbe5-4010-8a21-d5987251c91a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_058c0167-18e0-4443-8421-883f0d800a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_058c0167-18e0-4443-8421-883f0d800a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_15aff7e9-32fc-4969-8195-f53871829476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_058c0167-18e0-4443-8421-883f0d800a39" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_15aff7e9-32fc-4969-8195-f53871829476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95883f4c-c9ec-4cd3-8195-1b3044651838_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95883f4c-c9ec-4cd3-8195-1b3044651838_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_06fb3817-1a0e-4b39-be3d-fc34d42c102b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_06fb3817-1a0e-4b39-be3d-fc34d42c102b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b7841112-755d-4750-bace-d70359ab9ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b7841112-755d-4750-bace-d70359ab9ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5ace6139-c59c-4bc0-8ae1-4388a4a88c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5ace6139-c59c-4bc0-8ae1-4388a4a88c1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac34e91b-56ff-42bf-b791-08ee43ccdbeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac34e91b-56ff-42bf-b791-08ee43ccdbeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7ec8bf40-fff3-494f-96ab-f8340ae1270d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7ec8bf40-fff3-494f-96ab-f8340ae1270d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a1d6c6af-d147-4e68-b645-f0de4c4f5c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a1d6c6af-d147-4e68-b645-f0de4c4f5c0c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i40a02d350cd247f59629ad951423dc62_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c6d60d01-cb22-4dba-8f75-6df2af17f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c6d60d01-cb22-4dba-8f75-6df2af17f73f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_260674b7-50f8-40ee-8497-c7afcc4a2b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_260674b7-50f8-40ee-8497-c7afcc4a2b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcc1cde0-e6bd-4359-acf9-0c1d713cbee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcc1cde0-e6bd-4359-acf9-0c1d713cbee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b310526d-ec4f-4751-a7a0-0bd6adce3171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b310526d-ec4f-4751-a7a0-0bd6adce3171" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac181d64-cc31-4966-b26a-7433f7fe64ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac181d64-cc31-4966-b26a-7433f7fe64ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7b5ff7f8-7742-4f6e-989d-705803a689a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7b5ff7f8-7742-4f6e-989d-705803a689a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_46915046-bf1f-45da-8625-fb52e69c13bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_46915046-bf1f-45da-8625-fb52e69c13bd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RoyaltyMonetizationArrangementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails" xlink:type="extended" id="i7fca05a0dca3418398b4914ea51d30d8_RoyaltyMonetizationArrangementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_c98f50b0-11f1-4aa8-b6a8-4c4abdb192c8" xlink:href="mgnx-20230331.xsd#mgnx_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_UpfrontPayment_c98f50b0-11f1-4aa8-b6a8-4c4abdb192c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TransactionCost_d0958443-c232-48b7-a2d9-a96484f53c5e" xlink:href="mgnx-20230331.xsd#mgnx_TransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_TransactionCost_d0958443-c232-48b7-a2d9-a96484f53c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_b5740fd6-4190-473f-8f5b-c1c2a1bf920f" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_b5740fd6-4190-473f-8f5b-c1c2a1bf920f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_d57adc70-8385-4e93-b7c5-f5b51fd20e36" xlink:href="mgnx-20230331.xsd#mgnx_FutureRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_FutureRevenue_d57adc70-8385-4e93-b7c5-f5b51fd20e36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_df470a7e-2e42-4d3d-86af-284198c56e0d" xlink:href="mgnx-20230331.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_df470a7e-2e42-4d3d-86af-284198c56e0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties_1d95e10e-42cb-4af7-838a-2f8b39f3d7ee" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyalties_1d95e10e-42cb-4af7-838a-2f8b39f3d7ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashRoyaltyRevenue_d24c9dc7-a13b-4286-bf08-159dae8b5195" xlink:href="mgnx-20230331.xsd#mgnx_NonCashRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_NonCashRoyaltyRevenue_d24c9dc7-a13b-4286-bf08-159dae8b5195" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:to="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e41321e-7b28-41fe-9716-9b87a2b367a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e41321e-7b28-41fe-9716-9b87a2b367a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ccf327-10ec-4e9d-8f1a-6b04d9cfeb4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ccf327-10ec-4e9d-8f1a-6b04d9cfeb4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_3d33710c-65ef-481b-87ed-de4df280bbca" xlink:href="mgnx-20230331.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ccf327-10ec-4e9d-8f1a-6b04d9cfeb4b" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_3d33710c-65ef-481b-87ed-de4df280bbca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i4384d44f44fd4b4a80678061b52b2c8a_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_61b9e695-7fb9-4a7c-b835-57a03727d86c" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_61b9e695-7fb9-4a7c-b835-57a03727d86c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0d7a05-3f50-4522-8f0b-0dc742d81958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0d7a05-3f50-4522-8f0b-0dc742d81958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_53cf1963-57c5-474b-9219-0a07ccf7de5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_53cf1963-57c5-474b-9219-0a07ccf7de5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c1731a16-25df-4156-8ab7-6243f084d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c1731a16-25df-4156-8ab7-6243f084d0b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c3963d7a-3030-40a5-88a5-fc37b14d3d70" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c3963d7a-3030-40a5-88a5-fc37b14d3d70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2dbe2022-e7cb-43b2-8adf-4bca57cbd40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2dbe2022-e7cb-43b2-8adf-4bca57cbd40e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_abf276a5-703b-40b9-991e-bfc5e136caf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_abf276a5-703b-40b9-991e-bfc5e136caf2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0853bf2b-5c77-48f9-888e-c09a9e34beda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0853bf2b-5c77-48f9-888e-c09a9e34beda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_342b7e93-54d0-4dfc-9490-016a17c9d8d9" xlink:href="mgnx-20230331.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0853bf2b-5c77-48f9-888e-c09a9e34beda" xlink:to="loc_mgnx_AtTheMarketOfferingMember_342b7e93-54d0-4dfc-9490-016a17c9d8d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e672378a-fa15-42f3-a0a8-40e60b93c858_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:to="loc_us-gaap_EquityComponentDomain_e672378a-fa15-42f3-a0a8-40e60b93c858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_41e1de1f-a816-4a14-a7d2-16c93656bf52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:to="loc_us-gaap_EquityComponentDomain_41e1de1f-a816-4a14-a7d2-16c93656bf52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3ddd13fb-cdfd-4c64-9d9d-97dacc2b3261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_41e1de1f-a816-4a14-a7d2-16c93656bf52" xlink:to="loc_us-gaap_CommonStockMember_3ddd13fb-cdfd-4c64-9d9d-97dacc2b3261" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended" id="i1a2f8e1a32834a38b70485aa76fedad3_RevenueIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ef228bb9-5af4-4803-9ad6-0fbfac397d9a" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ef228bb9-5af4-4803-9ad6-0fbfac397d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_bc91b3e8-cc11-4b7b-aaef-5684ad80ba41" xlink:href="mgnx-20230331.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_TotalAnnualFixedPayments_bc91b3e8-cc11-4b7b-aaef-5684ad80ba41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_a7bfbaab-bfd1-4e0c-99cd-dc347a4e73fc" xlink:href="mgnx-20230331.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_a7bfbaab-bfd1-4e0c-99cd-dc347a4e73fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4b679f4e-5de7-4d2d-9b0e-923edcce0a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_Revenues_4b679f4e-5de7-4d2d-9b0e-923edcce0a7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_216a9918-f57a-483a-831a-2545fd19a921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ContractWithCustomerLiability_216a9918-f57a-483a-831a-2545fd19a921" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fcc0f33-b6b8-4a89-b936-3ddac1cf4153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fcc0f33-b6b8-4a89-b936-3ddac1cf4153" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8fd2ffea-9740-4ea6-9796-697f02d1a19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8fd2ffea-9740-4ea6-9796-697f02d1a19e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_3ab07136-cac5-46f2-934a-3452f198c810" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_3ab07136-cac5-46f2-934a-3452f198c810" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f4de0368-c1a5-44a5-9d3f-ae955e6d6ff5" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f4de0368-c1a5-44a5-9d3f-ae955e6d6ff5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_ec313305-b9ef-4786-b4e0-6e58af37c29a" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_ec313305-b9ef-4786-b4e0-6e58af37c29a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_f4fb0114-2f87-49b0-a26e-f7c97981b84a" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_f4fb0114-2f87-49b0-a26e-f7c97981b84a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_8d2a38a3-4f5a-4766-8a10-29f3c3173b6d" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_8d2a38a3-4f5a-4766-8a10-29f3c3173b6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fdf15d9e-7101-4ef0-b760-ca6222abd22b" xlink:href="mgnx-20230331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fdf15d9e-7101-4ef0-b760-ca6222abd22b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_b6a743f2-32e7-4e8e-8cb5-98898f3eea39" xlink:href="mgnx-20230331.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_NumberOfPerformanceObligations_b6a743f2-32e7-4e8e-8cb5-98898f3eea39" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_83522d7a-b9a5-4e12-b0d8-d088ccb3f686_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:to="loc_srt_ProductsAndServicesDomain_83522d7a-b9a5-4e12-b0d8-d088ccb3f686_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:to="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_3a759433-b251-4ba4-ab79-c3fa8d6f93f7" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_3a759433-b251-4ba4-ab79-c3fa8d6f93f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_2b3a8939-2cb2-4ab5-9041-2b078c208699" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_2b3a8939-2cb2-4ab5-9041-2b078c208699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_75d6b9d6-d8b3-49dc-884d-db895d7b4458" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_75d6b9d6-d8b3-49dc-884d-db895d7b4458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c67402df-9a6a-4cac-8562-2cb48cb6ed88_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:to="loc_srt_RangeMember_c67402df-9a6a-4cac-8562-2cb48cb6ed88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:to="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_09d55a2b-43ab-47a6-8920-83a379704cc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:to="loc_srt_MinimumMember_09d55a2b-43ab-47a6-8920-83a379704cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_597bedf0-3107-4659-b46b-31a009aa8548" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:to="loc_srt_MaximumMember_597bedf0-3107-4659-b46b-31a009aa8548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_d9299d90-1c38-4140-b02c-a3067692bff7" xlink:href="mgnx-20230331.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:to="loc_mgnx_IncyteCorporationMember_d9299d90-1c38-4140-b02c-a3067692bff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_80985154-0356-4d09-889f-d049629b3a1c" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:to="loc_mgnx_IMabBiopharmaMember_80985154-0356-4d09-889f-d049629b3a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0c94f2d8-6f7c-4935-af26-11cd559d0a2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0c94f2d8-6f7c-4935-af26-11cd559d0a2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_cc453448-fa91-47be-9a53-4cf7bb915092" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_cc453448-fa91-47be-9a53-4cf7bb915092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_239b9fb7-cc9a-461b-8772-3ed95fabfff1" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_cc453448-fa91-47be-9a53-4cf7bb915092" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_239b9fb7-cc9a-461b-8772-3ed95fabfff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_e86fbf4c-2c20-4aad-968d-2f2883bdf6b3" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_e86fbf4c-2c20-4aad-968d-2f2883bdf6b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_6dfffa43-231a-43c3-9616-d2b31599c206" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_6dfffa43-231a-43c3-9616-d2b31599c206" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadScienceIncDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueGileadScienceIncDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueGileadScienceIncDetails" xlink:type="extended" id="iec088353965147179790d85ee5dfc43f_RevenueGileadScienceIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_9815d97b-04fe-43f2-8fe6-7991422bca98" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_mgnx_NonRefundableUpfrontFees_9815d97b-04fe-43f2-8fe6-7991422bca98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c2bdd1fe-cd4d-4f0e-b41c-0da3502362d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_Revenues_c2bdd1fe-cd4d-4f0e-b41c-0da3502362d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8a98ab01-3cc8-43d6-aedb-9da49cce1fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8a98ab01-3cc8-43d6-aedb-9da49cce1fe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3b2115be-82be-4e17-8365-3219f529ce35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3b2115be-82be-4e17-8365-3219f529ce35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ee5a59d3-6a82-4b5e-8b7d-88dfd91a1daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ee5a59d3-6a82-4b5e-8b7d-88dfd91a1daf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_63b649ed-6b77-4338-b362-e7ec3f5d748e" xlink:href="mgnx-20230331.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_63b649ed-6b77-4338-b362-e7ec3f5d748e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:to="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89815b30-d3b5-4f89-9840-cba89dabe0e7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_89815b30-d3b5-4f89-9840-cba89dabe0e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83e938ab-0077-46c7-a9e4-c4237054f050" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83e938ab-0077-46c7-a9e4-c4237054f050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_c4e31ab8-9fdf-4ff2-86ab-5b682deb5de2" xlink:href="mgnx-20230331.xsd#mgnx_GileadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83e938ab-0077-46c7-a9e4-c4237054f050" xlink:to="loc_mgnx_GileadMember_c4e31ab8-9fdf-4ff2-86ab-5b682deb5de2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35ce9458-72d6-4024-9309-348736f7f69a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35ce9458-72d6-4024-9309-348736f7f69a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b15e1261-4a83-4322-97be-7ae0a14d935b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b15e1261-4a83-4322-97be-7ae0a14d935b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_b8c201c4-386f-434e-b8c1-f79465e7e7bd" xlink:href="mgnx-20230331.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b15e1261-4a83-4322-97be-7ae0a14d935b" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_b8c201c4-386f-434e-b8c1-f79465e7e7bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended" id="i6a22919daf9d4f89a522dc77d3271474_RevenueZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2884a52a-dae7-4475-9586-66ddf2a3f03f" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2884a52a-dae7-4475-9586-66ddf2a3f03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_dfb96ee8-2c23-4aee-baea-7377cd3afc63" xlink:href="mgnx-20230331.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_dfb96ee8-2c23-4aee-baea-7377cd3afc63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_44f91a6c-caf6-432c-aef1-a8d34537e06f" xlink:href="mgnx-20230331.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_44f91a6c-caf6-432c-aef1-a8d34537e06f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7ff5dd6c-8b57-43f3-a8e4-bf64475ed833" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7ff5dd6c-8b57-43f3-a8e4-bf64475ed833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_129488c2-f47c-432e-99be-a7c89aa61b8d" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_129488c2-f47c-432e-99be-a7c89aa61b8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_75f2e9b0-871f-4844-8fa0-39a545011daa" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_75f2e9b0-871f-4844-8fa0-39a545011daa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_56d5ef69-f85c-4666-8f91-7c1d63834ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_56d5ef69-f85c-4666-8f91-7c1d63834ccc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dc7a04b0-053d-4476-aca2-b96c3ed637b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_Revenues_dc7a04b0-053d-4476-aca2-b96c3ed637b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1acd157e-3ff8-42e6-89e7-2bf924f378d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1acd157e-3ff8-42e6-89e7-2bf924f378d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97f6b345-c425-46bb-98b6-ade02aaad5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97f6b345-c425-46bb-98b6-ade02aaad5bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1959e8d3-bcc9-4b9a-ac6f-5db240a37579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1959e8d3-bcc9-4b9a-ac6f-5db240a37579" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_1c110305-41c8-41e7-a590-912f15d036e5" xlink:href="mgnx-20230331.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_1c110305-41c8-41e7-a590-912f15d036e5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_72611354-c2f3-427c-8f87-be31343e7cd7" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_72611354-c2f3-427c-8f87-be31343e7cd7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_4a4dbc1c-b3c3-4898-aa45-e5798833f151" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_4a4dbc1c-b3c3-4898-aa45-e5798833f151" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b876efcb-77ac-43a3-8b30-929107720534" xlink:href="mgnx-20230331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b876efcb-77ac-43a3-8b30-929107720534" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6a1c9cb-dba4-401a-99a9-00b05773ef18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6a1c9cb-dba4-401a-99a9-00b05773ef18" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c629b741-7234-47c8-bd1b-745a7694d442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c629b741-7234-47c8-bd1b-745a7694d442" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonesValueAddedTax_57e0a848-6dd9-4dd7-98b4-e6ac272bb201" xlink:href="mgnx-20230331.xsd#mgnx_MilestonesValueAddedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_MilestonesValueAddedTax_57e0a848-6dd9-4dd7-98b4-e6ac272bb201" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ea60a3cb-3b33-48c7-8708-6bf62d975544_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ea60a3cb-3b33-48c7-8708-6bf62d975544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_636c73a2-adfe-4e52-87cd-8198a0816ae0" xlink:href="mgnx-20230331.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_636c73a2-adfe-4e52-87cd-8198a0816ae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_3657c7fd-f895-4abc-b8f0-70db5e2e63f3" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_3657c7fd-f895-4abc-b8f0-70db5e2e63f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_8ed1d3dc-09a6-4f3c-846d-26abe9943999" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_8ed1d3dc-09a6-4f3c-846d-26abe9943999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_d9b6c247-c2f6-4138-b9c0-9b6a1913968b" xlink:href="mgnx-20230331.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_d9b6c247-c2f6-4138-b9c0-9b6a1913968b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2829dccb-fe0d-493c-b18e-1cd8ecafd32d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2829dccb-fe0d-493c-b18e-1cd8ecafd32d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faffb83e-816b-4491-8d3a-cc436fe16901" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faffb83e-816b-4491-8d3a-cc436fe16901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_b199abe6-1c7d-48c4-b46a-39c1721062b4" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faffb83e-816b-4491-8d3a-cc436fe16901" xlink:to="loc_mgnx_ZaiLabMember_b199abe6-1c7d-48c4-b46a-39c1721062b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd06534f-7b18-4cc0-80bd-59d6e761a23a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:to="loc_srt_RangeMember_fd06534f-7b18-4cc0-80bd-59d6e761a23a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccbe6aa0-b774-4758-bd99-abc421376fd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:to="loc_srt_RangeMember_ccbe6aa0-b774-4758-bd99-abc421376fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10354bd6-24c7-4e03-8674-a244814aa92d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ccbe6aa0-b774-4758-bd99-abc421376fd1" xlink:to="loc_srt_MaximumMember_10354bd6-24c7-4e03-8674-a244814aa92d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d500acef-0cb3-4867-a249-36a03aea9df9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:to="loc_us-gaap_EquityComponentDomain_d500acef-0cb3-4867-a249-36a03aea9df9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a01cebc-e800-4f0b-bb44-dd087d9550ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:to="loc_us-gaap_EquityComponentDomain_0a01cebc-e800-4f0b-bb44-dd087d9550ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1525b986-7a83-4769-b6d8-fa22d66336d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a01cebc-e800-4f0b-bb44-dd087d9550ee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1525b986-7a83-4769-b6d8-fa22d66336d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="extended" id="i6220232299d2403a8365288efea79508_RevenueIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_efcf77f4-fe18-484e-985b-a267b6c68958" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_NonRefundableUpfrontFees_efcf77f4-fe18-484e-985b-a267b6c68958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_28981cfd-895a-41f3-87fa-ce3cba0ae87c" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_28981cfd-895a-41f3-87fa-ce3cba0ae87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_4f5397a6-fec2-4431-88eb-3d27a2c5deeb" xlink:href="mgnx-20230331.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_4f5397a6-fec2-4431-88eb-3d27a2c5deeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_0b1bbdc0-f13b-4103-9549-70b840918ff6" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationArrangementOneTimeCreditPaidPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_0b1bbdc0-f13b-4103-9549-70b840918ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_593cbaa0-e11e-4084-a60e-423247f9a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_Revenues_593cbaa0-e11e-4084-a60e-423247f9a1b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_421ef797-0911-41ac-ac8f-1febbee182c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_421ef797-0911-41ac-ac8f-1febbee182c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_34be527b-7a6c-44a3-bda1-de778c4ec3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_34be527b-7a6c-44a3-bda1-de778c4ec3b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_25edc058-1679-46ae-92e6-56f689bb667d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_25edc058-1679-46ae-92e6-56f689bb667d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_c6ff4ab8-e956-418b-873c-ec87cffab4d2" xlink:href="mgnx-20230331.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_OneTimeMillstoneCredit_c6ff4ab8-e956-418b-873c-ec87cffab4d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62851dcf-310b-4cc6-a70a-f4e52bae2c3c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62851dcf-310b-4cc6-a70a-f4e52bae2c3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_0a940cae-412b-4c23-87b8-4c4bff7d8406" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:to="loc_mgnx_IMabBiopharmaMember_0a940cae-412b-4c23-87b8-4c4bff7d8406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_af6b12ba-6fa9-4289-81d3-50997e19015d" xlink:href="mgnx-20230331.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:to="loc_mgnx_IncyteCorporationMember_af6b12ba-6fa9-4289-81d3-50997e19015d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_baafa86e-6f08-4301-9628-7a5bca8d17fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_baafa86e-6f08-4301-9628-7a5bca8d17fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_b74d6b02-5fec-4399-ad11-955ed230fe15" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_b74d6b02-5fec-4399-ad11-955ed230fe15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e28175cd-df08-4997-8fbf-0af0b3d3d5e8" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e28175cd-df08-4997-8fbf-0af0b3d3d5e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_435b5de1-8527-43a7-82b8-3bfba68af907_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:to="loc_srt_RangeMember_435b5de1-8527-43a7-82b8-3bfba68af907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c098fcee-8036-45c3-90f7-e8d1e8f733e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:to="loc_srt_RangeMember_c098fcee-8036-45c3-90f7-e8d1e8f733e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40f5b0aa-ba06-457f-b6e4-e7ebc7146441" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c098fcee-8036-45c3-90f7-e8d1e8f733e3" xlink:to="loc_srt_MaximumMember_40f5b0aa-ba06-457f-b6e4-e7ebc7146441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73978cff-78da-4965-9cb6-a5356e079dbb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:to="loc_srt_ProductsAndServicesDomain_73978cff-78da-4965-9cb6-a5356e079dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8682c1f-393c-45aa-8f63-2abfae8fc1d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:to="loc_srt_ProductsAndServicesDomain_e8682c1f-393c-45aa-8f63-2abfae8fc1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_530fb683-6558-497f-b4dc-97315201f041" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8682c1f-393c-45aa-8f63-2abfae8fc1d9" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_530fb683-6558-497f-b4dc-97315201f041" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended" id="i9e303c5d1bff498b9f68541355df24a2_RevenueNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_350ed640-bc4e-4408-b5e3-3885568ff623" xlink:href="mgnx-20230331.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_350ed640-bc4e-4408-b5e3-3885568ff623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_6066cb81-91f8-48bd-adc2-a3a26ed4dcc2" xlink:href="mgnx-20230331.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_6066cb81-91f8-48bd-adc2-a3a26ed4dcc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2d4fc1ef-166b-4506-aacd-0f3ca271e79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_us-gaap_Revenues_2d4fc1ef-166b-4506-aacd-0f3ca271e79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fbd6fa59-7570-4b9f-b4d5-09dff66b4622_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:to="loc_srt_ProductsAndServicesDomain_fbd6fa59-7570-4b9f-b4d5-09dff66b4622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05891846-5f73-4d15-bcf2-8aed36696b8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:to="loc_srt_ProductsAndServicesDomain_05891846-5f73-4d15-bcf2-8aed36696b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_f6182bfa-b86c-4776-b2ec-b2f99ac2b81f" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05891846-5f73-4d15-bcf2-8aed36696b8d" xlink:to="loc_mgnx_RevenuesFromGrantsMember_f6182bfa-b86c-4776-b2ec-b2f99ac2b81f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_773cb2c6-92aa-4a75-b85c-d35f3a9b056b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_773cb2c6-92aa-4a75-b85c-d35f3a9b056b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8d9fd817-afc3-4eb9-bc02-f2f8b15f6c97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8d9fd817-afc3-4eb9-bc02-f2f8b15f6c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_a3f623a9-fc3f-4019-8881-114bb4c723f4" xlink:href="mgnx-20230331.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8d9fd817-afc3-4eb9-bc02-f2f8b15f6c97" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_a3f623a9-fc3f-4019-8881-114bb4c723f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e64a884f-e001-4e51-a30d-378495bfc326_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:to="loc_srt_RangeMember_e64a884f-e001-4e51-a30d-378495bfc326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e1d612d-2b9e-4f82-8eb5-70713f7d0b34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:to="loc_srt_RangeMember_9e1d612d-2b9e-4f82-8eb5-70713f7d0b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4ab5988-9316-49e2-a70e-16ae5678b359" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e1d612d-2b9e-4f82-8eb5-70713f7d0b34" xlink:to="loc_srt_MaximumMember_a4ab5988-9316-49e2-a70e-16ae5678b359" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended" id="ie6dffc226b694d0cbef8ffb02d1d6b65_RevenueProventionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_cd955c79-4b87-4c9a-8f6c-264bb3a38c06" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_cd955c79-4b87-4c9a-8f6c-264bb3a38c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e2d79857-21b4-4c68-b1ad-269953c0295d" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e2d79857-21b4-4c68-b1ad-269953c0295d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_1775aa3c-90a4-49a0-8503-28ba417d8bff" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_1775aa3c-90a4-49a0-8503-28ba417d8bff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2a87106c-ba46-4827-92c7-42d9b0540b1d" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2a87106c-ba46-4827-92c7-42d9b0540b1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_71a1fed8-ee67-452b-931e-03fdcc2f6fc0" xlink:href="mgnx-20230331.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_71a1fed8-ee67-452b-931e-03fdcc2f6fc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_4446cab3-57cd-43f4-a219-240b6a4c8211" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_4446cab3-57cd-43f4-a219-240b6a4c8211" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_0aea4502-a2e6-41b7-aa2b-c8c7b0cee3af" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_0aea4502-a2e6-41b7-aa2b-c8c7b0cee3af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_23dea7e2-8219-40a7-8988-525d41e59cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_us-gaap_Revenues_23dea7e2-8219-40a7-8988-525d41e59cef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ReceivableFromCollaborationPartner_e21f3123-081a-44e0-a0c1-0e060a787125" xlink:href="mgnx-20230331.xsd#mgnx_ReceivableFromCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_ReceivableFromCollaborationPartner_e21f3123-081a-44e0-a0c1-0e060a787125" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_355b040b-05b8-49ad-a849-4d498ee0d7d8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_355b040b-05b8-49ad-a849-4d498ee0d7d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cebf688d-aedc-4dc7-9d4a-607397822bcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cebf688d-aedc-4dc7-9d4a-607397822bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_543601e3-bdd7-4c48-9521-c091a2b654de" xlink:href="mgnx-20230331.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cebf688d-aedc-4dc7-9d4a-607397822bcc" xlink:to="loc_mgnx_ProventionBioMember_543601e3-bdd7-4c48-9521-c091a2b654de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7d9e56f3-b034-4c94-a4c4-7bb928f4398e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7d9e56f3-b034-4c94-a4c4-7bb928f4398e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_93dcab1c-f0a0-4835-9462-7d1139bdf76d" xlink:href="mgnx-20230331.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:to="loc_mgnx_ProventionPRV3279Member_93dcab1c-f0a0-4835-9462-7d1139bdf76d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_cb930caf-ff50-4946-90d4-b8c4412d643a" xlink:href="mgnx-20230331.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:to="loc_mgnx_ProventionPRV031Member_cb930caf-ff50-4946-90d4-b8c4412d643a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20843487-02ce-4415-85ba-a9f6f3068546_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20843487-02ce-4415-85ba-a9f6f3068546_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_7c35e561-e411-4034-9752-c7a1ffa28d60" xlink:href="mgnx-20230331.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_7c35e561-e411-4034-9752-c7a1ffa28d60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_a4d4a8bd-f4b9-453a-9803-68791e15287d" xlink:href="mgnx-20230331.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_a4d4a8bd-f4b9-453a-9803-68791e15287d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:to="loc_srt_ProductsAndServicesDomain_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eca0b736-c059-4880-98a4-d4c6e67efd8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:to="loc_srt_ProductsAndServicesDomain_eca0b736-c059-4880-98a4-d4c6e67efd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b843a0a3-c439-4c72-9aff-7468c0ea3cf2" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eca0b736-c059-4880-98a4-d4c6e67efd8c" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b843a0a3-c439-4c72-9aff-7468c0ea3cf2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i6d8b89688ff74331a04600874fbac745_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2dcf2a9e-25eb-45da-af84-a9b4f8daaa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2dcf2a9e-25eb-45da-af84-a9b4f8daaa8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c3fc0404-5139-4f04-b53c-88474dd47424" xlink:href="mgnx-20230331.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c3fc0404-5139-4f04-b53c-88474dd47424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_c6f891bb-988d-44df-98c8-fcf468f15f4d" xlink:href="mgnx-20230331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_c6f891bb-988d-44df-98c8-fcf468f15f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_64cd8d9f-8ad4-44c7-b1ba-4967bb02e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_64cd8d9f-8ad4-44c7-b1ba-4967bb02e99f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13d08054-ffd0-4bf9-903e-2a494aa508c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13d08054-ffd0-4bf9-903e-2a494aa508c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9805314b-44c7-4833-bc4e-e0b4ece11c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9805314b-44c7-4833-bc4e-e0b4ece11c1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea62e7c3-757d-4120-a733-602c8d060617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea62e7c3-757d-4120-a733-602c8d060617" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e18abf57-1421-4ff9-8070-f521af540d3c" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e18abf57-1421-4ff9-8070-f521af540d3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_5e51cea8-973d-482e-ba13-36fc2d68944b" xlink:href="mgnx-20230331.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_5e51cea8-973d-482e-ba13-36fc2d68944b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:to="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc619086-bbac-4bc9-a82b-7928572f207a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:to="loc_us-gaap_PlanNameDomain_cc619086-bbac-4bc9-a82b-7928572f207a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:to="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b7201061-8b9c-427e-bc68-1f8256784203" xlink:href="mgnx-20230331.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b7201061-8b9c-427e-bc68-1f8256784203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_5e53ab7e-d092-4103-817f-f7ef12b3e4d4" xlink:href="mgnx-20230331.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_5e53ab7e-d092-4103-817f-f7ef12b3e4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_3370df9d-ad9d-439a-8a49-c784192a80e0" xlink:href="mgnx-20230331.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:to="loc_mgnx_StockIncentivePlan2013Member_3370df9d-ad9d-439a-8a49-c784192a80e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49432a6-9c82-4df5-bf86-94f54ff46d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c1e059b1-3c31-4527-a190-4bcd774e443e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49432a6-9c82-4df5-bf86-94f54ff46d30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c1e059b1-3c31-4527-a190-4bcd774e443e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49432a6-9c82-4df5-bf86-94f54ff46d30" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dadd7393-ede2-4940-a0fe-516974b9442c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dadd7393-ede2-4940-a0fe-516974b9442c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_40640c88-3bfd-4d66-b0b9-c53b9f51b00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_40640c88-3bfd-4d66-b0b9-c53b9f51b00f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e073900-5838-4a67-8e51-8e2d69a65ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e073900-5838-4a67-8e51-8e2d69a65ae8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i5374f23e9c8949e0abd0772cbadf7f6d_StockBasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8ecc212-3804-48e2-990e-d42a4055605a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8ecc212-3804-48e2-990e-d42a4055605a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b1ecb71-a229-4d85-8031-4dbf6b3aaaab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b1ecb71-a229-4d85-8031-4dbf6b3aaaab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_25b02e83-67a4-42d3-b6fb-3f263767c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_25b02e83-67a4-42d3-b6fb-3f263767c0a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1964792b-67a9-46b9-837a-271c222977ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1964792b-67a9-46b9-837a-271c222977ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:to="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:to="loc_srt_RangeMember_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:to="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d89a807e-4232-4db7-af89-f2770aafa90a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:to="loc_srt_MinimumMember_d89a807e-4232-4db7-af89-f2770aafa90a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_daf39c84-68fa-46bf-8de9-3a40d5d5ec8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:to="loc_srt_MaximumMember_daf39c84-68fa-46bf-8de9-3a40d5d5ec8e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="ifa1d4c732d2d4af39afead67041b4de5_StockbasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd6d3e1-90c9-4dd3-9f99-330d99f0639c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd6d3e1-90c9-4dd3-9f99-330d99f0639c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_13e4a077-05a8-4a45-af57-70c97be93df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_13e4a077-05a8-4a45-af57-70c97be93df2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_ae89e0e2-0521-4e48-8cf8-9268c7b71e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_ae89e0e2-0521-4e48-8cf8-9268c7b71e65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b30579a7-b044-4528-9a87-2e00d24d0b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b30579a7-b044-4528-9a87-2e00d24d0b84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6b26ee09-34eb-4942-90e9-76937d655c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6b26ee09-34eb-4942-90e9-76937d655c62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cb5da82-980e-416a-b5ec-928962b537a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49c545eb-2ebd-4b16-96f7-b3b6b4b0f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49c545eb-2ebd-4b16-96f7-b3b6b4b0f9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_97687d59-93a9-441d-b9dc-98f3d9cd32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_97687d59-93a9-441d-b9dc-98f3d9cd32cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82a6574a-8807-4098-b41c-0ac905fed516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82a6574a-8807-4098-b41c-0ac905fed516" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_103ebeae-0dfd-45ae-beb1-14e1c16249b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d9d7fea-3388-4118-9bba-a2511e3835c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d9d7fea-3388-4118-9bba-a2511e3835c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_a23fa4e7-3d02-43fd-a289-d04d94a59483" xlink:href="mgnx-20230331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_a23fa4e7-3d02-43fd-a289-d04d94a59483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d46d833-9701-4c2c-ba73-478fac1b980d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d46d833-9701-4c2c-ba73-478fac1b980d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f3b1040-fbc2-4198-8b8a-a8eb2bad2d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f3b1040-fbc2-4198-8b8a-a8eb2bad2d3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:to="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dab5bb29-7443-40ab-af4c-c749f15e704f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dab5bb29-7443-40ab-af4c-c749f15e704f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f5f2d9-6720-4625-b9dc-f8ab9608ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f5f2d9-6720-4625-b9dc-f8ab9608ef51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f7522000-d867-4def-8316-fd7a419b2020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f5f2d9-6720-4625-b9dc-f8ab9608ef51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f7522000-d867-4def-8316-fd7a419b2020" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentandContingenciesDetails" xlink:type="extended" id="i3b7849163e304d7d9311acea6f3653b6_CommitmentandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:href="mgnx-20230331.xsd#mgnx_InLicensingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_330c1f37-b087-4c8c-95bf-66b9516b7669" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_330c1f37-b087-4c8c-95bf-66b9516b7669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec5c1eab-34e8-42a0-b26e-44c66f083951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec5c1eab-34e8-42a0-b26e-44c66f083951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:href="mgnx-20230331.xsd#mgnx_InLicensingArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:to="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:to="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bf46298-0d87-4867-9f22-ea152fa3be0f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bf46298-0d87-4867-9f22-ea152fa3be0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f2ff346-5aa3-47d5-af76-4275e7a2a502" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f2ff346-5aa3-47d5-af76-4275e7a2a502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_cfd88241-93e4-4236-90e5-37b416a55cb0" xlink:href="mgnx-20230331.xsd#mgnx_SynaffixBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f2ff346-5aa3-47d5-af76-4275e7a2a502" xlink:to="loc_mgnx_SynaffixBVMember_cfd88241-93e4-4236-90e5-37b416a55cb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mgnx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4c965add-b010-4624-ba75-b98f8d64a55e,g:758eb5bc-71ca-48c1-8a86-febd43fa4ed1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mgnx_FutureRevenue_a19e6f96-ad97-4d2f-a10d-58e2103b1a1a_terseLabel_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Revenue</link:label>
    <link:label id="lab_mgnx_FutureRevenue_label_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Revenue</link:label>
    <link:label id="lab_mgnx_FutureRevenue_documentation_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue" xlink:href="mgnx-20230331.xsd#mgnx_FutureRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FutureRevenue" xlink:to="lab_mgnx_FutureRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_973e56ec-6c50-4031-8990-c9e366845579_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_65a86f7d-f049-4660-b9cc-5dc0fd39c455_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a50dc5b-dc96-409e-aff0-e82b94d0dbde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_bc1720c2-8816-439a-b1d7-faf1df1863c9_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_77b3db2d-b11c-4754-abae-35e566280ba7_terseLabel_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_label_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI) [Member]</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_documentation_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:href="mgnx-20230331.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:to="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_eae936a7-b332-4661-ab82-f9e0036e05cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_fd93ccfe-db47-491d-972d-07eace228ffd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_29d18ef0-8bf2-4c34-91cd-9f4f191d85d0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_49103400-e0b9-4098-a303-df33f3afb378_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_76973a60-0fc2-4667-9d12-a5172b0579e1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_06beba28-0bfa-41f2-9c99-48b7b1f73193_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_03874f7f-877a-4ec5-ad18-b0777619cd31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a5fdc323-8398-474b-839c-cf6e32d2c37e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_1edb0d23-d6f2-401a-8f80-62f607e86359_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f9621b8-fd86-42f7-9cde-765666d4f54b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d882e66-fb59-4cb7-a2c6-eedca7f2ba3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_a28f8469-baa3-4ece-89ee-b7ddf1655d95_terseLabel_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:href="mgnx-20230331.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:to="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_e2e0ca16-7487-4908-abf9-7a8f87085a12_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20230331.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_763884fa-383d-4f3e-a862-444b403dc9cc_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_adb7a18c-e573-4d60-b5f2-ff2735aa9ea5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7de9fb36-5f52-4a76-b4d3-6379a08c9a99_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,838,565 and 61,701,467 shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_b3fe2968-b1bd-4308-b926-1a32c7daf501_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20230331.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_20f78e40-7412-4f9f-81fc-0d05545025fd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_b6ca4085-1d6e-4b4d-96e3-7bc53ca91866_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalty [Line Items]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalty [Line Items]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalty [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2531b295-68e5-4720-a282-eafbc7e3a0a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4eb3a4b4-a798-4b52-a5da-d13c55b97e75_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6556b8eb-6e0d-46d0-b07a-3638ea4483bb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_94111c5d-81a1-4310-8dcb-2146fc7a7e42_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_ca32a306-edf2-44bb-9cc0-ee716f8f0569_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a3aec8a7-479f-492a-ae79-82f2daf70d54_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f171b874-b583-4927-a30a-100c370d3384_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cddeb8a-699f-4056-ad40-e1ddd23cb983_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_6f3e29ab-7e80-4060-824e-b109e2536338_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a424e071-a266-4e58-b126-e088d1b40f7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_316e0091-736d-41ae-a4a4-50c3f07a9a7b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8feb043a-94e2-4e23-95fb-92f45aff7352_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_404b9f2e-888e-4ad8-aef6-7488f3aa2990_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8bc1c89d-409e-4101-97f8-6285c7dc99eb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ada17a61-f783-4e28-a53b-4356a011bc08_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3c9b8603-53e2-4d78-b313-6a1fa64b28d6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b5cc5e83-0cec-40f9-ab37-561ba80b5fc9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2bbbfc5c-087d-42ae-b93e-24bfb6e109c2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software included in accounts payable or accruals</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4ceeb0ef-d252-4d82-b647-54842fea54da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonCashRoyaltyRevenue_1e8ac402-2005-4c8c-a50e-a8a7dee3e27b_negatedTerseLabel_en-US" xlink:label="lab_mgnx_NonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_mgnx_NonCashRoyaltyRevenue_label_en-US" xlink:label="lab_mgnx_NonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Royalty Revenue</link:label>
    <link:label id="lab_mgnx_NonCashRoyaltyRevenue_documentation_en-US" xlink:label="lab_mgnx_NonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Royalty Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashRoyaltyRevenue" xlink:href="mgnx-20230331.xsd#mgnx_NonCashRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonCashRoyaltyRevenue" xlink:to="lab_mgnx_NonCashRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyalties_623f8ed3-8251-46a6-bd42-d47355aafbd6_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties [Abstract]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyalties_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyalties" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6be43b7-95cc-49f7-ad4e-3791ee1cf7e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bc6c6241-2148-4520-8acb-34581d9ddf02_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ffb02d9d-d14d-4d4c-a2f5-610211253876_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4d1e618-cac9-4adf-a80d-a2df1ef7e667_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_6846a3ba-9a9e-49c5-9b88-ed226b30743f_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_17a77f94-461b-46ec-a959-a6f938ba395a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_fd047799-d374-44d4-924b-a8e460954e16_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5b56be74-4e5e-4c0d-800c-f55107395ef9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember_afd6a475-84ad-44ef-8545-da45e2cff004_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromRoyalityAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromRoyalityAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromRoyalityAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromRoyalityAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:to="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_fbb129db-d42a-42db-be1a-604e4954d30e_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:to="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_799013bb-f1d9-4e3e-ad98-a24b7da1b923_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df53252c-8c2d-43b2-a3ef-f1a93de87a9d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_58295b08-408c-41c2-90f9-bfc5427393ad_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f64636af-76ea-4cde-b2ed-2612bf75ee40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4b7ab441-933e-419e-8f64-3d7fd1a72dfd_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c7a6cfc-e0b8-4e0f-8e9f-a8e947327329_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f30d95f9-d1ec-4eb4-b98a-dd893287ea34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aba74e65-721f-45cb-b55b-0c92ccf7d091_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_a3852f51-66b4-405c-ade8-79c1291423d0_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5ba33840-a15f-497f-82d0-8f519b165f82_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dee4bb36-2abc-4794-9054-fc6e1b9a9db1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0aa74153-b889-4591-bfae-1cfe2e357e5c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6426e1f9-4a7f-410c-8986-330d886d5bfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MilestonesValueAddedTax_7f0cc589-6335-4d98-bdbf-f448d3b006a5_terseLabel_en-US" xlink:label="lab_mgnx_MilestonesValueAddedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Value Added Tax</link:label>
    <link:label id="lab_mgnx_MilestonesValueAddedTax_label_en-US" xlink:label="lab_mgnx_MilestonesValueAddedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Value Added Tax</link:label>
    <link:label id="lab_mgnx_MilestonesValueAddedTax_documentation_en-US" xlink:label="lab_mgnx_MilestonesValueAddedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Value Added Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonesValueAddedTax" xlink:href="mgnx-20230331.xsd#mgnx_MilestonesValueAddedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MilestonesValueAddedTax" xlink:to="lab_mgnx_MilestonesValueAddedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_798612a2-4dad-45fe-90d3-24964a8b308d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cc384a44-7a78-4402-8078-a55a737b8227_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_de29f306-8012-4179-93f1-cba21b0c49dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_853f9cc5-5e4c-4ca4-97db-b5b9be860b4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2868a4be-6d0a-46db-9e1f-7dabcce1c711_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17b92d1e-d56a-4961-9df0-0f77c8edfd0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12093c00-60e7-4267-8e51-405a8340844c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d031dd6b-d6ba-4ca2-8301-cd9251e6f90e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_35918612-f887-4f98-b384-8e2da3b68796_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_4f4f1c31-3a53-4534-9f45-ca737bf3881e_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20230331.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a75e2177-f9d5-4b28-a79b-de210a633afe_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_03a6a4b9-f6c4-490d-84ff-b21a9e5a14d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_2ca32673-bffd-4136-ac52-1d2ecad9ca77_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f86de6e-1bf9-4290-b030-6939c50906df_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6d65e351-e23f-411a-b436-bc180e882eec_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6a10eaa0-14f0-4945-b37c-c53f306f6f72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1011440f-a031-4010-a578-f6f209ee63ce_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a78fb329-20b4-4aa7-a41d-0481020eade1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7067767b-c45b-4375-ad3e-51000f3987b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_06be16dd-0449-48fe-93fc-9d5a7537c1f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2684ffb7-c2a3-42da-ba68-f24c7c4ec3bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_36d6c112-897e-4a86-8867-11804c27a2d7_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_4be7c9fa-9d6d-4390-a016-929d47e4b51c_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_478a82be-f72c-4f8b-9fbd-7d0f3a9e8a13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3186572c-209d-4361-8f97-172c300b1d31_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_0ba9ced4-8abd-434d-83da-fcbd1a334e5a_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_694d59cd-1db1-4c8f-90fb-87488257450a_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_04218bfd-d752-4d2f-9c7d-9df8f7a6b3de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_06b50463-8ca0-4314-bd8d-9bb40c512505_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5847ce5a-5b6f-4b85-8033-57d843f4634f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f3a50c9f-dfc3-4a2c-aa35-d400e4e7b45b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d946f02f-b83d-451c-8232-52df1f4e085a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_0a6dedfc-9e25-40e6-a4f8-7b2446993cd0_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20230331.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5eaca388-21c4-4885-9d7f-1102aadfbe8c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b392ea5b-67d8-4a61-89b4-85f13679c319_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94357c69-22d9-475d-a02b-1246ec6168bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1aa8b854-dbcf-4234-8a45-66001841e7a9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0cc7e91-009a-4914-ba4d-b630a67a0857_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f3f0af51-bcef-4923-9611-fe14d68ce0db_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_42a3fcd7-c14b-49b0-ac9b-93004a1d836d_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_06bc3264-a9c3-46d9-acab-e317747ae2a6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e365ec05-3b51-460d-9ea9-17d904ffee65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ContractManufacturingMember_7d09b444-09e4-4df6-aa76-141f73855b05_terseLabel_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_label_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_documentation_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember" xlink:href="mgnx-20230331.xsd#mgnx_ContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ContractManufacturingMember" xlink:to="lab_mgnx_ContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd9a5abc-4c1c-4c12-bfb6-9e7fcd4d398f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_f0498869-ea49-402b-8ee8-19c077115472_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_e63c9543-5cd2-4435-926f-63f3ea2bf3cc_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20230331.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_67ab8521-a1ce-4b76-9922-9c384eafd8a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a736cbbc-e816-486f-a4d0-a67353db573d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_1466d136-341f-4d33-b0e8-de5011db1a29_terseLabel_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Gilead Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_e37eb73b-cabb-4687-919a-6aa62547cc48_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b36d20b5-43bb-48a5-a698-2812bdb335a0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cc74e64f-4cf7-4a83-b6e0-c2471f0af87e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b97b6ed2-1a4a-4bae-adf5-94df3219f826_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4f8f9c0c-b7e6-4a72-a59b-5e3cf26bc3d9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_90c6ea8f-ff12-47e2-a135-7977a562a340_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3a6f7b34-4668-47ce-ab30-a40aa492b9d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_90e02e51-6b2d-4452-ad7a-8985ba31461b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_10728ee2-ef99-4c2c-9609-593f70ec9426_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ReceivableFromCollaborationPartner_56e828bb-6d0e-48de-ad99-80481b61b130_terseLabel_en-US" xlink:label="lab_mgnx_ReceivableFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partner</link:label>
    <link:label id="lab_mgnx_ReceivableFromCollaborationPartner_label_en-US" xlink:label="lab_mgnx_ReceivableFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partner</link:label>
    <link:label id="lab_mgnx_ReceivableFromCollaborationPartner_documentation_en-US" xlink:label="lab_mgnx_ReceivableFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ReceivableFromCollaborationPartner" xlink:href="mgnx-20230331.xsd#mgnx_ReceivableFromCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ReceivableFromCollaborationPartner" xlink:to="lab_mgnx_ReceivableFromCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_596aa38c-0065-4928-a0be-8d04a786c79d_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20230331.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_010457b9-f6af-45ac-b6ba-0c087116e001_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20230331.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_0cbdc16d-1ec0-4a4d-b85a-6f3d15f272a9_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties and related interest expense</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties and related interest expense [Policy Text Block]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties and related interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ca38b06a-4cba-4bed-921f-6a92df0ec8e2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a4ccea06-ef56-4b93-8553-d88db21cf61b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04a18b63-950b-4b71-ba0c-4dba44dfb063_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_79dd8d00-5b3d-4ba5-8e5f-0be11e839270_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_93556532-ac80-42c3-9d3c-aa1b86fa5ece_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9f492fd0-a419-4650-9bbc-e77f0a3fd803_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9b9f44b7-aafb-46d3-8dd1-6bda1f0d364f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db33522e-6500-4652-af3e-6cf9f0937ffa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_02743e95-9b33-4ec2-a99a-6048091f23c6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GileadMember_96610dbe-34ed-43ec-af16-bcc512badad8_terseLabel_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead</link:label>
    <link:label id="lab_mgnx_GileadMember_label_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead [Member]</link:label>
    <link:label id="lab_mgnx_GileadMember_documentation_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember" xlink:href="mgnx-20230331.xsd#mgnx_GileadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadMember" xlink:to="lab_mgnx_GileadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_00f947a3-c44f-4b1c-b0cb-781bf0531c97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_929d38fb-d8f4-47b0-8f6c-8f6cc76e696f_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:to="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_291412b4-97df-45c9-8612-35d5f9730b07_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0238f3ce-59bd-42b8-9eca-11b19977d2a4_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20230331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_52abc971-f48b-4581-89ac-6dfb4b3b3f6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_b7a98049-3249-48ad-ad40-1ed43f0be29a_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20230331.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b9d94ec0-a392-4080-ad22-d6d62bb8a40c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_edac5db9-cf82-4e29-93db-b451c3f692db_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_11614358-aeb7-48fb-a7fa-23a26987bc98_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_160f776f-0ebb-413e-8316-2d1383f35827_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and other agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e5438f93-1481-40a3-a9ad-4ef1c8b4aefb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_822f8762-9932-4663-b185-7cc081e1932c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_60be16e6-eb47-4980-ae1e-3b703dcb5f6c_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c165f7fd-26f0-470e-ab17-9099e27d2309_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_e4ee8a2e-b61d-43e7-8f72-a87ed696fc74_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20230331.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_fbc102d8-7d6c-497c-9bfd-5363178de346_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Future Royalty</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Future Royalty [Table Text Block]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Future Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e5d911b2-abbb-42a8-aae9-4482f2b1cd2e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ba3c3ad2-5171-4ab9-bb81-ce799f080e09_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CostOfManufacturingServices_f8f40a01-88db-4916-9cf5-bc13184d5b48_terseLabel_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_label_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_documentation_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices" xlink:href="mgnx-20230331.xsd#mgnx_CostOfManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CostOfManufacturingServices" xlink:to="lab_mgnx_CostOfManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3799d717-00f2-4717-b6c5-945a4ea6fc92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_d54dc883-ba3d-4dda-bc19-f0fa1e11e4a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cc744763-8efd-475c-a6d7-2ae19bde3982_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_97a9fcb9-a171-4e0d-95a2-6bba8bace239_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_1bc737eb-3969-4054-8188-b4ceb9930435_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b12ea394-c2ce-4021-877c-3221b0a496b7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_d4ea8084-07c1-4534-bdd8-30d3985fed14_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_26c2aa8b-882f-449a-b3d1-87056b94f15a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_dbe9888f-28ef-4584-8a59-46af94ddc150_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TransactionCost_cd676596-eee1-41f3-8f0a-98a7dfc023a9_terseLabel_en-US" xlink:label="lab_mgnx_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Cost</link:label>
    <link:label id="lab_mgnx_TransactionCost_label_en-US" xlink:label="lab_mgnx_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Cost</link:label>
    <link:label id="lab_mgnx_TransactionCost_documentation_en-US" xlink:label="lab_mgnx_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TransactionCost" xlink:href="mgnx-20230331.xsd#mgnx_TransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TransactionCost" xlink:to="lab_mgnx_TransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4464c83f-fc4c-4430-ab53-3e824e68bf28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_726daf5f-1cbd-420d-ad8d-de0bafab1472_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4eba7889-a912-40a7-b61e-c4077c1a2ae3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_860f4388-fd37-4c61-845a-bf9158f3a046_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fc98ff9-8d08-453a-97cf-aed34d8f2c7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_b6ebf5fc-5cd6-44ae-8460-fc2babd1c601_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_145c4e2c-d712-4992-9642-bd99f4394156_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e6beb6a7-4b19-42c0-9d65-106baad81fc3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d570352a-80f3-4464-a9b9-90e260c91b4b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_0b620f3a-e11e-4c48-beb8-005cc2082736_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e3ba2356-56a3-44b4-a5ca-33f2caa944cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2d1ca6d3-46e9-4013-9eb2-2d4b9b1a170b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a35b9ff1-d7f0-436f-b5c4-07adb588e144_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e3ea08c1-44f6-4020-bb23-d804166ee28e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_9a58e4bb-1efa-42ad-880f-1c17e297a86b_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties [Abstract]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties [Abstract]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9a03edc7-f002-4ac1-a36e-13178a38123d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_30045c3a-1e64-488b-b0f2-f134703e2c5e_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_eebb9872-c945-4891-ac46-b64f597c04a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_d7a5dd26-e11b-48c6-baaa-944e5e25f1f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_SynaffixBVMember_922f7523-ee0f-444a-996d-e5844fae5cd0_terseLabel_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_label_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix B.V. [Member]</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_documentation_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember" xlink:href="mgnx-20230331.xsd#mgnx_SynaffixBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_SynaffixBVMember" xlink:to="lab_mgnx_SynaffixBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTransactionCosts_8d91510f-8682-4fc7-bc5a-8538ee147df4_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:label id="lab_mgnx_DeferredTransactionCosts_label_en-US" xlink:label="lab_mgnx_DeferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:label id="lab_mgnx_DeferredTransactionCosts_documentation_en-US" xlink:label="lab_mgnx_DeferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTransactionCosts" xlink:href="mgnx-20230331.xsd#mgnx_DeferredTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTransactionCosts" xlink:to="lab_mgnx_DeferredTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_adc6414d-54d3-44c6-b321-4590cab6bd18_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4a41bdc7-211a-4f1d-aa96-f0870693a01d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7c000e9c-0043-47e7-a4f2-4aafb4fd8ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1317c557-d2cc-43c6-91bc-c29aec1a9ebd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94620ca0-5c64-4020-9fd7-6552bba48acc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d94c44f5-573b-451c-9d52-3e21a8cd647d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_bedd4d4a-e32b-4fba-b79a-e611e0fbc3d0_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8969cfde-af69-4520-a43e-b758779d806c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_8b9b5561-d686-46d8-b902-a21e138ddd8a_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20230331.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67f474a6-bf1b-4f5d-b427-6e9b34d1adfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsFromSaleOfFutureRoyalties_f250f29a-fc5e-4138-bcd7-f2c7778ab667_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_21a40c9b-3c65-4c6b-b961-d38d9466297f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_028f6661-bfcb-486f-9602-95ec8df9dab7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_59acd557-6a88-40f1-908c-f61a4fc32385_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares per employee</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:href="mgnx-20230331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_21fad2b5-f24a-4558-81fe-f07161d2e6e0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2e7c7007-9f49-4445-ab66-2cf73d515b6c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c22243dd-181e-4b09-a602-f78800936fc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3bc4661-cb66-483c-af10-e092a9190ab8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2e4da96-b1f5-47c8-bb5d-162f7c77e9fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38950691-16fd-4e59-9134-c7302dcc3c20_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1f8e7a1e-bba3-4f68-ab3d-be2209e6df37_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_def8987b-2a49-44cb-81ab-20c0d229735d_terseLabel_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_label_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_documentation_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit" xlink:href="mgnx-20230331.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OneTimeMillstoneCredit" xlink:to="lab_mgnx_OneTimeMillstoneCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPayment_d336f9ca-4bae-4676-98eb-b4aa98d40573_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_label_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_documentation_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment" xlink:href="mgnx-20230331.xsd#mgnx_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPayment" xlink:to="lab_mgnx_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4881045-477c-4ad1-a5e6-df3f586eea72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_75a70e3e-5427-41f2-8ebe-72d523737b15_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20230331.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b09030a5-c10e-4019-b85d-75e5a980a5f4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_fdcd8726-3835-4502-a137-04a6ad469313_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_label_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_documentation_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense" xlink:href="mgnx-20230331.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLeaseNoncashExpense" xlink:to="lab_mgnx_OperatingLeaseNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6345b6f7-06d9-40f9-8662-7b7e19637eea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c97954c1-ef6c-453e-9692-bddb4b5d77df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fefd8f98-7192-4c45-85d0-ce3e082aac9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d46bfef1-01cc-4fd2-85a3-ffcb00e4e38d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_8bba22c1-6d7b-4f96-bc26-ea56473961bf_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ad31b262-53e9-45cb-9cb3-753597e66650_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d449cdc-ca6c-46a3-a538-f065cd99ac94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_f62638d0-15bf-4da4-977b-30c44d162bc5_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20230331.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c3dd38c2-3051-4238-88df-2a06840d027c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_658c619a-51fd-4534-8899-5973f42414ec_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_309b0ece-c3a7-4a61-ad05-f4d9207bbf9a_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction percentage</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20230331.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_519d0029-27e6-4f2c-b420-2fa2fe90427d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c495e884-a385-40d8-8daf-98a3eb17ae37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_61debcff-0b6b-4666-aa32-489475a7f2da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fafe4a6c-6424-460e-b655-1d0325357c38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_87eade79-d40c-4471-8dbc-37ff3ad2a086_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8ae1ea0a-4b44-49ef-a433-43bd6e41a5e7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dfc9f40f-40c1-4916-bc4b-1d117ee63d0f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_eda0f301-39c2-481d-86a1-85bf20e08548_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b1f78f3d-2e94-4146-bd08-cc9607381858_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1b28e42a-9067-4bcf-82b5-82939c44824d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_027a60ce-b360-4b21-9aee-af51ff8df9b8_terseLabel_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_label_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_documentation_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized" xlink:href="mgnx-20230331.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonCashInterestExpenseRecognized" xlink:to="lab_mgnx_NonCashInterestExpenseRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_3734d23e-00d2-4cc7-b080-bfe7c16e7962_terseLabel_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments" xlink:href="mgnx-20230331.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalAnnualFixedPayments" xlink:to="lab_mgnx_TotalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7c7d0d11-b248-4951-b1e8-61ca7fe5b267_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bdfe6805-33d8-4b36-bc84-db2070ea71c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0271bc6d-4450-433b-a660-2f40b1d4fd55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d20529ac-564f-4f27-84b9-74279c0d972d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e420dedb-b914-4c04-9481-7822bcaf7f5a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_292fd837-ef3f-4bde-846c-81bc91300186_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_18541ab4-eac8-4769-95df-c64ade608331_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2f25b78b-1c78-4f83-8de4-c761520dbee3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5aed0baa-ff99-460d-9bb7-3d9b5152b873_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a28cef74-7bbf-499a-a530-1d4664f751dd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5bbd503d-1403-434b-997f-9604159bfe15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_09691dda-fadf-4ed6-bfb9-ae01124a6e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_0c9a849e-4969-4500-9469-0e4d27b3bbd8_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c5679965-6473-466d-8fbb-bab6054995cf_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04ca003e-5764-427b-88b0-ae7efb226319_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_cf3bb3eb-6822-444c-821c-6ba0bf270aa8_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercialized molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20230331.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_3ac0d14c-12e8-4a18-80c2-b5f665906c13_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e4997bca-241b-4002-a3ff-5570c47cf569_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_47b8fc2c-5f96-490b-a5db-5f0c733bb909_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time credit paid, percent</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, One-time Credit Paid, Percent</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_documentation_en-US" xlink:label="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, One-time Credit Paid, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationArrangementOneTimeCreditPaidPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:to="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_57c79fdc-f2df-4b74-9c33-1200a6ad3133_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments" xlink:href="mgnx-20230331.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalAnnualFixedPayments" xlink:to="lab_mgnx_AdditionalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_74d2b729-27a6-4fdc-9644-b598471fa31e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_InLicensingArrangementTable_3affe510-7955-43d5-b5ad-c97626bb6014_terseLabel_en-US" xlink:label="lab_mgnx_InLicensingArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-licensing arrangement[Table]</link:label>
    <link:label id="lab_mgnx_InLicensingArrangementTable_label_en-US" xlink:label="lab_mgnx_InLicensingArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Licensing arrangement [Table]</link:label>
    <link:label id="lab_mgnx_InLicensingArrangementTable_documentation_en-US" xlink:label="lab_mgnx_InLicensingArrangementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Licensing arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_InLicensingArrangementTable" xlink:href="mgnx-20230331.xsd#mgnx_InLicensingArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_InLicensingArrangementTable" xlink:to="lab_mgnx_InLicensingArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c7c830aa-796c-4bb4-a550-c0f076868d23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_64bd0df3-cb35-4fc0-8a0a-251497aabf20_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20230331.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b4d45f74-bc95-4c22-8926-fe9096849a97_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_895c42c5-f4e0-4970-8fdf-582ac6f4863c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3e5d2f6f-fa33-4baf-9389-e82768c95ed8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_110f750b-290c-4a3a-b761-10784b91cc38_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2f94c2cd-9528-46f7-a816-7826d0518fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1bed7cdb-1068-4157-880e-dd0402090992_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_e4e9b810-a3b4-4fe8-9b0d-7d53ede56933_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_619c1580-6a92-4289-98fa-2e1222ef8abe_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a439fffa-d152-4ae7-a66d-84da714e7247_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5fc61946-f053-4675-be95-2e2f34cf6009_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_150a0ab9-6f89-49f8-905d-a4d020f32ca2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_899e7a25-83aa-4158-a1a5-2995d71f79d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f83d6a59-a2b0-4da7-ab69-e186feb13604_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8dec818d-3f56-4a69-868f-4c27a79cc0b2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_b240a2b2-5a89-47bf-9781-c6d7fef75782_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_68bdce9e-b547-4e41-b97f-9b7b06ed8779_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ec38b8de-7dc8-4827-9eed-5a58336b3458_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f24619a1-4717-4666-87ac-b442aafad42c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_71160d71-4c8b-4465-b4d6-5c0966504c57_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_275b0381-3c9e-49da-8f70-147f94864df9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_256fa254-150d-4691-8958-74a082094fc3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2239f523-799c-4209-8a5b-11a897a3b8ad_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ab200c30-a794-451d-b5bb-45b527f354b9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_81479663-a785-4766-bff7-302874c65087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_441a4bb8-c0b9-4f86-aaa9-bc314cbe6d9e_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9d32b79b-ad20-4fb7-9d73-94de0200a984_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9aba9f8f-e6f8-4c8c-8b7c-0b66a2ddef11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_02ec7dd7-4d5b-4b04-87cb-5894b3bee92b_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20230331.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_13dc83f1-2609-4b54-8259-f59c07853fd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_d9bec87e-6fe2-43be-a089-d5bc8cf02c73_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_755f805c-8522-4ba9-8495-75f888ec09c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_7206234c-ac36-496d-a871-13c1cf17ca94_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c60aac23-afec-417d-8eea-c67857b1bea6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_InLicensingArrangementLineItems_fcb9f52c-7c1f-46a9-a185-f797ea94ae5d_terseLabel_en-US" xlink:label="lab_mgnx_InLicensingArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Licensing arrangement [Line Items]</link:label>
    <link:label id="lab_mgnx_InLicensingArrangementLineItems_label_en-US" xlink:label="lab_mgnx_InLicensingArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Licensing arrangement [Line Items]</link:label>
    <link:label id="lab_mgnx_InLicensingArrangementLineItems_documentation_en-US" xlink:label="lab_mgnx_InLicensingArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Licensing arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_InLicensingArrangementLineItems" xlink:href="mgnx-20230331.xsd#mgnx_InLicensingArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_InLicensingArrangementLineItems" xlink:to="lab_mgnx_InLicensingArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d7212a68-c57d-4dd9-bb9e-7244e5b6fa19_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_caddd3ef-4c95-48c9-af38-2bcf25462cc4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_2b00899e-7bf2-499d-8af8-bcbba4db6ce6_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_33df2b7b-64d4-4a38-87a4-fdcda10fabe6_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_006f25ef-405a-4246-89b4-e614d5200349_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_bd4bbbdd-6dc8-4dc7-84aa-41eaaeb9c76a_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_098b8d59-882b-4c7f-b1a2-b6bbbfe9d3fe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_23c23cdb-a33c-4834-bc61-14316f5266b1_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_a0a154c0-1e07-425b-823f-58f468e442d2_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20230331.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_88eca151-68cd-46b5-9bbb-c2c0ce6f6ba3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3d56db7b-5683-4dcd-a775-27a93be6b509_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_97441d9c-d7ba-47ca-b914-3dd48181555f_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20230331.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_994e0ded-a76e-409b-bc5b-1dd6397beacf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_35e8da91-b02e-4290-883d-4431a8e3422c_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20230331.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_dd8cadf6-1c52-4c5a-ae79-70c86f4c52ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f55511f5-baf4-4915-ad37-23be2f66cad4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_761fc84e-9c24-44c6-819e-243e262258af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bb705f9b-20d9-4a14-b3b7-0ecd6ca15760_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96f97902-615d-4cd0-8bac-a4e3eaff65cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_e7b53976-3f0f-41d3-aa11-36609407770f_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20230331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable_ff8c171a-9508-4e04-b2b4-e785d85f00cd_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalty [Table]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalty [Table]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalty [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_aef2dfca-7c30-4b05-9c82-2627d8d811b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_83504e6d-a315-4bfe-9689-b5cf055e1cbf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a50a366-68f3-4915-84cb-96f9d5df8b32_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4c22ad15-6f21-4a29-b22f-b215b41f071e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_110ec394-d3ee-490c-85fe-e7ae2ab22e58_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3412d444-a1b9-4a1f-9edd-b92f8212ece8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ab05107a-2183-4a61-a645-50492e2652f3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9fbab1c3-8e73-48d6-80c0-2255dc758d51_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7eca760a-c8d8-486d-921e-6e4ea1f4fcb6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_83dbd143-38c7-445b-81cb-8ca8ac05b018_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20230331.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_f3525bd8-549b-476e-a0ec-466328f5928c_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20230331.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_800e3712-0a43-46d2-979c-fbf849295e78_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26f52e3-b39a-4d1f-8f7f-05856afa9482_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1deed1fd-5bda-4fee-9d54-4e56bb4a429b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68b9d581-a71d-4ced-8b12-93eaf1dc2dc0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0915ee61-b627-400e-b38e-794986ddee3b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a66f8296-34b1-4a5e-870c-0bfe8eeb0a7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_78f2eee7-7def-4a5e-813a-dd3d9a6d07ba_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance, increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_ca13f83c-0f38-49a0-819d-0d0caa18be26_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_dcd8ff22-24da-4bd0-ab7b-cdee3da54a10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_cf1c8698-f866-4294-b62e-0a86921ce364_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_4a147494-2839-4473-b4cb-93a944f4c3a8_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties [Roll Forward]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties [Roll Forward]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65e235be-fbaf-4fdc-8548-4de4b06fe82a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_cf001fcb-2bc5-4e46-abf3-2cbe88844aca_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20230331.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f1ac6224-8789-4f94-bcb0-847a7e9bd967_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d13de50d-6256-4f89-a6ad-89183d449160_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_01830259-7e99-4e56-bd7a-54ae7756f432_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2669aeb9-bd37-4981-b958-30733b214f94_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_a247b7e2-34eb-46b2-a061-34a54ee6a5e5_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20230331.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da34c44f-1de8-4a4e-8b8f-d9106bdadd78_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_32464c24-71ca-43b8-b17a-8d7c45469102_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_320def67-95a4-4800-b739-f8cbcf108de1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fc4327cf-65d3-4199-b1f5-c0b0605ea096_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e280e626-4430-4fb2-b618-d0eb4adc2891_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_8372bc19-c4ae-43aa-9f3a-18ea7f57f9c7_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_757aa13c-b955-4f3f-addd-8ddfba0bd103_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d1cd538b-47e3-4e8a-b2e9-862597d1ceb3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_85d04dcb-6bb3-453e-a23d-62c3f227c8d6_terseLabel_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential target nomination, option fees and milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_label_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential target nomination, option fees and milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_documentation_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential target, nomination, option fees and milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:href="mgnx-20230331.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:to="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mgnx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4c965add-b010-4624-ba75-b98f8d64a55e,g:758eb5bc-71ca-48c1-8a86-febd43fa4ed1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c8ef6a49-dab8-4e3f-a544-76a9e46e486b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_DocumentType_c8ef6a49-dab8-4e3f-a544-76a9e46e486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c4c6a4d8-19f2-4901-8000-49b357083ad9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_DocumentQuarterlyReport_c4c6a4d8-19f2-4901-8000-49b357083ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bff3908a-96f8-4407-b569-16ed2a9ee93e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_DocumentPeriodEndDate_bff3908a-96f8-4407-b569-16ed2a9ee93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_261ecf9f-1fef-47bf-bcc5-8592e3977ef6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_DocumentTransitionReport_261ecf9f-1fef-47bf-bcc5-8592e3977ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1297a40d-02fd-4edf-874b-512b9ab4cc43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityFileNumber_1297a40d-02fd-4edf-874b-512b9ab4cc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_00ceabd1-a1c7-4702-a16b-57d3f09f5a13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityRegistrantName_00ceabd1-a1c7-4702-a16b-57d3f09f5a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b63f29cf-913e-4224-9fb4-5dd41d37daad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b63f29cf-913e-4224-9fb4-5dd41d37daad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_093fd6c9-4b2f-4f93-81d5-b71b22433492" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityTaxIdentificationNumber_093fd6c9-4b2f-4f93-81d5-b71b22433492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_36542444-9186-4fa3-ba59-fc50b9838e71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityAddressAddressLine1_36542444-9186-4fa3-ba59-fc50b9838e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cfd8ee3f-4fab-4615-9bc0-fec4645ceb84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityAddressCityOrTown_cfd8ee3f-4fab-4615-9bc0-fec4645ceb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_431fd53b-e20d-470f-962e-8aa212fb3ef8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityAddressStateOrProvince_431fd53b-e20d-470f-962e-8aa212fb3ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_159a490f-afc3-4f58-8776-8b9258618b29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityAddressPostalZipCode_159a490f-afc3-4f58-8776-8b9258618b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7b226315-a84d-4815-93ae-1d4c77488626" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_CityAreaCode_7b226315-a84d-4815-93ae-1d4c77488626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d65b45c-2fbc-49bb-9835-9556373d7a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_LocalPhoneNumber_3d65b45c-2fbc-49bb-9835-9556373d7a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8b7b9895-21f7-4bdd-98e4-4c967633d8e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_Security12bTitle_8b7b9895-21f7-4bdd-98e4-4c967633d8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cd88053b-1763-41f0-8611-9a984c183fd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_TradingSymbol_cd88053b-1763-41f0-8611-9a984c183fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e633d66-6482-4a56-9b08-27e4a13dfa32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_SecurityExchangeName_8e633d66-6482-4a56-9b08-27e4a13dfa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_703c15b6-d233-4834-b8d4-95d1ce0bd697" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityCurrentReportingStatus_703c15b6-d233-4834-b8d4-95d1ce0bd697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f1708a34-c633-428f-8cd2-f42ff59aed23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityInteractiveDataCurrent_f1708a34-c633-428f-8cd2-f42ff59aed23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_640da219-ce9c-4402-86d8-2ec249842417" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityFilerCategory_640da219-ce9c-4402-86d8-2ec249842417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3dd85baf-0a47-4662-a940-21ee11deedd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntitySmallBusiness_3dd85baf-0a47-4662-a940-21ee11deedd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c1663d67-4e7b-4261-a304-3faaed8f4155" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityEmergingGrowthCompany_c1663d67-4e7b-4261-a304-3faaed8f4155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f913e2b9-aac8-4f91-974d-9dfba312b1b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityShellCompany_f913e2b9-aac8-4f91-974d-9dfba312b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fbc8c521-8452-4140-9a59-6290465b0006" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fbc8c521-8452-4140-9a59-6290465b0006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fb832a06-764f-4e52-823d-39478fc05799" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_AmendmentFlag_fb832a06-764f-4e52-823d-39478fc05799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5cd29827-706a-42c7-8a9d-191b6446ea30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_DocumentFiscalYearFocus_5cd29827-706a-42c7-8a9d-191b6446ea30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b6b5cedd-0821-482d-b9df-d15c29860292" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b6b5cedd-0821-482d-b9df-d15c29860292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4b3c2e45-4f3c-410a-9686-c783ba9bb2fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_EntityCentralIndexKey_4b3c2e45-4f3c-410a-9686-c783ba9bb2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a8d2b2f1-0fb8-43d0-aa37-a2d593acd01c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4fa2240a-4de9-43fb-81b2-70bd022a5f51" xlink:to="loc_dei_CurrentFiscalYearEndDate_a8d2b2f1-0fb8-43d0-aa37-a2d593acd01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5ea67dd0-2a42-4cce-8e28-2007a3d5f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ea67dd0-2a42-4cce-8e28-2007a3d5f66e" xlink:to="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:to="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61d7b33d-586f-4155-92c1-231073f62f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61d7b33d-586f-4155-92c1-231073f62f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_4c6fc06a-5f1b-4c5f-a7ea-adcb347cf3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:to="loc_us-gaap_Investments_4c6fc06a-5f1b-4c5f-a7ea-adcb347cf3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a1c60e5b-0bcd-44da-835f-c889c5d2ea7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a1c60e5b-0bcd-44da-835f-c889c5d2ea7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f2ee9578-bf06-413d-b8d9-2a57a7c32f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:to="loc_us-gaap_InventoryNet_f2ee9578-bf06-413d-b8d9-2a57a7c32f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_843a4842-dbef-40d7-99c0-e0e56f0e2879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_843a4842-dbef-40d7-99c0-e0e56f0e2879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f08c1262-4e04-4031-b1c8-d9e1e2120b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04c6c882-90c8-4cac-8750-5262d335757d" xlink:to="loc_us-gaap_AssetsCurrent_f08c1262-4e04-4031-b1c8-d9e1e2120b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45dfc934-0652-430d-9047-dd05c8d75557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_45dfc934-0652-430d-9047-dd05c8d75557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4d6f2c32-4039-4d53-b0aa-9683764efa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4d6f2c32-4039-4d53-b0aa-9683764efa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8273d39c-77e2-4175-98e0-80a7fea324bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8273d39c-77e2-4175-98e0-80a7fea324bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_090a3d47-1274-40c5-9443-675275a97182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_179c2561-a0b5-4638-bf7b-1b5f16f92f23" xlink:to="loc_us-gaap_Assets_090a3d47-1274-40c5-9443-675275a97182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ea67dd0-2a42-4cce-8e28-2007a3d5f66e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d95ca7f0-385e-4f13-b3f9-92a06e8a1d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:to="loc_us-gaap_AccountsPayableCurrent_d95ca7f0-385e-4f13-b3f9-92a06e8a1d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f3a6c901-341f-47b5-ba33-eeb0a6819de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f3a6c901-341f-47b5-ba33-eeb0a6819de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8ef2e01d-b3aa-4012-8537-5649ab1c8ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8ef2e01d-b3aa-4012-8537-5649ab1c8ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_49c4f1ea-d979-4ccb-84d3-a540d73a7368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_49c4f1ea-d979-4ccb-84d3-a540d73a7368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8b181407-48df-45dd-8d8d-cb6374fbd0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:to="loc_us-gaap_LiabilitiesCurrent_8b181407-48df-45dd-8d8d-cb6374fbd0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties_e1d83c12-ba2a-4f89-b8f9-2168f0a3b191" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bb31caa-9520-44de-8d6b-4515de82e6f2" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyalties_e1d83c12-ba2a-4f89-b8f9-2168f0a3b191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_75100970-426c-45d8-bd19-399bb04400b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_75100970-426c-45d8-bd19-399bb04400b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_49c0a352-8cb7-4b52-b488-31f4e5bdcd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_49c0a352-8cb7-4b52-b488-31f4e5bdcd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0613dc0c-8033-451c-a68d-6ce440d6e635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0613dc0c-8033-451c-a68d-6ce440d6e635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_71d05262-240e-470e-83b4-b15cece720c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_Liabilities_71d05262-240e-470e-83b4-b15cece720c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_45d5f6bc-9808-4936-897d-fb72606c211a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:to="loc_us-gaap_CommonStockValue_45d5f6bc-9808-4936-897d-fb72606c211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6acd4059-de97-48d9-b6f8-01d4fd724496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6acd4059-de97-48d9-b6f8-01d4fd724496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2d717cf3-28a4-4bd5-b0a1-5d50ee855a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2d717cf3-28a4-4bd5-b0a1-5d50ee855a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b173973d-b4b8-4a3d-b1e2-4444ff36c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b173973d-b4b8-4a3d-b1e2-4444ff36c1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c0c8f8a-ae56-427b-a16f-02ceeedd3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2df3318a-637b-4224-a583-1955828506f2" xlink:to="loc_us-gaap_StockholdersEquity_6c0c8f8a-ae56-427b-a16f-02ceeedd3c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e86bd4d-7459-4007-953d-326c470962a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7d86387-58f3-4e4f-99f1-b8f2a86f4189" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e86bd4d-7459-4007-953d-326c470962a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a56c71a8-f1fd-4313-90ea-cc9535267d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63b8fe03-9f61-4555-8b65-1f56e44dc0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a56c71a8-f1fd-4313-90ea-cc9535267d51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63b8fe03-9f61-4555-8b65-1f56e44dc0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e3d277e7-c0b4-4612-8e30-f1ae4500e852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63b8fe03-9f61-4555-8b65-1f56e44dc0de" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e3d277e7-c0b4-4612-8e30-f1ae4500e852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_652ad624-e2ef-40bb-8cfb-eb45f6a00e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3d277e7-c0b4-4612-8e30-f1ae4500e852" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_652ad624-e2ef-40bb-8cfb-eb45f6a00e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a5b0f5ff-02b7-40cf-ae32-044a1d9c0076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3d277e7-c0b4-4612-8e30-f1ae4500e852" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a5b0f5ff-02b7-40cf-ae32-044a1d9c0076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_470973b8-c767-44d0-8893-b08cc8295fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3d277e7-c0b4-4612-8e30-f1ae4500e852" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_470973b8-c767-44d0-8893-b08cc8295fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4ed1266b-568c-4428-b69b-a4696b6c66d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4ed1266b-568c-4428-b69b-a4696b6c66d1" xlink:to="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:to="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ec5eb785-0e95-492a-9f52-3399214741d0" xlink:to="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c21d7e95-9fac-4632-bd63-253d8f0bc1ed" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c21d7e95-9fac-4632-bd63-253d8f0bc1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0f973848-6931-4af9-a1db-0aeb29dcf13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_us-gaap_ProductMember_0f973848-6931-4af9-a1db-0aeb29dcf13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_8dda60ab-cb53-4c85-bc30-f52802a898a8" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_8dda60ab-cb53-4c85-bc30-f52802a898a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_3b0bfdcb-5adf-490c-96c4-760353e2bc6b" xlink:href="mgnx-20230331.xsd#mgnx_ContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_ContractManufacturingMember_3b0bfdcb-5adf-490c-96c4-760353e2bc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_72a02e3e-f56d-4248-89eb-24ddb0f556a6" xlink:href="mgnx-20230331.xsd#mgnx_RevenueFromRoyalityAgreementsMemberMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a18d3bd4-c64a-43db-8317-f87464e42e85" xlink:to="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_72a02e3e-f56d-4248-89eb-24ddb0f556a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b065cc54-656e-442d-ad9b-ae6c505c2201" xlink:to="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f3653a0-369d-42ae-9abf-e8fd815c4a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_RevenuesAbstract_3f3653a0-369d-42ae-9abf-e8fd815c4a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_467cae38-9384-4caa-b689-68f3be5d5c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3f3653a0-369d-42ae-9abf-e8fd815c4a79" xlink:to="loc_us-gaap_Revenues_467cae38-9384-4caa-b689-68f3be5d5c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_13596ce9-10cb-4b0c-b919-2b8d2877307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_13596ce9-10cb-4b0c-b919-2b8d2877307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_d4911c70-1379-4d93-b5f3-c7ef6860c1a2" xlink:href="mgnx-20230331.xsd#mgnx_CostOfManufacturingServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_mgnx_CostOfManufacturingServices_d4911c70-1379-4d93-b5f3-c7ef6860c1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_36774ed7-e635-41cc-a044-7143eccde7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_36774ed7-e635-41cc-a044-7143eccde7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ab764c47-da20-4f27-8edd-1aa5009af0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ab764c47-da20-4f27-8edd-1aa5009af0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_91d9c058-a62b-4669-b12f-be0f548a4057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_CostsAndExpenses_91d9c058-a62b-4669-b12f-be0f548a4057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6778411d-d81b-474a-9425-d78a6416f5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_OperatingIncomeLoss_6778411d-d81b-474a-9425-d78a6416f5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_27b61011-28fe-4771-9dc2-9cd87e4c73dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_OtherNonoperatingIncome_27b61011-28fe-4771-9dc2-9cd87e4c73dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_6359e9fa-211a-494b-a1bb-3f708658f679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_OtherNonoperatingExpense_6359e9fa-211a-494b-a1bb-3f708658f679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9669dc02-51d4-47f2-b1c3-c3364724b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_50adc0cf-d1a7-4d57-a599-af1ac1e14393" xlink:to="loc_us-gaap_NetIncomeLoss_9669dc02-51d4-47f2-b1c3-c3364724b70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb5cf332-b300-4f4a-958c-0a6217607d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb5cf332-b300-4f4a-958c-0a6217607d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41bc38b9-4cc5-464e-9596-5f9a4b2bcc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eb5cf332-b300-4f4a-958c-0a6217607d3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41bc38b9-4cc5-464e-9596-5f9a4b2bcc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd2df178-0578-44f8-b550-15bd18d2d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd2df178-0578-44f8-b550-15bd18d2d18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_876d2a23-0742-4fd8-b921-47bb2d597835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_EarningsPerShareBasic_876d2a23-0742-4fd8-b921-47bb2d597835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b89c93c9-bb16-4132-b181-cf78e8ac2701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b89c93c9-bb16-4132-b181-cf78e8ac2701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74d18b3f-a6c4-4eaa-aee9-61f42978ec42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74d18b3f-a6c4-4eaa-aee9-61f42978ec42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6c92e387-7fad-4da2-9620-74f0ce233b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2115688c-089e-4f6f-bc61-939603bbf0ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6c92e387-7fad-4da2-9620-74f0ce233b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e65b5163-c783-49b7-83d3-2d3a3e0c2a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e65b5163-c783-49b7-83d3-2d3a3e0c2a68" xlink:to="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f0e6a5d-00f0-40b4-b6c5-568cd41c9843" xlink:to="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3e3627a0-d435-4dfb-b3a8-2e6a61d841a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_CommonStockMember_3e3627a0-d435-4dfb-b3a8-2e6a61d841a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f2a1e2cb-537e-406c-a3bd-c7f6d4f936ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f2a1e2cb-537e-406c-a3bd-c7f6d4f936ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2cbcf12e-fe18-4a8c-86bb-19243664fb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_RetainedEarningsMember_2cbcf12e-fe18-4a8c-86bb-19243664fb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_891cc99e-c239-43ca-a5f9-b9e8042fb6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00f18db1-96d8-4671-8d80-4aaf5f425778" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_891cc99e-c239-43ca-a5f9-b9e8042fb6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b64c76c5-07b9-409b-a84f-a0aef44844a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fec76974-9306-41e7-be46-49cf1d8c3a57" xlink:to="loc_us-gaap_StatementLineItems_b64c76c5-07b9-409b-a84f-a0aef44844a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b64c76c5-07b9-409b-a84f-a0aef44844a2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8e3536a6-dfad-42ee-89d9-fbd72f658d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_SharesIssued_8e3536a6-dfad-42ee-89d9-fbd72f658d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c63e26a8-8a66-4fc1-bdb5-5f73747bd013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c63e26a8-8a66-4fc1-bdb5-5f73747bd013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6d1ed942-5980-4e39-bb97-0fb5ca861ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6d1ed942-5980-4e39-bb97-0fb5ca861ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0949f38e-69da-4ace-b32e-f9b9b3558eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0949f38e-69da-4ace-b32e-f9b9b3558eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_69d78367-abce-4571-bac2-a8582403f2e3" xlink:href="mgnx-20230331.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_69d78367-abce-4571-bac2-a8582403f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_0f23d760-f306-4304-8694-fb290807b898" xlink:href="mgnx-20230331.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_0f23d760-f306-4304-8694-fb290807b898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3c5cc65-d0ee-4ad7-b893-8f434a6128b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3c5cc65-d0ee-4ad7-b893-8f434a6128b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_68feb96e-7f41-48b2-ad5d-40285fd7f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_68feb96e-7f41-48b2-ad5d-40285fd7f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_39fe1c61-b99d-4375-b111-e8dfd249e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_39fe1c61-b99d-4375-b111-e8dfd249e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_483e49a8-db66-4dbd-882b-46f348be0382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_NetIncomeLoss_483e49a8-db66-4dbd-882b-46f348be0382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_bca75c8b-aa1f-4c77-85f1-cc49804486c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_SharesIssued_bca75c8b-aa1f-4c77-85f1-cc49804486c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87687483-c6e7-4948-badc-36ff9fb830b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1516d9b7-ca38-4d8d-8a33-8e54555a8067" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87687483-c6e7-4948-badc-36ff9fb830b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f13564c-95f7-45c6-a2cf-e780997d2fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f13564c-95f7-45c6-a2cf-e780997d2fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb2c49dd-365a-41c5-a91f-f7d748af1e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f13564c-95f7-45c6-a2cf-e780997d2fff" xlink:to="loc_us-gaap_NetIncomeLoss_cb2c49dd-365a-41c5-a91f-f7d748af1e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f13564c-95f7-45c6-a2cf-e780997d2fff" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6593ec5b-d51a-42eb-9b1e-cb22ab6ee9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6593ec5b-d51a-42eb-9b1e-cb22ab6ee9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_910cc151-8cc3-4529-9871-8736f50b8090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_910cc151-8cc3-4529-9871-8736f50b8090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3d4ced2f-92b8-48ec-b8d2-d205976dff05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:to="loc_us-gaap_ShareBasedCompensation_3d4ced2f-92b8-48ec-b8d2-d205976dff05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashRoyaltyRevenue_7611664e-ab65-42a0-a14e-93a8aefb8ff1" xlink:href="mgnx-20230331.xsd#mgnx_NonCashRoyaltyRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:to="loc_mgnx_NonCashRoyaltyRevenue_7611664e-ab65-42a0-a14e-93a8aefb8ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_e0c4c215-3446-431b-bd9d-07808325e3d4" xlink:href="mgnx-20230331.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_e0c4c215-3446-431b-bd9d-07808325e3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aaae28bc-d8dc-48d6-9e0f-fac23ecfd071" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c2028276-b84d-4802-8444-a856893679c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c2028276-b84d-4802-8444-a856893679c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8808c5b6-1fa6-4f04-b212-8c3c69e2157d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8808c5b6-1fa6-4f04-b212-8c3c69e2157d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ca3ac81e-f492-401e-84a3-90ea85d10a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ca3ac81e-f492-401e-84a3-90ea85d10a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense_ba59727e-d4a1-4264-a5da-abaaccaae707" xlink:href="mgnx-20230331.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_mgnx_OperatingLeaseNoncashExpense_ba59727e-d4a1-4264-a5da-abaaccaae707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_31778e91-b003-4415-b165-279380dcd602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_31778e91-b003-4415-b165-279380dcd602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_bdc9f1fd-aeff-4404-8dae-dc76a0939b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_bdc9f1fd-aeff-4404-8dae-dc76a0939b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9310962c-6f46-4bc4-8137-e88bd5ef8930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9310962c-6f46-4bc4-8137-e88bd5ef8930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d126a311-20ce-4b70-9520-23b3471f2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d126a311-20ce-4b70-9520-23b3471f2c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f552450d-5d8b-4964-ad80-7eceb691fd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5d90e10d-05d7-4b45-9afb-55580aeb039f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f552450d-5d8b-4964-ad80-7eceb691fd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f33e3be-f74c-477e-a039-3dad75010324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f13564c-95f7-45c6-a2cf-e780997d2fff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f33e3be-f74c-477e-a039-3dad75010324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3493408c-8ed0-4c32-bfbb-135b89fdf0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3493408c-8ed0-4c32-bfbb-135b89fdf0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3f1f6235-4579-4dcf-9561-9d0397b938da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3493408c-8ed0-4c32-bfbb-135b89fdf0f4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3f1f6235-4579-4dcf-9561-9d0397b938da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6eacb0af-dd9c-4939-b209-07b86cbbcb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3493408c-8ed0-4c32-bfbb-135b89fdf0f4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6eacb0af-dd9c-4939-b209-07b86cbbcb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1bba0d3-6cd1-4bcd-a191-6cfdc59af98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3493408c-8ed0-4c32-bfbb-135b89fdf0f4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1bba0d3-6cd1-4bcd-a191-6cfdc59af98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00193c21-f2ec-4e8d-bf56-58a16adc56f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3493408c-8ed0-4c32-bfbb-135b89fdf0f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00193c21-f2ec-4e8d-bf56-58a16adc56f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_412b403a-0ed7-40c3-ad2f-468443c11656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_412b403a-0ed7-40c3-ad2f-468443c11656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_940787f6-5355-483b-a06a-2cb66a1c0e98" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_940787f6-5355-483b-a06a-2cb66a1c0e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_027f398d-e6d1-4437-b5a1-855b145a3c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_027f398d-e6d1-4437-b5a1-855b145a3c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_a0d247f7-4457-49c3-a6f4-12e068469977" xlink:href="mgnx-20230331.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_a0d247f7-4457-49c3-a6f4-12e068469977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbb63a67-a5fb-4738-b4f7-e07a2b202bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63c79b80-9275-4df7-b7ff-2cffc434fc41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbb63a67-a5fb-4738-b4f7-e07a2b202bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ba8bd22-a6ff-4418-ac23-5e7289ff9452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ba8bd22-a6ff-4418-ac23-5e7289ff9452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64fb1803-94e9-4d15-8b5e-15b773a111f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64fb1803-94e9-4d15-8b5e-15b773a111f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cddacc03-e418-4a6a-ac1f-6822d864518e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cddacc03-e418-4a6a-ac1f-6822d864518e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e6241408-a781-4746-98a4-596b973ea287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0ed97ab3-3061-4861-9200-e36d5cd41a3a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e6241408-a781-4746-98a4-596b973ea287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a81bcf94-19a3-4ea3-a594-b5888a97dad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e6241408-a781-4746-98a4-596b973ea287" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a81bcf94-19a3-4ea3-a594-b5888a97dad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NatureofOperations" xlink:type="simple" xlink:href="mgnx-20230331.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86c94754-f05b-46bc-a3aa-f78530e4b295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c135b5b4-91ec-4b9c-9589-f33515b84a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86c94754-f05b-46bc-a3aa-f78530e4b295" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c135b5b4-91ec-4b9c-9589-f33515b84a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bf6c10c-9119-454b-a91f-9f4d9e53cf36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cd0b8716-645f-48ef-af71-5c4e317e92a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bf6c10c-9119-454b-a91f-9f4d9e53cf36" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cd0b8716-645f-48ef-af71-5c4e317e92a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20230331.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90c88962-9a7e-4b29-acae-a7567bb63705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_011c5c00-713c-490a-ae28-a4f76a14f590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90c88962-9a7e-4b29-acae-a7567bb63705" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_011c5c00-713c-490a-ae28-a4f76a14f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20230331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54768926-60eb-4b8d-b9e4-c259d16ff9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b136f741-26db-4f0e-aef1-cb8c700e4484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54768926-60eb-4b8d-b9e4-c259d16ff9a0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b136f741-26db-4f0e-aef1-cb8c700e4484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNet" xlink:type="simple" xlink:href="mgnx-20230331.xsd#InventoryNet"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b3951f3c-a3a4-4a22-8111-c505954b24ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_65259916-7f80-460b-b475-06583c8418d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b3951f3c-a3a4-4a22-8111-c505954b24ec" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_65259916-7f80-460b-b475-06583c8418d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangement" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RoyaltyMonetizationArrangement"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_4082e17c-2178-4155-b457-fd525cbb2c98" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_e9a051ce-d411-49df-91ce-2149d3d28aac" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_4082e17c-2178-4155-b457-fd525cbb2c98" xlink:to="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_e9a051ce-d411-49df-91ce-2149d3d28aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_419a98b1-655e-4741-877f-3cc7c10e4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2fef97a6-72d4-4ceb-a133-4dcffb26f664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_419a98b1-655e-4741-877f-3cc7c10e4d7e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2fef97a6-72d4-4ceb-a133-4dcffb26f664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Revenue" xlink:type="simple" xlink:href="mgnx-20230331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_c830588b-7735-4ab1-9e67-b17a1aca7c3e" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_f791e27a-f823-439a-bfeb-56e04cea57d6" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_c830588b-7735-4ab1-9e67-b17a1aca7c3e" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_f791e27a-f823-439a-bfeb-56e04cea57d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_340090ec-bb67-4e6c-8cda-c2aded50072b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_489f8c06-d4b8-4e28-8219-d6e15413423f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_340090ec-bb67-4e6c-8cda-c2aded50072b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_489f8c06-d4b8-4e28-8219-d6e15413423f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_945bce3e-59f8-4111-b536-5464146d5a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b332d12d-c020-4a54-821d-1957b98b56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_945bce3e-59f8-4111-b536-5464146d5a57" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b332d12d-c020-4a54-821d-1957b98b56f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9a6e9d4e-ce08-469c-bca8-8654732d367a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2f2f33cd-f316-4095-8f67-56735b4800db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a6e9d4e-ce08-469c-bca8-8654732d367a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2f2f33cd-f316-4095-8f67-56735b4800db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_fce2e96b-d26e-4828-bf4f-1cf2a4ef26b2" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a6e9d4e-ce08-469c-bca8-8654732d367a" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_fce2e96b-d26e-4828-bf4f-1cf2a4ef26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ec720aca-8baf-4f18-b1cf-1a3ce8995e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a6e9d4e-ce08-469c-bca8-8654732d367a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ec720aca-8baf-4f18-b1cf-1a3ce8995e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_bd238be5-1985-42bd-bc3e-f31fd84a7638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a6e9d4e-ce08-469c-bca8-8654732d367a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_bd238be5-1985-42bd-bc3e-f31fd84a7638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20230331.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f081431e-3a5a-4705-af84-6a2d5f6bb89a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5a3d443c-e042-4652-b83d-d0b712dd7f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f081431e-3a5a-4705-af84-6a2d5f6bb89a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5a3d443c-e042-4652-b83d-d0b712dd7f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20230331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cee5603c-bb56-4c61-94a8-04255ef90d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c4e67a46-3c41-4b71-9d57-4df9d819ad88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cee5603c-bb56-4c61-94a8-04255ef90d6e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c4e67a46-3c41-4b71-9d57-4df9d819ad88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20230331.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ae90d554-71bd-4e40-834c-4dc0e97a8d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_da8a0e51-fb31-46e4-8332-3807f12c164c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae90d554-71bd-4e40-834c-4dc0e97a8d53" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_da8a0e51-fb31-46e4-8332-3807f12c164c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementTables" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RoyaltyMonetizationArrangementTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_abdba196-86ca-4bbb-86e8-b4cfa76c5d93" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_ff1df127-0850-44e2-b27e-5f519cedbe12" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_abdba196-86ca-4bbb-86e8-b4cfa76c5d93" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_ff1df127-0850-44e2-b27e-5f519cedbe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32e47f86-7821-48f9-aad3-1258c227ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_60d4af83-c5d7-4c22-996b-578bb88dba64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32e47f86-7821-48f9-aad3-1258c227ae88" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_60d4af83-c5d7-4c22-996b-578bb88dba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a8435d40-5121-4ee9-ac85-7a8b0c2de0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32e47f86-7821-48f9-aad3-1258c227ae88" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a8435d40-5121-4ee9-ac85-7a8b0c2de0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_5c727a31-0ab3-4a55-915a-24277c53a15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32e47f86-7821-48f9-aad3-1258c227ae88" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_5c727a31-0ab3-4a55-915a-24277c53a15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_23e79768-cf1c-4a42-b335-5b499c2c6947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32e47f86-7821-48f9-aad3-1258c227ae88" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_23e79768-cf1c-4a42-b335-5b499c2c6947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6fce6e4f-4a08-4ed3-a178-f48d4f5ec76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fce6e4f-4a08-4ed3-a178-f48d4f5ec76f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_058c0167-18e0-4443-8421-883f0d800a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7ab79f1e-bbe5-4010-8a21-d5987251c91a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_058c0167-18e0-4443-8421-883f0d800a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_15aff7e9-32fc-4969-8195-f53871829476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_058c0167-18e0-4443-8421-883f0d800a39" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_15aff7e9-32fc-4969-8195-f53871829476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_95883f4c-c9ec-4cd3-8195-1b3044651838" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_06fb3817-1a0e-4b39-be3d-fc34d42c102b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_06fb3817-1a0e-4b39-be3d-fc34d42c102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b7841112-755d-4750-bace-d70359ab9ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b7841112-755d-4750-bace-d70359ab9ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5ace6139-c59c-4bc0-8ae1-4388a4a88c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ae2a0c9f-3c69-4911-ae03-577fac8cf9dc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5ace6139-c59c-4bc0-8ae1-4388a4a88c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac34e91b-56ff-42bf-b791-08ee43ccdbeb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7ec8bf40-fff3-494f-96ab-f8340ae1270d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7ec8bf40-fff3-494f-96ab-f8340ae1270d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a1d6c6af-d147-4e68-b645-f0de4c4f5c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfad303f-0578-4a6d-a37d-c5499eb0791e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a1d6c6af-d147-4e68-b645-f0de4c4f5c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0970a99f-196c-4f33-bbd5-48006880d916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8eb206a5-fdf8-4c73-86a1-5cd11756cb12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0970a99f-196c-4f33-bbd5-48006880d916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0970a99f-196c-4f33-bbd5-48006880d916" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7688956-89a0-4a03-adf9-c1120f08aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7688956-89a0-4a03-adf9-c1120f08aa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6895b6fb-6089-494d-b252-c8aecdc0331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6895b6fb-6089-494d-b252-c8aecdc0331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e676b9aa-943a-4e3b-81f5-1f8cbdd15634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b08269a5-369d-443f-ba43-ae807bd05e2f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e676b9aa-943a-4e3b-81f5-1f8cbdd15634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_521356b9-7db6-4ce3-8c79-129d452c1390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_521356b9-7db6-4ce3-8c79-129d452c1390" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac181d64-cc31-4966-b26a-7433f7fe64ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7b5ff7f8-7742-4f6e-989d-705803a689a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7b5ff7f8-7742-4f6e-989d-705803a689a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_46915046-bf1f-45da-8625-fb52e69c13bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f021a0d2-b2ae-4bc4-80ce-fe6190a67611" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_46915046-bf1f-45da-8625-fb52e69c13bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_eb3f8f8b-e9d0-4620-8ebe-401aa7cc78e6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c6d60d01-cb22-4dba-8f75-6df2af17f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c6d60d01-cb22-4dba-8f75-6df2af17f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_260674b7-50f8-40ee-8497-c7afcc4a2b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_260674b7-50f8-40ee-8497-c7afcc4a2b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcc1cde0-e6bd-4359-acf9-0c1d713cbee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcc1cde0-e6bd-4359-acf9-0c1d713cbee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b310526d-ec4f-4751-a7a0-0bd6adce3171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72254580-d423-4b26-9fca-2167b8f65fc8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b310526d-ec4f-4751-a7a0-0bd6adce3171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a1fab95e-d552-4723-af99-e05148de0795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_521356b9-7db6-4ce3-8c79-129d452c1390" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a1fab95e-d552-4723-af99-e05148de0795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_db239aa4-c704-4178-8329-0de1b295ec01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_7a6732a1-8e53-4b17-968f-dfaa0eeb2bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db239aa4-c704-4178-8329-0de1b295ec01" xlink:to="loc_us-gaap_InventoryWorkInProcess_7a6732a1-8e53-4b17-968f-dfaa0eeb2bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_d9102a67-ad2f-44e1-94e0-c25f31ac3508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db239aa4-c704-4178-8329-0de1b295ec01" xlink:to="loc_us-gaap_InventoryFinishedGoods_d9102a67-ad2f-44e1-94e0-c25f31ac3508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_599f9948-e19c-4788-aae0-b377a40cabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db239aa4-c704-4178-8329-0de1b295ec01" xlink:to="loc_us-gaap_InventoryNet_599f9948-e19c-4788-aae0-b377a40cabdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_ebd0ff9d-9564-48bd-989b-a474219ea371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db239aa4-c704-4178-8329-0de1b295ec01" xlink:to="loc_us-gaap_InventoryValuationReserves_ebd0ff9d-9564-48bd-989b-a474219ea371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RoyaltyMonetizationArrangementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_1969e03e-9c37-485a-90bc-9046077508e5" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_1969e03e-9c37-485a-90bc-9046077508e5" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:to="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ccf327-10ec-4e9d-8f1a-6b04d9cfeb4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7e41321e-7b28-41fe-9716-9b87a2b367a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ccf327-10ec-4e9d-8f1a-6b04d9cfeb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_3d33710c-65ef-481b-87ed-de4df280bbca" xlink:href="mgnx-20230331.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ccf327-10ec-4e9d-8f1a-6b04d9cfeb4b" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_3d33710c-65ef-481b-87ed-de4df280bbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyTable_0f580512-bbce-43f7-84da-a2c7c64d006d" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_c98f50b0-11f1-4aa8-b6a8-4c4abdb192c8" xlink:href="mgnx-20230331.xsd#mgnx_UpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_UpfrontPayment_c98f50b0-11f1-4aa8-b6a8-4c4abdb192c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TransactionCost_d0958443-c232-48b7-a2d9-a96484f53c5e" xlink:href="mgnx-20230331.xsd#mgnx_TransactionCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_TransactionCost_d0958443-c232-48b7-a2d9-a96484f53c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_b5740fd6-4190-473f-8f5b-c1c2a1bf920f" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_b5740fd6-4190-473f-8f5b-c1c2a1bf920f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_d57adc70-8385-4e93-b7c5-f5b51fd20e36" xlink:href="mgnx-20230331.xsd#mgnx_FutureRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_FutureRevenue_d57adc70-8385-4e93-b7c5-f5b51fd20e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_df470a7e-2e42-4d3d-86af-284198c56e0d" xlink:href="mgnx-20230331.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_df470a7e-2e42-4d3d-86af-284198c56e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties_1d95e10e-42cb-4af7-838a-2f8b39f3d7ee" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyalties_1d95e10e-42cb-4af7-838a-2f8b39f3d7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashRoyaltyRevenue_d24c9dc7-a13b-4286-bf08-159dae8b5195" xlink:href="mgnx-20230331.xsd#mgnx_NonCashRoyaltyRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_edb9aadf-596b-4783-aa46-ffe7d5552c42" xlink:to="loc_mgnx_NonCashRoyaltyRevenue_d24c9dc7-a13b-4286-bf08-159dae8b5195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RoyaltyMonetizationArrangementRollforwardDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_51da4efc-7f36-4d45-916f-4c315bdc90a9" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_3c49d222-ecdd-40ca-9f0d-6ae601d202e8" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_51da4efc-7f36-4d45-916f-4c315bdc90a9" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_3c49d222-ecdd-40ca-9f0d-6ae601d202e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsFromSaleOfFutureRoyalties_0b906aca-7e04-4e5e-9f60-5d6a33e4f6a0" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_3c49d222-ecdd-40ca-9f0d-6ae601d202e8" xlink:to="loc_mgnx_ProceedsFromSaleOfFutureRoyalties_0b906aca-7e04-4e5e-9f60-5d6a33e4f6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTransactionCosts_ee222386-7c84-44a1-a84d-1ea239233673" xlink:href="mgnx-20230331.xsd#mgnx_DeferredTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_3c49d222-ecdd-40ca-9f0d-6ae601d202e8" xlink:to="loc_mgnx_DeferredTransactionCosts_ee222386-7c84-44a1-a84d-1ea239233673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_12bcfa56-9c12-4249-b91e-4df91041c210" xlink:href="mgnx-20230331.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward_3c49d222-ecdd-40ca-9f0d-6ae601d202e8" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_12bcfa56-9c12-4249-b91e-4df91041c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties_18393609-a429-4baa-b3d1-8a7798730daa" xlink:href="mgnx-20230331.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_51da4efc-7f36-4d45-916f-4c315bdc90a9" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyalties_18393609-a429-4baa-b3d1-8a7798730daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashRoyaltyRevenue_b68ae73c-c62d-477f-abff-476d65194632" xlink:href="mgnx-20230331.xsd#mgnx_NonCashRoyaltyRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract_51da4efc-7f36-4d45-916f-4c315bdc90a9" xlink:to="loc_mgnx_NonCashRoyaltyRevenue_b68ae73c-c62d-477f-abff-476d65194632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6d8448a9-bc6c-4880-80f6-ca84b0f884ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6d8448a9-bc6c-4880-80f6-ca84b0f884ca" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0853bf2b-5c77-48f9-888e-c09a9e34beda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c280cebc-88aa-4f2e-b8ba-549e6e9d0c39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0853bf2b-5c77-48f9-888e-c09a9e34beda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_342b7e93-54d0-4dfc-9490-016a17c9d8d9" xlink:href="mgnx-20230331.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0853bf2b-5c77-48f9-888e-c09a9e34beda" xlink:to="loc_mgnx_AtTheMarketOfferingMember_342b7e93-54d0-4dfc-9490-016a17c9d8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_41e1de1f-a816-4a14-a7d2-16c93656bf52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e672378a-fa15-42f3-a0a8-40e60b93c858" xlink:to="loc_us-gaap_EquityComponentDomain_41e1de1f-a816-4a14-a7d2-16c93656bf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3ddd13fb-cdfd-4c64-9d9d-97dacc2b3261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_41e1de1f-a816-4a14-a7d2-16c93656bf52" xlink:to="loc_us-gaap_CommonStockMember_3ddd13fb-cdfd-4c64-9d9d-97dacc2b3261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7bdeefa1-3bca-4f23-a217-9e40acacd5eb" xlink:to="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_61b9e695-7fb9-4a7c-b835-57a03727d86c" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_61b9e695-7fb9-4a7c-b835-57a03727d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0d7a05-3f50-4522-8f0b-0dc742d81958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0d7a05-3f50-4522-8f0b-0dc742d81958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_53cf1963-57c5-474b-9219-0a07ccf7de5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_53cf1963-57c5-474b-9219-0a07ccf7de5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c1731a16-25df-4156-8ab7-6243f084d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c1731a16-25df-4156-8ab7-6243f084d0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c3963d7a-3030-40a5-88a5-fc37b14d3d70" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_c3963d7a-3030-40a5-88a5-fc37b14d3d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2dbe2022-e7cb-43b2-8adf-4bca57cbd40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2dbe2022-e7cb-43b2-8adf-4bca57cbd40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_abf276a5-703b-40b9-991e-bfc5e136caf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ea386fca-6e83-4813-93cb-cb321523c942" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_abf276a5-703b-40b9-991e-bfc5e136caf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_dbbc80d9-3654-45e5-b35a-1a065c9250e9" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_dbbc80d9-3654-45e5-b35a-1a065c9250e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_83522d7a-b9a5-4e12-b0d8-d088ccb3f686" xlink:to="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_3a759433-b251-4ba4-ab79-c3fa8d6f93f7" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_3a759433-b251-4ba4-ab79-c3fa8d6f93f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_2b3a8939-2cb2-4ab5-9041-2b078c208699" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_2b3a8939-2cb2-4ab5-9041-2b078c208699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_75d6b9d6-d8b3-49dc-884d-db895d7b4458" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a7ae00a7-d6d2-4d1c-8247-db4203d80cd7" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_75d6b9d6-d8b3-49dc-884d-db895d7b4458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c67402df-9a6a-4cac-8562-2cb48cb6ed88" xlink:to="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_09d55a2b-43ab-47a6-8920-83a379704cc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:to="loc_srt_MinimumMember_09d55a2b-43ab-47a6-8920-83a379704cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_597bedf0-3107-4659-b46b-31a009aa8548" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_612011fd-66cb-4c2d-b052-ca9cdd37eef8" xlink:to="loc_srt_MaximumMember_597bedf0-3107-4659-b46b-31a009aa8548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d4cc49c7-6306-44bf-9d2d-52d7986ac1d3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_d9299d90-1c38-4140-b02c-a3067692bff7" xlink:href="mgnx-20230331.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:to="loc_mgnx_IncyteCorporationMember_d9299d90-1c38-4140-b02c-a3067692bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_80985154-0356-4d09-889f-d049629b3a1c" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09252f30-c6fc-405f-b335-9605f4265260" xlink:to="loc_mgnx_IMabBiopharmaMember_80985154-0356-4d09-889f-d049629b3a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c94f2d8-6f7c-4935-af26-11cd559d0a2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_cc453448-fa91-47be-9a53-4cf7bb915092" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_cc453448-fa91-47be-9a53-4cf7bb915092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_239b9fb7-cc9a-461b-8772-3ed95fabfff1" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_cc453448-fa91-47be-9a53-4cf7bb915092" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_239b9fb7-cc9a-461b-8772-3ed95fabfff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_e86fbf4c-2c20-4aad-968d-2f2883bdf6b3" xlink:href="mgnx-20230331.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_e86fbf4c-2c20-4aad-968d-2f2883bdf6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_6dfffa43-231a-43c3-9616-d2b31599c206" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66bc4aba-9730-475c-b030-b07cac7d3d2f" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_6dfffa43-231a-43c3-9616-d2b31599c206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae2f6fd-a2a0-4b5e-b179-a53adebca98d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ef228bb9-5af4-4803-9ad6-0fbfac397d9a" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ef228bb9-5af4-4803-9ad6-0fbfac397d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_bc91b3e8-cc11-4b7b-aaef-5684ad80ba41" xlink:href="mgnx-20230331.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_TotalAnnualFixedPayments_bc91b3e8-cc11-4b7b-aaef-5684ad80ba41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_a7bfbaab-bfd1-4e0c-99cd-dc347a4e73fc" xlink:href="mgnx-20230331.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_a7bfbaab-bfd1-4e0c-99cd-dc347a4e73fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4b679f4e-5de7-4d2d-9b0e-923edcce0a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_Revenues_4b679f4e-5de7-4d2d-9b0e-923edcce0a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_216a9918-f57a-483a-831a-2545fd19a921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ContractWithCustomerLiability_216a9918-f57a-483a-831a-2545fd19a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fcc0f33-b6b8-4a89-b936-3ddac1cf4153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fcc0f33-b6b8-4a89-b936-3ddac1cf4153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8fd2ffea-9740-4ea6-9796-697f02d1a19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8fd2ffea-9740-4ea6-9796-697f02d1a19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_3ab07136-cac5-46f2-934a-3452f198c810" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_3ab07136-cac5-46f2-934a-3452f198c810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f4de0368-c1a5-44a5-9d3f-ae955e6d6ff5" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f4de0368-c1a5-44a5-9d3f-ae955e6d6ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_ec313305-b9ef-4786-b4e0-6e58af37c29a" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_ec313305-b9ef-4786-b4e0-6e58af37c29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_f4fb0114-2f87-49b0-a26e-f7c97981b84a" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_f4fb0114-2f87-49b0-a26e-f7c97981b84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_8d2a38a3-4f5a-4766-8a10-29f3c3173b6d" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_8d2a38a3-4f5a-4766-8a10-29f3c3173b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fdf15d9e-7101-4ef0-b760-ca6222abd22b" xlink:href="mgnx-20230331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fdf15d9e-7101-4ef0-b760-ca6222abd22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_b6a743f2-32e7-4e8e-8cb5-98898f3eea39" xlink:href="mgnx-20230331.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60525d63-f4a2-47ce-a636-35d26ede2275" xlink:to="loc_mgnx_NumberOfPerformanceObligations_b6a743f2-32e7-4e8e-8cb5-98898f3eea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadScienceIncDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueGileadScienceIncDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueGileadScienceIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2463c2dd-f2bd-42e2-8d3b-250fb627087a" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2463c2dd-f2bd-42e2-8d3b-250fb627087a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:to="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83e938ab-0077-46c7-a9e4-c4237054f050" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_89815b30-d3b5-4f89-9840-cba89dabe0e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83e938ab-0077-46c7-a9e4-c4237054f050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_c4e31ab8-9fdf-4ff2-86ab-5b682deb5de2" xlink:href="mgnx-20230331.xsd#mgnx_GileadMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83e938ab-0077-46c7-a9e4-c4237054f050" xlink:to="loc_mgnx_GileadMember_c4e31ab8-9fdf-4ff2-86ab-5b682deb5de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b15e1261-4a83-4322-97be-7ae0a14d935b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35ce9458-72d6-4024-9309-348736f7f69a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b15e1261-4a83-4322-97be-7ae0a14d935b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_b8c201c4-386f-434e-b8c1-f79465e7e7bd" xlink:href="mgnx-20230331.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b15e1261-4a83-4322-97be-7ae0a14d935b" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_b8c201c4-386f-434e-b8c1-f79465e7e7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ab4faf-b49b-4235-ad58-3ab653565420" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_9815d97b-04fe-43f2-8fe6-7991422bca98" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_mgnx_NonRefundableUpfrontFees_9815d97b-04fe-43f2-8fe6-7991422bca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c2bdd1fe-cd4d-4f0e-b41c-0da3502362d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_Revenues_c2bdd1fe-cd4d-4f0e-b41c-0da3502362d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8a98ab01-3cc8-43d6-aedb-9da49cce1fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8a98ab01-3cc8-43d6-aedb-9da49cce1fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3b2115be-82be-4e17-8365-3219f529ce35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3b2115be-82be-4e17-8365-3219f529ce35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ee5a59d3-6a82-4b5e-8b7d-88dfd91a1daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ee5a59d3-6a82-4b5e-8b7d-88dfd91a1daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_63b649ed-6b77-4338-b362-e7ec3f5d748e" xlink:href="mgnx-20230331.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf15b8de-59a2-47f3-bb62-711e71695e5d" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_63b649ed-6b77-4338-b362-e7ec3f5d748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a185bd99-eff2-469f-9d1b-16b92860a1f1" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a185bd99-eff2-469f-9d1b-16b92860a1f1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ea60a3cb-3b33-48c7-8708-6bf62d975544" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_636c73a2-adfe-4e52-87cd-8198a0816ae0" xlink:href="mgnx-20230331.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_636c73a2-adfe-4e52-87cd-8198a0816ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_3657c7fd-f895-4abc-b8f0-70db5e2e63f3" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_3657c7fd-f895-4abc-b8f0-70db5e2e63f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_8ed1d3dc-09a6-4f3c-846d-26abe9943999" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_8ed1d3dc-09a6-4f3c-846d-26abe9943999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_d9b6c247-c2f6-4138-b9c0-9b6a1913968b" xlink:href="mgnx-20230331.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c782b0b-f861-47c2-a3ab-25720f6f67da" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_d9b6c247-c2f6-4138-b9c0-9b6a1913968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faffb83e-816b-4491-8d3a-cc436fe16901" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2829dccb-fe0d-493c-b18e-1cd8ecafd32d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faffb83e-816b-4491-8d3a-cc436fe16901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_b199abe6-1c7d-48c4-b46a-39c1721062b4" xlink:href="mgnx-20230331.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faffb83e-816b-4491-8d3a-cc436fe16901" xlink:to="loc_mgnx_ZaiLabMember_b199abe6-1c7d-48c4-b46a-39c1721062b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccbe6aa0-b774-4758-bd99-abc421376fd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd06534f-7b18-4cc0-80bd-59d6e761a23a" xlink:to="loc_srt_RangeMember_ccbe6aa0-b774-4758-bd99-abc421376fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10354bd6-24c7-4e03-8674-a244814aa92d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ccbe6aa0-b774-4758-bd99-abc421376fd1" xlink:to="loc_srt_MaximumMember_10354bd6-24c7-4e03-8674-a244814aa92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a01cebc-e800-4f0b-bb44-dd087d9550ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d500acef-0cb3-4867-a249-36a03aea9df9" xlink:to="loc_us-gaap_EquityComponentDomain_0a01cebc-e800-4f0b-bb44-dd087d9550ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1525b986-7a83-4769-b6d8-fa22d66336d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a01cebc-e800-4f0b-bb44-dd087d9550ee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1525b986-7a83-4769-b6d8-fa22d66336d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42ad57ad-e8b4-4a86-88de-98708d0b0a76" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2884a52a-dae7-4475-9586-66ddf2a3f03f" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2884a52a-dae7-4475-9586-66ddf2a3f03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_dfb96ee8-2c23-4aee-baea-7377cd3afc63" xlink:href="mgnx-20230331.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_dfb96ee8-2c23-4aee-baea-7377cd3afc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_44f91a6c-caf6-432c-aef1-a8d34537e06f" xlink:href="mgnx-20230331.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_44f91a6c-caf6-432c-aef1-a8d34537e06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7ff5dd6c-8b57-43f3-a8e4-bf64475ed833" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7ff5dd6c-8b57-43f3-a8e4-bf64475ed833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_129488c2-f47c-432e-99be-a7c89aa61b8d" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_129488c2-f47c-432e-99be-a7c89aa61b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_75f2e9b0-871f-4844-8fa0-39a545011daa" xlink:href="mgnx-20230331.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_75f2e9b0-871f-4844-8fa0-39a545011daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_56d5ef69-f85c-4666-8f91-7c1d63834ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_56d5ef69-f85c-4666-8f91-7c1d63834ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dc7a04b0-053d-4476-aca2-b96c3ed637b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_Revenues_dc7a04b0-053d-4476-aca2-b96c3ed637b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1acd157e-3ff8-42e6-89e7-2bf924f378d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1acd157e-3ff8-42e6-89e7-2bf924f378d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97f6b345-c425-46bb-98b6-ade02aaad5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97f6b345-c425-46bb-98b6-ade02aaad5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1959e8d3-bcc9-4b9a-ac6f-5db240a37579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1959e8d3-bcc9-4b9a-ac6f-5db240a37579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_1c110305-41c8-41e7-a590-912f15d036e5" xlink:href="mgnx-20230331.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_1c110305-41c8-41e7-a590-912f15d036e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_72611354-c2f3-427c-8f87-be31343e7cd7" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_72611354-c2f3-427c-8f87-be31343e7cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_4a4dbc1c-b3c3-4898-aa45-e5798833f151" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_4a4dbc1c-b3c3-4898-aa45-e5798833f151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b876efcb-77ac-43a3-8b30-929107720534" xlink:href="mgnx-20230331.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_b876efcb-77ac-43a3-8b30-929107720534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6a1c9cb-dba4-401a-99a9-00b05773ef18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6a1c9cb-dba4-401a-99a9-00b05773ef18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c629b741-7234-47c8-bd1b-745a7694d442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c629b741-7234-47c8-bd1b-745a7694d442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonesValueAddedTax_57e0a848-6dd9-4dd7-98b4-e6ac272bb201" xlink:href="mgnx-20230331.xsd#mgnx_MilestonesValueAddedTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb7594c2-6da2-4722-a8c5-b7a8779756c0" xlink:to="loc_mgnx_MilestonesValueAddedTax_57e0a848-6dd9-4dd7-98b4-e6ac272bb201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8d1b7f9a-0b66-4718-8fe0-791403b694a5" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8d1b7f9a-0b66-4718-8fe0-791403b694a5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_62851dcf-310b-4cc6-a70a-f4e52bae2c3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_0a940cae-412b-4c23-87b8-4c4bff7d8406" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:to="loc_mgnx_IMabBiopharmaMember_0a940cae-412b-4c23-87b8-4c4bff7d8406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_af6b12ba-6fa9-4289-81d3-50997e19015d" xlink:href="mgnx-20230331.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53293fcb-1134-4a0c-81f6-accb475a9823" xlink:to="loc_mgnx_IncyteCorporationMember_af6b12ba-6fa9-4289-81d3-50997e19015d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_baafa86e-6f08-4301-9628-7a5bca8d17fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_b74d6b02-5fec-4399-ad11-955ed230fe15" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_b74d6b02-5fec-4399-ad11-955ed230fe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e28175cd-df08-4997-8fbf-0af0b3d3d5e8" xlink:href="mgnx-20230331.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cf0edc17-1c09-4440-beac-865e0887684f" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e28175cd-df08-4997-8fbf-0af0b3d3d5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c098fcee-8036-45c3-90f7-e8d1e8f733e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_435b5de1-8527-43a7-82b8-3bfba68af907" xlink:to="loc_srt_RangeMember_c098fcee-8036-45c3-90f7-e8d1e8f733e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40f5b0aa-ba06-457f-b6e4-e7ebc7146441" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c098fcee-8036-45c3-90f7-e8d1e8f733e3" xlink:to="loc_srt_MaximumMember_40f5b0aa-ba06-457f-b6e4-e7ebc7146441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8682c1f-393c-45aa-8f63-2abfae8fc1d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73978cff-78da-4965-9cb6-a5356e079dbb" xlink:to="loc_srt_ProductsAndServicesDomain_e8682c1f-393c-45aa-8f63-2abfae8fc1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_530fb683-6558-497f-b4dc-97315201f041" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8682c1f-393c-45aa-8f63-2abfae8fc1d9" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_530fb683-6558-497f-b4dc-97315201f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6e5afa92-5de1-420e-a67e-2b0854288b77" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_efcf77f4-fe18-484e-985b-a267b6c68958" xlink:href="mgnx-20230331.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_NonRefundableUpfrontFees_efcf77f4-fe18-484e-985b-a267b6c68958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_28981cfd-895a-41f3-87fa-ce3cba0ae87c" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_28981cfd-895a-41f3-87fa-ce3cba0ae87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_4f5397a6-fec2-4431-88eb-3d27a2c5deeb" xlink:href="mgnx-20230331.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_4f5397a6-fec2-4431-88eb-3d27a2c5deeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_0b1bbdc0-f13b-4103-9549-70b840918ff6" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationArrangementOneTimeCreditPaidPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_0b1bbdc0-f13b-4103-9549-70b840918ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_593cbaa0-e11e-4084-a60e-423247f9a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_Revenues_593cbaa0-e11e-4084-a60e-423247f9a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_421ef797-0911-41ac-ac8f-1febbee182c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_421ef797-0911-41ac-ac8f-1febbee182c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_34be527b-7a6c-44a3-bda1-de778c4ec3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_34be527b-7a6c-44a3-bda1-de778c4ec3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_25edc058-1679-46ae-92e6-56f689bb667d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_25edc058-1679-46ae-92e6-56f689bb667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_c6ff4ab8-e956-418b-873c-ec87cffab4d2" xlink:href="mgnx-20230331.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2edc134b-0e6c-40ff-a6b0-12c32d67073c" xlink:to="loc_mgnx_OneTimeMillstoneCredit_c6ff4ab8-e956-418b-873c-ec87cffab4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_bc17582f-33dd-42db-81b7-6bc6d62d065a" xlink:href="mgnx-20230331.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_bc17582f-33dd-42db-81b7-6bc6d62d065a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05891846-5f73-4d15-bcf2-8aed36696b8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fbd6fa59-7570-4b9f-b4d5-09dff66b4622" xlink:to="loc_srt_ProductsAndServicesDomain_05891846-5f73-4d15-bcf2-8aed36696b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_f6182bfa-b86c-4776-b2ec-b2f99ac2b81f" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05891846-5f73-4d15-bcf2-8aed36696b8d" xlink:to="loc_mgnx_RevenuesFromGrantsMember_f6182bfa-b86c-4776-b2ec-b2f99ac2b81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8d9fd817-afc3-4eb9-bc02-f2f8b15f6c97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_773cb2c6-92aa-4a75-b85c-d35f3a9b056b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8d9fd817-afc3-4eb9-bc02-f2f8b15f6c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_a3f623a9-fc3f-4019-8881-114bb4c723f4" xlink:href="mgnx-20230331.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8d9fd817-afc3-4eb9-bc02-f2f8b15f6c97" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_a3f623a9-fc3f-4019-8881-114bb4c723f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e1d612d-2b9e-4f82-8eb5-70713f7d0b34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e64a884f-e001-4e51-a30d-378495bfc326" xlink:to="loc_srt_RangeMember_9e1d612d-2b9e-4f82-8eb5-70713f7d0b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4ab5988-9316-49e2-a70e-16ae5678b359" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e1d612d-2b9e-4f82-8eb5-70713f7d0b34" xlink:to="loc_srt_MaximumMember_a4ab5988-9316-49e2-a70e-16ae5678b359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1bd44ac0-6d40-4949-8fea-38869ced85ef" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_350ed640-bc4e-4408-b5e3-3885568ff623" xlink:href="mgnx-20230331.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_350ed640-bc4e-4408-b5e3-3885568ff623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_6066cb81-91f8-48bd-adc2-a3a26ed4dcc2" xlink:href="mgnx-20230331.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_6066cb81-91f8-48bd-adc2-a3a26ed4dcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2d4fc1ef-166b-4506-aacd-0f3ca271e79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02d54db0-aba2-4674-b75f-dbeafed6addb" xlink:to="loc_us-gaap_Revenues_2d4fc1ef-166b-4506-aacd-0f3ca271e79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#RevenueProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d712e261-7f4f-4bad-a9ba-8c033f352178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d712e261-7f4f-4bad-a9ba-8c033f352178" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cebf688d-aedc-4dc7-9d4a-607397822bcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_355b040b-05b8-49ad-a849-4d498ee0d7d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cebf688d-aedc-4dc7-9d4a-607397822bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_543601e3-bdd7-4c48-9521-c091a2b654de" xlink:href="mgnx-20230331.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cebf688d-aedc-4dc7-9d4a-607397822bcc" xlink:to="loc_mgnx_ProventionBioMember_543601e3-bdd7-4c48-9521-c091a2b654de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7d9e56f3-b034-4c94-a4c4-7bb928f4398e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_93dcab1c-f0a0-4835-9462-7d1139bdf76d" xlink:href="mgnx-20230331.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:to="loc_mgnx_ProventionPRV3279Member_93dcab1c-f0a0-4835-9462-7d1139bdf76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_cb930caf-ff50-4946-90d4-b8c4412d643a" xlink:href="mgnx-20230331.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fd91e841-b5bf-449b-8a5e-a1d81c29dded" xlink:to="loc_mgnx_ProventionPRV031Member_cb930caf-ff50-4946-90d4-b8c4412d643a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20843487-02ce-4415-85ba-a9f6f3068546" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_7c35e561-e411-4034-9752-c7a1ffa28d60" xlink:href="mgnx-20230331.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_7c35e561-e411-4034-9752-c7a1ffa28d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_a4d4a8bd-f4b9-453a-9803-68791e15287d" xlink:href="mgnx-20230331.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2601e98e-2b82-4cbe-9825-cce3eba06848" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_a4d4a8bd-f4b9-453a-9803-68791e15287d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eca0b736-c059-4880-98a4-d4c6e67efd8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dbb07bd7-aca3-414d-a0fe-fbeda8796d8f" xlink:to="loc_srt_ProductsAndServicesDomain_eca0b736-c059-4880-98a4-d4c6e67efd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b843a0a3-c439-4c72-9aff-7468c0ea3cf2" xlink:href="mgnx-20230331.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eca0b736-c059-4880-98a4-d4c6e67efd8c" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b843a0a3-c439-4c72-9aff-7468c0ea3cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b1d2da6-abcb-423c-8e03-bd8ba4f0849e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_cd955c79-4b87-4c9a-8f6c-264bb3a38c06" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_cd955c79-4b87-4c9a-8f6c-264bb3a38c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e2d79857-21b4-4c68-b1ad-269953c0295d" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e2d79857-21b4-4c68-b1ad-269953c0295d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_1775aa3c-90a4-49a0-8503-28ba417d8bff" xlink:href="mgnx-20230331.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_1775aa3c-90a4-49a0-8503-28ba417d8bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2a87106c-ba46-4827-92c7-42d9b0540b1d" xlink:href="mgnx-20230331.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2a87106c-ba46-4827-92c7-42d9b0540b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_71a1fed8-ee67-452b-931e-03fdcc2f6fc0" xlink:href="mgnx-20230331.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_71a1fed8-ee67-452b-931e-03fdcc2f6fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_4446cab3-57cd-43f4-a219-240b6a4c8211" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_4446cab3-57cd-43f4-a219-240b6a4c8211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_0aea4502-a2e6-41b7-aa2b-c8c7b0cee3af" xlink:href="mgnx-20230331.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_0aea4502-a2e6-41b7-aa2b-c8c7b0cee3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_23dea7e2-8219-40a7-8988-525d41e59cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_us-gaap_Revenues_23dea7e2-8219-40a7-8988-525d41e59cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ReceivableFromCollaborationPartner_e21f3123-081a-44e0-a0c1-0e060a787125" xlink:href="mgnx-20230331.xsd#mgnx_ReceivableFromCollaborationPartner"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b3fdaa8a-772d-4ba3-b148-9b70914c0a74" xlink:to="loc_mgnx_ReceivableFromCollaborationPartner_e21f3123-081a-44e0-a0c1-0e060a787125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21ed7c33-52ff-4e4d-85bc-15e3e0df72b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21ed7c33-52ff-4e4d-85bc-15e3e0df72b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:to="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_cc619086-bbac-4bc9-a82b-7928572f207a" xlink:to="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b7201061-8b9c-427e-bc68-1f8256784203" xlink:href="mgnx-20230331.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b7201061-8b9c-427e-bc68-1f8256784203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_5e53ab7e-d092-4103-817f-f7ef12b3e4d4" xlink:href="mgnx-20230331.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_5e53ab7e-d092-4103-817f-f7ef12b3e4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_3370df9d-ad9d-439a-8a49-c784192a80e0" xlink:href="mgnx-20230331.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bb6a2740-2925-41a5-a340-9a0fee53bf30" xlink:to="loc_mgnx_StockIncentivePlan2013Member_3370df9d-ad9d-439a-8a49-c784192a80e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cad4b65-fe0c-4d5e-80ee-0b7df155c8ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2dcf2a9e-25eb-45da-af84-a9b4f8daaa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2dcf2a9e-25eb-45da-af84-a9b4f8daaa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c3fc0404-5139-4f04-b53c-88474dd47424" xlink:href="mgnx-20230331.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_c3fc0404-5139-4f04-b53c-88474dd47424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_c6f891bb-988d-44df-98c8-fcf468f15f4d" xlink:href="mgnx-20230331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_c6f891bb-988d-44df-98c8-fcf468f15f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_64cd8d9f-8ad4-44c7-b1ba-4967bb02e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_64cd8d9f-8ad4-44c7-b1ba-4967bb02e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13d08054-ffd0-4bf9-903e-2a494aa508c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13d08054-ffd0-4bf9-903e-2a494aa508c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9805314b-44c7-4833-bc4e-e0b4ece11c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9805314b-44c7-4833-bc4e-e0b4ece11c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea62e7c3-757d-4120-a733-602c8d060617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea62e7c3-757d-4120-a733-602c8d060617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e18abf57-1421-4ff9-8070-f521af540d3c" xlink:href="mgnx-20230331.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_e18abf57-1421-4ff9-8070-f521af540d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_5e51cea8-973d-482e-ba13-36fc2d68944b" xlink:href="mgnx-20230331.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc1037c9-979f-48ba-97b7-b04828668baa" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_5e51cea8-973d-482e-ba13-36fc2d68944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21ed7c33-52ff-4e4d-85bc-15e3e0df72b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dadd7393-ede2-4940-a0fe-516974b9442c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_40640c88-3bfd-4d66-b0b9-c53b9f51b00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_40640c88-3bfd-4d66-b0b9-c53b9f51b00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e073900-5838-4a67-8e51-8e2d69a65ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7f9ef6ac-2ed6-438c-8597-39771616fad4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e073900-5838-4a67-8e51-8e2d69a65ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49432a6-9c82-4df5-bf86-94f54ff46d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b44b14fa-c51e-42db-8233-62981356b1fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49432a6-9c82-4df5-bf86-94f54ff46d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c1e059b1-3c31-4527-a190-4bcd774e443e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49432a6-9c82-4df5-bf86-94f54ff46d30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c1e059b1-3c31-4527-a190-4bcd774e443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc3ae7d0-1194-4023-9e01-6241a545ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc3ae7d0-1194-4023-9e01-6241a545ab22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:to="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_40cc2e12-5a0d-456c-9fe7-49023ff4d9ad" xlink:to="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d89a807e-4232-4db7-af89-f2770aafa90a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:to="loc_srt_MinimumMember_d89a807e-4232-4db7-af89-f2770aafa90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_daf39c84-68fa-46bf-8de9-3a40d5d5ec8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc62b9a3-51d7-4dfe-be77-65261a5e1ff0" xlink:to="loc_srt_MaximumMember_daf39c84-68fa-46bf-8de9-3a40d5d5ec8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709e4c8a-20ed-4f1c-9dd5-640bd1964e76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8ecc212-3804-48e2-990e-d42a4055605a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8ecc212-3804-48e2-990e-d42a4055605a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b1ecb71-a229-4d85-8031-4dbf6b3aaaab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b1ecb71-a229-4d85-8031-4dbf6b3aaaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_25b02e83-67a4-42d3-b6fb-3f263767c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_25b02e83-67a4-42d3-b6fb-3f263767c0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1964792b-67a9-46b9-837a-271c222977ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa87ced4-0431-45cc-8b5c-85bd29ccbdba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1964792b-67a9-46b9-837a-271c222977ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b9e36945-1a38-4345-ad92-7ce1e57d8253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b9e36945-1a38-4345-ad92-7ce1e57d8253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2378a533-c011-44a2-8547-d1fd3eb0dcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2378a533-c011-44a2-8547-d1fd3eb0dcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e125aa22-4482-4f6a-a116-796253881a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e125aa22-4482-4f6a-a116-796253881a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2caedf83-b9f4-4fa8-b99e-530d7a661e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2caedf83-b9f4-4fa8-b99e-530d7a661e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_005a0edc-b579-4f0c-8a26-3b007c623d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_005a0edc-b579-4f0c-8a26-3b007c623d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7eb1beed-ce5d-4e3a-83ee-7cfffe222553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7eb1beed-ce5d-4e3a-83ee-7cfffe222553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7f28f067-5c43-4928-9c0a-3c1f7c1a3b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7f28f067-5c43-4928-9c0a-3c1f7c1a3b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_67fdbfb2-ff89-4998-80a6-e5f123c3b920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5708c191-4bc9-464e-b4f8-80baab010851" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_67fdbfb2-ff89-4998-80a6-e5f123c3b920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce8ebc85-aba1-44c4-86c3-ca5addc611ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce8ebc85-aba1-44c4-86c3-ca5addc611ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9518ceab-3bfd-440b-8f9a-ea7de7b86f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9518ceab-3bfd-440b-8f9a-ea7de7b86f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a849c1e-cedb-41de-a83c-78a5bdc1423e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a849c1e-cedb-41de-a83c-78a5bdc1423e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e558b737-db9d-4946-aa32-9ea9e2b53678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e558b737-db9d-4946-aa32-9ea9e2b53678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8a6bd416-f584-46f7-8c98-bbe4765954a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8a6bd416-f584-46f7-8c98-bbe4765954a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da115b38-8d68-4088-926f-65581c07a03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da115b38-8d68-4088-926f-65581c07a03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_788fb184-b3dd-4dd9-8770-a4ee9063b5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_788fb184-b3dd-4dd9-8770-a4ee9063b5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_75d41969-3460-436b-a965-35e7556cf060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb30d767-0619-40f7-b9bf-a92fcaef4a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_75d41969-3460-436b-a965-35e7556cf060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_77891525-8479-4212-a568-6a4769e6dc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_77891525-8479-4212-a568-6a4769e6dc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2c4e5322-68a4-4565-8504-6df90179c65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2c4e5322-68a4-4565-8504-6df90179c65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_adc0fe8b-e681-4e7b-b3d3-100f36e08fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_adc0fe8b-e681-4e7b-b3d3-100f36e08fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e995db8b-a952-4330-a76b-3a6f7a28c2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e995db8b-a952-4330-a76b-3a6f7a28c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_32bda96c-0d29-4768-9b7f-387245d0df1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_32bda96c-0d29-4768-9b7f-387245d0df1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c9bac4a0-2200-4377-83ed-b6a01066d696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c6d6012-6b9e-4393-8726-ea8721cc495f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c9bac4a0-2200-4377-83ed-b6a01066d696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d9da65d-282a-41e3-ae7c-7ffa8cbe2aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d9da65d-282a-41e3-ae7c-7ffa8cbe2aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1c5085a2-5d70-4f11-884c-0163c09413a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1c5085a2-5d70-4f11-884c-0163c09413a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_076ff540-e6eb-41ae-8e85-ae56f9f5faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_076ff540-e6eb-41ae-8e85-ae56f9f5faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5c884930-2d1f-4dd5-931b-4b3e2068a8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5c884930-2d1f-4dd5-931b-4b3e2068a8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f8b59af4-5670-496d-b891-d5cd2fd9dfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f64f4c-6457-4a5b-9ba8-89f8958be367" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f8b59af4-5670-496d-b891-d5cd2fd9dfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c679ff4c-f09d-4ea9-96a0-3ef17b2f8058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c679ff4c-f09d-4ea9-96a0-3ef17b2f8058" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:to="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f5f2d9-6720-4625-b9dc-f8ab9608ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dab5bb29-7443-40ab-af4c-c749f15e704f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f5f2d9-6720-4625-b9dc-f8ab9608ef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f7522000-d867-4def-8316-fd7a419b2020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f5f2d9-6720-4625-b9dc-f8ab9608ef51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f7522000-d867-4def-8316-fd7a419b2020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91c71283-715e-47a5-8996-db8f21496ee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd6d3e1-90c9-4dd3-9f99-330d99f0639c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd6d3e1-90c9-4dd3-9f99-330d99f0639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_13e4a077-05a8-4a45-af57-70c97be93df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_13e4a077-05a8-4a45-af57-70c97be93df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_ae89e0e2-0521-4e48-8cf8-9268c7b71e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_ae89e0e2-0521-4e48-8cf8-9268c7b71e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b30579a7-b044-4528-9a87-2e00d24d0b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b30579a7-b044-4528-9a87-2e00d24d0b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6b26ee09-34eb-4942-90e9-76937d655c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6b26ee09-34eb-4942-90e9-76937d655c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cb5da82-980e-416a-b5ec-928962b537a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4719ad8c-3021-4d36-bb6f-3d1ef7bdf8b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cb5da82-980e-416a-b5ec-928962b537a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49c545eb-2ebd-4b16-96f7-b3b6b4b0f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49c545eb-2ebd-4b16-96f7-b3b6b4b0f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_97687d59-93a9-441d-b9dc-98f3d9cd32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_97687d59-93a9-441d-b9dc-98f3d9cd32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82a6574a-8807-4098-b41c-0ac905fed516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82a6574a-8807-4098-b41c-0ac905fed516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_103ebeae-0dfd-45ae-beb1-14e1c16249b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a240f3a-77ce-4b31-a2c0-73a885f3a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_103ebeae-0dfd-45ae-beb1-14e1c16249b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d9d7fea-3388-4118-9bba-a2511e3835c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d9d7fea-3388-4118-9bba-a2511e3835c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_a23fa4e7-3d02-43fd-a289-d04d94a59483" xlink:href="mgnx-20230331.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_a23fa4e7-3d02-43fd-a289-d04d94a59483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d46d833-9701-4c2c-ba73-478fac1b980d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d46d833-9701-4c2c-ba73-478fac1b980d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f3b1040-fbc2-4198-8b8a-a8eb2bad2d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bddf7e1-e83b-4832-a96f-142a7818a05c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f3b1040-fbc2-4198-8b8a-a8eb2bad2d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20230331.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5a25622-b48a-48ed-9d63-1f083a4c96a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:href="mgnx-20230331.xsd#mgnx_InLicensingArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5a25622-b48a-48ed-9d63-1f083a4c96a5" xlink:to="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:to="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f2ff346-5aa3-47d5-af76-4275e7a2a502" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2bf46298-0d87-4867-9f22-ea152fa3be0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f2ff346-5aa3-47d5-af76-4275e7a2a502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_cfd88241-93e4-4236-90e5-37b416a55cb0" xlink:href="mgnx-20230331.xsd#mgnx_SynaffixBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f2ff346-5aa3-47d5-af76-4275e7a2a502" xlink:to="loc_mgnx_SynaffixBVMember_cfd88241-93e4-4236-90e5-37b416a55cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:href="mgnx-20230331.xsd#mgnx_InLicensingArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_InLicensingArrangementTable_98fa15fb-4636-489d-95aa-072e615a00ba" xlink:to="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_330c1f37-b087-4c8c-95bf-66b9516b7669" xlink:href="mgnx-20230331.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_330c1f37-b087-4c8c-95bf-66b9516b7669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec5c1eab-34e8-42a0-b26e-44c66f083951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_InLicensingArrangementLineItems_e93fc474-cfab-4dcf-af14-799d7d5d7ae4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec5c1eab-34e8-42a0-b26e-44c66f083951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309586001968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,838,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585802656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 224,264<span></span>
</td>
<td class="nump">$ 108,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">17,392<span></span>
</td>
<td class="nump">45,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">36,160<span></span>
</td>
<td class="nump">56,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,718<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">288,943<span></span>
</td>
<td class="nump">222,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">26,783<span></span>
</td>
<td class="nump">29,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">26,394<span></span>
</td>
<td class="nump">27,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">343,498<span></span>
</td>
<td class="nump">280,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">28,188<span></span>
</td>
<td class="nump">28,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">9,249<span></span>
</td>
<td class="nump">9,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,418<span></span>
</td>
<td class="nump">4,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,614<span></span>
</td>
<td class="nump">48,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyalties', window );">Liability related to future royalties [Abstract]</a></td>
<td class="nump">100,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">58,006<span></span>
</td>
<td class="nump">59,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">30,130<span></span>
</td>
<td class="nump">30,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">234,230<span></span>
</td>
<td class="nump">138,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,838,565 and 61,701,467 shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,240,345<span></span>
</td>
<td class="nump">1,235,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,131,703)<span></span>
</td>
<td class="num">(1,093,694)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">109,268<span></span>
</td>
<td class="nump">142,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 343,498<span></span>
</td>
<td class="nump">$ 280,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588672880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">61,838,565<span></span>
</td>
<td class="nump">61,701,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309586056848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CostOfManufacturingServices', window );">Cost of manufacturing services</a></td>
<td class="nump">3,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">45,872<span></span>
</td>
<td class="nump">61,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,527<span></span>
</td>
<td class="nump">16,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">62,922<span></span>
</td>
<td class="nump">77,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,426)<span></span>
</td>
<td class="num">(66,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest and other income</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Interest expense</a></td>
<td class="num">(656)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,009)<span></span>
</td>
<td class="num">(66,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (37,996)<span></span>
</td>
<td class="num">$ (66,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,809,817<span></span>
</td>
<td class="nump">61,324,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,809,817<span></span>
</td>
<td class="nump">61,324,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Collaborative and other agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 16,686<span></span>
</td>
<td class="nump">$ 7,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="nump">3,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember', window );">Contract Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromRoyalityAgreementsMemberMember', window );">RevenueFromRoyalityAgreementsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromRoyalityAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromRoyalityAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585847040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 1,213,002<span></span>
</td>
<td class="num">$ (973,936)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,333,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">178,214<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,218,263<span></span>
</td>
<td class="num">(1,040,379)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,701,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">142,013<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">1,235,095<span></span>
</td>
<td class="num">(1,093,694)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 4,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">2,914,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="num">$ (154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,838,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 109,268<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 1,240,345<span></span>
</td>
<td class="num">$ (1,131,703)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309586061808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (38,009)<span></span>
</td>
<td class="num">$ (66,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(372)<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashRoyaltyRevenue', window );">Non-cash royalty revenue</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashInterestExpenseRecognized', window );">Non-cash interest expense recognized</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">20,062<span></span>
</td>
<td class="num">(4,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">6,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLeaseNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="num">(11,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(677)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,213)<span></span>
</td>
<td class="nump">11,280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,833)<span></span>
</td>
<td class="num">(57,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(17,296)<span></span>
</td>
<td class="num">(54,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">45,750<span></span>
</td>
<td class="nump">37,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(359)<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">28,095<span></span>
</td>
<td class="num">(18,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(158)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NetProceedsFromSaleOfFutureRoyalties', window );">Net proceeds from sale of future royalties</a></td>
<td class="nump">99,655<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">100,118<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">115,380<span></span>
</td>
<td class="num">(76,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">108,884<span></span>
</td>
<td class="nump">123,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">224,264<span></span>
</td>
<td class="nump">47,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property, equipment and software included in accounts payable or accruals</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLeaseNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLeaseNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588136912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.  The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, product sales and royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates, adverse events involving financial institutions or the financial services industry and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div>The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588422688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company adopted the following significant accounting policies in addition to those disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the relevant accounting criteria under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#8217;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588389840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at March&#160;31, 2023 includes approximately $75.5 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588389840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>All available-for-sale marketable debt securities held as of March&#160;31, 2023 and December&#160;31, 2022 had contractual maturities of less than one year. All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of  December&#160;31, 2022 were in a loss position for less than twelve months. Unrealized losses on available-for-sale debt securities as of  December&#160;31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588312880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March&#160;31, 2023 and December&#160;31, 2022 is net of a reserve of $4.9&#160;million for unsaleable inventory.  These reserves are reflected in cost of product sales during the period they are recorded.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588382976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract', window );"><strong>Liability related to future royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock', window );">Liability Related To Sale Of Future Royalties</a></td>
<td class="text">Royalty Monetization Arrangement <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company&#8217;s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) (the DRI Transaction) under the Company&#8217;s Asset Purchase Agreement dated May 7, 2018, as amended (the Asset Purchase Agreement), with Provention Bio, Inc. (Provention). The Company retains its other economic interests related to TZIELD, including future potential development, regulatory, and commercial milestones.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Royalty Purchase Agreement, the Company received $100.0&#160;million from DRI for its single-digit royalty interest on global net sales of TZIELD under the Asset Purchase Agreement. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0&#160;million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. The Company may also receive an additional $50.0&#160;million milestone from DRI if TZIELD achieves a certain level of net sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $100.0&#160;million proceeds received from DRI under the Royalty Purchase Agreement were recorded as a liability for future royalties, net of transaction costs of $0.3&#160;million, which will be amortized over the term of the arrangement using the effective interest rate method. The Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company has significant continuing involvement in the delivery of future royalty payments to DRI and other existing obligations under the Asset Purchase Agreement. Royalty revenue will be recognized as earned on net sales of TZIELD, and the Company will record the royalty payments to DRI as a reduction of the liability when paid. The aggregate future estimated payments, less the $99.7&#160;million of net proceeds, will be recorded as interest expense over the term of the arrangement. As such payments are made to DRI, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement. The Company will estimate the payments to be made to DRI over the term of the Royalty Purchase Agreement based on forecasted royalties and will calculate the effective interest rate required to discount such payments back to the liability balance. Over the course of the Royalty Purchase Agreement, the actual effective interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as necessary.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the liability related to future royalties were as follows for the three months ended March 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:66.352%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue payable to DRI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588675520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' EquityIn November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The Company sold 3,622,186 shares of common stock resulting in net proceeds of approximately $98.2&#160;million through December 31, 2021 under the Sales Agreement. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increased the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million. In March 2023, the Company terminated the Sales Agreement and entered into a new sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0&#160;million through an ATM Offering. During the three months ended March 31, 2023, the Company sold 95,000 shares of common stock at a weighted average price per share of $6.60, resulting in net proceeds of approximately $0.6 million, net of offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309582896704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte), which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. MacroGenics will manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte in multiple indications, the Company could receive up to a total of $435.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $115.0 million in development milestones under the Incyte License Agreement, including $15.0 million received following the FDA approval of ZYNYZ. The Company is also eligible to receive tiered royalties of 15% to 24% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606) at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $115.0 million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and regulatory activities related to the further advancement of retifanlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized the $15.0&#160;million ZYNYZ approval milestone as revenue under the Incyte License Agreement during the three months ended March 31, 2023. During the three months ended March 31, 2022, no revenue was recognized under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $1.3 million and $0.3 million, respectively, for services performed under the Incyte Clinical Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will reassess the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company will defer revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Gilead Agreement. As of March&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$59.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$57.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current. As of December&#160;31, 2022, $59.8&#160;million in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$58.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#174; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through March&#160;31, 2023. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab: (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million. Therefore, the associated consideration, $8.1&#160;million net of value-added tax withholdings, was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the three months ended March 31, 2023, no revenue was recognized, and during the three months ended March 31, 2022, $5.0&#160;million in revenue was recognized under the 2018 Zai Lab Agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company. In August 2022, the Company and Zai Lab agreed to discontinue research and development of the Lead Program. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a stock purchase agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the stock purchase agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the remaining Programs, the Company could receive up to approximately $680.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in 2021. During the three months ended March 31, 2023 the Company recognized no revenue under the 2021 Zai Lab Agreement, and the Company recognized revenue of $0.3&#160;million during the three months ended March 31, 2022 under the 2021 Zai Lab Agreement.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of March&#160;31, 2023, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into the Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. Under the Asset Purchase Agreement, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones. In addition, Provention is obligated to make contingent milestone payments to the Company totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. In March 2023, the Company entered into a Royalty Purchase Agreement with DRI; see Note 6, Liability Related to Future Royalties, for additional information. The FDA approved the BLA for TZIELD (teplizumab-mzwv) in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amended the Asset Purchase Agreement. Under this amendment, the milestone for first approval was split into four equal payments, the first two of which were received prior to March 31, 2023. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company recognized $0.4 million in royalty revenue under these agreements based on the sales of TZIELD, and no revenue under these agreements during the three months ended March 31, 2022. As of March&#160;31, 2023, Provention owed the Company $30.0 million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet. This receivable was due to be paid on June 1, 2023 and September 1, 2023 under the amended Asset Purchase Agreement. Provention was acquired by Sanofi in April 2023. Sanofi accelerated the payment schedule and paid the Company the balance due subsequent to March 31, 2023. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. In August 2022, I-Mab notified the Company of its intention to terminate the I-Mab License Agreement effective February 25, 2023. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million, and $5.0&#160;million of milestone revenue has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement was recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment, was the best measure of progress towards satisfying the performance obligations. During the three months ended March 31, 2023 the Company recognized no revenue under the I-Mab License Agreement, and during the three months ended March 31, 2022 the Company recognized revenue of $0.2 million under the I-Mab License Agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023, the Company recognized no revenue for research and development activities performed under the I-Mab Clinical Supply Agreement. During the three months ended March 31, 2022, the Company recognized $0.9&#160;million under the agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $19.5&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur. Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $3.6&#160;million under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue during</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three months ended March 31, 2022. As of March&#160;31, 2023, $7.8&#160;million in revenue was deferred under this agreement, $7.1&#160;million of which was current and $0.7&#160;million of which was non-current.  </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div>Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March&#160;31, 2023 is $25.1&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended March 31, 2023 and 2022, the Company recognized revenue under the NIAID Contract of $0.3 million and $0.4 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588413968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the three months ended March&#160;31, 2023, no shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Equity Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of March&#160;31, 2023, under the 2003 Plan, there were options to purchase an aggregate of 61,572 shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the three months ended March&#160;31, 2023, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of March&#160;31, 2023, there were options to purchase an aggregate of 12,778,040 shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee stock options</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6% -94.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9% - 88.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 2.4%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,839,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,048,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,763,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the three months ended March&#160;31, 2023 and 2022 was $3.77 and $7.48, respectively. The total intrinsic value of options exercised during the three months ended March&#160;31, 2023 was de minimis and the total intrinsic value of options exercised during the three months ended 2022 was approximately $0.3 million. The total cash received for options exercised during the three months ended March&#160;31, 2023 and 2022 was de minimis. The total fair value of shares vested in the three months ended March&#160;31, 2023 and 2022 was approximately $0.6 million and $5.4 million, respectively. As of March&#160;31, 2023, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $29.2 million, which the Company expects to recognize over a weighted-average period of approximately 1.5 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company awards restricted stock units (RSUs) to employees. RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980,811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, there was $4.9 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.6 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309589476144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesIn-licensing arrangement<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V. (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $2.8&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  The Company incurred $1.5&#160;million and $1.0&#160;million under this agreement during the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserted a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal in the Fourth Circuit. The Company did not accrue any liability associated with this action as of December 31, 2022. The 4th Circuit affirmed the District Court&#8217;s dismissal in a decision published on March 2, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588612192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div>The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock', window );">Liability related to future royalties and related interest expense</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the relevant accounting criteria under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#8217;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties and related interest expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309588332528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at March&#160;31, 2023 includes approximately $75.5 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309692758144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309590923264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309671363536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract', window );"><strong>Liability related to future royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock', window );">Liability Related to Future Royalty</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the liability related to future royalties were as follows for the three months ended March 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:66.352%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue payable to DRI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related to Future Royalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585752400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6% -94.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9% - 88.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 2.4%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,839,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,048,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,763,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980,811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309586291984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 17,392<span></span>
</td>
<td class="nump">$ 45,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">75,500<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">92,909<span></span>
</td>
<td class="nump">92,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">52,843<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">40,066<span></span>
</td>
<td class="nump">50,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">52,843<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">52,843<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">28,879<span></span>
</td>
<td class="nump">32,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">28,879<span></span>
</td>
<td class="nump">32,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">11,187<span></span>
</td>
<td class="nump">17,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 11,187<span></span>
</td>
<td class="nump">$ 17,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309583123520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 17,384,000<span></span>
</td>
<td class="nump">$ 45,467,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">17,392,000<span></span>
</td>
<td class="nump">45,462,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,168,000<span></span>
</td>
<td class="nump">32,812,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">13,176,000<span></span>
</td>
<td class="nump">32,810,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,216,000<span></span>
</td>
<td class="nump">12,655,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,216,000<span></span>
</td>
<td class="nump">$ 12,652,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585695872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309586293504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltyLineItems', window );"><strong>Liability related to future royalty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NetProceedsFromSaleOfFutureRoyalties', window );">Net proceeds from sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,655<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyalties', window );">Liability related to future royalties [Abstract]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashRoyaltyRevenue', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember', window );">DRI Healthcare Acquisitions LP (DRI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltyLineItems', window );"><strong>Liability related to future royalty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TransactionCost', window );">Transaction Cost</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureRevenue', window );">Future Revenue</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NetProceedsFromSaleOfFutureRoyalties', window );">Net proceeds from sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalty [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309587717808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement - Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward', window );"><strong>Liability related to future royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTransactionCosts', window );">Deferred transaction costs</a></td>
<td class="num">(344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashInterestExpenseRecognized', window );">Non-cash interest expense recognized</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyalties', window );">Liability related to future royalties [Abstract]</a></td>
<td class="nump">100,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashRoyaltyRevenue', window );">Non-cash royalty revenue</a></td>
<td class="num">$ (90)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred transaction costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309586016880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 98.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Maximum amount available for issuance, increase</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309581713264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue- Incyte Corporation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">63 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="nump">9,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="nump">$ 9,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">58,006<span></span>
</td>
<td class="nump">58,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,006<span></span>
</td>
<td class="nump">$ 59,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember', window );">RevenuesFromCMOAgreementsMember | Incyte Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Annual Fixed Payments</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember', window );">RevenuesFromCMOAmendmentAgreement | Incyte Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Annual Fixed Payments</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AdditionalAnnualFixedPayments', window );">Additional Payments</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309587580320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue- Gilead Science Inc (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 14, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead | 2022 Gilead Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,400<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments', window );">Potential target nomination, option fees and milestone payments</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential target, nomination, option fees and milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_GileadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_GileadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309582748096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Zai Lab (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_MilestonesValueAddedTax', window );">Milestones Value Added Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Labs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MilestonesValueAddedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones Value Added Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MilestonesValueAddedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PremiumReceivedOnStockPurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309583222896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">9,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">58,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationArrangementOneTimeCreditPaidPercent', window );">One-time credit paid, percent</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OneTimeMillstoneCredit', window );">One Time Millstone Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | RevenuesFromCMOAgreementsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOneTimeCreditPaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, One-time Credit Paid, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOneTimeCreditPaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OneTimeMillstoneCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One Time Millstone Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OneTimeMillstoneCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585979392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - NIAID Contract (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Number of commercialized molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309582528592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue- Provention (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,496<span></span>
</td>
<td class="nump">$ 11,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio | Provention PRV3279 | Provention License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio | Provention PRV031 | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ReceivableFromCollaborationPartner', window );">Receivable from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReceivableFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable from collaboration partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ReceivableFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585844880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,839,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,098,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,833<span></span>
</td>
<td class="nump">$ 5,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,816,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,778,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,461<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,372<span></span>
</td>
<td class="nump">$ 2,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309587776016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.60%<span></span>
</td>
<td class="nump">87.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.30%<span></span>
</td>
<td class="nump">88.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309583132992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">10,098,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">2,914,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(3,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(87,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(82,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">12,839,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,098,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">7,048,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">11,763,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 18.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Expired (in dollars per share)</a></td>
<td class="nump">22.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">20.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 16.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding (in years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 7,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 29,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309585761360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares) | shares</a></td>
<td class="nump">415,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">656,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised | shares</a></td>
<td class="num">(62,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(27,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares) | shares</a></td>
<td class="nump">980,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">4.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">6.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140309587704960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_InLicensingArrangementLineItems', window );"><strong>In-Licensing arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 45,872<span></span>
</td>
<td class="nump">$ 61,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember', window );">Synaffix B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_InLicensingArrangementLineItems', window );"><strong>In-Licensing arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_InLicensingArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Licensing arrangement [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_InLicensingArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_SynaffixBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>mgnx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20230331.xsd" xlink:type="simple"/>
    <context id="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if1d79286ab6a47cfacb994e1f0f15d94_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="i03d2ebaff189455d9264808a3a02d4ce_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9dc12bf419854569b3c1bc5f89a77e19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4f0f1e8de514b11931ce86e1ce9c0ee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id4a98792199545d0b1e0ce65290c98a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2696e59aade645e6a31de5ce306ad24e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66bdc4231fb4465bb7766711b27e85fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c0dc21a4b854d46b133215409b5edaf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if6cdb2f256d447d2b9f7754d52c55373_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i948a349b6ef34738bd4d665ba4bfee46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i718ca217b2c94e7faf44f187ecac2ab6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i71e0feec85c148ad8d5f82bfac85f208_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie3c12373f1db407a9b6f037cab5d3651_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id2e71cae35f640ea991981fd8926b735_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if92410bd27764e678b82f7b1d39f6a03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i553278606eff41f39a304b10b3fbc2b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie232f14bbd714187ba2bfd7b2e021484_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d1954c9399f4d6a8e5a2d1a10e70b32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95e7c5864d42448aaf643c7bb82ddeba_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i68bcba7d3ffe49fe849dfa82a6c68caa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibc5a90075d424a33b6caf03ea64c1fe6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84d72584774b4de49861a1a693f96eaa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ffdb2f49280412891db80c368a3b88d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia39c37d66f564a8191cf294376ecc067_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f22b26d7b774c3c8a78ab4bca00737c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief28b87fc8be4092a7fb1df32ca29e1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33d36c0ce38b4033be7b52fdc3f1139b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie24b857dee5b4a5b835b0e031ba00304_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id066d12821a94a4da435f27478529262_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i225ebb75186c4e83acb6a1f0a73da7ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0dcaaeed8124d08ad0445d456f82fb0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39aa1c5f5b9f4d4caba6633baf8cb5a0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i549e08742d14433d91f8b2d470a14ae3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i090e20f1694842edaabcb0092ed0ebfe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d8b7cbe2f8041ab946f4daf94549f23_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia4d893440bf04325a0c84a2fc57bc8ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i301a3cb5a7284b718c396f6fbad527ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5b294fc0b3654d22a51d4b9b63e8fc3d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ea8b4c0cee9423cb8076b969da02716_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0d3d2b649df941eb8fa3c1e7cc8c023f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2cb01d2775284756822f388b6d2e16a3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icacdb818e9174a62a35cd37cde8493fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic0d1469f54904ec9974d404f50d6b074_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i346fa1f03c994f03af0d92e026a3ec33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3379a8d83154bc7a2f3dfcf35bf0466_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7897989264334daca83be8205e1f9066_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia862e744faeb4ae98a11485e9fc56db7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7781c40faa9749489c6481063c576abe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i980ce273d57d43e180d24954e57132ed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e168dd44f5c4d8590a34135fb61acb0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i59f34ccbd0974b3fa3aedac0a0794404_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i232dd89d03094cb0b9b34b4c2be81444_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00a81484002646ca86c7980bdcde7f36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia556b2d5cb5245a1893a8a5f302714c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia75e544fa68641f8940ee5f29bc524c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5b5e32b9dcb4adfbcbcbfb2e6c5bcb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i931c2e63969e41f787594bffd508c45e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66b5beeee5f64179b2145f46e3032766_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea1a641b6ade4b1197580a782d03ccff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib24dc0ddf9a849be8ab92812afd2d286_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13a5923cf7e84a8bbedc65e244cd7791_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd6f07e499e8471bb13f4992e6f93740_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i95d80c05867546299ae2cae022aee461_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1914dd9539bd46cd9d50436b60dae7d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8430871688c24161b99e79ce00cc373a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0595b4044d4e48a4b54395ad62ddc89c_I20230308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="iab71ac1d87d8415a9550205dc1aa8b3b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i8125884812c4401b8b311bdffc16d974_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9309ea0208184fa4b37705ea22d3a556_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i6d36e822023b4273a9509235bd8c6acd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5a1a46d9b1045c9b6ee53abe05a7ead_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieef59164d9804d038bd3cc080e152e53_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id2e1ac7059204d649fe5363543d08fd8_D20180101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iafe7647445614121a80a6be8d87248c3_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a1a941fe6dc4e42b16747db51f11bd9_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i1cd6332acd224939b6e64d01df3361e7_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i2682097a1f3e4a89a96cab41f8cbd4ea_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i6b07faa5b7d643d883cf0c135e8f3d80_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic1857d4cd8f7406fa5bbf069c7a857d6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iafc0cdb960994c118fa8a5cfd0f2a280_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if334a8dd8b764a01a900c1c6d7f9b363_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbbd06906d6345b2afe1b89f2851967a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i374c14d1f7814bd99693ece7e091f00d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6896341f33cd4b08985cd9e24146387e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06dd337e669d44fda86ff6918e8c7999_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5999119dfc294e80ad0713a177c361f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic98612cc5ba1468d888c8629fe2b15bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if40b3c7658dd4cf3af7b29395be88093_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3fe661497ec1436ea3ea36041dec66b1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic55a0f9ecd9b4ceda005b981bf2f7d8e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ief1057cf41b349daa7c0fc063798c809_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="i02aba6ee80e4485593c6ef2dd3196270_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie16b1ce65ef4498e985806621089d540_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3dee982850e549a68b6a81eb6c007052_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ibf999f4a23674de6901577a7a2e0e94d_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i5fbed9f54de04d85a3e8c55feabc0565_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i7079bd55b0684e16805a5c2352089fd5_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i4475f726644746db8a9d6f1b092abe4c_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="iee007f50b7b54e878349b22a7469557d_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ied8b4fcaac5140cca18c505dac7f2417_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i83b508f7b0c74f06858ab827b8a99958_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae198fa14cb849eba1d6619f7acc0b25_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i831ccd6f3347498497b72f53753edd5e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b7f5ae7b36f40efb495d731d6421605_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b2edd43ee5f4027854eb6a336bdca71_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97eb432defc54b6ea97bda7a332c90f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i50d8b24b3b4c46df987acd17c19050e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieddfecbe8ad14ef7a8ff835b12b95d4a_D20220101-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i17159c2a9e9f40a68a48e3051433e894_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7595340e36ea4d09bf2116e33b8641f3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaa3eccd028da467f83bd22324f391a17_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4e3306c0844c488aa3ac28c64699528b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i800a7e6440dc4197a9837d73a114cba7_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="iabee161e88cd43838204d199c20da652_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic4a1d67968a747cca217bd0b0428cf02_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i56231c20b15840d1afa950fe878367de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cbab60f55fa402c96d89e18f0e3beb9_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ie14822659c7d4a8e9cf7fcec3ee0ae7f_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ie58506024e45456592bc19755da226d2_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ifa174cd3914f4d469152f496ac824c06_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie45d01decd32435a8498c793207f66fd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie39a7a5272cb4b76897f3e799b70f9ab_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="i7aa16b089d85451b96f0b9061c2797e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib6e4cfb9ea29453487b8acb62f27c309_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b0c52ec53274fdba3171ff3170db6a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1660944dc73f45fea86496b594fce178_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iceb09aa6ccd548e5b5a67339e277f132_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9e6a705742804457a4eb1b0d964ea1e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icaf39a1c94944731b2514e5c45e8ecee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5317a874bbfc4ef6baca4f516aa0f218_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i921b7f549052407f832cadb468c93a6c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i799a33353e9a49a4b78a98bda1c4c308_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica024959f8ab45b2aee0bf2b8219b68e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i036d859b9f664d9d82dd693c3f33d537_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i214d7afe999940ae898ec280e17de7a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i91c83b9d58eb41a8a4f5d2bbc203e254_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib91e3da1af4b4728802be58d315b3279_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae7da4578181431996ca6f580a7f5d94_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGFibGU6YzYyODJkNDQwZWFkNDA5OWE2YjlmMGM0NmE5MzYyMmIvdGFibGVyYW5nZTpjNjI4MmQ0NDBlYWQ0MDk5YTZiOWYwYzQ2YTkzNjIyYl8yLTEtMS0xLTczNDI3_2495f99c-21ee-45d6-9c43-712e3e7bd9cc">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGFibGU6YzYyODJkNDQwZWFkNDA5OWE2YjlmMGM0NmE5MzYyMmIvdGFibGVyYW5nZTpjNjI4MmQ0NDBlYWQ0MDk5YTZiOWYwYzQ2YTkzNjIyYl80LTEtMS0xLTczNDI3_2ffbf323-179c-4faa-b5df-c259a0498941">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGFibGU6YzYyODJkNDQwZWFkNDA5OWE2YjlmMGM0NmE5MzYyMmIvdGFibGVyYW5nZTpjNjI4MmQ0NDBlYWQ0MDk5YTZiOWYwYzQ2YTkzNjIyYl81LTEtMS0xLTczNDI3_61caa675-f573-4c66-ad77-ae632c98e271">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGV4dHJlZ2lvbjo4YzQ1OTE0ZTliOGY0ZWJmOWIyYzEzMTU0M2Q4NjRmMF8xMjk_691684b8-cb25-4a79-868a-1e26a9a12845">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80L2ZyYWc6OGM0NTkxNGU5YjhmNGViZjliMmMxMzE1NDNkODY0ZjAvdGV4dHJlZ2lvbjo4YzQ1OTE0ZTliOGY0ZWJmOWIyYzEzMTU0M2Q4NjRmMF8xMzA_54dc2353-bac2-4db9-9e58-32491f4d9de0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV84Mg_0126c285-e5d7-4f1e-997c-1e8d3d8466de">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDNjNjVhOTRhNjk4NDQ0MmEwM2RjMzlkODgyNDEzMTUvdGFibGVyYW5nZTpkM2M2NWE5NGE2OTg0NDQyYTAzZGMzOWQ4ODI0MTMxNV8wLTAtMS0xLTczNDI3_534666f3-6b67-4d1c-abe1-c14fabadac06">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xMTc_092c810e-bcc4-4b3e-a888-f9a706916c3a">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NmU1MGRiMDdhYjUwNDJmMThkOTNiZTFhMGExNjgwNGUvdGFibGVyYW5nZTo2ZTUwZGIwN2FiNTA0MmYxOGQ5M2JlMWEwYTE2ODA0ZV8wLTAtMS0xLTczNDI3_2be8aa9a-0c7d-466e-b8d8-4f5f04a36d43">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yMDg_f228ee0c-5f7a-45fb-97e5-ffc087ddcf3d">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yMTE_d05a2a1c-1681-4254-bdc1-b6cdf0c9d39a">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8wLTAtMS0xLTczNDI3_18357a96-2894-4c44-9152-c8414c1c44a8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8wLTEtMS0xLTczNDI3_4b169c8e-2304-40df-af20-8b52e95e5ccd">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTAtMS0xLTczNDI3L3RleHRyZWdpb246NDU1MDY2ODA0N2FmNGM5YzllZWM0NTY2MDRkODgzYTBfNQ_be30d4b9-bcf1-4186-9755-06bb472f01e4">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTAtMS0xLTczNDI3L3RleHRyZWdpb246NDU1MDY2ODA0N2FmNGM5YzllZWM0NTY2MDRkODgzYTBfOA_e2e1582b-5033-4e92-9988-d344f1c76a70">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTAtMS0xLTczNDI3L3RleHRyZWdpb246NDU1MDY2ODA0N2FmNGM5YzllZWM0NTY2MDRkODgzYTBfMTI_611d0fc3-a241-4740-b084-ff667c3dd486">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6NTlmOTNhMmU3YzZmNGQ1MWJjMzJhZmFiN2Y1OTMxN2QvdGFibGVyYW5nZTo1OWY5M2EyZTdjNmY0ZDUxYmMzMmFmYWI3ZjU5MzE3ZF8zLTEtMS0xLTczNDI3_990241b5-dcf0-4536-a466-4cc43db15e87">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yNzA_9225a555-46da-4b88-8134-989d997a309e">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8yNzM_22adba2f-6a05-4742-9c1e-cd3285c1c3ce">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDEyYTg0YTgwYTYxNDZiODk0NjMwY2NkNjA5ODdjMmMvdGFibGVyYW5nZTpkMTJhODRhODBhNjE0NmI4OTQ2MzBjY2Q2MDk4N2MyY18xLTAtMS0xLTczNDI3_5f5e2eb0-1dd5-42f2-b39b-aecdde1da83d">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDEyYTg0YTgwYTYxNDZiODk0NjMwY2NkNjA5ODdjMmMvdGFibGVyYW5nZTpkMTJhODRhODBhNjE0NmI4OTQ2MzBjY2Q2MDk4N2MyY18xLTEtMS0xLTczNDI3_eccf166b-3d9c-4d9e-a048-8888b313d868">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDEyYTg0YTgwYTYxNDZiODk0NjMwY2NkNjA5ODdjMmMvdGFibGVyYW5nZTpkMTJhODRhODBhNjE0NmI4OTQ2MzBjY2Q2MDk4N2MyY18xLTItMS0xLTczNDI3_031cf641-801a-4517-9830-846e2f3ef655">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xOTE1_773f7e61-1000-4db3-ac9b-11699dc50142">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xOTE2_c4405986-6862-4ac7-8aa1-a5ab39a2a632">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDY4NTM1ZTRjMzAxNDA1YjgwMWM0NmYxZmI4Y2ZhMWQvdGFibGVyYW5nZTpkNjg1MzVlNGMzMDE0MDViODAxYzQ2ZjFmYjhjZmExZF8yLTAtMS0xLTgxNTA1_429a301c-1450-41f0-8a98-450b28725060">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDY4NTM1ZTRjMzAxNDA1YjgwMWM0NmYxZmI4Y2ZhMWQvdGFibGVyYW5nZTpkNjg1MzVlNGMzMDE0MDViODAxYzQ2ZjFmYjhjZmExZF8yLTMtMS0xLTczNDI3_dccda90e-57ac-4aa6-8221-dcd0e2381dbf">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGFibGU6ZDY4NTM1ZTRjMzAxNDA1YjgwMWM0NmYxZmI4Y2ZhMWQvdGFibGVyYW5nZTpkNjg1MzVlNGMzMDE0MDViODAxYzQ2ZjFmYjhjZmExZF80LTEtMS0xLTczNDI3_6366be9c-369b-46b7-8c78-f8db3a49bef3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xOTE3_8ca051b9-4b42-49b1-b5f2-c988d2d5a319">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if1d79286ab6a47cfacb994e1f0f15d94_I20230505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xL2ZyYWc6MDNlZjEwOGY3ZjlmNGYwM2EyODJjNTIzYjcyMzIyNWUvdGV4dHJlZ2lvbjowM2VmMTA4ZjdmOWY0ZjAzYTI4MmM1MjNiNzIzMjI1ZV8xODI4_553dfde2-ef73-493b-ad8f-5ff7dcef59ff"
      unitRef="shares">61838893</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNC0xLTEtMS03MzQyNw_4ec5a410-0d7b-45ce-bfbb-df9b84d73055"
      unitRef="usd">224264000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNC0zLTEtMS03MzQyNw_73d0eca3-48f6-46eb-ba8b-7635effe7491"
      unitRef="usd">108884000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNS0xLTEtMS03MzQyNw_387e3fbb-54ab-414f-b000-b730822c88cd"
      unitRef="usd">17392000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNS0zLTEtMS03MzQyNw_167f2bfc-2817-48e5-ad33-9b96f28ec4da"
      unitRef="usd">45462000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNi0xLTEtMS03MzQyNw_0125296b-46b8-4421-80d0-8ac938aab1a8"
      unitRef="usd">36160000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNi0zLTEtMS03MzQyNw_ee31647f-c3d3-44bc-9823-01d8afecfa6c"
      unitRef="usd">56222000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNy0xLTEtMS03MzQyNw_d9f98ba2-af09-4372-bf61-cc27e8af8035"
      unitRef="usd">1409000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfNy0zLTEtMS03MzQyNw_8529c992-55ee-475d-820d-3e90e0274cba"
      unitRef="usd">1451000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfOC0xLTEtMS03MzQyNw_ee3d41d1-e69e-4f58-90c1-a356d7e1aa8b"
      unitRef="usd">9718000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfOC0zLTEtMS03MzQyNw_95d983f4-dbcb-442a-bce7-c2ad99b25da9"
      unitRef="usd">10161000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTAtMS0xLTEtNzM0Mjc_64d8c47c-83bd-4358-8ad2-06e4f97891ca"
      unitRef="usd">288943000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTAtMy0xLTEtNzM0Mjc_b31640f0-1774-4576-af88-5ddaba67660a"
      unitRef="usd">222180000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTEtMS0xLTEtNzM0Mjc_2edd41b7-6f04-470c-91d6-782f71a5a6c1"
      unitRef="usd">26783000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTEtMy0xLTEtNzM0Mjc_c342a2a7-7ddc-4320-8f72-fa39adf0eb74"
      unitRef="usd">29575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTItMS0xLTEtNzM0Mjc_3e636d02-4a3f-4cdc-aba1-8161215af778"
      unitRef="usd">26394000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTItMy0xLTEtNzM0Mjc_1ee446d4-b3a9-4649-b481-ae6e07f173b2"
      unitRef="usd">27335000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTMtMS0xLTEtNzM0Mjc_71c5acb1-7bb7-408a-982a-c3cb0b2b7d29"
      unitRef="usd">1378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTMtMy0xLTEtNzM0Mjc_95a54a56-5749-4e1d-ab70-6c4bed510c9a"
      unitRef="usd">1378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTQtMS0xLTEtNzM0Mjc_3c83517d-6459-480d-88e7-672b31dbe3fc"
      unitRef="usd">343498000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTQtMy0xLTEtNzM0Mjc_c69f4317-b8a0-48bf-9bf4-014ec7a7f688"
      unitRef="usd">280468000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTgtMS0xLTEtNzM0Mjc_33fc34fd-07ec-46c1-b29a-6162140a3dcb"
      unitRef="usd">3759000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTgtMy0xLTEtNzM0Mjc_e155452c-65c7-4a6a-98d0-0ef800bd610c"
      unitRef="usd">4899000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTktMS0xLTEtNzM0Mjc_4a711703-cd33-4ba3-af4d-6b77abe2fe04"
      unitRef="usd">28188000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMTktMy0xLTEtNzM0Mjc_6cc66929-8854-4e26-ba81-afb47931b14f"
      unitRef="usd">28998000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjAtMS0xLTEtNzM0Mjc_84db1b18-6908-4df5-8838-4931cc93b66d"
      unitRef="usd">9249000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjAtMy0xLTEtNzM0Mjc_0698582f-fa56-4022-9768-c058f93ffba3"
      unitRef="usd">9988000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjEtMS0xLTEtNzM0Mjc_c011ea48-11e3-4f2c-968f-56a7642253e0"
      unitRef="usd">4418000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjEtMy0xLTEtNzM0Mjc_4a5d39a0-ed98-4dd3-a145-8452fcd68d52"
      unitRef="usd">4726000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjMtMS0xLTEtNzM0Mjc_3c6e10f7-985d-4a76-933a-c1456591dbe6"
      unitRef="usd">45614000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjMtMy0xLTEtNzM0Mjc_268c74ed-104a-4695-803b-1379e1b26538"
      unitRef="usd">48611000</us-gaap:LiabilitiesCurrent>
    <mgnx:LiabilityRelatedToFutureRoyalties
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMS0xLTEtNzY0Mzc_a3320024-e2b5-470f-8591-7d1c2c6a087c"
      unitRef="usd">100222000</mgnx:LiabilityRelatedToFutureRoyalties>
    <mgnx:LiabilityRelatedToFutureRoyalties
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMy0xLTEtNzY0NDU_4dd60fe3-c3e7-45b8-80b3-0324d5c959fa"
      unitRef="usd">0</mgnx:LiabilityRelatedToFutureRoyalties>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjQtMS0xLTEtNzM0Mjc_ec29f168-6182-4a6e-8633-c3f4ce65fbdb"
      unitRef="usd">58006000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjQtMy0xLTEtNzM0Mjc_a6b05251-0242-490a-ab05-e66cd7572f07"
      unitRef="usd">59480000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMS0xLTEtNzM0Mjc_f0d715f5-b5bd-4193-9ffb-79a2bf126a5b"
      unitRef="usd">30130000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjUtMy0xLTEtNzM0Mjc_9e1d565d-71ad-4efd-baaa-897be188395f"
      unitRef="usd">30106000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjYtMS0xLTEtNzM0Mjc_371f1765-f166-4f5f-a0a4-acbc4a033b95"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjYtMy0xLTEtNzM0Mjc_8856e998-1482-4851-ad70-2f793bb23018"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjctMS0xLTEtNzM0Mjc_efa66add-d698-445a-bbfd-2f4cfb8c9691"
      unitRef="usd">234230000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjctMy0xLTEtNzM0Mjc_a545f132-cd67-4105-845f-a643c0a2fa23"
      unitRef="usd">138455000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8xOA_e24eb610-c6a5-400f-aa42-0653fda5a1e7"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8xOA_e2ffebc8-eff5-4611-8cb9-1825366a7dfa"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8zNA_9ed3223d-ae5d-44ca-83ee-8044d5220411"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl8zNA_ad783e86-0fd0-4b85-8be6-dde4d45d1ff6"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl81Ng_006b2682-32fd-4d35-8cb0-801419614948"
      unitRef="shares">61838565</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMC0xLTEtNzM0MjcvdGV4dHJlZ2lvbjozYzE2ZDk1NTc3Yjk0ZTIwYjkwMTQ5NGQ5MzhiMzI4Zl82Mw_c6d12b26-ad6e-4577-a3f5-aea3d0833c0f"
      unitRef="shares">61701467</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMS0xLTEtNzM0Mjc_23311034-d991-4a47-b8d9-aa051e83a976"
      unitRef="usd">618000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMjktMy0xLTEtNzM0Mjc_bf971965-5c5b-4998-b67b-102f0ae7c612"
      unitRef="usd">617000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzAtMS0xLTEtNzM0Mjc_1402bd2e-1154-4dcc-bb13-4fedcc3e5379"
      unitRef="usd">1240345000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzAtMy0xLTEtNzM0Mjc_4c63b9c0-c272-4088-ab14-3e525a071ae3"
      unitRef="usd">1235095000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzEtMS0xLTEtNzM0Mjc_aa27815e-f2fc-4b51-872d-f5316b0bec8d"
      unitRef="usd">8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzEtMy0xLTEtNzM0Mjc_0a4477b8-90d2-4b32-ae4f-b1b0e54f015b"
      unitRef="usd">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzItMS0xLTEtNzM0Mjc_41c70819-16ec-444c-996c-8c43626ac6a8"
      unitRef="usd">-1131703000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzItMy0xLTEtNzM0Mjc_630dc626-7e17-44ff-a886-a85cc03857af"
      unitRef="usd">-1093694000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzMtMS0xLTEtNzM0Mjc_a3cc145d-fca2-4a27-8273-ba90ac2e442d"
      unitRef="usd">109268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzMtMy0xLTEtNzM0Mjc_eb034d53-33e2-4c5d-9407-0b507a71ad35"
      unitRef="usd">142013000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzQtMS0xLTEtNzM0Mjc_4bbbff10-f735-489a-923c-de17ada031c7"
      unitRef="usd">343498000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8xOS9mcmFnOjM5YjkxYjU2ODFmMTQ3YWVhZDEyZGY2ZTc5NDdhNWEwL3RhYmxlOmNhOWE0ZjU5OTI4MzQxZTJiMDY1Y2Q1OTc2OTZhZThkL3RhYmxlcmFuZ2U6Y2E5YTRmNTk5MjgzNDFlMmIwNjVjZDU5NzY5NmFlOGRfMzQtMy0xLTEtNzM0Mjc_f8d36d5e-0f2f-46bf-b5ac-d4fce47c48db"
      unitRef="usd">280468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ic4f0f1e8de514b11931ce86e1ce9c0ee_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMy01LTEtMS03MzQyNw_a8c2511d-da07-4988-bfb1-a5d0b6839e44"
      unitRef="usd">16686000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4a98792199545d0b1e0ce65290c98a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMy03LTEtMS03MzQyNw_e9632f5b-8492-45fb-b1c3-04979c2ab6cc"
      unitRef="usd">7093000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2696e59aade645e6a31de5ce306ad24e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNC01LTEtMS03MzQyNw_e207de16-777f-4ae1-8f80-3df5df53fbe2"
      unitRef="usd">3490000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66bdc4231fb4465bb7766711b27e85fe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNC03LTEtMS03MzQyNw_bb36171a-abf9-4fc7-987b-c40550bf59e3"
      unitRef="usd">3580000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c0dc21a4b854d46b133215409b5edaf_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNS01LTEtMS03MzQyNw_f335d889-890f-4b5c-a6ab-ae6b22fc802c"
      unitRef="usd">3615000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6cdb2f256d447d2b9f7754d52c55373_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNS03LTEtMS03MzQyNw_e09fecb8-deb4-44da-aa51-44bf31d680d6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i948a349b6ef34738bd4d665ba4bfee46_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi01LTEtMS03ODczMg_f294b183-b6a6-4be7-83c1-f6df8ab61d92"
      unitRef="usd">422000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i718ca217b2c94e7faf44f187ecac2ab6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi03LTEtMS03ODczMg_83a862ec-0f7f-4e87-9a30-22f01dc84ee9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71e0feec85c148ad8d5f82bfac85f208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi01LTEtMS03MzQyNw_171a4109-d718-4b02-bddf-e5a3baf48968"
      unitRef="usd">283000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3c12373f1db407a9b6f037cab5d3651_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNi03LTEtMS03MzQyNw_69308411-0fd7-4f9e-af39-70e32f9ff93c"
      unitRef="usd">428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNy01LTEtMS03MzQyNw_c0051920-779e-4587-9429-3be488277c96"
      unitRef="usd">24496000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfNy03LTEtMS03MzQyNw_05e3840b-9776-45ef-9cb5-5a5b91bb4587"
      unitRef="usd">11101000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfOS01LTEtMS03MzQyNw_b5d9ead6-f7f5-4614-9208-f41ab408fcb6"
      unitRef="usd">113000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfOS03LTEtMS03MzQyNw_63927aec-6506-48b5-9860-2ff05672a626"
      unitRef="usd">48000</us-gaap:CostOfGoodsAndServicesSold>
    <mgnx:CostOfManufacturingServices
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTAtNS0xLTEtNzM0Mjc_1ee20d75-3666-47f7-a37d-638624699f6c"
      unitRef="usd">3410000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTAtNy0xLTEtNzM0Mjc_d30166a2-9bfa-4f88-93a3-1ebcf8089466"
      unitRef="usd">0</mgnx:CostOfManufacturingServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTEtNS0xLTEtNzM0Mjc_733ee195-5a55-4b01-b242-6b18156a77a9"
      unitRef="usd">45872000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTEtNy0xLTEtNzM0Mjc_7cf95b71-2617-4266-ac9a-f4d84c25874d"
      unitRef="usd">61438000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTItNS0xLTEtNzM0Mjc_b4b275d6-be46-497c-9ddd-e1b5c410dea0"
      unitRef="usd">13527000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTItNy0xLTEtNzM0Mjc_1cb81bff-8134-4a2b-9ea5-bac26f10d95d"
      unitRef="usd">16253000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTMtNS0xLTEtNzM0Mjc_1bd630d6-031d-4c7a-97f0-161338375daa"
      unitRef="usd">62922000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTMtNy0xLTEtNzM0Mjc_c9c0a48c-2cb9-46ee-b8db-c499d5a5d2f7"
      unitRef="usd">77739000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTQtNS0xLTEtNzM0Mjc_e67e1e68-036d-4fd2-8f2b-bab09ab66d2c"
      unitRef="usd">-38426000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTQtNy0xLTEtNzM0Mjc_b8c3d34e-6ae8-4a88-b8c9-8e18139b5583"
      unitRef="usd">-66638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTUtNS0xLTEtNzM0Mjc_0b91e762-3d44-49c0-950e-9efe784a7620"
      unitRef="usd">1073000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTUtNy0xLTEtNzM0Mjc_87448bf2-aee3-436c-ab69-ec13b290b444"
      unitRef="usd">195000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTctNS0xLTEtNzkxODY_7c872ef7-231d-45cd-b52e-aa6c348d0331"
      unitRef="usd">656000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTctNy0xLTEtNzkxODY_6101af6e-a083-4765-aedf-6912765b1806"
      unitRef="usd">0</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTYtNS0xLTEtNzM0Mjc_9de77551-a03d-4e9f-bd60-f967ab1c7723"
      unitRef="usd">-38009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTYtNy0xLTEtNzM0Mjc_79772213-1f8a-440b-8792-535fedde5f73"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTgtNS0xLTEtNzM0Mjc_523a0be2-e420-4a05-a20f-d9beeb5fe1eb"
      unitRef="usd">13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTgtNy0xLTEtNzM0Mjc_bac45067-abef-4b32-aef6-966c8be380d0"
      unitRef="usd">-222000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTktNS0xLTEtNzM0Mjc_65627bc6-92c3-46e9-b359-810285d40272"
      unitRef="usd">-37996000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMTktNy0xLTEtNzM0Mjc_ac2d42d9-0ebc-4aa7-ba7d-ac800f26a3bb"
      unitRef="usd">-66665000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNS0xLTEtNzM0Mjc_174f8203-3507-4cb6-9e0a-493692189b82"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNS0xLTEtNzM0Mjc_ec8cf3c8-d6e7-42ab-9bcc-bd84892b942b"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNy0xLTEtNzM0Mjc_6d83e6b6-1181-4029-9b97-07f8b1b8b7ac"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjEtNy0xLTEtNzM0Mjc_ae5bcf27-855f-499b-941d-84065d6a07f7"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNS0xLTEtNzM0Mjc_78a2b207-a9b1-4494-b292-e9a339791464"
      unitRef="shares">61809817</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNS0xLTEtNzM0Mjc_9a2610b4-2475-4f8f-a74a-588e8db0c98c"
      unitRef="shares">61809817</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNy0xLTEtNzM0Mjc_2b4a5627-2971-49ab-ab22-0ddd88cb25ca"
      unitRef="shares">61324163</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yMi9mcmFnOmJlMDNhYzQzYTIwMDRkMWFhMjQ5MGU2MzI5OThiZGVmL3RhYmxlOmY0ZmE5NDQ0ZGU4MzQwYjVhMTM3ZDIyZTZmYmU1Y2NiL3RhYmxlcmFuZ2U6ZjRmYTk0NDRkZTgzNDBiNWExMzdkMjJlNmZiZTVjY2JfMjItNy0xLTEtNzM0Mjc_9f030a2d-65a3-45b1-a247-72e3cc2219e5"
      unitRef="shares">61324163</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="if92410bd27764e678b82f7b1d39f6a03_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xLTEtMS03MzQyNw_7b4871a0-2666-4c00-bd4f-64a90800fb84"
      unitRef="shares">61701467</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if92410bd27764e678b82f7b1d39f6a03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0zLTEtMS03MzQyNw_4140591a-432f-415b-8b72-efb38abe96b6"
      unitRef="usd">617000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i553278606eff41f39a304b10b3fbc2b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi05LTEtMS03MzQyNw_98bc5270-2934-4108-9150-8dfb9a5491ce"
      unitRef="usd">1235095000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie232f14bbd714187ba2bfd7b2e021484_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xMS0xLTEtNzM0Mjc_1d377f4d-2777-4bd9-a1aa-2eea39ed6e2a"
      unitRef="usd">-1093694000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d1954c9399f4d6a8e5a2d1a10e70b32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xMy0xLTEtNzM0Mjc_966c40bd-32e6-49e3-8119-4044ae90808f"
      unitRef="usd">-5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMi0xNS0xLTEtNzM0Mjc_a008cdd9-14a0-4cbb-b6f0-0e9c418f7177"
      unitRef="usd">142013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMy05LTEtMS03MzQyNw_789fb6f4-2bd5-4fe3-b65a-c68108891031"
      unitRef="usd">4788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfMy0xNS0xLTEtNzM0Mjc_c1670a18-e5a9-4f65-bba4-519298922ce9"
      unitRef="usd">4788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC0xLTEtMS03MzQyNw_659491c1-a643-4778-8b60-8df42a12c798"
      unitRef="shares">95000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC0zLTEtMS03MzQyNw_f0bff172-379d-4e7a-867e-c40687009761"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC05LTEtMS03MzQyNw_95f4fdb2-2f47-4893-9ad6-3c5bfbba3bcf"
      unitRef="usd">616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNC0xNS0xLTEtNzM0Mjc_57de98bf-d24a-4679-b05f-1eda8b340e73"
      unitRef="usd">617000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i09bdba7a566747cf91704d8ff1d6f8d2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNS0xLTEtMS03MzQyNw_4e1c49ca-8d66-41b8-b7b6-50fe29a2cbe0"
      unitRef="shares">42098</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i4641cf236cdf41aab66132895a1b2f2e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNS05LTEtMS03MzQyNw_99e6a29b-a65d-4d7f-be4b-22c1f32a5242"
      unitRef="usd">-154000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNS0xNS0xLTEtNzM0Mjc_704f6d7d-e2b1-4b9b-b219-e9cbc2df98f4"
      unitRef="usd">-154000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i95e7c5864d42448aaf643c7bb82ddeba_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNi0xMy0xLTEtNzM0Mjc_53a1b2b4-b126-48d4-b343-d590db2120fa"
      unitRef="usd">13000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNi0xNS0xLTEtNzM0Mjc_68f2da0c-299e-4fdc-80a6-ef6857dfd0b2"
      unitRef="usd">13000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i68bcba7d3ffe49fe849dfa82a6c68caa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNy0xMS0xLTEtNzM0Mjc_8c6c5c70-684b-460b-ac62-14b05e28c3d9"
      unitRef="usd">-38009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfNy0xNS0xLTEtNzM0Mjc_6ec78708-be90-4c1b-b23c-ab47b2891b58"
      unitRef="usd">-38009000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ibc5a90075d424a33b6caf03ea64c1fe6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xLTEtMS03MzQyNw_f967ca0c-fb5c-4c68-b95b-d1d652c9c5c6"
      unitRef="shares">61838565</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc5a90075d424a33b6caf03ea64c1fe6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0zLTEtMS03MzQyNw_fa821c69-2f65-45d9-85d8-a866169e847f"
      unitRef="usd">618000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84d72584774b4de49861a1a693f96eaa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC05LTEtMS03MzQyNw_54f23a5b-4e55-41a1-90d4-5fa00b3e370c"
      unitRef="usd">1240345000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ffdb2f49280412891db80c368a3b88d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xMS0xLTEtNzM0Mjc_52264ead-0156-4439-b28c-5f7f6df7db8c"
      unitRef="usd">-1131703000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia39c37d66f564a8191cf294376ecc067_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xMy0xLTEtNzM0Mjc_fa74d8c5-f36d-4ee8-97a7-d45c93dc52ac"
      unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOmIyZjRhY2Q5MGQ1YjQ1Mzg4MTIwOWJjNmViMDY2OTZlL3RhYmxlcmFuZ2U6YjJmNGFjZDkwZDViNDUzODgxMjA5YmM2ZWIwNjY5NmVfOC0xNS0xLTEtNzM0Mjc_9ba5eebe-dff0-4650-8136-7ee4f876a951"
      unitRef="usd">109268000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6f22b26d7b774c3c8a78ab4bca00737c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xLTEtMS03MzQyNw_e5c10b85-bb15-41b4-8096-0465464fa3a3"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f22b26d7b774c3c8a78ab4bca00737c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0zLTEtMS03MzQyNw_d8203dbb-fac3-4d95-be1a-c17851c1e2ef"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief28b87fc8be4092a7fb1df32ca29e1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi05LTEtMS03MzQyNw_efd22c33-7e7c-4159-8e0d-d204fc33e36a"
      unitRef="usd">1213002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33d36c0ce38b4033be7b52fdc3f1139b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xMS0xLTEtNzM0Mjc_4250afc0-aaa2-45e6-b0aa-0b96135d8589"
      unitRef="usd">-973936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie24b857dee5b4a5b835b0e031ba00304_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xMy0xLTEtNzM0Mjc_69dc36a2-747c-414e-a499-94fd86bd613f"
      unitRef="usd">-61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id066d12821a94a4da435f27478529262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMi0xNS0xLTEtNzM0Mjc_9dd1e643-3b5e-4046-bf50-7a8561d30df8"
      unitRef="usd">239618000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i225ebb75186c4e83acb6a1f0a73da7ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMy05LTEtMS03MzQyNw_6be7886b-a1d6-423a-9a72-222e5705ca11"
      unitRef="usd">5224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfMy0xNS0xLTEtNzM0Mjc_c28c6cf4-985f-47be-8b35-8bc0c6fbca67"
      unitRef="usd">5224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ic0dcaaeed8124d08ad0445d456f82fb0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNS0xLTEtMS03MzQyNw_a8b798fe-c299-4b5b-a35c-72e93db1742a"
      unitRef="shares">25646</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i225ebb75186c4e83acb6a1f0a73da7ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNS05LTEtMS03MzQyNw_f4cf46c5-46d8-44f3-a5d5-53370c4c29b5"
      unitRef="usd">37000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNS0xNS0xLTEtNzM0Mjc_1f373f35-7262-42e6-8eb7-f82727eaea05"
      unitRef="usd">37000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i39aa1c5f5b9f4d4caba6633baf8cb5a0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNi0xMy0xLTEtNzM0Mjc_0c8889fc-e666-4fec-9680-36ac2936d17e"
      unitRef="usd">-222000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNi0xNS0xLTEtNzM0Mjc_5c89ade2-ced5-45c2-8599-f3a02d9cdd4d"
      unitRef="usd">-222000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i549e08742d14433d91f8b2d470a14ae3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNy0xMS0xLTEtNzM0Mjc_53f40e59-065f-41a6-a4bf-e20fbdd7a10e"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfNy0xNS0xLTEtNzM0Mjc_15dff939-bae5-4e83-9159-62b225f6f00a"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i090e20f1694842edaabcb0092ed0ebfe_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xLTEtMS03MzQyNw_7967c1b8-0088-49eb-9aaf-1b6e8fb7efcd"
      unitRef="shares">61333074</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i090e20f1694842edaabcb0092ed0ebfe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0zLTEtMS03MzQyNw_a47f41ee-a318-476e-9464-d652ad7e7594"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d8b7cbe2f8041ab946f4daf94549f23_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC05LTEtMS03MzQyNw_95d1d00d-502f-42ba-9cce-a9408c357826"
      unitRef="usd">1218263000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4d893440bf04325a0c84a2fc57bc8ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xMS0xLTEtNzM0Mjc_b984117e-2a6c-4f99-b2bb-39689ece71d8"
      unitRef="usd">-1040379000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i301a3cb5a7284b718c396f6fbad527ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xMy0xLTEtNzM0Mjc_ec5e244a-d0a8-4a29-88fe-7bc8ffc2f806"
      unitRef="usd">-283000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b294fc0b3654d22a51d4b9b63e8fc3d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yNS9mcmFnOjQ4NmEwODg5ZGNmZDQ1NDJiMjgwY2UzMWZlNTY4OTJkL3RhYmxlOjA5MGJmNGIxNmM4ODQzNTJhNjIzNjA5ZjQ3YmQzMWFkL3RhYmxlcmFuZ2U6MDkwYmY0YjE2Yzg4NDM1MmE2MjM2MDlmNDdiZDMxYWRfOC0xNS0xLTEtNzM0Mjc_0352cf0b-2841-4f61-8b70-84ef38522895"
      unitRef="usd">178214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMy0xLTEtMS03MzQyNw_eb7f8f03-15e7-478a-b508-89419f1872f3"
      unitRef="usd">-38009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMy0zLTEtMS03MzQyNw_91b0901c-92a5-4d09-bf9d-90a58b951787"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNS0xLTEtMS03MzQyNw_1b207949-6d55-48ec-acdf-d329c218a43c"
      unitRef="usd">2983000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNS0zLTEtMS03MzQyNw_8fbbb717-c8ca-41ff-aadf-d99ae7198bc3"
      unitRef="usd">2913000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNi0xLTEtMS03MzQyNw_23d48823-cae1-4681-b872-d5628fd64f5d"
      unitRef="usd">372000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNi0zLTEtMS03MzQyNw_8127cae4-72ba-411f-a156-99dc9f62caf1"
      unitRef="usd">-334000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNy0xLTEtMS03MzQyNw_7c9f20c0-e855-4013-8a87-bad3ab7048cb"
      unitRef="usd">4833000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfNy0zLTEtMS03MzQyNw_ca27e354-da15-4f01-b5cc-d7e931c91f7b"
      unitRef="usd">5274000</us-gaap:ShareBasedCompensation>
    <mgnx:NonCashRoyaltyRevenue
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOC0xLTEtMS03MzQyNw_2262cf16-354d-4b7e-8427-9761e6bd7e5d"
      unitRef="usd">90000</mgnx:NonCashRoyaltyRevenue>
    <mgnx:NonCashRoyaltyRevenue
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOC0zLTEtMS03MzQyNw_52d5ae8d-aff5-47c1-ad3d-6a9a2ada122a"
      unitRef="usd">0</mgnx:NonCashRoyaltyRevenue>
    <mgnx:NonCashInterestExpenseRecognized
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOS0xLTEtMS03MzQyNw_845ed1c6-fc81-4dad-8a1d-d4bc0d4a2a0c"
      unitRef="usd">656000</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:NonCashInterestExpenseRecognized
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfOS0zLTEtMS03MzQyNw_4a6fe726-33b9-4c8b-8058-1bd2e736719e"
      unitRef="usd">0</mgnx:NonCashInterestExpenseRecognized>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTEtMS0xLTEtNzM0Mjc_14717272-08f8-4552-ae5d-5ce74fcc78c4"
      unitRef="usd">-20062000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTEtMy0xLTEtNzM0Mjc_8cd822c7-9147-4d6f-8bb5-6e6a985ad1d4"
      unitRef="usd">4520000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTItMS0xLTEtNzM0Mjc_b50a892a-f80f-46ef-84ff-122a455d1c14"
      unitRef="usd">-42000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTItMy0xLTEtNzM0Mjc_ac79dc25-b628-4d94-841a-b50e99ac2adc"
      unitRef="usd">210000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTMtMS0xLTEtNzM0Mjc_3bbe14fb-fb87-49df-89e8-ad5e62a33e31"
      unitRef="usd">-443000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTMtMy0xLTEtNzM0Mjc_6e386460-799b-4b43-bf56-aa8163a123e3"
      unitRef="usd">-6457000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <mgnx:OperatingLeaseNoncashExpense
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMS0xLTEtNzk5OTI_8ba9bb7f-e9a5-4a13-a22f-d75479bc70d5"
      unitRef="usd">941000</mgnx:OperatingLeaseNoncashExpense>
    <mgnx:OperatingLeaseNoncashExpense
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMy0xLTEtNzk5OTI_59745249-a90f-4bf5-8c34-fa6132b71ad6"
      unitRef="usd">0</mgnx:OperatingLeaseNoncashExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMS0xLTEtNzM0Mjc_83494aab-fd1b-46b8-a5f8-a3545e1b06b1"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTQtMy0xLTEtNzM0Mjc_ee78b4fb-4a01-4e82-b334-18544fa78e7a"
      unitRef="usd">-801000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTUtMS0xLTEtNzM0Mjc_11638a6a-7751-4a49-a91d-144c712284ea"
      unitRef="usd">-1148000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTUtMy0xLTEtNzM0Mjc_f58fedb0-978e-4799-a7b8-fe167a88531c"
      unitRef="usd">-11920000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTYtMS0xLTEtNzM0Mjc_617df105-a058-4e58-9a52-4fa9dacbe420"
      unitRef="usd">-677000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTYtMy0xLTEtNzM0Mjc_06f7f83a-c9ad-444e-a172-d21c15cf102c"
      unitRef="usd">-543000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTctMS0xLTEtNzM0Mjc_3184018b-766b-44de-b014-b0a10038e64c"
      unitRef="usd">-284000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTctMy0xLTEtNzM0Mjc_c191596d-cc31-4ef7-bd19-3dd937d5e45c"
      unitRef="usd">-1119000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTgtMS0xLTEtNzM0Mjc_7ed207de-96e3-4517-bacc-6e5a9a58d39c"
      unitRef="usd">-2213000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMTgtMy0xLTEtNzM0Mjc_ee86d865-5a0a-401c-8222-cf1d74ebf754"
      unitRef="usd">11280000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjAtMS0xLTEtNzM0Mjc_94b26c9c-1da6-4399-b79c-c055cde27d6d"
      unitRef="usd">-12833000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjAtMy0xLTEtNzM0Mjc_50ddfd79-4190-4ed2-9324-ca0d473c3544"
      unitRef="usd">-57696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjItMS0xLTEtNzM0Mjc_dd38ed9a-ee30-4759-8a63-f90b93034654"
      unitRef="usd">17296000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjItMy0xLTEtNzM0Mjc_2537fca5-2b81-4e9f-90ce-df00c4d7e02d"
      unitRef="usd">54077000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjMtMS0xLTEtNzM0Mjc_614f3e06-d3f4-4f2b-a14c-de539220bc1f"
      unitRef="usd">45750000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjMtMy0xLTEtNzM0Mjc_912b2926-ba48-42d3-bfc9-5edad738f937"
      unitRef="usd">37010000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjQtMS0xLTEtNzM0Mjc_66b9a1c5-c88f-45a7-a429-fdedd6019bb6"
      unitRef="usd">359000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjQtMy0xLTEtNzM0Mjc_53e40d97-296b-4fed-8d24-e951cd3b3299"
      unitRef="usd">1415000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjUtMS0xLTEtNzM0Mjc_1bb277a0-9171-4656-8314-93487433b5ab"
      unitRef="usd">28095000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjUtMy0xLTEtNzM0Mjc_4c6660db-c19c-4753-b760-3a6a22b3c98f"
      unitRef="usd">-18482000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjctMS0xLTEtNzM0Mjc_474a7c72-9262-4478-8971-9298d0a0c807"
      unitRef="usd">616000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjctMy0xLTEtNzM0Mjc_74202fb3-b568-4955-b972-b805df733e06"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjgtMS0xLTEtNzM0Mjc_aa7d94fb-cb4b-4143-b7e5-59bab9f239fa"
      unitRef="usd">5000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjgtMy0xLTEtNzM0Mjc_85176b94-2dbb-4fc1-908d-ebebe0354794"
      unitRef="usd">37000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjktMS0xLTEtNzM0Mjc_eb4d4c22-a76c-447f-b7d2-ed067a908ab9"
      unitRef="usd">158000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMjktMy0xLTEtNzM0Mjc_21cb7605-ab99-457b-b010-9bd16d3c8714"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMS0xLTEtNzc2ODM_e27929e6-99fc-4ed8-ad5c-af68fddc10f3"
      unitRef="usd">99655000</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMy0xLTEtNzc2ODM_1b6eea49-61c3-4ec0-a3d3-d7cf932a97aa"
      unitRef="usd">0</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMS0xLTEtNzM0Mjc_bfab234f-2736-445b-9b39-01ee3092f936"
      unitRef="usd">100118000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzAtMy0xLTEtNzM0Mjc_b6e495f4-b613-4502-8bee-e73b1887e51e"
      unitRef="usd">37000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzEtMS0xLTEtNzM0Mjc_7679704c-12c4-4f9e-8392-81c04548e164"
      unitRef="usd">115380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzEtMy0xLTEtNzM0Mjc_3c0105c2-2e3f-4769-9d63-c57a7b8abec5"
      unitRef="usd">-76141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzItMS0xLTEtNzM0Mjc_371d2477-dd03-4779-bc3b-bc679edcc041"
      unitRef="usd">108884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id066d12821a94a4da435f27478529262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzItMy0xLTEtNzM0Mjc_b3b96105-4079-4aff-8f69-c86c500300f9"
      unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzMtMS0xLTEtNzM0Mjc_2e9067af-b910-48f2-821f-f34927194dd7"
      unitRef="usd">224264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b294fc0b3654d22a51d4b9b63e8fc3d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzMtMy0xLTEtNzM0Mjc_bfad0e16-a95f-413c-9201-7b78cdef5d3c"
      unitRef="usd">47328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzYtMS0xLTEtNzM0Mjc_8add7f99-5877-40a5-85dd-f676ce6535bf"
      unitRef="usd">177000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8yOC9mcmFnOmYzNWMyOTI1YzAxMTRmNGRiZWQzM2Y3NmY4NmUzNDllL3RhYmxlOjQ2ZDljNTNlYWQwZDRjNzQ5YmIzYjU4NWFlYjQ1NjQ5L3RhYmxlcmFuZ2U6NDZkOWM1M2VhZDBkNGM3NDliYjNiNTg1YWViNDU2NDlfMzYtMy0xLTEtNzM0Mjc_291d4d98-5c3c-4b0e-92f4-ab026660ec5d"
      unitRef="usd">151000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNC9mcmFnOjZkZWJmM2QzNmE1ZDRkMGM4MGMzOGY4MWIyNTAwYzU3L3RleHRyZWdpb246NmRlYmYzZDM2YTVkNGQwYzgwYzM4ZjgxYjI1MDBjNTdfNTY4Ng_da4a21de-9327-45a8-97e7-2d0cfe46ee1e">Nature of Operations&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of the business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple oncology programs, some of which were created primarily using the Company&#x2019;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital, and accordingly, its ability to execute its future operating plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital.  The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, product sales and royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates, adverse events involving financial institutions or the financial services industry and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNC9mcmFnOjZkZWJmM2QzNmE1ZDRkMGM4MGMzOGY4MWIyNTAwYzU3L3RleHRyZWdpb246NmRlYmYzZDM2YTVkNGQwYzgwYzM4ZjgxYjI1MDBjNTdfNTY4NQ_dd2c803a-3b5f-432b-9ec1-ef7046bfc05d">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNy9mcmFnOmZkOGZkMTVjMGQ1OTRhZTE4N2M0ZTgwZjUwMjljOGU3L3RleHRyZWdpb246ZmQ4ZmQxNWMwZDU5NGFlMTg3YzRlODBmNTAyOWM4ZTdfNTQx_10627b43-68c8-4a49-b88c-0f5cdb64c0bd">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company adopted the following significant accounting policies in addition to those disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability related to the sale of future royalties and related interest expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the relevant accounting criteria under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#x2019;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#x2019;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <mgnx:LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNy9mcmFnOmZkOGZkMTVjMGQ1OTRhZTE4N2M0ZTgwZjUwMjljOGU3L3RleHRyZWdpb246ZmQ4ZmQxNWMwZDU5NGFlMTg3YzRlODBmNTAyOWM4ZTdfNTQ5NzU1ODI0OTMw_f3366100-35bd-4265-b27f-c12790cc1d4c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability related to the sale of future royalties and related interest expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the relevant accounting criteria under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#x2019;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#x2019;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</mgnx:LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl8zNy9mcmFnOmZkOGZkMTVjMGQ1OTRhZTE4N2M0ZTgwZjUwMjljOGU3L3RleHRyZWdpb246ZmQ4ZmQxNWMwZDU5NGFlMTg3YzRlODBmNTAyOWM4ZTdfNTQy_fa0a2125-cc5e-467d-8dce-28c65c877b99">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjgzNg_59a8a871-e83d-4627-a16c-5367dd4bdfea">Fair Value of Financial Instruments&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at March&#160;31, 2023 includes approximately $75.5 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjgzNw_e6a4c759-e371-4fdc-aff5-4f83957d5c9b">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjgzOQ_e3af0081-9ad5-4097-918a-f367f70b1e50">&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at March&#160;31, 2023 includes approximately $75.5 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ea8b4c0cee9423cb8076b969da02716_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfMy0xLTEtMS03MzQyNw_62815ae3-1503-4265-989e-7ce94c2b4620"
      unitRef="usd">52843000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d3d2b649df941eb8fa3c1e7cc8c023f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfMy0zLTEtMS03MzQyNw_3b8b3d6b-656e-42a5-a2ec-ed557d7aa945"
      unitRef="usd">52843000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2cb01d2775284756822f388b6d2e16a3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfMy01LTEtMS03MzQyNw_a65926b2-f9b0-43c6-b29a-a99541c4a317"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icacdb818e9174a62a35cd37cde8493fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNS0xLTEtMS03MzQyNw_46c47444-2f7d-452c-b9db-52099a2c6dc1"
      unitRef="usd">28879000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0d1469f54904ec9974d404f50d6b074_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNS0zLTEtMS03MzQyNw_5aa6fe6e-90a2-4ceb-a7e4-c1c4a90b314f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i346fa1f03c994f03af0d92e026a3ec33_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNS01LTEtMS03MzQyNw_65cb21c3-dc1f-4116-bf4b-bd65ff9a8d7f"
      unitRef="usd">28879000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3379a8d83154bc7a2f3dfcf35bf0466_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNi0xLTEtMS03MzQyNw_d7f4b70e-d905-4de4-a1e4-fa2a6ab15742"
      unitRef="usd">11187000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7897989264334daca83be8205e1f9066_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNi0zLTEtMS03MzQyNw_967e55a9-9307-4a3e-af49-bda0ace4ba49"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia862e744faeb4ae98a11485e9fc56db7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfNi01LTEtMS03MzQyNw_d2a0d521-3b32-45cc-b4d1-eae264da76a2"
      unitRef="usd">11187000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7781c40faa9749489c6481063c576abe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfOC0xLTEtMS03MzQyNw_0cf00357-97bf-47ef-8266-76926c8accbd"
      unitRef="usd">92909000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i980ce273d57d43e180d24954e57132ed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfOC0zLTEtMS03MzQyNw_ebb2be73-faad-4685-9da0-6877fc582cc7"
      unitRef="usd">52843000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e168dd44f5c4d8590a34135fb61acb0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjFkMjlmOWVjMjQxMDRkN2I5ZTNhYWE0YjA4ZGE3NDA5L3RhYmxlcmFuZ2U6MWQyOWY5ZWMyNDEwNGQ3YjllM2FhYTRiMDhkYTc0MDlfOC01LTEtMS03MzQyNw_437275f7-1e2b-408e-a17a-5a9caa6e8c67"
      unitRef="usd">40066000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i59f34ccbd0974b3fa3aedac0a0794404_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfMy0xLTEtMS03MzQyNw_cc48a1fd-c235-4b9c-810e-401e99f9f391"
      unitRef="usd">41564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i232dd89d03094cb0b9b34b4c2be81444_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfMy0zLTEtMS03MzQyNw_35d40c1c-ce8a-4efa-abb5-9bd32630ef5c"
      unitRef="usd">41564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i00a81484002646ca86c7980bdcde7f36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfMy01LTEtMS03MzQyNw_d780dcb6-94cb-4e06-a59a-e8b4f180bb61"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia556b2d5cb5245a1893a8a5f302714c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNS0xLTEtMS03MzQyNw_0ed0723c-9ffc-4024-a2f5-c9eec071bf7d"
      unitRef="usd">32811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia75e544fa68641f8940ee5f29bc524c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNS0zLTEtMS03MzQyNw_6f58a9d3-1739-40af-a7ef-aa9ed6a0e9ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5b5e32b9dcb4adfbcbcbfb2e6c5bcb8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNS01LTEtMS03MzQyNw_6ff09bfc-b57a-446d-bf40-006e047dde76"
      unitRef="usd">32811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i931c2e63969e41f787594bffd508c45e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNi0xLTEtMS03MzQyNw_d5f9cc06-d41c-43cd-a554-9774457963ec"
      unitRef="usd">17626000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66b5beeee5f64179b2145f46e3032766_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNi0zLTEtMS03MzQyNw_8426c6d3-447e-4522-9a7a-e2f1cbaa35a2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea1a641b6ade4b1197580a782d03ccff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfNi01LTEtMS03MzQyNw_a191befc-27cd-47d6-aaa7-b8209513d485"
      unitRef="usd">17626000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib24dc0ddf9a849be8ab92812afd2d286_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfOC0xLTEtMS03MzQyNw_2168b50b-b1cf-4160-a72d-d45d0cdbc777"
      unitRef="usd">92001000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13a5923cf7e84a8bbedc65e244cd7791_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfOC0zLTEtMS03MzQyNw_795799e8-e01c-41dd-b95b-3728ac811011"
      unitRef="usd">41564000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifd6f07e499e8471bb13f4992e6f93740_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RhYmxlOjIxZDJiNzJjNDJmNzQ4YTk4YjAzMmFhNGVkYjBiODI4L3RhYmxlcmFuZ2U6MjFkMmI3MmM0MmY3NDhhOThiMDMyYWE0ZWRiMGI4MjhfOC01LTEtMS03MzQyNw_cbedfab8-c57f-4661-89fc-25091fff2cfc"
      unitRef="usd">50437000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7781c40faa9749489c6481063c576abe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjYxNg_a7f1a219-63e2-42a1-86d6-6d8452489512"
      unitRef="usd">75500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib24dc0ddf9a849be8ab92812afd2d286_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80MC9mcmFnOjYyMzUzM2Q1Y2EzMzQ2ZTc5YjA4NWNlN2RlZjc2ZjE4L3RleHRyZWdpb246NjIzNTMzZDVjYTMzNDZlNzliMDg1Y2U3ZGVmNzZmMThfMjc2MQ_8d229d1e-0ae5-4228-ad24-e1996dbdfe45"
      unitRef="usd">46500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfMTAzMQ_da9d7d22-0cd0-4de0-9d77-219f89db51c3">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;All available-for-sale marketable debt securities held as of March&#160;31, 2023 and December&#160;31, 2022 had contractual maturities of less than one year. All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of  December&#160;31, 2022 were in a loss position for less than twelve months. Unrealized losses on available-for-sale debt securities as of  December&#160;31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfMTAzMg_4e87ea7e-d336-47f5-94f6-8c3344817b5a">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy0xLTEtMS03MzQyNw_763bac69-0728-4fce-8a2e-dec5ab98bbef"
      unitRef="usd">13168000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy0zLTEtMS03MzQyNw_c30ee4a7-e32e-4327-bbdb-26046d6e7e36"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy01LTEtMS03MzQyNw_61c6b885-7ed9-4f7b-9d59-4c57e957f713"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34e0d080973a4c64a22e1a22bfeb76c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfMy03LTEtMS03MzQyNw_5e240378-d397-45f5-add3-c7cc0316aa05"
      unitRef="usd">13176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i95d80c05867546299ae2cae022aee461_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC0xLTEtMS03MzQyNw_f79323d9-d71b-49dc-a11d-dd1c494b0016"
      unitRef="usd">4216000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95d80c05867546299ae2cae022aee461_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC0zLTEtMS03MzQyNw_9d0cfb39-1b07-484e-8c6f-3af0376f3648"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95d80c05867546299ae2cae022aee461_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC01LTEtMS03MzQyNw_6a5b8c4d-ebc9-4dd2-ac0b-2af0dee3ade3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95d80c05867546299ae2cae022aee461_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNC03LTEtMS03MzQyNw_d7ae1538-8b07-4190-a077-751f748c5288"
      unitRef="usd">4216000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS0xLTEtMS03MzQyNw_0097fe24-4719-4f2d-b4b4-b45b88d5234c"
      unitRef="usd">17384000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS0zLTEtMS03MzQyNw_654e7bdc-0217-4d9e-a3de-504822d95504"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS01LTEtMS03MzQyNw_e8033a7a-61d9-42c3-ac56-bffaf50c4490"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ4YTZhYTMwN2I3NDRlYjZiNDRjNDQzNGI2MWJjMzI1L3RhYmxlcmFuZ2U6ZDhhNmFhMzA3Yjc0NGViNmI0NGM0NDM0YjYxYmMzMjVfNS03LTEtMS03MzQyNw_5b4c12d6-492d-45c1-b114-f1151af0ec8b"
      unitRef="usd">17392000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy0xLTEtMS03MzQyNw_18137495-0c69-4e24-a99a-e73e86dfad1f"
      unitRef="usd">32812000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy0zLTEtMS03MzQyNw_432e2dfe-1f00-46f2-9dee-f3dd80f805d3"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy01LTEtMS03MzQyNw_20ab68a9-7f46-4263-97be-818e8c003b43"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1914dd9539bd46cd9d50436b60dae7d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfMy03LTEtMS03MzQyNw_dcbb37eb-6346-4675-b866-83046954f7cc"
      unitRef="usd">32810000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8430871688c24161b99e79ce00cc373a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC0xLTEtMS03MzQyNw_c29cb443-b72d-4596-b96e-5049b58c0700"
      unitRef="usd">12655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8430871688c24161b99e79ce00cc373a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC0zLTEtMS03MzQyNw_20d740ec-1c73-4a56-9f32-c6a4a76fcbf3"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8430871688c24161b99e79ce00cc373a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC01LTEtMS03MzQyNw_d7c82141-5390-4f68-a10b-55effc127163"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8430871688c24161b99e79ce00cc373a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNC03LTEtMS03MzQyNw_225dd646-11ed-4496-a806-7fdf3d8ceafe"
      unitRef="usd">12652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS0xLTEtMS03MzQyNw_52d23c21-7896-49ea-af34-463c862c62a8"
      unitRef="usd">45467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS0zLTEtMS03MzQyNw_04d32eef-76e0-46a1-9b92-bb2d60529160"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS01LTEtMS03MzQyNw_a59df274-9f66-42bd-88d9-3a4a2e727fea"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RhYmxlOmQ0ODBiMWYzZjE2YzQzOTdhMDFmNTQ3ZmEyNzRmYTljL3RhYmxlcmFuZ2U6ZDQ4MGIxZjNmMTZjNDM5N2EwMWY1NDdmYTI3NGZhOWNfNS03LTEtMS03MzQyNw_f1058c2c-c7e8-4c75-85c4-13f0f30592e0"
      unitRef="usd">45462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfNjgw_8479362e-47bf-4c1c-92f8-e41ad892fdf0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80My9mcmFnOmVhMjM1OWE2NjQyYjRkNGU4MTk5YTE2ZWZjZDRjMGNlL3RleHRyZWdpb246ZWEyMzU5YTY2NDJiNGQ0ZTgxOTlhMTZlZmNkNGMwY2VfNjgw_c1e16cc2-b41f-4408-828b-8105c66ac80e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNjky_e7022fb6-0f65-4b0c-8567-21ccef028ad8">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March&#160;31, 2023 and December&#160;31, 2022 is net of a reserve of $4.9&#160;million for unsaleable inventory.  These reserves are reflected in cost of product sales during the period they are recorded.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNjkz_cc0bf09d-3e8a-42bd-9692-17a61b94137f">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMi0xLTEtMS03MzQyNw_0f8115fb-bb98-4dd1-8680-08f8efe23a25"
      unitRef="usd">206000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMi0zLTEtMS03MzQyNw_1f7a3817-bf8a-4398-9c73-3e24289d46ea"
      unitRef="usd">409000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMy0xLTEtMS03MzQyNw_c445dc0a-8a16-4901-a7c7-eaafc96a25c3"
      unitRef="usd">1203000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfMy0zLTEtMS03MzQyNw_e939c674-f76a-49bc-a69e-4569476b8de3"
      unitRef="usd">1042000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfNC0xLTEtMS03MzQyNw_1a4c3ffb-3b84-4a30-a8e4-771405219479"
      unitRef="usd">1409000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RhYmxlOjAxNjcxMzQ4MjUzMjQ3YjNhNjFhMTY2OGFjNmMxYTA3L3RhYmxlcmFuZ2U6MDE2NzEzNDgyNTMyNDdiM2E2MWExNjY4YWM2YzFhMDdfNC0zLTEtMS03MzQyNw_b2b1f3ca-00c6-4f9d-93a2-1da7ab6f38a8"
      unitRef="usd">1451000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNTQ4_772b9d06-9f69-40b9-95ba-f29338550c12"
      unitRef="usd">4900000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80Ni9mcmFnOjU3MTQyNTE5Zjg3ZDRjNWE4NDBlN2ZjYjFmM2Y5M2IyL3RleHRyZWdpb246NTcxNDI1MTlmODdkNGM1YTg0MGU3ZmNiMWYzZjkzYjJfNTQ4_beeb7cc9-1a86-4e8f-8336-24a071b9be3e"
      unitRef="usd">4900000</us-gaap:InventoryValuationReserves>
    <mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTkyOA_41931acb-47f3-486a-a457-d5a8226c2411">Royalty Monetization Arrangement &lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company&#x2019;s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) (the DRI Transaction) under the Company&#x2019;s Asset Purchase Agreement dated May 7, 2018, as amended (the Asset Purchase Agreement), with Provention Bio, Inc. (Provention). The Company retains its other economic interests related to TZIELD, including future potential development, regulatory, and commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Royalty Purchase Agreement, the Company received $100.0&#160;million from DRI for its single-digit royalty interest on global net sales of TZIELD under the Asset Purchase Agreement. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0&#160;million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. The Company may also receive an additional $50.0&#160;million milestone from DRI if TZIELD achieves a certain level of net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $100.0&#160;million proceeds received from DRI under the Royalty Purchase Agreement were recorded as a liability for future royalties, net of transaction costs of $0.3&#160;million, which will be amortized over the term of the arrangement using the effective interest rate method. The Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company has significant continuing involvement in the delivery of future royalty payments to DRI and other existing obligations under the Asset Purchase Agreement. Royalty revenue will be recognized as earned on net sales of TZIELD, and the Company will record the royalty payments to DRI as a reduction of the liability when paid. The aggregate future estimated payments, less the $99.7&#160;million of net proceeds, will be recorded as interest expense over the term of the arrangement. As such payments are made to DRI, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement. The Company will estimate the payments to be made to DRI over the term of the Royalty Purchase Agreement based on forecasted royalties and will calculate the effective interest rate required to discount such payments back to the liability balance. Over the course of the Royalty Purchase Agreement, the actual effective interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as necessary.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the liability related to future royalties were as follows for the three months ended March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue payable to DRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock>
    <mgnx:UpfrontPayment
      contextRef="i0595b4044d4e48a4b54395ad62ddc89c_I20230308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk0NA_0f7be5c9-b0a3-4f85-87a8-4dd063245ea5"
      unitRef="usd">100000000</mgnx:UpfrontPayment>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk1NA_ac20e140-4103-4c39-9a50-953f29f9ecb9"
      unitRef="number">0.50</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:FutureRevenue
      contextRef="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk3MA_2844b3ee-92fb-43cb-a6ff-ce3693d6e861"
      unitRef="usd">50000000</mgnx:FutureRevenue>
    <mgnx:FutureRevenue
      contextRef="i7f77a5da90844bf8a3ce14222f59d98c_D20230308-20230308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMTk5MQ_7a3cdcc8-b638-46b9-bc77-cb551fbe96ec"
      unitRef="usd">50000000</mgnx:FutureRevenue>
    <mgnx:UpfrontPayment
      contextRef="i0595b4044d4e48a4b54395ad62ddc89c_I20230308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMjAxMQ_8e2d84a5-4d24-4688-9755-02b1282f720c"
      unitRef="usd">100000000</mgnx:UpfrontPayment>
    <mgnx:TransactionCost
      contextRef="i0595b4044d4e48a4b54395ad62ddc89c_I20230308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyMjAyOQ_a166ace8-fc93-4b97-a849-16b83e4c4e50"
      unitRef="usd">300000</mgnx:TransactionCost>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="iab71ac1d87d8415a9550205dc1aa8b3b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzU0OTc1NTgyNzg0Mg_af381487-574b-493b-a006-f2ac42ab9ab1"
      unitRef="usd">99700000</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90ZXh0cmVnaW9uOjIzOTUxNDllMjE4ODQyY2U4NmVmMWVkNDIyYmE4YjdkXzE2NDkyNjc0NTA0MjQ_058ef93e-573f-43aa-b3e8-020884ef234f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the liability related to future royalties were as follows for the three months ended March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue payable to DRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock>
    <mgnx:LiabilityRelatedToFutureRoyalties
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzAtMS0xLTEtNzk0NDI_4acc6dac-c97d-407e-a767-77346402e11e"
      unitRef="usd">0</mgnx:LiabilityRelatedToFutureRoyalties>
    <mgnx:ProceedsFromSaleOfFutureRoyalties
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzEtMS0xLTEtNzk0NDI_4b601b33-e9e2-42d6-989c-725ee1dd904d"
      unitRef="usd">100000000</mgnx:ProceedsFromSaleOfFutureRoyalties>
    <mgnx:DeferredTransactionCosts
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzItMS0xLTEtNzk0NDI_7578f881-b1bb-48db-aad1-f1eeff308c03"
      unitRef="usd">-344000</mgnx:DeferredTransactionCosts>
    <mgnx:NonCashRoyaltyRevenue
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzMtMS0xLTEtNzk0NDI_0a6d53f6-06d5-4733-a92d-1c7a7c2208e0"
      unitRef="usd">90000</mgnx:NonCashRoyaltyRevenue>
    <mgnx:NonCashInterestExpenseRecognized
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzQtMS0xLTEtNzk0NDI_e4689ff6-9b15-4776-aefd-7707dda6b5c0"
      unitRef="usd">656000</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:LiabilityRelatedToFutureRoyalties
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80ODEvZnJhZzoyMzk1MTQ5ZTIxODg0MmNlODZlZjFlZDQyMmJhOGI3ZC90YWJsZToyMjAyZWQxY2JhMTk0NGJmOWUyZTE1YjM2ODMyNzRjMi90YWJsZXJhbmdlOjIyMDJlZDFjYmExOTQ0YmY5ZTJlMTViMzY4MzI3NGMyXzUtMS0xLTEtNzk0NDI_81e0b33e-96c6-4254-87b6-a98d5700f3a6"
      unitRef="usd">100222000</mgnx:LiabilityRelatedToFutureRoyalties>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTcyOA_e3f5d656-09f8-4d3d-bd54-dcada8066ca9">Stockholders' EquityIn November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The Company sold 3,622,186 shares of common stock resulting in net proceeds of approximately $98.2&#160;million through December 31, 2021 under the Sales Agreement. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increased the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million. In March 2023, the Company terminated the Sales Agreement and entered into a new sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0&#160;million through an ATM Offering. During the three months ended March 31, 2023, the Company sold 95,000 shares of common stock at a weighted average price per share of $6.60, resulting in net proceeds of approximately $0.6 million, net of offering expenses.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMjE4_ba788eef-54ad-4a8f-a520-4b3d5c10df34"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8125884812c4401b8b311bdffc16d974_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfNTQ5NzU1ODE3NDI5_16be229b-6989-4e38-9f57-27d150b88db5"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8125884812c4401b8b311bdffc16d974_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfNTQ5NzU1ODE3NDQ2_4ea0dd8b-5d70-4567-83ee-e6403829e489"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTAwOQ_a67012e7-7e7d-4e76-9a3d-d8439424174b"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="i9309ea0208184fa4b37705ea22d3a556_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTA1Mg_41a58934-6432-4db7-b024-908daa849c6e"
      unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0ODA0NA_41ec4d97-53d6-47d5-a6c4-b274caba679e"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6d36e822023b4273a9509235bd8c6acd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0Mzc2Mg_c39d1257-034f-48d0-8da4-453e4e5c2ec1"
      unitRef="shares">95000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if5a1a46d9b1045c9b6ee53abe05a7ead_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0MzgzMA_e94c0908-5290-4d8c-8a84-253d80175b39"
      unitRef="usdPerShare">6.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6d36e822023b4273a9509235bd8c6acd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl80OS9mcmFnOjkzYTFkOGEyYjFhOTQzOWRiYjk5YzA1ZDQ4N2U2MzBiL3RleHRyZWdpb246OTNhMWQ4YTJiMWE5NDM5ZGJiOTljMDVkNDg3ZTYzMGJfMTY0OTI2NzQ0Mzg3OA_bc21a35b-822e-495b-a722-84af990be73b"
      unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQ0Nzc_a0c86dfd-e28f-4cc0-a455-a5b18a3d671f">Revenue &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborative and Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte), which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. MacroGenics will manufacture a portion of Incyte&#x2019;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte in multiple indications, the Company could receive up to a total of $435.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $115.0 million in development milestones under the Incyte License Agreement, including $15.0 million received following the FDA approval of ZYNYZ. The Company is also eligible to receive tiered royalties of 15% to 24% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606) at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $115.0 million related to &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical and regulatory activities related to the further advancement of retifanlimab&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized the $15.0&#160;million ZYNYZ approval milestone as revenue under the Incyte License Agreement during the three months ended March 31, 2023. During the three months ended March 31, 2022, no revenue was recognized under the Incyte License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $1.3 million and $0.3 million, respectively, for services performed under the Incyte Clinical Supply Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Gilead Sciences, Inc &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#x2019;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ng to a development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#x2019;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.7&#160;billion &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a flat royalty on worldwide net sales of any products resulting from the two research programs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the license under the MGD024 developme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nt plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and development activities are not distinct from one another, as the license has limited value without the Company&#x2019;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will reassess the amount of variable consideration included in the transaction price every reporting period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#x2019;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the pre-option development timeline.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company will defer revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company recorded revenue of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to the Gilead Agreement. As of March&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$59.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.1&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$57.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current. As of December&#160;31, 2022, $59.8&#160;million in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$58.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#xae; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through March&#160;31, 2023. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab: (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million. Therefore, the associated consideration, $8.1&#160;million net of value-added tax withholdings, was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uring the three months ended March 31, 2023, no revenue was recognized, and during the three months ended March 31, 2022, $5.0&#160;million in revenue was recognized under the 2018 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company. In August 2022, the Company and Zai Lab agreed to discontinue research and development of the Lead Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a stock purchase agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the stock purchase agreement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the remaining Programs, the Company could receive up to approximately $680.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in 2021. During the three months ended March 31, 2023 the Company recognized no revenue under the 2021 Zai Lab Agreement, and the Company recognized revenue of $0.3&#160;million during the three months ended March 31, 2022 under the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of March&#160;31, 2023, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2018, the Company entered into the Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. Under the Asset Purchase Agreement, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones. In addition, Provention is obligated to make contingent milestone payments to the Company totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. In March 2023, the Company entered into a Royalty Purchase Agreement with DRI; see Note 6, Liability Related to Future Royalties, for additional information. The FDA approved the BLA for TZIELD (teplizumab-mzwv) in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amended the Asset Purchase Agreement. Under this amendment, the milestone for first approval was split into four equal payments, the first two of which were received prior to March 31, 2023. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;herefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company recognized $0.4 million in royalty revenue under these agreements based on the sales of TZIELD, and no revenue under these agreements during the three months ended March 31, 2022. As of March&#160;31, 2023, Provention owed the Company $30.0 million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet. This receivable was due to be paid on June 1, 2023 and September 1, 2023 under the amended Asset Purchase Agreement. Provention was acquired by Sanofi in April 2023. Sanofi accelerated the payment schedule and paid the Company the balance due subsequent to March 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. In August 2022, I-Mab notified the Company of its intention to terminate the I-Mab License Agreement effective February 25, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million, and $5.0&#160;million of milestone revenue has been earned from the inception of the I-Mab License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement was recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;judgment, was the best measure of progress towards satisfying the performance obligations. During the three months ended March 31, 2023 the Company recognized no revenue under the I-Mab License Agreement, and during the three months ended March 31, 2022 the Company recognized revenue of $0.2 million under the I-Mab License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#x2019;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2023, the Company recognized no revenue for research and development activities performed under the I-Mab Clinical Supply Agreement. During the three months ended March 31, 2022, the Company recognized $0.9&#160;million under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#x2019;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $19.5&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur. Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $3.6&#160;million under the Incyte Manufacturing and Clinical Supply Agreement during the three months ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenue during&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the three months ended March 31, 2022. As of March&#160;31, 2023, $7.8&#160;million in revenue was deferred under this agreement, $7.1&#160;million of which was current and $0.7&#160;million of which was non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March&#160;31, 2023 is $25.1&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended March 31, 2023 and 2022, the Company recognized revenue under the NIAID Contract of $0.3 million and $0.4 million, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ieef59164d9804d038bd3cc080e152e53_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNzM5_fde8f90b-c21f-4e8c-bc5f-8c65a3662e62"
      unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjY2NQ_534d37dc-90be-4c19-ace0-5d47f1ac5a1f"
      unitRef="usd">435000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjcxOQ_2cd067d4-3096-4bbc-8efa-75397b93d828"
      unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id2e1ac7059204d649fe5363543d08fd8_D20180101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjgzOA_db1c0265-9305-4916-a36e-8f88adfa42b3"
      unitRef="usd">115000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="iafe7647445614121a80a6be8d87248c3_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc0OTc2_b26430d9-d33e-4bc2-841f-841a681b263a"
      unitRef="usd">15000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i2a1a941fe6dc4e42b16747db51f11bd9_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzAxMg_2c5aaa05-881e-4e7a-9c1f-cec6f454adbf"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i1cd6332acd224939b6e64d01df3361e7_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzAxOA_76ecf3f7-2915-4f60-9dfb-724b5447196e"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzY3Nw_1a061c84-5c1a-46d5-b899-86c595daf1c5"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i1cfacae19f474e9da815bdf9d86a8bf1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNDQ2Mw_8605df75-be65-4a45-b9f2-aca28f3b796c"
      unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id2e1ac7059204d649fe5363543d08fd8_D20180101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjA0Mw_db1c0265-9305-4916-a36e-8f88adfa42b3"
      unitRef="usd">115000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i2682097a1f3e4a89a96cab41f8cbd4ea_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjM0OQ_8e60fbb6-2ece-4b0f-83ee-2e2fc3ebc58f"
      unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i6b07faa5b7d643d883cf0c135e8f3d80_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjQ3Mw_80b26973-7974-47af-95b3-527da0790ca6"
      unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="ic1857d4cd8f7406fa5bbf069c7a857d6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjYwOA_20ceb27b-41c7-493d-b5fa-2e1a0b9f8156"
      unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1857d4cd8f7406fa5bbf069c7a857d6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjYwOA_5c906f63-d058-4061-9308-34197be5b06e"
      unitRef="usd">15000000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="iafc0cdb960994c118fa8a5cfd0f2a280_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNjc5NA_5ab44606-41a0-4498-bb1e-6f3353d8b2ba"
      unitRef="usd">0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="if334a8dd8b764a01a900c1c6d7f9b363_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfODEwMQ_059226ca-5ff6-4585-be36-ea33e3e350f8"
      unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbbd06906d6345b2afe1b89f2851967a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfODEwOA_7fc89d6b-dc35-4fa3-92b6-04bc4145f4a3"
      unitRef="usd">300000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODQ5Njky_e526d17f-3059-42fe-9a24-93159f1a5124"
      unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments
      contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNDg5NTg_167e4c2d-4170-424d-8bd0-0696542a195a"
      unitRef="usd">1700000000</mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNDEzNjU_e526d17f-3059-42fe-9a24-93159f1a5124"
      unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODUyNTYx_e526d17f-3059-42fe-9a24-93159f1a5124"
      unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:Revenues
      contextRef="i374c14d1f7814bd99693ece7e091f00d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODUzOTMz_7bc2f130-fe90-4e16-944b-d84ae60b2cf5"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6896341f33cd4b08985cd9e24146387e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODUzOTk1_d9124ad1-7195-4761-b801-cd6d26e7d083"
      unitRef="usd">59500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6896341f33cd4b08985cd9e24146387e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODU0MDQ1_9a9738ad-cb30-4cdd-8cc2-677b4eeca3a5"
      unitRef="usd">2100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i06dd337e669d44fda86ff6918e8c7999_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODU0MDc0_180e4465-a60a-4e6d-ae0e-d5e289d76c9a"
      unitRef="usd">57400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5999119dfc294e80ad0713a177c361f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzUxNDg3Mw_d1295790-b997-427d-827a-1a03cff60a0e"
      unitRef="usd">59800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5999119dfc294e80ad0713a177c361f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzUxNDg3Nw_81173e57-b4f4-46f6-b077-facefdb70765"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5999119dfc294e80ad0713a177c361f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzUxNDg4MQ_84d41465-5aa7-4cb3-9341-91f4641aec20"
      unitRef="usd">58000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA3MjY_f24b612f-5933-4e6a-aff6-b43fe0e81df5"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA3MzA_8a41972b-33f1-4a6c-91c9-406c6b02639b"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA3Nzk_624c8cbd-f870-420c-ab04-a0c2ee47e9d4"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ic98612cc5ba1468d888c8629fe2b15bb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA5MjU_7fdc8859-3421-4e7a-9826-fef7b0b1bca3"
      unitRef="usd">140000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTEwMDI_49d4ff32-aae5-4179-83dc-43c25517ad63"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="if40b3c7658dd4cf3af7b29395be88093_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTExMTM_be074028-eb9b-43c0-9cb5-8015cf8161f7"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i3fe661497ec1436ea3ea36041dec66b1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTEyMzY_3d7cc8c8-78a6-43af-87e7-64111964577b"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTI1NDA_8a41972b-33f1-4a6c-91c9-406c6b02639b"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTM5MTY_49d4ff32-aae5-4179-83dc-43c25517ad63"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:MilestonesValueAddedTax
      contextRef="id6b318e88e474ee5a802f96a3891077b_D20200701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTM5NjE_87e0c846-58b0-4e91-8140-eb4f143a1ff4"
      unitRef="usd">8100000</mgnx:MilestonesValueAddedTax>
    <us-gaap:Revenues
      contextRef="ic55a0f9ecd9b4ceda005b981bf2f7d8e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTQxNjE_42afe166-6f1c-4b37-b799-b2aa46fd8131"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief1057cf41b349daa7c0fc063798c809_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTQxOTk_04da8ec1-411c-47a0-a24e-9bbefd178089"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief1057cf41b349daa7c0fc063798c809_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTQxOTk_96220393-c3b3-447a-bc55-8f8b07a0e052"
      unitRef="usd">5000000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTcxNjU_984181da-b76c-4d87-9958-546fd746bfb9"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTczOTM_8cac8f8b-e617-49c9-8431-69ca825a1d79"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc0NTY_424644ce-d8cf-4a10-9b6a-e18d8f08ecf0"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc0ODA_da30726f-39b8-4621-842b-92a78d736f80"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i02aba6ee80e4485593c6ef2dd3196270_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc1MDM_9d135127-e88d-48d0-a710-e1e92fd59883"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc3MDE_5df5b82f-0d94-4464-afa2-2707923f9049"
      unitRef="usd">680000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTc3NDk_c7402184-1475-4eda-9d35-977b816f670b"
      unitRef="usd">600000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk0MDY_3ad5258e-a6fb-4561-a2a9-500ef126dbd9"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk0Mjg_c28b0c0a-654f-4bd4-bf68-7e038d49afac"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i02aba6ee80e4485593c6ef2dd3196270_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk0NTI_d5a4debc-a436-4b84-83f8-2923882d10ed"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="iaa3389bb62654ba8b566b73f41283feb_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTk1MjY_eb8f934e-3c43-44b8-8e77-0ae5caee6928"
      unitRef="usd">5000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i0dce7a11e4fd47a18e71a07d65f3c80e_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjAzOTg_d36dc21f-3fdf-4a92-9e66-d0da17922921"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="ie16b1ce65ef4498e985806621089d540_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjE5OTAyMzMxNTA5Mg_80a5668a-4c8b-45cd-b9cf-b91bff4bdcf1"
      unitRef="usd">300000</us-gaap:Revenues>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i3dee982850e549a68b6a81eb6c007052_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NTUwMQ_c23ac013-bb68-469b-9017-80f4aa239e66"
      unitRef="usdPerShare">2.5</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ibf999f4a23674de6901577a7a2e0e94d_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NTY2MQ_40f4e9e9-6a56-4bb0-9801-8a25b9f43d07"
      unitRef="usd">65000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ibf999f4a23674de6901577a7a2e0e94d_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NTcxNg_787f0e57-227e-4e95-93a2-1ef008c1c6e9"
      unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i5fbed9f54de04d85a3e8c55feabc0565_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NjczNg_8cedd32b-c779-4364-80fb-6936f2b99bbf"
      unitRef="usdPerShare">2.5</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i7079bd55b0684e16805a5c2352089fd5_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4Njg3MA_ba694d37-cd70-440d-93ed-b14c45b7767e"
      unitRef="usd">170000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i7079bd55b0684e16805a5c2352089fd5_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NzAyOQ_0539868e-7a0a-41ee-9727-8b75343d6850"
      unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i4475f726644746db8a9d6f1b092abe4c_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4NzIzNQ_cd5e489f-4c44-42ea-b2a8-c1165a1ee537"
      unitRef="usd">60000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="i7079bd55b0684e16805a5c2352089fd5_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4Nzg2NA_3aef1bd7-8f8a-4be0-8e61-68f9fc7332af"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iee007f50b7b54e878349b22a7469557d_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4ODYzNA_5992ceeb-5baf-46d9-9287-7e13de2d7534"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="iee007f50b7b54e878349b22a7469557d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4ODcxNQ_1a918806-6080-461a-bc93-d1757047b0b6"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="ied8b4fcaac5140cca18c505dac7f2417_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ4OTY1NQ_61158fc3-49a0-4ce3-8a9e-11875b6f85fe"
      unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i4475f726644746db8a9d6f1b092abe4c_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ5MDE4OQ_cd5e489f-4c44-42ea-b2a8-c1165a1ee537"
      unitRef="usd">60000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i83b508f7b0c74f06858ab827b8a99958_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc1MjYz_64ea04e9-75ae-4fa1-80a3-90e241bbec7e"
      unitRef="usd">400000</us-gaap:Revenues>
    <mgnx:ReceivableFromCollaborationPartner
      contextRef="iae198fa14cb849eba1d6619f7acc0b25_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTY0OTI2NzQ5MDQ5Mw_d363b5e9-e9cb-46c9-80eb-16cfd1216bec"
      unitRef="usd">30000000</mgnx:ReceivableFromCollaborationPartner>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjY4NDA_74509b57-5621-4048-bafb-6a6ccc9a7c67"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjY4NDk_41e92f41-b9f1-4e7a-acba-3f4911a31717"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjc3MTU_74509b57-5621-4048-bafb-6a6ccc9a7c67"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjgxMzA_6754ee88-e69e-47f1-b63c-09dc8605b89f"
      unitRef="usd">1000000</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <mgnx:CollaborationArrangementOneTimeCreditPaidPercent
      contextRef="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMTA5OTUxMTcwMTAwNg_30c9d605-7658-4f9f-aeb3-e2370ea42156"
      unitRef="number">0.80</mgnx:CollaborationArrangementOneTimeCreditPaidPercent>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i831ccd6f3347498497b72f53753edd5e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjg0ODM_63f9f3eb-eb23-43c9-a160-1e36807834ff"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:OneTimeMillstoneCredit
      contextRef="i6b7f5ae7b36f40efb495d731d6421605_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjg0OTc_33ca8409-d860-4e67-bcf4-5cd991890248"
      unitRef="usd">4500000</mgnx:OneTimeMillstoneCredit>
    <us-gaap:Revenues
      contextRef="i37774c1e63924618a2955aecb5689f3b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMjkyMjk_512b44a0-8efc-42d2-b799-a87a20ccaee7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b2edd43ee5f4027854eb6a336bdca71_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODY3MzIy_0bf967dc-3407-4e50-afc6-d987fa2d4646"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97eb432defc54b6ea97bda7a332c90f5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODY3NDE5_20f1ac17-b490-4055-8a5d-4fe9c3eb113b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50d8b24b3b4c46df987acd17c19050e2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc0OTMz_8e67d0fd-beb4-44db-8235-1142d82e8102"
      unitRef="usd">900000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ieddfecbe8ad14ef7a8ff835b12b95d4a_D20220101-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzEwOTU_0ee7238c-bde9-4e8f-8f94-931773382453"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzEyMDE_43a6ce16-48c9-4017-8b7e-b442b79e5dc8"
      unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <mgnx:AdditionalAnnualFixedPayments
      contextRef="i7595340e36ea4d09bf2116e33b8641f3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzE1NTk_e73538c3-9bb8-42ff-b7db-dc04aa37329c"
      unitRef="usd">5100000</mgnx:AdditionalAnnualFixedPayments>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ieddfecbe8ad14ef7a8ff835b12b95d4a_D20220101-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzIwMjU_0c4b2568-4d46-4022-9018-0c3fbf9a6322"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="i7595340e36ea4d09bf2116e33b8641f3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzIwNjc_acd40a74-7f03-439a-b58b-f8cc9fecf50c"
      unitRef="usd">19500000</mgnx:TotalAnnualFixedPayments>
    <us-gaap:Revenues
      contextRef="iaa3eccd028da467f83bd22324f391a17_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzI5NjI_899ee857-77fa-42de-9f4b-fa17dbb238f6"
      unitRef="usd">3600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e3306c0844c488aa3ac28c64699528b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfNTQ5NzU1ODc0OTg1_20f42c7a-0421-4352-b35f-b8fe5ac5f31c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzMwODg_f1e43aed-c481-4c2b-9e2d-41be3764c41e"
      unitRef="usd">7800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzMxMzc_4d2ba97a-9070-4be9-b40b-73704ca8572e"
      unitRef="usd">7100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i17159c2a9e9f40a68a48e3051433e894_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzMxNjU_3f2e94bd-6a86-4c2a-921e-9bdc10ddefa9"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i800a7e6440dc4197a9837d73a114cba7_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzM0MjQ_6fc7a507-7415-4c0b-9d9e-0853ab20e22f"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="iabee161e88cd43838204d199c20da652_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQxMzY_ebdc4d4c-b701-4538-a216-cfc911216208"
      unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues
      contextRef="ic4a1d67968a747cca217bd0b0428cf02_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQ0NTA_b90e0d93-7c8f-4299-b709-a3c206960f57"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56231c20b15840d1afa950fe878367de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81Mi9mcmFnOmNlOTcwZmI4OTkxYjRhZTBhNTIxNzFmODJjNTQzODdkL3RleHRyZWdpb246Y2U5NzBmYjg5OTFiNGFlMGE1MjE3MWY4MmM1NDM4N2RfMzQ0NTc_068a0489-4e6c-4ab3-99cc-3eaced69679b"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyNQ_a597db41-ec47-4e5e-a736-65d8167d7eb0">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period. During the three months ended March&#160;31, 2023, no shares of common stock were purchased under the 2016 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Equity Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of March&#160;31, 2023, under the 2003 Plan, there were options to purchase an aggregate of 61,572 shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the three months ended March&#160;31, 2023, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of March&#160;31, 2023, there were options to purchase an aggregate of 12,778,040 shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6% -94.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9% - 88.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,914,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,839,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of March 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,048,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,763,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the three months ended March&#160;31, 2023 and 2022 was $3.77 and $7.48, respectively. The total intrinsic value of options exercised during the three months ended March&#160;31, 2023 was de minimis and the total intrinsic value of options exercised during the three months ended 2022 was approximately $0.3 million. The total cash received for options exercised during the three months ended March&#160;31, 2023 and 2022 was de minimis. The total fair value of shares vested in the three months ended March&#160;31, 2023 and 2022 was approximately $0.6 million and $5.4 million, respectively. As of March&#160;31, 2023, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $29.2 million, which the Company expects to recognize over a weighted-average period of approximately 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company awards restricted stock units (RSUs) to employees. RSUs are valued based on the closing price of the Company&#x2019;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award&lt;/span&gt;&lt;span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, there was $4.9 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.6 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1cbab60f55fa402c96d89e18f0e3beb9_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDI3_432b6bc5-bec2-4ca7-880c-2116f9f0f84f"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie14822659c7d4a8e9cf7fcec3ee0ae7f_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNjI2_b52d4277-57f3-4f94-94f8-4935d947e836"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="ie58506024e45456592bc19755da226d2_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIzMg_748af8d0-3eb4-4f09-ab84-0b7212c841ff">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie14822659c7d4a8e9cf7fcec3ee0ae7f_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfODcy_f898d4b1-e3c4-4a8f-a834-95c2ab31f75c"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ifa174cd3914f4d469152f496ac824c06_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMTAwMg_b6ea393f-0f30-49b9-af43-c86b7df990d5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie45d01decd32435a8498c793207f66fd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMTkyNA_793f260a-fae7-43cd-b64e-a3baf812e315"
      unitRef="shares">61572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="ie39a7a5272cb4b76897f3e799b70f9ab_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMjM2MQ_da71c223-65d0-4092-8afc-8e616991812c"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i7aa16b089d85451b96f0b9061c2797e3_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMjM3Ng_acc4b49f-c6b0-4c85-9996-c47f84191ad9"
      unitRef="number">0.04</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib6e4cfb9ea29453487b8acb62f27c309_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMjcyOA_a0ed29cf-d64e-45ee-8217-7dd7808daf3c"
      unitRef="shares">15816949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib6e4cfb9ea29453487b8acb62f27c309_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzMwNA_515a322b-c022-4880-a946-2df3d985260c"
      unitRef="shares">12778040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIzNA_00d263d7-5493-4eb3-8cde-f2eabb656531">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b0c52ec53274fdba3171ff3170db6a3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMi01LTEtMS03MzQyNw_398d67af-6e80-4695-9d9b-7724760e9e62"
      unitRef="usd">2461000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1660944dc73f45fea86496b594fce178_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMi03LTEtMS03MzQyNw_88cf437c-9311-48a4-8752-bb86d217caaf"
      unitRef="usd">2392000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iceb09aa6ccd548e5b5a67339e277f132_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMy01LTEtMS03MzQyNw_da56d134-d9aa-4651-9576-8627942279be"
      unitRef="usd">2372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9e6a705742804457a4eb1b0d964ea1e0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfMy03LTEtMS03MzQyNw_a0289387-5919-4ee8-9691-a7c0d69d1d78"
      unitRef="usd">2882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfNC01LTEtMS03MzQyNw_427c83fb-3b1d-4a30-a97b-ac7240534fb9"
      unitRef="usd">4833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjY5ZDk4OTJhMWYyZjQ3ZWRhOTcwMmVjNzM2OWU1N2VkL3RhYmxlcmFuZ2U6NjlkOTg5MmExZjJmNDdlZGE5NzAyZWM3MzY5ZTU3ZWRfNC03LTEtMS03MzQyNw_edc89341-f96b-40fa-af9a-6de35ca3ad54"
      unitRef="usd">5274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyNg_6ef6e146-68d4-44b8-826e-6990983029ca">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6% -94.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.9% - 88.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMi0xLTEtMS03MzQyNw_dd31f4f2-e623-458a-84bb-2eb4a0face69"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMi0zLTEtMS03MzQyNw_7a480c5d-23fe-42ae-8fc7-da9f2911320c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icaf39a1c94944731b2514e5c45e8ecee_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmE2MzlhMjk0ZjAwZjQ3OTBiZjZhOTA5YTJiODQ3NGVkXzQ_cf51e8c0-7a8a-428a-9d0c-c3c31a3b4287"
      unitRef="number">0.926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5317a874bbfc4ef6baca4f516aa0f218_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmE2MzlhMjk0ZjAwZjQ3OTBiZjZhOTA5YTJiODQ3NGVkXzg_baee93f5-8233-4d2b-98a5-56ccc3274114"
      unitRef="number">0.943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i921b7f549052407f832cadb468c93a6c_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjU0NDY3Yzc2MWQ2OTQzZWViYTEzY2MwNTA3MDE0YWQ3XzQ_ed4de384-eefc-4c84-ac35-bc6320d219c8"
      unitRef="number">0.879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i799a33353e9a49a4b78a98bda1c4c308_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfMy0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjU0NDY3Yzc2MWQ2OTQzZWViYTEzY2MwNTA3MDE0YWQ3Xzk_c468b12a-119c-4b0d-ba23-22fdfe1a0a5d"
      unitRef="number">0.883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icaf39a1c94944731b2514e5c45e8ecee_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmQyNDdmNDE1ZTAwZjRiMjNiM2FmNzBlZmM0ODk3ZmNhXzQ_78974185-c0b7-4c7f-9f60-a10fd0648a9a"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5317a874bbfc4ef6baca4f516aa0f218_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0xLTEtMS03MzQyNy90ZXh0cmVnaW9uOmQyNDdmNDE1ZTAwZjRiMjNiM2FmNzBlZmM0ODk3ZmNhXzk_6cb3fef2-3f09-4021-8f28-60cac47e1696"
      unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i921b7f549052407f832cadb468c93a6c_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjAzY2Q0MzhmNmUzYTRhNWVhMDEzNjA1MWJhOTkxMWNiXzQ_c8fda62d-7a32-4844-a138-f3aad9fdc5d4"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i799a33353e9a49a4b78a98bda1c4c308_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNC0zLTEtMS03MzQyNy90ZXh0cmVnaW9uOjAzY2Q0MzhmNmUzYTRhNWVhMDEzNjA1MWJhOTkxMWNiXzk_223d7596-ea8b-4c00-a74c-1ab231e06a72"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNS0xLTEtMS03MzQyNw_817e3475-9878-4ff0-b314-e08fa6492ea9">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOmMwZjVkOWViMmVkMjRlZjVhZmVjMjYzODRkOWRiNDlkL3RhYmxlcmFuZ2U6YzBmNWQ5ZWIyZWQyNGVmNWFmZWMyNjM4NGQ5ZGI0OWRfNS0zLTEtMS03MzQyNw_bb0d6cf9-f976-4583-a25b-82d67d9635b4">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyNw_63021d7e-3b57-42a0-b151-703cefd543be">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,914,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,839,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of March 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,048,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,763,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMS0xLTEtMS03MzQyNw_cae87d6b-ee00-4f30-b07b-77f76344d6e7"
      unitRef="shares">10098929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9dc12bf419854569b3c1bc5f89a77e19_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMS0zLTEtMS03MzQyNw_4359e322-8d1d-439a-9477-2f42aaafd0db"
      unitRef="usdPerShare">18.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ica024959f8ab45b2aee0bf2b8219b68e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMS01LTEtMS03MzQyNw_4ad03425-c9a8-46af-b27c-a4a96d2687bd">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMi0xLTEtMS03MzQyNw_6bf8e4ee-0958-4d53-a2e3-2d018bb5138a"
      unitRef="shares">2914405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMi0zLTEtMS03MzQyNw_b8f525a1-b75d-4756-a6dd-7129fcca813d"
      unitRef="usdPerShare">4.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMy0xLTEtMS03MzQyNw_d0950368-594c-4e5e-b858-82ec136f2ec4"
      unitRef="shares">3531</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfMy0zLTEtMS03MzQyNw_26dfd769-886d-422f-a5a1-a08fc4a7ddc0"
      unitRef="usdPerShare">1.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNC0xLTEtMS03MzQyNw_53dba7f7-4c02-47ab-831f-85423820fe14"
      unitRef="shares">87556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNC0zLTEtMS03MzQyNw_792facaf-d5d8-4ad1-b635-84a937e522cd"
      unitRef="usdPerShare">11.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNS0xLTEtMS03MzQyNw_41204806-0a42-4687-85cb-a2a9fb0aa3ff"
      unitRef="shares">82635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNS0zLTEtMS03MzQyNw_a0b78216-6825-4838-83d2-cc388a367218"
      unitRef="usdPerShare">22.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi0xLTEtMS03MzQyNw_112c951d-5d00-402f-a6c8-1bf59c8a1b84"
      unitRef="shares">12839612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi0zLTEtMS03MzQyNw_9cb75f4b-bf57-47c9-9565-451e69b12c54"
      unitRef="usdPerShare">15.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi01LTEtMS03MzQyNw_7a2714a4-f88d-4987-889e-f6468da9c660">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfNi03LTEtMS03MzQyNw_3e0a8866-0a73-405b-9c4c-2a731efd60a9"
      unitRef="usd">7827000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC0xLTEtMS03MzQyNw_b4f3d9e3-0242-482f-84d8-c3746dda2397"
      unitRef="shares">7048779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC0zLTEtMS03MzQyNw_86297494-5f8d-4ba8-bfa6-33c012af4d10"
      unitRef="usdPerShare">20.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC01LTEtMS03MzQyNw_833aa6cc-ac13-486d-a0a7-227445424028">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOC03LTEtMS03MzQyNw_3b487b6c-cbe2-405d-89cc-895fdee3b9e6"
      unitRef="usd">660000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS0xLTEtMS03MzQyNw_299a6d1d-4304-4b38-848e-0e0f8aa1a156"
      unitRef="shares">11763189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS0zLTEtMS03MzQyNw_b5f5af19-7bb5-49fe-b739-96da95b01742"
      unitRef="usdPerShare">16.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS01LTEtMS03MzQyNw_e23553f3-03f0-45b1-bfee-94c06c92eea7">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjgyNzc5MDRmMWY3NTQ2NTc5MWQxOTUzMWU2NjU5N2MwL3RhYmxlcmFuZ2U6ODI3NzkwNGYxZjc1NDY1NzkxZDE5NTMxZTY2NTk3YzBfOS03LTEtMS03MzQyNw_24fd53e2-3e69-413e-ae25-7ab283e19108"
      unitRef="usd">6669000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzg0OA_bf1c27cd-a121-4db4-b47d-89dbab660368"
      unitRef="usdPerShare">3.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzg1NQ_88d8fb45-d19d-4f12-a7e0-92611a790620"
      unitRef="usdPerShare">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfMzk4Mg_3689bdb1-568d-4653-8430-b6cb477242b2"
      unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDIwMg_c812a3fd-6a5d-4f95-91de-17a20680b9b8"
      unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id2e71cae35f640ea991981fd8926b735_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTQ5NzU1ODE5MjQ3_c94351cf-5444-491a-81c2-85681b65c155"
      unitRef="usd">5400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i03d2ebaff189455d9264808a3a02d4ce_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDM3MQ_c4bf8e71-06b4-48da-9bd6-a5bd4bd6e7bf"
      unitRef="usd">29200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNDQ2Mg_8482dbaa-1899-4548-b3a7-e1ce91e48990">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIzMA_3b378631-eb0e-457d-afd2-4a25d33f9ec6">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i036d859b9f664d9d82dd693c3f33d537_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMS0xLTEtMS03MzQyNw_7a4b4f9b-af3f-402b-9d9d-04d862bc4473"
      unitRef="shares">415084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i036d859b9f664d9d82dd693c3f33d537_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMS0zLTEtMS03MzQyNw_daee6706-3b07-4e26-a7a2-cf0845b27b08"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMi0xLTEtMS03MzQyNw_3e535d39-dacd-405c-96a1-6a627924336a"
      unitRef="shares">656135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMi0zLTEtMS03MzQyNw_d44b535c-c165-459f-a705-66c35612518d"
      unitRef="usdPerShare">4.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMy0xLTEtMS03MzQyNw_e3ff4917-36e7-4a2f-8c5f-6b5c7f55e576"
      unitRef="shares">62751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfMy0zLTEtMS03MzQyNw_5c07efc0-d16b-4e38-b791-2d916777aac4"
      unitRef="usdPerShare">10.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNC0xLTEtMS03MzQyNw_fed7dc7a-466b-4389-85a2-54bb442559fd"
      unitRef="shares">27657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNC0zLTEtMS03MzQyNw_76253cec-c83f-4032-b7fa-08cd3bde63a1"
      unitRef="usdPerShare">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i214d7afe999940ae898ec280e17de7a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNS0xLTEtMS03MzQyNw_5a65016c-ae57-4bb6-b4f7-4ba9a988f3da"
      unitRef="shares">980811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i214d7afe999940ae898ec280e17de7a4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RhYmxlOjEyZWM3NTdmMzg0YjQxOGI4M2M2NDM0ZDBhNjA1NjAwL3RhYmxlcmFuZ2U6MTJlYzc1N2YzODRiNDE4YjgzYzY0MzRkMGE2MDU2MDBfNS0zLTEtMS03MzQyNw_b3f986c5-5c1d-4814-9fb0-5b7f70b60b41"
      unitRef="usdPerShare">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i214d7afe999940ae898ec280e17de7a4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTA1Nw_d242b728-71b4-48f8-9934-d91af75aee1e"
      unitRef="usd">4900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idb09a086c8a84fb0bc24b5914c51718d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl81OC9mcmFnOjRlZDdkZTNkYjUxNTQyOTZiYjBkNTJmZWNlODU5NzBmL3RleHRyZWdpb246NGVkN2RlM2RiNTE1NDI5NmJiMGQ1MmZlY2U4NTk3MGZfNTIyMw_ece77096-1cdb-482b-b634-b5bcb5dc6447">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfMTI5Mw_c17f8e00-df50-48d8-8132-5d7097404df2">Commitments and ContingenciesIn-licensing arrangement&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V. (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#x2019;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $2.8&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#x2011;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#x2019; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  The Company incurred $1.5&#160;million and $1.0&#160;million under this agreement during the three months ended March 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial. On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserted a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal in the Fourth Circuit. The Company did not accrue any liability associated with this action as of December 31, 2022. The 4th Circuit affirmed the District Court&#x2019;s dismissal in a decision published on March 2, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i91c83b9d58eb41a8a4f5d2bbc203e254_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfNTQ5NzU1ODIwOTgx_5cdf8380-aee6-4765-84cc-83f0051606ee"
      unitRef="usd">2800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib91e3da1af4b4728802be58d315b3279_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfNTQ5NzU1ODIwOTk1_7321ef5f-9b64-4f76-9dcd-e0953a3e775b"
      unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iae7da4578181431996ca6f580a7f5d94_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMDNlNDBlOGY0ZjRiNjk5YmQ5NTk1ZDBkM2RkY2EyL3NlYzo5YTAzZTQwZThmNGY0YjY5OWJkOTU5NWQwZDNkZGNhMl82MS9mcmFnOmEyOTBhNmQ4NjI5NDQyM2ZiMzJhYjdlNTg4YzIzNTNhL3RleHRyZWdpb246YTI5MGE2ZDg2Mjk0NDIzZmIzMmFiN2U1ODhjMjM1M2FfNTQ5NzU1ODIxMDA5_0a793117-f9ff-4ff8-9905-be3629ab3b20"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MVB9-FWAL*.E*2EYJE"C%M3JVY;,)X-D#U._6L5HG*3\=P<NCN'S@H]FOOY
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MHW?X"!- NT305E<<32:(4'^,,:Y_D%K!WAN(6NF5D-E_?#%& 1E'+!K[@=^
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MBB<@NS: [Y="Z)>;^H"Y_8?"[']02P,$%     @ FH"I5I6+=/J& @  E08
M !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RME6UOVC 4A?^*E4U;*W7D
MC0!B(1(-5*W4M:ATVV<WN1"K3IS:#K3[];.=- *6ODGC ]C./<?G2?!-N&7\
M7F0 $CWFM! 3*Y.R'-NV2#+(L>BQ$@IU9<5XCJ6:\K4M2@XX-:*<VI[C#.P<
MD\**0K.VX%'(*DE) 0N.1)7GF#^= F7;B>5:SPLW9)U)O6!'88G7L 3YLUQP
M-;-;EY3D4 C""L1A-;&F[C@.=+TI^$5@*W;&2)/<,7:O)Q?IQ')T(*"02.V
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M^6(!SL"WQ0UX_^X#> >B%#QNV$Z0-!2COE30] _TET<8USD,U (#@QE+Y4:
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MHLKSMYKYA63;[,7@$Y.2)=G'#24AY=I ?;]B3#Y?Z!\HWBV/_P-02P,$%
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M(,PHB<:5WB%&DV"*[,G F<3/F4<QV$F30/KQ'>)_-\6N:OD)3%-BHQ^8=)<
MFR7G-!IOR5U2.,31!/R!3XF?3_<5 *#?%SE4@=M']'-?#GYY>5HYMI5IL(S&
M5MAB<YR&*9DP8V!<DKRJ'&R*FM79"W![B?S5Y>"-M!T[8:!TXJ?TX[PJE&K
M!]RL2]C)5M R*;.Y?=>>L<"@V  _&1=E0KD;*&)S=XRM,F$+3275P.[$S^ZC
M"F%@ S7UYQ]<9L53P_)Q?7V-=D\IZ+3!9G=K5=HB=*+(T8']J9_];]@/;AK
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M.#!6J0JQ#4@7ZU(N;1&-8XH>>["$Q8$?D9,%L(3+9Z-C*WC]/ $%>A_.6**
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MG;9,);[KNLPA&Z\22SS.5,0R4YP=_%[F2KZU*+@X) IT8XSR37+IK:UY5AG
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M=\O3G?H[S/O %$RY-;:>+G_\?@%TXGOJ]!!=SW?#A8O1=?RS50 U3POPO7;
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M\E8J'5-&[;IHF\PI4)$A)J@<1>%QK4?W>&7/XI7<(2QT=LS%=%H=H%G \'E
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MEM#9#1_?8Z<-A\&HFI\YJ'X!,3(^$!H8YBZ9C-/DHT>M$6N0NH6:H8&O[.Z
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M$^.-?:)><]5VAAW]K&YPE&(F]X#)A#7*H 58PS?'5IVI2JUV[G$>PIJRL9-
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MD]:@%8$;</AB!].%@Z3S@!8S%*A%)]1\PH N>3]TM1L#2-H[6 @L<I>/$EC
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MT47D.7X4MX@<<;(\%5.WKW]P>HWFX[O(!QXF_=^HI"U8?B<(K6:B>!QPD8&
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MYNN<0K;;TJ#DQD$S?4X4.KFHON7'@Q&;&@U$\@O*$J4F17" "A4ZG>0ZSU2
M'4S]#7/0B#.(:%JJPV'"4^ !8TP!ACC:.[[I4=MC-IEEX\ZP[@_GL-UQ<XFU
M!LX1>,%S4BJ9L*RT:[?$I#AW-V"#KAG7%AB2\+872F@E&</(&: S$#%9N5/P
M-JRE:F:2<;"MTE#*?=A7GW7VN)"A>EJ&M M15D.3Q<V)!D[$/[L3N8-29KG)
M%R8%7H:GXO0.G-DF@M@@O=P4$#%+KRI:[*#<N! .$8CSGD"<'QSF']$&CQ87
M##/\+I(AN^C!_R>1JA9%\Z"8;@&1'[:)ZM:[/#[X58)IZE9LDZJ0]3"O:#^
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M!"6)1/I=H=DAQF,IEC#*=C-PO7/R3P<?J&OEE_P9G@8M%*5OU?W=_DO_3?K
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MN0,2 U,&\OF64O$\4(??YF-'^#]02P,$%     @ FH"I5E4\K:^% @  V08
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MRA5BL#0P?/39&)5M(VTG6M2N%RV$-IW-#4OS[P%I \SWI1#Z>6+;6_\WR_X
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M"T[$"WJD&0CR$^?1FS"&LQ7(?!#H"GW&LJG"B2X"$)@D_%+V/C\%Z.+#)?J
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MC("&P,L7U/,58_+EI@S0'JTO_@-02P,$%     @ FH"I5G4$J;? "P  =)T
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M7HB\WJ#Z_766E8\_U!W<9_F7[=LY_3]02P,$%     @ FH"I5F'\F@X]!
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MT1\?)08]"LCXGQT3OB\-N-T&BK!URW,<P=R0<8D#VX&Q^/X[>VS]T*6]3K)
M)UFHB:SE);?VDMO'?MAS7;OGOA<Y5/Z2;*S(BHRQ6SBN.QW/S%U3U_-1MFU;
M=GM4J&EB+<&\6C"O5[  5L 8Q#(S*>6N9&24;2*Z%.RE&JI@2>8UM)DZ[O1$
M0)T60^_,&].I[]<66_J-:_W& _4CL@2AJX.,**>LB!A=<O8R#Y5S?":GY\N*
MYD1/G2;##I-3U[>Z!9W4@DYZ!:V2Y=\J;A]2YWGP_9A$LJ2"8_CM$KC7TE"!
M=9(%.LE"360M=_FUN_S_.RWZ.KVDDRS0219J(FMY:5I[:=J[J7ZAY%J>$K8D
MQLL4T#9?,5K$)OSMTM:9GL7*L27_VN'DH=?J4+5UDH6:R%IJV]:Q\K?^=1G2
M#QWZO5=LS2#LGKHIT&HRU,76UK9QJK('9=Q.C7LI!FML=R0Z[UQEG4;#3J.^
M=2&[VLY1/D=?P=?/-5A'Y[QHML]EU&DSK-B:,MJ753P>!NW>4\Q_*OOZJ0>+
MJO4@6+$U7>1-S@)*V#7,MR[*>CR]V?W'MV<JI'@)3I' ;"T5)31+B*HMKA#-
M58VQ N (RT(CD[4A%U36%E4>ZPZW'6>PB=61R_JG-EA(G6RA+K;2+6;C3BL#
MJ7-QF<A11+=$E+=#=6]]87FGKNE.^A_LVZ"\=CS2E+>@3])]">$HA96DM&XF
M<@.R\F*Q; B:JYNS)16"9NIQ(RM]8,4 ^7Y%Y:=0-0H#]?7NXA]02P,$%
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M-S\!L%G)Q:J<'_Y>Y+E(RL4E9ZH@+W90KR^$R+<K18+=#S%<_A]02P,$%
M  @ FH"I5G^31E9*!@  QS,  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULM9M=;]LV%(;_"N$50PLTL23;LITY!A+K8QGJ-4C:[6+8!2W1ME")U"C:
M:8;^^%$?EBQ+9BWL]":Q9)WG4'R/2/J%.'MA_$NR)42@KU%(D]O>5HCXIM]/
MO"V)<'+-8D+E-VO&(RSD(=_TDY@3[&=!4=@W-,WL1SB@O?DL._?(YS.V$V%
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M.9#P?-=(?B!8G&U:6#$A6)1]W!+L$YY>(+]?,R8.!VF"<N_._#]02P,$%
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M%@'!M(P8-1DQ,M%G7Q8+PM)BB=;RA?8-]RLSP$-Y.=S[]#-&'JL?)"R$A$5
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MEYLK@A/"U 'R\P65UW'U&]5 \Z3B[!]02P,$%     @ FH"I5C2I%BYF P
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MIE5J)536[L.T#VYR)%83.[,=*/]^9X=FH0UHE1@?B%_NGKOG\?EEO!;R2:4
MFCSG&5<3)]6ZN'!=%:604]41!7"<60J94XU=F;BJD$!CZY1GKM?M#MV<,NZ$
M8SLVE^%8E#IC'.:2J#+/J=Q,(1/KB=-S7@;N6))J,^"&XX(FL !]7\PE]MP:
M)68Y<,4$)Q*6$^>R=S$+C+TU>&"P5HTV,4P>A7@RG>MXXG1-0I!!I T"Q<\*
M9I!E!@C3^+W%=.J0QK'9?D'_:KDCET>J8":R'RS6Z<0)'!+#DI:9OA/K;[#E
M,S!XD<B4_2?KRG;D.20JE1;YUADSR!FOOO1YJT/# 7':';RM@_?:H;_'P=\Z
M^)9HE9FE=44U#<=2K(DTUHAF&E8;ZXUL&#>KN- 29QGZZ7 F\IQI7!9-*(_)
M3'#-> (\8J#(Z15HRC)U1L[)_>**G)Z<D1/"./F>BE*AO1J[&I,P4&ZT#3BM
M GI[ OKD%F.DBGSA,<2[_BXF7S/P7AA,O8. MU1VB-_[1+RNY[?D,_MW=^]
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M( .EJ-B _:N+B0DE]&R4Q,CT=BMY!DJ_(^-?I5VHN&R81T+/(EF '=BRM3;
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M'FI=<CZT93-Q)6FV_VBR_^#S[0]02P,$%     @ FH"I5D"[PRV' 0  O!<
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M_>/SM^5]$W$>W7!V<%F_^@502P,$%     @ FH"I5O]Y:I*? 0  '1@  !,
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M0E:)0E:)0E;YGV3]T'KYUQ^LVS6I5=D<_%GW5V#V!5!+ 0(4 Q0    ( )J
MJ58'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ FH"I5N@MW<GO    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ FH"I5IE<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " ":@*E6*E947,\%  #,'@  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ FH"I5@VB ?P"!@
M7!@  !@              ("!$PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( )J J5:5BW3ZA@(  )4&   8              " @4L4
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " ":@*E6/$;2
M5!<&  !G'@  &               @($'%P  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ FH"I5@YXMU-H!@  \BD  !@
M ("!5!T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( )J
MJ5;O+0A:-@<  /<>   8              " @?(C  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " ":@*E6#C#R74 *   X&   &
M        @(%>*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ FH"I5IEMB=^Y!0  F@X  !@              ("!U#4  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )J J59EPW@PDP8  /41   8
M              " @<,[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " ":@*E6!OWCA-P"  "O!@  &0              @(&,0@  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )J J58?_M&,E@(
M +X%   9              " @9]%  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ FH"I5E@IUK#;!@  T1$  !D              ("!
M;$@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " ":@*E6
MY$%!J> #  "^"0  &0              @(%^3P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( )J J599X/O74B   !F%   9
M      " @953  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ FH"I5@L+M>6P"@  >!T  !D              ("!'G0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " ":@*E6SBI?)&,&  !Q#@
M&0              @($%?P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( )J J59_W8?Q' D   L9   9              " @9^%  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ FH"I5B;_]]MO
M P  RP@  !D              ("!\HX  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " ":@*E6)5<]V.P"  "U!@  &0
M@(&8D@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( )J
MJ5;K!Z%'I (  +\%   9              " @;N5  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ FH"I5K/>8$3> @  B08  !D
M         ("!EI@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " ":@*E6;'>I\ H%  ""#   &0              @(&KFP  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )J J58GN0$X204  -DE
M   9              " @>R@  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ FH"I5OG/:;[& P  ^!   !D              ("!;*8
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " ":@*E653RM
MKX4"  #9!@  &0              @(%IJ@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( )J J5;8/F4)'P0  /$4   9
M  " @26M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MFH"I5G]*:=M$ P  )PL  !D              ("!>[$  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " ":@*E6U-@ E[0$  !F'P  &0
M            @('VM   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( )J J59U!*FWP L  '2=   9              " @>&Y  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ FH"I5F'\F@X]!
MZA4  !D              ("!V,4  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " ":@*E6BHU"M!H)  "480  &0              @(%,
MR@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( )J J59_
MDT962@8  ,<S   9              " @9W3  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ FH"I5GVJ_DYJ P  '@\  !D
M     ("!'MH  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )J J5:5(5+Q$00  ,(.   9              "
M@>CU  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ FH"I
M5DF:N*KR @  20D  !D              ("!,/H  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " ":@*E6TR;S3RX#  #J$@  #0
M        @ %9_0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )J J5:7BKL<
MP    !,"   +              "  ;(  0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( )J J59H[]=NW ,  '0:   /              "  9L! 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " ":@*E60+O#+8<!  "\%P  &@
M    @ &D!0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" ":@*E6_WEJDI\!   =&   $P              @ %C!P$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     +P O , ,   S"0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>222</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Royalty Monetization Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangement</Role>
      <ShortName>Royalty Monetization Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNet</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Royalty Monetization Arrangement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangementTables</Role>
      <ShortName>Royalty Monetization Arrangement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/RoyaltyMonetizationArrangement</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Royalty Monetization Arrangement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails</Role>
      <ShortName>Royalty Monetization Arrangement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Royalty Monetization Arrangement - Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails</Role>
      <ShortName>Royalty Monetization Arrangement - Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenue- Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueIncyteCorporationDetails</Role>
      <ShortName>Revenue- Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Revenue- Gilead Science Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueGileadScienceIncDetails</Role>
      <ShortName>Revenue- Gilead Science Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenue - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueZaiLabDetails</Role>
      <ShortName>Revenue - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueIMabBiopharmaDetails</Role>
      <ShortName>Revenue - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenue - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueNIAIDContractDetails</Role>
      <ShortName>Revenue - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Revenue- Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueProventionDetails</Role>
      <ShortName>Revenue- Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20230331.htm">mgnx-20230331.htm</File>
    <File>exhibit101driredactedagree.htm</File>
    <File>exhibit31-1q12023.htm</File>
    <File>exhibit31-2q12023.htm</File>
    <File>exhibit32-1q12023.htm</File>
    <File>exhibit32-2q12023.htm</File>
    <File>mgnx-20230331.xsd</File>
    <File>mgnx-20230331_cal.xml</File>
    <File>mgnx-20230331_def.xml</File>
    <File>mgnx-20230331_lab.xml</File>
    <File>mgnx-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="367">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 367,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 358,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 48,
   "keyStandard": 174,
   "memberCustom": 34,
   "memberStandard": 16,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Inventory, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://macrogenics.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Royalty Monetization Arrangement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangement",
     "shortName": "Royalty Monetization Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://macrogenics.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Inventory, Net (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Royalty Monetization Arrangement (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangementTables",
     "shortName": "Royalty Monetization Arrangement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i7781c40faa9749489c6481063c576abe_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Inventory, Net (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:NetProceedsFromSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Royalty Monetization Arrangement - Narrative (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails",
     "shortName": "Royalty Monetization Arrangement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i0595b4044d4e48a4b54395ad62ddc89c_I20230308",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:UpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ProceedsFromSaleOfFutureRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Royalty Monetization Arrangement - Rollforward (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails",
     "shortName": "Royalty Monetization Arrangement - Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ProceedsFromSaleOfFutureRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i6a92a232f3cc4ece87937e838f0203aa_D20201101-20201130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:CommonStockMaximumAmountAvailableForIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenue- Incyte Corporation (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
     "shortName": "Revenue- Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "ieef59164d9804d038bd3cc080e152e53_D20180101-20180630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i03d2ebaff189455d9264808a3a02d4ce_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Revenue- Gilead Science Inc (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
     "shortName": "Revenue- Gilead Science Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i9206e5dc0bd441178b6b8da96ac35472_D20221014-20221014",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenue - Zai Lab (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://macrogenics.com/role/RevenueZaiLabDetails",
     "shortName": "Revenue - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "ic9b25f44d614465bb474c287b5677b0d_D20190101-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue - I-Mab Biopharma (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
     "shortName": "Revenue - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "ie96aa8b283ef4dc4a55d34410a410d39_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenue - NIAID Contract (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://macrogenics.com/role/RevenueNIAIDContractDetails",
     "shortName": "Revenue - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i800a7e6440dc4197a9837d73a114cba7_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Revenue- Provention (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://macrogenics.com/role/RevenueProventionDetails",
     "shortName": "Revenue- Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "iee007f50b7b54e878349b22a7469557d_I20180531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "ie58506024e45456592bc19755da226d2_D20170501-20170531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "ie58506024e45456592bc19755da226d2_D20170501-20170531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i9dc12bf419854569b3c1bc5f89a77e19_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i036d859b9f664d9d82dd693c3f33d537_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Commitment and Contingencies (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://macrogenics.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i91c83b9d58eb41a8a4f5d2bbc203e254_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i6f22b26d7b774c3c8a78ab4bca00737c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i6f22b26d7b774c3c8a78ab4bca00737c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Nature of Operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://macrogenics.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20230331.htm",
      "contextRef": "i4e24751086124b70b3bee8533a6f96a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2022GileadCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Gilead Collaboration And License Agreement",
        "label": "2022 Gilead Collaboration And License Agreement [Member]",
        "terseLabel": "2022 Gilead Collaboration And License Agreement"
       }
      }
     },
     "localname": "A2022GileadCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AdditionalAnnualFixedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Annual Fixed Payments",
        "label": "Additional Annual Fixed Payments",
        "terseLabel": "Additional Payments"
       }
      }
     },
     "localname": "AdditionalAnnualFixedPayments",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20230331",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborationArrangementOneTimeCreditPaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, One-time Credit Paid, Percent",
        "label": "Collaboration Arrangement, One-time Credit Paid, Percent",
        "terseLabel": "One-time credit paid, percent"
       }
      }
     },
     "localname": "CollaborationArrangementOneTimeCreditPaidPercent",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "terseLabel": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "terseLabel": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Maximum amount available for issuance, increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Manufacturing",
        "label": "Contract Manufacturing [Member]",
        "terseLabel": "Contract Manufacturing"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CostOfManufacturingServices": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of manufacturing services",
        "label": "Cost of manufacturing services",
        "terseLabel": "Cost of manufacturing services"
       }
      }
     },
     "localname": "CostOfManufacturingServices",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DRIHealthcareAcquisitionsLPDRIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DRI Healthcare Acquisitions LP (DRI)",
        "label": "DRI Healthcare Acquisitions LP (DRI) [Member]",
        "terseLabel": "DRI Healthcare Acquisitions LP (DRI)"
       }
      }
     },
     "localname": "DRIHealthcareAcquisitionsLPDRIMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_DeferredTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred transaction costs",
        "label": "Deferred transaction costs",
        "terseLabel": "Deferred transaction costs"
       }
      }
     },
     "localname": "DeferredTransactionCosts",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_FutureRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Revenue",
        "label": "Future Revenue",
        "terseLabel": "Future Revenue"
       }
      }
     },
     "localname": "FutureRevenue",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_GileadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead",
        "label": "Gilead [Member]",
        "terseLabel": "Gilead"
       }
      }
     },
     "localname": "GileadMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply",
        "label": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_InLicensingArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-Licensing arrangement [Line Items]",
        "label": "In-Licensing arrangement [Line Items]",
        "terseLabel": "In-Licensing arrangement [Line Items]"
       }
      }
     },
     "localname": "InLicensingArrangementLineItems",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mgnx_InLicensingArrangementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-Licensing arrangement",
        "label": "In-Licensing arrangement [Table]",
        "terseLabel": "In-licensing arrangement[Table]"
       }
      }
     },
     "localname": "InLicensingArrangementTable",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to future royalties",
        "label": "Liability related to future royalties",
        "terseLabel": "Liability related to future royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyalties",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to future royalties [Abstract]",
        "label": "Liability related to future royalties [Abstract]",
        "terseLabel": "Liability related to future royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyaltiesAbstract",
     "nsuri": "http://macrogenics.com/20230331",
     "xbrltype": "stringItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to future royalties and related interest expense",
        "label": "Liability related to future royalties and related interest expense [Policy Text Block]",
        "terseLabel": "Liability related to future royalties and related interest expense"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to future royalties",
        "label": "Liability related to future royalties [Roll Forward]",
        "terseLabel": "Liability related to future royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyaltiesRollForward",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyaltyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to future royalty [Line Items]",
        "label": "Liability related to future royalty [Line Items]",
        "terseLabel": "Liability related to future royalty [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyaltyLineItems",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyaltyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to future royalty [Table]",
        "label": "Liability related to future royalty [Table]",
        "terseLabel": "Liability related to future royalty [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyaltyTable",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related to Future Royalty",
        "label": "Liability Related to Future Royalty [Table Text Block]",
        "terseLabel": "Liability Related to Future Royalty"
       }
      }
     },
     "localname": "LiabilityRelatedToFutureRoyaltyTableTextBlock",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Future Royalties",
        "label": "Liability Related To Sale Of Future Royalties [Text Block]",
        "terseLabel": "Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_MilestonesValueAddedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones Value Added Tax",
        "label": "Milestones Value Added Tax",
        "terseLabel": "Milestones Value Added Tax"
       }
      }
     },
     "localname": "MilestonesValueAddedTax",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NetProceedsFromSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from sale of future royalties",
        "label": "Net proceeds from sale of future royalties",
        "terseLabel": "Net proceeds from sale of future royalties"
       }
      }
     },
     "localname": "NetProceedsFromSaleOfFutureRoyalties",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonCashInterestExpenseRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense recognized",
        "label": "Non-cash interest expense recognized",
        "terseLabel": "Non-cash interest expense recognized"
       }
      }
     },
     "localname": "NonCashInterestExpenseRecognized",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonCashRoyaltyRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Royalty Revenue",
        "label": "Non-cash Royalty Revenue",
        "negatedTerseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenue",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Number of commercialized molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OneTimeMillstoneCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Millstone Credit",
        "label": "One Time Millstone Credit",
        "terseLabel": "One Time Millstone Credit"
       }
      }
     },
     "localname": "OneTimeMillstoneCredit",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLeaseNoncashExpense": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Noncash Expense",
        "label": "Operating Lease, Noncash Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNoncashExpense",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CommitmentandContingenciesDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "terseLabel": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential target, nomination, option fees and milestone payments",
        "label": "Potential target nomination, option fees and milestone payments",
        "terseLabel": "Potential target nomination, option fees and milestone payments"
       }
      }
     },
     "localname": "PotentialTargetNominationOptionFeesAndMilestonePayments",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PremiumReceivedOnStockPurchase",
        "label": "PremiumReceivedOnStockPurchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsFromSaleOfFutureRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of future royalties",
        "label": "Proceeds from sale of future royalties",
        "terseLabel": "Proceeds from sale of future royalties"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Potential proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProventionBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention Bio",
        "label": "Provention Bio [Member]",
        "terseLabel": "Provention Bio"
       }
      }
     },
     "localname": "ProventionBioMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "terseLabel": "Provention License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "terseLabel": "Provention PRV031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "terseLabel": "Provention PRV3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ReceivableFromCollaborationPartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from collaboration partner",
        "label": "Receivable from collaboration partner",
        "terseLabel": "Receivable from collaboration partner"
       }
      }
     },
     "localname": "ReceivableFromCollaborationPartner",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Collaborative and other agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromRoyalityAgreementsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenueFromRoyalityAgreementsMember",
        "label": "RevenueFromRoyalityAgreementsMember [Member]",
        "terseLabel": "RevenueFromRoyalityAgreementsMember"
       }
      }
     },
     "localname": "RevenueFromRoyalityAgreementsMemberMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromCMOAgreementsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenuesFromCMOAgreementsMember",
        "label": "RevenuesFromCMOAgreementsMember [Member]",
        "terseLabel": "RevenuesFromCMOAgreementsMember"
       }
      }
     },
     "localname": "RevenuesFromCMOAgreementsMemberMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromCMOAmendmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenuesFromCMOAmendmentAgreement",
        "label": "RevenuesFromCMOAmendmentAgreement [Member]",
        "terseLabel": "RevenuesFromCMOAmendmentAgreement"
       }
      }
     },
     "localname": "RevenuesFromCMOAmendmentAgreementMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award",
        "terseLabel": "Number of shares per employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_SynaffixBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Synaffix B.V.",
        "label": "Synaffix B.V. [Member]",
        "terseLabel": "Synaffix B.V."
       }
      }
     },
     "localname": "SynaffixBVMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalAnnualFixedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Annual Fixed Payments",
        "label": "Total Annual Fixed Payments",
        "terseLabel": "Annual Fixed Payments"
       }
      }
     },
     "localname": "TotalAnnualFixedPayments",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TransactionCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Cost",
        "label": "Transaction Cost",
        "terseLabel": "Transaction Cost"
       }
      }
     },
     "localname": "TransactionCost",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment",
        "terseLabel": "Upfront Payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20230331",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r213",
      "r218",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentandContingenciesDetails",
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r243",
      "r341",
      "r351",
      "r358",
      "r359",
      "r372",
      "r377",
      "r382",
      "r415",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r243",
      "r341",
      "r351",
      "r358",
      "r359",
      "r372",
      "r377",
      "r382",
      "r415",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r172",
      "r343",
      "r373",
      "r381",
      "r410",
      "r411",
      "r416",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r172",
      "r343",
      "r373",
      "r381",
      "r410",
      "r411",
      "r416",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r236",
      "r243",
      "r270",
      "r271",
      "r272",
      "r317",
      "r341",
      "r351",
      "r358",
      "r359",
      "r372",
      "r377",
      "r382",
      "r409",
      "r415",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r236",
      "r243",
      "r270",
      "r271",
      "r272",
      "r317",
      "r341",
      "r351",
      "r358",
      "r359",
      "r372",
      "r377",
      "r382",
      "r409",
      "r415",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r213",
      "r218",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentandContingenciesDetails",
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r380"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r401",
      "r402",
      "r403",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r69",
      "r70",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r18",
      "r19",
      "r76",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r93",
      "r108",
      "r134",
      "r163",
      "r166",
      "r170",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r285",
      "r287",
      "r301",
      "r380",
      "r413",
      "r414",
      "r449"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r104",
      "r113",
      "r134",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r285",
      "r287",
      "r301",
      "r380",
      "r413",
      "r414",
      "r449"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r178",
      "r189"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r44",
      "r177",
      "r189",
      "r344"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property, equipment and software included in accounts payable or accruals"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r35",
      "r106",
      "r361"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r30",
      "r35",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r87"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r50",
      "r198",
      "r199",
      "r357",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r401",
      "r402",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r380"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,838,565 and 61,701,467 shares outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r118",
      "r120",
      "r125",
      "r345",
      "r349"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r374",
      "r376",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r24",
      "r343"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r179",
      "r189",
      "r192",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r33",
      "r162"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r247",
      "r275",
      "r276",
      "r278",
      "r282",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r150",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r292",
      "r293",
      "r346",
      "r350",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r292",
      "r293",
      "r346",
      "r350",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r54",
      "r101",
      "r121",
      "r122",
      "r123",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r149",
      "r158",
      "r183",
      "r232",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r291",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r294",
      "r295",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r295",
      "r314",
      "r315",
      "r316",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r214",
      "r237",
      "r242",
      "r295",
      "r314",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r214",
      "r237",
      "r242",
      "r295",
      "r315",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r314",
      "r315",
      "r316",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r194",
      "r215",
      "r229",
      "r289",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r369",
      "r405",
      "r406",
      "r407",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r342",
      "r398"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r398",
      "r448"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other non current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r112",
      "r362",
      "r380"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r48",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r47",
      "r88",
      "r92",
      "r99",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r134",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r286",
      "r287",
      "r288",
      "r301",
      "r367",
      "r413",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r90",
      "r95",
      "r380",
      "r400",
      "r408",
      "r447"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r105",
      "r134",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r286",
      "r287",
      "r288",
      "r301",
      "r380",
      "r413",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r31",
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r34",
      "r91",
      "r98",
      "r103",
      "r117",
      "r119",
      "r123",
      "r134",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r153",
      "r163",
      "r165",
      "r169",
      "r171",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r293",
      "r301",
      "r368",
      "r413"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r163",
      "r165",
      "r169",
      "r171",
      "r368"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r40",
      "r41",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Interest and other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r27",
      "r43",
      "r128"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r43",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r49",
      "r96",
      "r348",
      "r380"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r71",
      "r100",
      "r457"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r61",
      "r94",
      "r355",
      "r356",
      "r380"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r101",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r149",
      "r183",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r291",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r124",
      "r134",
      "r160",
      "r161",
      "r164",
      "r167",
      "r168",
      "r172",
      "r173",
      "r174",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r301",
      "r347",
      "r413"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sales of stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadScienceIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r244",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r109",
      "r110",
      "r111",
      "r159",
      "r216",
      "r217",
      "r218",
      "r220",
      "r224",
      "r229",
      "r231",
      "r372",
      "r389",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedTerseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r54",
      "r101",
      "r121",
      "r122",
      "r123",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r149",
      "r158",
      "r183",
      "r232",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r291",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r158",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r54",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued or sold (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r54",
      "r61",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r54",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r42",
      "r380",
      "r400",
      "r408",
      "r447"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r75",
      "r77",
      "r101",
      "r102",
      "r122",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r183",
      "r232",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r291",
      "r302",
      "r303",
      "r307",
      "r310",
      "r353",
      "r354",
      "r400",
      "r408",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r133",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r232",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r215",
      "r229",
      "r289",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r405",
      "r406",
      "r407",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r417",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r150",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r386": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r387": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r388": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001125345-23-000076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-23-000076-xbrl.zip
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M-0X6$MK!LY*N"R+QGRH(YWB+NYLXO"'/#6\]GGM!^#G-[A(178N(?RI]([H
MQ"=$E8+:AVZ%+X$>WB1+D@QIYU?6VSM/U.?ZR$9:2)]&?NJ&3V.4**RX)5XS
M=MA^*?6I&R^UR'A8L7?C5S\Y7CNM48P.D(X:A58#RB$-1(Y$L=)!E!>=9SXJ
MH@H/0E:3OE?<!'#:W@2W@C19?3URYN%LPQ=3$:2,'!C$Y'0[9>!TT.YX,HF3
M."B% V$[$B.00&K (J4+C:T@G9,E=YU2JN"3R L\DO%C/KWY$Q#/ ,PUYC-,
MX+L<[ GU+Q\/]#+/$K@_&&7R'W!$(\T#7@E2C[,"WTRG6:HNX+$4%9SOK1&,
MO'?P0[ K9UG!G57)WHMP?\=L-3B]]/(575AXF+M K2() 1M-&3AE14$SV;>J
MRD#,[F#M0%;X&[PJ#$"-T9>18JA25\.X@VL&^J !-LN2.(QY"6FIE83=W0B2
MK_(FSZKK&_IMIGJ&X=6W&=5&%R*L\A@-/!_%B28VX%&0@-Z![5J[)^PWK(-H
MP/9P03IPXM9BND 67)@O.JO5D8S)487A4)XK^$'B.H-OG],E?=W.DNSN[=)A
M_=4/XKW=HZ$/8AS"TJ1\Y!U/3<S:8+-$4L1:6 J2'=EP<PX-)I\A9W TK+9:
M2=*&@W_<0\IDZ">8CA/A^J3.9F!$4.1HLX6?8 N_&AUN!=N#[N+'N*0O-Q[I
M@SW2GDR,"Y:5\DV"T@M%7@:PC?H31PQL^Q#,O2,$M.V^(N< C5F%:BMM)%"=
M::(H3( 5..R@VD]4E3G>>3;R=M&HZZUC,,%UYW#WZ1B>M;]# +N]%:V_@P>;
M?QOQ[A!O9 Z7O2A<$&D'SXCE $K-SSYH_'2#C5ZC?==5Q^7843*60RQ@B+ZE
MNG&#:CIF^-SWQ!<15J4Z'?H!I3YFK8LR(-Z^9*ZL:B3Y\(*R#,(;&>K'.&OA
MZ(;7U7AN;O?VCEQIPZL"E/W1<[::*\DGT;_,85)?P)0EP:P0/ZB_O(GB8I8$
M\Q_BE%Z<?O1&JC'Y.-0]MTA^%P:)?%MZ<?Y:/?GE:.=H#Q]>PIN7D7JP_'9$
MX_J^C-K?O7XU>KW3__7.:%=_]SW=F^\/;U#,@O3_?+?_74.1_K W^^+MV@H3
M=6OS)7C\WRU4X':Z?'\P#=M@#*AGXWM:L:YRJB$KHQZX,1855&T.QB<_&"LX
M5D11P,$R=^=@I)Q?(#V?N/#2K/0".+S+*H>/?>\2WB"8ZPP+70LF(4-Q,(<G
M\A KG<=!^KG 4P]'^5N6?_;UWPBQ$\@>OW *PKUR1>^*CEH=T7D?W#&";XK'
M--*>BNAKA\Z/#D=#Z)TUB)P3+;MLZ+>)NFT"Y\\H:&2!;V3L43+V<K2[D;%E
M,D9>WD;0UEK0[A'IV=BIR^W4DRQR*G CO)]'ER.N$TC!TKP0M\B%Y^$X,6:S
M^_K52S..7P. <G%=27I)_'<NZ"V_MD&YLSLZV!B4W9)6M[J ]25"7+QFHX\?
MF=+='/RK"5U,W<J+,F>FS8W</19*L)&[_G($[N.":TJ,MQMA6VLEMS$ZG[98
M1W<Y\BXQ558E3A"<&$9HUPB]B%NVMM*#S9I9A*J'59Z#""1SKG7 [SFY&,NR
M5WFSN:YP^#H5K1L173$Y&N3IBX]5205E+LAF4WL'19C'8ZZ;I_(*+(!0B>@^
MY-(PQ=*;--+#Q1!6.;MKDJZZH2,+ 6)US7@*'I\'UG4P3N("X0]-+HA/P1SE
M]O@:$70&H"].X0+.,&T%VQ[<)DXD+=?KW3=_^]O?X,_]-SZ5*$W:7[ RS00G
MLV9Y=@OV/G77;?P>ZRUGW(J\0 5N,%!PC=IBPHHX#9,JHHK.A<P&.AYQ(1!^
M E?4G >8&H.7'6.P0C;\:\[2$BYAO/G6>-NH%VV\9><4R5DI[CDMH$Q4O:!$
MR\B7]67QD'&C%35+*_/<%4/IXU?X^E&5@^&C*@>++>3EG42'&[?;KL>2B36[
MF@PYA2-OL[,&$0!+O;FPB?CD?3:MVVVE;22C+1GOWAZ[(P\Z9?).D>V\S2LP
MLZ)IG,+1H!A_<L+^%*HUF1> &1;..5%29D-'TY9,./=,PL,,+*-CQA8-%E/K
M68-K/49E+/V<$JOO98E-C4UBA=3*>]QSZ]X+JC>02R6E#1D "!.*:&EXP1A)
M!UCDLDG- U#@!*&$)AE<R[8E_IQ%U%=@,K!IMFHCO*AF>< 3B8Q5ZI)MGV!J
ML>0WB,ET9L&)T6Z52<(LGWOC+"+^BBH'RQS9BG();(.A/ Q$R0[P4'-N<G:(
M+PC4H_"SC#HA15XBKN."4="^]SO,(V+Y?*\,OL"%UMS@ AH*Y%92013XQ:1*
M0\ZR(L]7[LT89T^>469L@TT8RX'XP6)WTJUX0DTHD@CPC2FN:GNCZUMC<>)F
MC<4& _%U\UEZ.ZH TZ=\ Z]];')P;[0W=%&[V\GHLXM+[]>XO+G)$K*=WF5#
MI32^&9D['.WN;$6.,BEL2N V)7#W-!$:/2A=+X';. ,/,4;_5477;G%^H)O_
MNQP59O@B*JTNXYE$\A*_)+6_EM_E54*^:IS^+MU0! ,CGR'? ALJ1;YWE\?$
M$PCSD NQH0A?+SG]MZ+Y=D90V^RI)M7]0T+R3TD=O<%7/%C4W@=WS@@9:<,D
MN/,I(EHA'P6H.^$;E0U4F9O#\@=I*+RX*"JNL)WEV;1*&(N!1;9>=\3\Z\OF
M!OOS"-F,A4,1.DH?,2,O\ITH2,L4_+5KL/]\;T8JV_=NYC.,18>!/IUAX25W
MER#'PJ/^$=<26"/2L)J.<Y1HWTO@G;TMEG\9B-9<OQC;OP$Y%5YP'6!DGUF+
M)>P&7$;8!1B,-NK79WG,F0/:(]@ 4-:?&",@FF1XN<]Q2GLIQ6IXX=W=!&61
MB=OG+2':$"\\^:[)"H>PQ*32842=5BIS::/X24LVQ)I[)>5H^Q9$>#>E_26^
MS 38PF823'Y$F9@XO85M$%\'&B<6@/N9IV)>X)!VC]YX$R$*V$38*,'W_J7-
M[B0.QC&GQ[)Q(N\ ^UFDB/5Z8NEO-5I9);NY.44>OA\^@%&0H\H[CD"7@?R<
M3B9@P[JS11#T&7A3-<Q #E/0,#U.&&/J4F9P;^'/2*IT@56$H9#BJQ2Y3+]?
M@88O>&=Y;[.P8H1CM@SGB>C*I<,QGFC7 <#Y0PFJ&!^E-Y/J@K#*Z%;!HFZ%
M*XR1=D_!_"M3$<5"<Y[5A0HK#DL#=&-BC0FH\1*LQ59TCW%84[7\+9FCAD*6
M")IE_&]ZFR6WPK(*O(">MKSAV): P:;-05++JGG]#AKPRH,OXRG%&P)B'Z:0
M0F4WT5J !(:KMR8+'MIX%O>T:ZU1W>1NR?-6)1Y]3DWM=@,\MQ5UG, B9BDA
MY6G?N:.C4?#.L_0%TCP67FND=9=&_/[%CR2>[:NV1!#>8.?S]5H'!Y9A^ZE)
MA9=L[@W-<$^K8CBJ2,8=D(FO6!&V(@AQ8Z8_0K) NWZ"]>*JH L1N8;0(C.=
M8D#EBVPR(>0D&A[29XVRNQ2]6C!U<-G93@USL#M+#&#*U^&<C/S'HJY.$L#(
MX4RK5S!'?I987EN9[# 5L*75,;/;C?*F@+UOZPDJP%][W(1+)5NP0*^](O9?
M1$O"A=<BPG_<==4'FZ_PP-*I#5_\$V^W'F/&F2TW3-O'56*/1WN#2=5@2"^2
M*!NML3^BW77657*);G)X$XM;$6GKV+X"CV\N616W<585H#O&V+Y"_:R15Z2F
MYD,DLE=PZ8:4A[%+\K"SFD"T"YCO+QZRO6;W/4E8'(5$KU9=\;0ZS6T1#ET2
MX=4D&.R8IQ#BY\5.;)S<!VU0DZC!&6/(^S5.,!0+EIIWE5<8T#T?'8^("E(P
M20;6BZT<!'W6?-4F"OHDPC<TAT%W0K<6-X,;!-Q'ROOD(BBR-!B#H@O"4,P8
M)&WAQ;JZR<@.9N!92GX1Y7DVKM,_-69I$QIT17!KR\:EL* #517+YLZJJK@>
MT!I:N59N<WZXN@U=CJ$:B79-X$11'AU=K:.G!6+KHG@2,Y"N4-%4^$LVF<"F
M+HRX:F$%5BEAKSF=EN>IIT$D^EEF-M5$FVJB>TK]_GI5$SVACAYHPDT6.768
MPGY%+)/<_DL 3X.JGK[1ATM'[S7Y[%S P&S2H(\ZO@O73FP"A <)8OL*S%I.
MXAQ!NED^DR^ $-HI<?UH*"VRT("^G_L$E4OAES?QS/=^SV)X(\P$5KD@3' 6
MQO(>]-V+HLS"S_6O2PYU5&#)JP=2Z/<:;/L_Y ^[:ST4Y1-G0@D_Z6$&$G%[
M=3YS5HV3.$0NG!@YBA0E#R( X5O"J<%_D;LGJI K9@)_PH@-9+X7!K,@'*2X
M9#U@\HW ?!-6U8S;#Y#R>[E)^=TS/KX5;]/B4046HP?D3IKEV/01;&.!!Q5L
M$DD$+IF28MAH(7R-?<IA,R6PF34_^.7IB8&+)4ZW2RZX0>SNZ1<X^])K./P8
MK[#[>O_ ;H0SGC>B[U(#7-W$><1M"-3&A@-V+&Z"9()WLG_DYKDP;&C%VXJ;
M"R[KBWC1HYHMOKD(SS/LW=6&_2 !H& FBC$>*(Q8*0FS:=$&$\ LZ%!A_C-)
MT"JO/(0$K;@4($%2A%AF-(8\2%M3B]/.1>X>(F;AA*6RG^T7?!<PV7>W&1[?
MSKAM$5#?)Z9GJE2XS>*(JD7A65%6C<&:*&Z0]!F/H"XZ;6VV1T3+U^Q. ,,:
MB9'?0\2]M2='1O+Q50$,N_M#.;R+Q XF90/:6 ?0ACK2@S3-*M@O=0U*DX>>
M=PTBQN! CCJXT.MKZ)#@JVZ"V^:&P?J0>+7'DB;WCB=@,L1R6]KW6GFD+4W>
M-U9!/GK$_/P!N/B3&-G+;D6=^2(M$S3?BK5'.9^!"A$*DTP=GJG>$4.=:!?)
M?]4ABB8Q/0RVR!*1S)'4ODESWU"-K'QP,F_C8($UUG=L4QR"3KYA[352FWJ9
M^7K=,=M7U6L=2P\JFHJR-/A[0&#%/;720$KH'0MA3AXQ]>>YI:"5E2]C*57H
M9^Z]8,]^D7E)1NC[AT6BGGO.-]&H1T2C\BP4(G*BVD/&H\!P:^'/<QA\5U\J
M5!X(<:\237( PETF.G0*WV$^1ENB<UF)7J!]3_'>&<\ 2%0AR],YWAL7LZH4
MA:S/C)HML+J+(66YKLF1W1O8M?NB/* ]UO.&>!W?4QT.Z-=10X=M.MC#QF2%
M9%ALU$VGNI%%(NXH'*-PY<<X\V$_AR,Z";'"7;<3*-BT)*J78H! L./;<2UD
MSG.K07-?-H8$#4[!OM&"J5:PL\)>QZ)39ENY *TZ,P37@X!K2[RXWVU7H#?
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M@<.$H"O=Z!TU%WA$4L D:EW?;IM4F^I=H#QQV:($Y'Z#+]O@RYYJ"^[NK!?
M;.T09>:I1?OZ.F:Z8MS)G^"4R-*Z^Q*;_G7+9[_F(_:)BR(1M;,0HIN9)-IC
MW))U2GV,,_@;*F:J>8"FZL *:CKO:9:7UP'VJ(H$!GLFR%Y?\'D)%Q"G#N@U
MU) 9%L'IH"+#W *3&+R GZI'&V4LVN L&R%M:=CU']U*+8NB5LP%$_"3ZESU
M;.<8)JKHC'.^F:PJFH&E""^O-/63V0!?E]+X41R>3L2A]EU-#QV;<7*V[$Y5
M*P4JV1H^.M5(V^@H[/*TC831Z*B6&=1:%L/*ZA"6N'?T:O6PVF(2GZ>*IOD<
M029D"Z4;-*\]\V_U3*L<D.REH*KYS%R**3TMXB!,]F1!3DJ76P1DN0SN(T$\
MUNC>9 F(8H'J4N6<[-YOW2ND83KT,AHMA;>6,UUCIXSN<;6QRUFL!)1G(K.+
M=,$XYIA\'Q&:OTKGNQ FD!&>I)$)-H2-I_5! (/GU!D<-M-8PKQD9S"S!Q@\
M&N<$9'D+U7P>);)WI.* 4RR[C*L*S+YZ04G^))\5?!<N>+4;^M4M^GRC09\/
MBY$9B6(Z10-8O;B:4LVTI+VG-&O C5C@F2$,),8UEFQLR@C03<]\_98T(AJ!
M\;ZT-ZS75\CS#/X[?U[\T-H?,:XRN'U4C5.=.DDH!X<"QYN?R=CNWT-=)M*Y
M[_)6*RMHJ66FRE8D;TLZA-ZGC9G%#.>F$+C3F'%;99<%,@L6Q"SM(8RU3(1N
MK:K;TA"B5/&1+UF&D?<SLGNH-C]RV7K8>IO8RV8A_5VL6T$Q?1^X)D4U_EW6
MUY !@(>*AE?$DE_3Y-=K]H>ZE]!_P^W;-MOYV]G.<M<1[$)V2))]G=I=B;"R
M3.02UR1]Z 1QVFC/"FF.;V9\"3=ES=LC0F3QS2E)12UJM;6L_J$ >&;?:DW^
MCY&-"'9%+#TL[JK8W5*1]2,VD/ US!S1: 5H$]WF#/;GK9B;?M6#&Q-:F[#!
M/1T7!I_RC4ATD\0Q-1+D,?9I<\/;J-M[3>(<]WT>L^NZJ(O?DC-H0W#<8QX?
MNAJ!L4"8N,A7-S'XS)^(6\H*SZP/4LC86(L#'%W!#8/;^ &((9UHPMO(4(4O
MF][[&OQIQ'DIX^,W0QD8@@W!QY4-;/)LZJOT%RHC^2:4U[J.BU)>-Z;HK#R'
MN+ +1M$)LYW;%/8<.K=BQ411Y9U(&C59=@8/>8?1JU<O_MV8:*V6?QY=CDP&
M-9PCS:)VDDVG<5&HL [27]%O^CH)-GO+NKF'W#D=-UC,7@W\TE'A.<_ X"]E
MO&_H+AA2LZ"SAXAV(Z)'H;Q;..-59'(L$$J]0,-@3JG*.5";C^.20GC$6R@H
MS(FZ3[=D^G>:W8$'?"V:$<_R!DP=,,S0 ^V(>&*:#O1"70PJVTR%6+,HTFM%
M'$]FCU1[PLHPJ ?VM^3E]E*<]J_;?"C;!QZ-V&Z_ZT,X1DON+YN;7_N</+RU
M;VHE$KG7\GV ->N44'LHK8,3BN3(55,.MN^/>?99U!'P=T(,;[6!DB!21ZD_
MR(?!P#_N[C&-U\?#/Y)_HA& IFAT&Q=9W8-"9??O;K(Z_V)V<9'4RW5FB7A@
MR&09"] &DT8#%[P1QN&,V!ONP(D0W)5"&RK<L;@93P'+))4BH4V??GN1;"4[
M&F8WPFD_5M%N9LOZ6FQZMFX03$^'8-I=+P33UVLCN#:&[BM7SR=P_F9)7*>F
M,7\[^.FD#4EP=U5)ID2M@L4IV8A!WVO4%"'/+'9XQ* Q[*RF?6GT!;-_373G
MRPQ?^6@&JMJF=X/N#$,#G%:,Y8AJHUG&!>'HR*\EZ3GWL6^.R,K+R]R]6?&@
M(Q7(SH'AEQ!.,CS%?J]2Y3.4\:Q*6B6O]"NND27L+D<^5.H"7[2HN Z22"14
M3[;>P 7,WB.3ZFY5I&(01"ZVD6)[^-S+IEKU[-]WAAF'A< -1,*H_@D=U.6Z
MT0)V4I"@ED>X1<\9O'C]DF1A<.7\>KUZ,*&-22V0*\PAJ\+E#^2??DOMF!8E
ME0]?#=B]"T\H3:,B"VX,+A4,L%KL5DK2#L%-71+8\.Z(X2"73:]A^1$C1V$"
MHJ>@XZ5H<K,LN>G(NXSQ@/\0S+TCW]O;V7WEF\ 7#I%+7J\&T5.3UJLC0BT#
M]#Y'W:5?*>-)K$WTP9?-E//B<R)K K^ H2&Z##D,-2C<5*.@Y.*IBGZI6%@8
MEX&*BDVG_.=XEHDT $- !#G%LN(4X_Z$8S./ZJVQZIH,(^ GPDZZRK%/B1$,
M-SLM;OL$^8"1$$Y=ALX8!T<ME&7^8TIF!!\&VDM&-XLQIW%A@,?M0!Z]96^(
MS&\%R'*B*B 452-#TJ/8W0Q##UF;Y4YI-1<#+DQG2$XG/*Z&SO93(0/J*%\K
M*%96R$%*W#DS$L;3+S<Q;!1O3]G5O5KO"?29R735U&FX.1Z@UYK190J:8#YN
M%M<U*A(15%>TK+8;??5$-2X"'H."C%-NSQ,05:"X%A)Q9MQ2FH[-.\^D 8?8
M"E!XA"G(L%&S 5!V$@SP3;.S/H"+]7["W2/)1N%5FP"5$N%TX$BG0UYM'C]X
M9J8(W:83QCYN>$1=S8'Q2C/QT^B=I4$KNHT62ZT\UOS%.2'VB;MWE%\W-[=H
M3R-Q*Y)L)BN_@K3"5DA4XA5/,7VNK B"Z&03I*JDJJR .S%7A>C;R7$Z03.#
MTNES^1ZU1HA-*UW3"]531F5?/.T#G,QN;TKWJO2OEF9$EYF^9A)7,DXIZX\1
MQ;@=BUIN+5&M\-P!8?@L2C)LNZ35$FA"JR ()1Y79LU*4X:I87DFT6A*H#VI
M-^XKTFW'(#>+R<&N)JS-+(_M@]+XB0[.E62-%P0G+%8;PIKD2S=L!-9IM\+.
MHF:2F0:6&1J]5ZSC2//XJ0-323=R1\I8,LH52&552!OQ?@)_E]9!NY( >E3<
M._*6O5)=\Y4@$2>V[W,T.V!Y'6)0K\,W;9QZ35_(T#4OX((%\TB"E%_=;Q60
MJNVS!EC#]DB=$_WX'#>WAY2A!Y_L7^DLMB!3?#)K+E(\GO$?)C=+JE6:4H64
M0R*_[]L\NI\JE]R;@W)[\TS<V3R'(V[FLVSWI)EY-'(^M#Z'+;$R^C9CQ-5(
M^#**2/Z.]IPMCVQK-W])%VY@.!L8SI/!</;6&(;S:"TXT*0OCZ3:H5MY\$F3
M#WUJ9?)A>%IN6;RCQ/-*RB(ZY45YDT7\W6>I5) L^KHS7_ZLB?$C![+BNSOK
ME1;ORQ9\0QGQ)VI@\DWGW.B.#^Z&QBX!I;9.C-36B4IMG62S@>F/CE?)O"U,
MMF'ZKBR18BR2E;08BG!S4ZL4XO&?:Q<['D9<BY:&YYGWD4P"+?D%@^C@BV/%
M.5B,!A1\LY_3ND0"!P4>N#DU:"H-#<G 4\#B)EE4.V<FJQ"HE@>("0U,%DV^
M%^'99'AI2S&,J6PRU0$%R;8W%N4= YQKOU\6R& 7PAN"1.$ S;RPNH!NB9>,
MY&Y]DO$_C*AF#;A6GV5= I-?H&-I)*280B.B>$BMI;_8(FE CIO$7!CX5*0Z
M)IZ!*_B-'E^+'B";E-M22"UZ,AG;3RE(Y3.@PN#9KYG_BA6>U3GZ7K"&^3H8
MS\H*)"(PTU93#*9V78;K8+X+FG%XK%$Z%V>FNT%'[[@WR*"O#$)X D\%3)FZ
MERQNN.$I0=;/I*%8QZ"8$\QN(G DR\W\T *B(EULFZY2KA\7S2(6QGYUE.Z;
M%$>:LYO@2J)\D4TFQ!^ HY"@["B[2^^0SS6(</_R^<RDGXCIEB+)W"GR'SXF
MNM2Q;0?NMP(/LTA[KH:86GMM2)&AF=I]LVU6+5O+AWFY*9X943U@XI/@)@Z<
MX6.20.ZBJ:C%*V1/JQL[- C#56N'Y1P'LK[,..[@0VRE1R%7XK[2,,+ZJZ"M
MTJSF>IWO9?-06(;$DDH-&[W84[>Q>_# PHU[ ILW9_!7QBL]1:#A%P59)58E
MQYC2%T4!0<0G59)X-&(:/?>:5W2HA'F_+Q]VR]-;0H]M7_[-L&4;[-BU;VZ1
M9,,PU)#E_6@"S*(#S&RM3J6]V//H (+?BX^'\=58D:#H,6194[OR^5Y^![N&
MMC39)\8LF"^SAR@B4#%=B>U,/K *ZH&,X>NH8Y\=DO4T?LZ/LBL*KN];V0IE
MV.!MQVZ3K5L:$%/9N07^(44TE8@6*NSDW^!U9OF_5#RJ_9;\X>*-U$MAH!R!
M#@3ED".NJ1IE,(\-4PHV-6Q0KA1I-*Y9V1"EAD1,U\UN3?T&:KBRAW>#J'(%
MY\I"[:VH778>  $]:$-AUK/J\ME1;(_1-X>CG7VI<*[JDKZ!]<QRC!UO'-S3
M61A63&>-NX@W!O?CZBG1LETP5<<HEL930^J%!6>SLAX6L>#?TS A=*GD?I8<
MJK9)H(?I=VSEY3':GL OOI4TB<1R@VBED+;=$NPAEDQ0]B\=V_#JO9\N7%TW
MS-G@)S?XR2?#3^ZO+7[RL8?O@.#)Y:K54"^NJ-857<TE(QE(?SYEEY2CT:OA
M&I%K(3%;=LK3?J%-KY.V1,+62'?6@M@@3;BW6#UKN+1[/0X92.VP>7WMLGF]
M#P<L41Q0$S>LVQN:;'"ENFYDU  K6PV9^MW5;Z )W&##9 U;M8M6I%8J0S#U
MW)-_SQFYOED'N3ZNX$P;6J3;]KSX(O(P1G\##S@9-^9VIB1WF%7#D2MQC5,Z
M8:5>'F?9YX(A-!B85Z>B62G@7F++]2A([+(X'XY>OL:I^:1ZWGT((K%!RCX$
M5O+LZ[P$5E+:VD!'7?!S2OX%4P1T4*H,C7W5JE QG6-7M-7L?KN5%]';Z)Z)
ME.L/LZGPHNIY.:C6M+3W=[?5P=&!#(J>P51-TWBBLI4GQ%KCW(&'/L8DML">
M"Y@K%??.A%P+^P57 )<JHF=CJUG!S4?=W=>Y:A/;<XQ!(-B=K]E 98]9XZBL
M*9$LQMQR3[ZOD6<Q(L0Z02+A80\;\*98IK&U/[N\M8UB&>YP"FM^K#LH.K>Q
M301(1^\W7[9[I+Y$]!:<SHQ38^O?81!>MHO,^7L37-YN],J?X&XH@R^2E&,.
MLA])K)<\*K<Y9YGEK2@54O=*[6- /+4I[LNNNX2ZZ>[NJ!S%;)FRZ-!%DG:\
M[J9"1W/=)K-NGHFWQY>U,\D-UGSM*J\ICQ'89,^^(^]/9&1*:XV'72JFO1)7
M5R\HCI?\GH'-1TKL8E;Y9RJB?Q!CTFO'/<7$Y?-#>XJ\G@.?%__?V>G[MZ"I
M#E[MO?&V2C%+XC^J:3!^,?WC[G:;>8N58&[!SHO$1&%]%VV%;2=QN4[TM=G=
M=53C8_=2%UHB&$:,/D+%%ZQ\8,+G-)@B^HEKOB922V*^;FMW9QO,C" OO'C*
M'/,B05PEN!:1RL*<)!D2E'AO$;&!9PFS1A,^BBM$?%51\2$(\^R?(HU#>-A9
M&HYD_4#7 "6$%L&T2<"YFC$RH2!Z]EG'FF0AF7-R0^J>X1^"?)Y0D6C':&'O
MY#PR[_71SH'W 9X9PMA/*"[OO<W!N?%A,<//MW&"W&SJ;M[>SJO#G<Y[_EZ!
M-P2WJ;%MUT&J.@$_ZQ18[ZUZI0^!6EV7UEJ[>XZJH"OT%@9O'AN915AH)]YD
M"0GD).-&C@RXKVH&0?!RZ@(S*C_5%;$J.M@&9-7^AHLA@M?K(LO[KO:)NY25
M#:X<IJ2$K3:\['Q<RV)X53A25.,B!FV<4ZT7UGB@/YPE<<0]0(,";\1OUR&8
MCP?I'KX<[;8CTNI30RA#.JX&$L'CBZNSD_>GWMDOJVVSPWW:4XV7VF]NM '?
M:6$=Y^FGB]/+T_.KXZNSC^>7WO'Y6^_7XXN+X_.KL]-+[^,[[^JG4^_3SQ<G
M/QU?GEX\(9O$_131P_MCK:,:O+HQV_ER1*^NWK0*-XO&F=,HLY0Q\0"C=DF2
MW2'QSZLW3WOJ; "P&P#L?0&P!^L%@'VRS*H#MM7!:-=5T^JCX5L.;UX9#=4Q
M7*8*;!%OJ?K_1%4R5QXQ58XAEA<^(A(!ANR2"W^=9:@' BX8KOT"5?ZJO%N-
M&45?>);=P6.8ET@U/Y4T1?"MPMRIYK4%TO4$:7@3TX>JTSQ'N77#6WD[9(R&
ML3+A.=RLL]-JC/?)L> WYY1)=I>2):DIR[F^GY%3^(4.C01X$1U6R5Q=(:)!
MX YKTAC[8+3GZJX$U_DD2R<@<$.G0<^1K4N:-^*+""L)I8Y4G<Y<H?CKO6OW
MH+O"/!(W(/+>9F'%H!R0[;N;.+QI_!2V_8R)P*CH4N23+)]2-7[74^PBI\ZL
MK,S]&'^E?5E-IQ;TNZP'N?0VU ^!.63 ;R,V5%XJV4P;=B$B^JFFGZL8_+I6
M%:[&UTGJSLPV$-VWNBSH\H M\BEE$"6K2J,ZE:RP5EWJMJJ!E=H$E8,*H,AO
MKA5-E\2C6+5X"K7)1#QB*B)N^SE&AA+N#AXQ?0NH+YGFJRO'@A!>4>2JE _F
MNLIEO86YI@P=:0Q+WEXF%'UO*]Y>J1MYNZ&XE,.>KN$]$JB0.IQQQ)YNG$"4
M&A@]>4G_H&B-:,8K3%IOQ7*LN*;R1S41 <%QLA9C($42X$_J[T$T<;YZ VSF
MBF=<B'UA);^125: X(*BS&E++=A1@6R D%&)\0-?&NY#;\G4/5/)@0/_@)=>
M]M9JJQJV!BQ%I)5!@W,J=R$SNS:'F+-1NV/3'F+V6]<(:@R/?X$%*/5AR(UO
M],G'AJ'49]W56_XJ)V!<ZF-/@1CT$256.YTTE\%8$K'T'-4*:/N8HUD];.GI
MW)P175Q<#Y?_20!="OB3<:_L:&;6L16#=_KHX>OL CU,KFMDSM,S/;@^V._-
M;J3OUL]H9#RPF\5('JA4CL^$1B8OWW)2H5R8^MLB&<IJ=B'[E"[N0R'D:THB
M8CRB>QA\2K39+'JE&95!P9:%_\Z_<A>G-09.'(P.7#TR+%,-%]S@!O:L\\0!
M8,4]W*%G]H-6UK1*=3==(,-(6WS6=-XURB2I!GL:TLXMF!9(QCT,FY8"R8UP
M"==YAZ!!^)^8]/65DT.T7CJ-G(MK[&<7J IR^&@"Y@1H&%)U"RS^#A"^B2.-
M1!'F\9@1(&[NCSI9>_@-]:18F$O:7VOC_-!102+(?2D5QN"J5'-P;07;5J]J
MV/?Y.%:;O29(]#U% 2RF!!</8]U+'?0:A5_!NIEE(@U\:B9?E(;7++MUU7R+
MFL<^C&_C!$F$L747L:%'\!>I;Q#)!=JG2M#NF5OWO974 *2FDVVC#;>&LG]N
MEGD;1IW1JILU6J=EYW?Q0E*\96N\#9^@^IWSE^8+/_G+\1#' OZ-,:H>;?OP
M*>AY>>8'QA='4SRD0(GF]>"Z>"$^TY$ZRS7-,)S+DOCH08>>;+'\F#/<U9)#
M)Q3D2T<5Y#OX>^$=WP;@U8R'[3S3%:HHJLDD#F.4<=@(-QY5<W#LH(!W*2;S
MAE%H,H"=I:#Z8:]J<-RG',TL25:C<**Z]2^YYP]^(&W6#S&X;"6F$F15MQ=/
M^ $W A-<H$RP0+=HEC5U^;)NRHN2Z+V!+;.&K 2AUKDRJ(5A9^9:[R4< L5E
M4.H0_0@U?T8WGK1J*O, A.2$HP1\\O3ZB=7<!N*R@;C<%^)RN,80E[V=(W9K
M[*-<?^P&L+$&:_[BJ"(^^?C+Z?GQ^=7E5\=YOUP/I_3073#2)P[H'J=I5L%Y
M/W@#7=5/"-U2K%@("&)3J'9>Y&;$654D<QGGXM@1Y8/PL$7\=VE&[8RV ]T)
M6$FV0-,0&-/ O:#5#=%Z2_B.!99PX91Z9!4B[XDU1'P4>H=&K)]^)A BY%%M
MMLS$T[GOIEP8HCML\;2D@PS!1*YR42.UQDUX@J]6/*]4[D(ZUV1I2>\35J%B
MU!>&(6^PK1Y* BBHSX+,+'8KC4O)$Y7T-I3,XA:ZNB%%(9/RX-!&_#?IP/:%
M1"?4OU<0;8Y9=^9[J60EMP4UE2 :*<D%^M^<")4,/L:HZ$MP%RJ00[0UCR<8
MJ*4V?FA18EA7P5DHRIW'6=U)4$:0-7: =X9Y^RV>'74A/XUHY068L@8A.Q4>
MB23R.1@@(JO]D(BPBU%15*IGG;E]:#4^B_;F-*2@S0MJ&= UMJ)^C^XX@GWE
M/2!)"ZU^:>JS+P=3DXH0WC#(Y[J$L.9?A?41S?'3Z]%EIR<J/TUSTC,?.'G8
M[D35'5*R42L8HP=,*M.26.1?T*,CZV&^UI-*;5J^"[\084TBT9#2H.;CAW'.
M\ E5*C/YJ+-!'\C6U5/IT,BV(> S"-RJD9IXJ2_KWM;6.R#EHN@>>N'="62X
MHL(?VK&]\T5E;O8)839B:9T4;0%;+"\*N+8E1M<CWY9PDKH39&V'.UW06N"
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M-Z'71GMQ%XX'K?RE D&FFU53+-K_-[CA[W=P6#1:QMG1]$SO?7RHAFAX=FQ
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MTW2:T+G#AIB9OD!>HB97J]] &REC::6YOK]]^"=$ !RM%P+@%+EHZQZ=&P3
MFG(JN)7_QWGXI!&_V"IG$>];LU!)=B,IO'^KQBXJABY/#)N$NE7^N"P'7S?J
M?H2[T&2"6T6#=C*\+2%X\^K&=E3R+"16AU(*V''2]\(X#ZLIYE ESR'-,G?
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MT.(4[%_TROH.AB:6>+E]JW@$'IL:[$;4#I4*C+=592J*?T=Q*JSO=99%6.9
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M_Y4+Y%[6O3\1)A3D>-S.F;RTW3*DKDGJ";M039;U( (038(J42VR\>L0+=^
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MNPVU=XR^FB2)CRK1L@\Z[K!%)K[NF=!%[D\$/./?C9XZ1 3.$^]3<ZM"8@K
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M[""2\;5.>F1K(8N(.S-RHWN6/0KIUYTB L_"FUU[ KFIVF YUV)@T=*NHIW
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MB4G*0A* 6B!\)BBA)E[@S?VDKG2IBH,DSN_7E28W=7GGONKNJ>6DLWL#V05
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M]I8XG8"C%'/\"_[A+;B%4*Q[\*.P2$]"75EP+\\^(&Y9ND(P?H1ES0@-B,D
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M6<<SWEH8X[\FX>P>_G>3+!?_^O]02P,$%     @ FH"I5C=@)Q,_!P  5R,
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MR%Q+49G'(G]S,UP_FTMJ?5T>?P902P,$%     @ FH"I5EPE^X#= P  Y X
M !4   !E>&AI8FET,S(M,G$Q,C R,RYH=&WM5UESVS80?N^OV,A3QYX1;TFV
M*$4SC>PT;N,CME*W3QV( $7$(,$"H&7UUW=!6#Y&;9ITVK';*1\X)/; [GY[
M .,7!Z?3V4]GAU"84L#9A]?OCJ;0\8+@,ID&P<'L -[.CM]!SP\CF"E2:6ZX
MK(@(@L.3#G0*8^HT");+I;],?*D6P>P\L*IZ@9!2,Y\:VIF,[0J^&:&3K\8O
M/ \.9-:4K#*0*48,H]!H7BW@DC)]!9YWRS65]4KQ16$@#N,$+J6ZXM?$T0TW
M@DW6>L:!^Q\'[2;CN:2KR9CR:^#T58</Z: _Z"<1(?-A+^FQ>7_ !B0>]FDV
M3P:D]W.$1@;([F2T60GVJE/RRBN8W3_=BVLS6G)JBC0*PZ\[+=]DG,O*X&8*
MA=VGTW&GZ0\Y'NQBV(WQB."+*FU][3BA-3F30JIT*VR?D:5X.2FY6*4O9[QD
M&D[8$LYE2:J778WX>)HIGCM&S7]E:"^:WOXNG2\]U"-XQ=:^1;%UZ/#'MT>O
MCV:0Q'Z\8>NG_/A"'S-$BZE_W,F]WW5RRI3A.<^(36*0.9PI7F6\)@+>\(K@
M)WZ=YLC!U-J9IP #GGTDSQJE&X+[&@G1/GSP+_RI#U'2#_^/VZ?BMG/!LC;Y
MAN' )J I&%P0-2<5T][IC6 K^"8SEA*'8;S[Q?Y\=AU^;#26PNJ)NLU1%[XC
M5M_W1"DF=!<N6,6E@A^P]+ JF>;4C@=249@6G.6;]0D[]5WQYG=$Z8B[-H+'
M)%/R6]2;H?ZC*O-AQX;[G"VX-CC+S&X7LK8CK+HVCRUQSG0;_7(%5Y5<"D87
MK MSHNV,JA$W HI=<XS"+7CO&Z(P_&*%>FNI4+B"-U*5$(7>>\C1)<M58Y@D
M!5911K>WHD$X.B8J*]QG$G7; >?^;O7>6[FVVFI'BTU!S/96?W_TESIQ2=0"
MQ]I<&B/+=(A@U812G+V>8+E)DP&NM%G"*PM ZMF5)TJ2R'^Z7O(X+/&^W[=A
MF-T! 7DC$/-,EK7@N.F2FZ+%3;%?&JZ8/91HFR/K>H^2';)[5_$L:Q2>I%#P
M\"8K2+5@Z[*/ADFO"T0#EH?+EOYP9.O@/P%I_"PAY176:>D.!1EJ(2A)<17,
M [P)MT5>8VNRT'8MF0@!*(;&8.=!0HU8ZVXK==^14"%M#\UM,T.N1KC,D-@4
MVCTU;-2\_[<?P1X[WX^?* 5<)E*62>=[VF!2*LO5F6QO]?9&NGT_G@[/W:G.
MY 3-;9ORO\WP TQ?9_@Q6;D!-'33:/,L]3EI]O"^5$MW6TPQ% CV-=NX0:VE
M;GM7>"]"YEJ*QFR*_,FEZ_;M[G_M373R&U!+ P04    " ":@*E60^MRLI5B
M 0 ,[@T $0   &UG;G@M,C R,S S,S$N:'1M[+UY6QO)DC?Z_WR*NLS<=[J?
M2^'<%Y\^?A\:L \]EK!!;@_\XR=7**R%H\4LG_Y&5DGLV& DD'#US#&2JBHK
M,R/BEQ&1D1%__-^33CO[%OJ#HM?]YQ)>04O9_WWSQ_^3Y__[Y_;[;+WG1IW0
M'69K_6"&P6?'Q? @^^S#X&L6^[U.]KG7_UI\,WE>/K/6.SKM%_L'PXP@0J]=
M[+]F3@MNO,\MPBAG@K#<&LESJU547C##>5C>?RVY"I9;ETOL3,Z4P[DR2N0Q
M6,]H-"QXO.Q?:X-H8"BHR"*S0FOK-=?<(T^]=X:DUQX,870PPN[@]8GMMWWQ
MSZ6#X?#H]:M7Z>M*K[__BB D7E47EZI;S^\Y/CY>.:;E75AK_>HD-3>^Z75Q
M,LP'P5VY&;ZO[/>^O2JZ[:(;T@R^&O9-=Q![_8X9P@S#VS#/D<HIGK0S&N3[
MQAR=MQ/-P):O'%^ 1PB9W'P"[7Z]NW_IZN36SG[WY/S.CG']WG[H%FZPXGJ=
MU"9%]*(3-YJ]/#WT5;ILS2"<=V-0W-8)N!>_^M_&^QUW$#HF+[J#H>FZBZ>@
MS>([;[E^OP_7R#697KAP958&_>'-Z8,?K]Q4G-SU:DPO$>P2>6^__WNT)2A'
M),<7[QST&,'R>V.N[B@?>-TVW?U_+H5N_FEG"7@W&/_FCTX8FBP]GH=_CXIO
M_UQ:ZW6'()%YZ_0(9LI5W_ZY- PGPU<E?[YZ\Q__\1]_#(MA.[Q)3)!/B/W'
MJ^K'/UY53=N>/WWSAR^^98/A:3O\<\D7@Z.V.7W=[74#=* X>9UN#/WJ8^%]
MZ)8?X7H38*%?N.K])\/M$/^Y5+! F.08*8$)LQ)9:D-0G%(CHA8&?UDONX(1
MSB\8L&LZZ=6A>+T*2.,3VKQMF_VEK)I8:/9D^#H6)\'GT;03#Q8>?O3T[U.[
MWOOVGFQ_VZ6-D3_<^+;W3A]N';8/&NO-=G/]S_;6NUVT=[A=- ^_\MW.1]YL
M?<5[ZW]^;9#MK[MDX_0];;9WSWI\M[5ZMM?Z>+S7.N@TX9G=PUV^]?FOKUNM
M3[SY&7Y?;W[=>]<\:+05>D_V3G<_.['UKH&@O9/FNT]\]S ]]W>Q=]@N&IW&
M2>-L S?AF:WU]/[5;_[=V\*^^R1VSW9/M];_^MI<AS8_OX6_J_">#;)[V.XT
M4GN=#=Z >QJ=S?$S?\.[>'>O=738/-QDC<Y'E,:U^_DC:JS#F%I[Q=;GW>/=
MLX]DM_7U#.XYW6VKT_>MC6%C!YV\;[FSYOHF_4*8YE%KEQ,<0LZX%[EVC +
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MA76R.#2C4@3GD) OAC[SHZS,A(XB$F*)\-("(#KJE)'*6&:=@>6+2E?2$;\
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MA=3W)@<<-TYW6_L(_G>\V]H]::[O%5OK7U'SL'&\2YI?FX>K?&O='X+>=_.
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M1Y([K90GGAN*]9U@>A>-;]G$$3\O0<\D,*OE?D?#G%:CX%62^/.CXV_+W4#
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M3E?.QU/B>.IMK" 'NM[II94BS>,@^^VB3F3U_D$8IM<,#\;@M53Y+5=7LJO
M!21/XU_M=M, ;P++_YP'%9Z&)$UE,.$=9Q9*$/P ()5M;BYG=[_PQVCV^_)X
MC@U,,:#/>,&XM$B4+W,F09>Y2AQ8F+Y+&?AUF*9L# Q5EH^K1+J;/J_OB1$I
MN\/82*G*X1!U#37R=/#]F6#C__RG(N0B4\73=^'JW&"V4IJ=Y_I$24, B7;O
MJ*)SK],)_;1B3J08Y-./@#%<RC*0@L &]\V[P6K*/)PR2?YA\0 Z5/DA$@D
M?7IE7=I4OP"HEO+E.&BN7#N&2>XJP"H#DF'1J=3:2@8G;5VN;WM\ /K)]0:2
M=E J+2DU>QGK-\F7%.#+,N!1'[ RB6;9>/E0A>IE<SZ5A9BT4:GD51/]JM)#
MKW\ZKKMR\:J.\:%FIADSTP5#3%9@8X$.P]/2KK!IQ2NO=-+2E[Y<(A@HZ; Z
M)^Z8Z DWT>"<\]HF+>WPJEC6 )@\G7)E50_5P#%K2)_H_V6Q9UA6$S5*RVX0
M;MB"%[;?E3I(B9J5T5>2T5=&$]QU;A/65)PQ%2_)9]\42>VZH,*$9L.#?F^T
M?U *WN2W3AG:5MKXD\NIOCE\[?3ZI8I]E#R1H32XNZ"8'11'P!:A.I?52XI<
M@N=E4 CL\(+>@Z0AMD&ZQVY,^-XN7#JL6)9*[R=WQ_B(3#_9(* .#TS[&=6$
MU;0VO5CNN&*I78CY+< \-AA!)[<AW3+6\RK%N[0HS\D*]D(MUD\GUJ7_%S0M
M^)C23UX5KU)^>Q/GT>EEZ9\LI*4;[R;!RYR6@V*_6T30[$!1N]#FLZ/>,+57
M0H<9EL:\@Y>E6M>I8%9ZLF*)\R<N'(TU:\Q81[L@C@W=$(OQ.CQ>L'L3#^7$
M'@@G0+:BK'MTF7'^D=5T>KJ5.3C0;2M_3=$%(1F6IE%1^>J@!Z/D/JK*VL$"
M73U9U+(T<UDJ-9PD/3[LI[.Y(#.58E361SH:7KBT)@;P:%A1=2Q=M;7R1-)T
MV=<T=I-7E)KX.NZ6HFK?8;R;4!-JAH2ZIDX< 77*I6@,=#!Q(Z!#38-9TL#U
M!M5>96+^?7.^BYG@+IJBG92$JK:Q"X-!'"4WO \QP"UM<SP83?2):@O7M4W1
M@1_V3=$=#+/1X-PQ=(=I<<DE6;F13B_[B$ 5;9>AOT<7H;\U-\R0&T#QZ/8Z
MA5L&M3$Q1%K"+JC;+P9?RZW GJN\N.>J?=HF[E?;CQ=;CDEMK(GUE%IC2.<2
M^V$0RLPV<53F;BX):-Q!N5][L=\/2V J4CSL=:&7U>[B5;N]IM_3T@\P;IAV
M21.Y0HIS<<F;-CSWG$Z"9(:AG>I3C"I8!%$;UBODDZR0Y895<:[C)_)=6B&K
M\A\5)";'2TG&B3&]G^RY;K+B2I_XI#[YX')H1PJ&2$$+96A'65M\.1N:D\NW
MUW2>(9W;*3=>N:DX'.]8)*)_#:=9IPR3&%3FWB0XK*;%#&EQE^893H(;#:O@
M@7&)GXFE=GD3.JF1/K3-Z6!B2TRVML=NK^K9FH0S7MTND?%\"SB4L4!)41DK
MC>VR!$DZ&_Z/!)H/"-^K:?(3/JP!J(']I'*4?JS1A?>W]#9VCDP57&RR_7;/
M)AT#[@M@$F3C4$$[+ENY?$G-7[YP>(%*LM\WG<'R50_+\J7B5Y,0KPNEQ@R2
M<7@>DS)YQ7U#.=FST3GEKPK_'I4[8<O?BPZ' 9JO,(6 8>:\-HLO([#3ELEY
M$&0*6ZD<4&4@;17PDHQEP*Y!KQW&SU\*V1R';E]LSU^*L%S)=GNC25-E0&3;
M@/8"VOXHM3M69H"PWPME_)QV@;OIZ?V1285D0KC8[B\IN7P>$MY.VX#E^%(U
MFF_ 9LM7POW2+FYEB8P;WSA)?M,TIG&D0+F!V#;'J09-YGMEKTOK9&B^CF<&
M>*7T&E6NB,1YH43\GFU//!BI:MM1FM[E%"\T@@N#@XM*;-\C5&E(Q?:E<,5J
M;&7$4M%WH\Z@=/-.MM(F-Y>.#%<1Q57A5:/N96NK:N:'A72H6)BS,G0J9V5F
M>5)F7L[%C N+9'>4K+C.$?><?['T0V3$9(Y.!VVV-AH9OCP+WSL?=,])T+=-
MPKR,^/_+'UR7ZJF[V%A=V]YZM]'<7-M9!JY<NQN@YJ7':UO-G:WWF^O .NO9
MGZOO@9<VLIU_;6Q\YY39O/3]M_(44&\$;:23&*%:_<JB:U4$[J0$6QGS^OMD
M/$];C0IP> 556/S0<E1<KV Z_7)46*U0QGZJV>]?$_)^1:X>W%DQS=I9CSM*
M73'\7"6HNIJ,?39%CA=C)B9G<,[3T-]6?7X*LS(&C52C-*6K*)/N9I/A+=:4
M7<D(/$W.N=<</205@C7NZWZ_!^9+/IX<YT*(\7L3?EOB ^C1,\WU:@JY'=QC
MFG\XU/O,_Y.W\6#ZQ?*_>:3?[1E?UL9.@C)T^M*QMX=,X+4Q_Q019MW&E 2Q
M3.,CYYJ@J4Q$=6@2/B27R3?3K@J[727M0T:.LOG*:GG[T/_K44.\/+1^:G6N
MQG9GE>[1P%\KT8VH)\&:&+'2C'.OB6 **4,-(IZY,"[175:7ORC1G=-)A>[1
M(-\WYNAUXJ35KD]_-B[8:'6X9OK]4YBVOU-EZ/L5ZJ;/7*A[:T=W7.=M=^NP
MP7</OY[L'GXB6^MO.XW61[K[^>^#O?6-T[UWNV2OY7ASW1\T/V\<OZ?;![N=
MD_96IWFP]7D#^O2);Z7"W&<?3_9:?Q6-]5V\2S[BK98C6ZV] ^C'U\DS\*[1
M'ODDH+_0S^T.C($W#O?/FNMOVXW.YG'S\._#O77HY]DN;W;>PIBW8W,-G;QO
M;0P;.XC".TZ;QU]8<-PPC'+DI<T9=R&WT=K<1VT5\Y(BSI?>$,*6@<0WZGQ/
M"J;\O$Q, .\!LC'-U;M&J!>*4-H[3&QD6"O.N-"6.FP=CTH;*0/6)4(13&J$
MFC>$.KN&4))Z%)RA.5-1Y$P$FUNC;"X%Y6D?5[*4NA@CM:S4/"'4E/3Z^5<'
MJXH#E7?P/%'4G5H^>=@,W JZ"XU,T]*=-L\/Y0QJ_)D:_NS<T)"HDH$FE8@S
M QH29C&WP$RY!=U($>*4<A[P1RY331X+/]^!@%DI2/>UBG]YN9V61E'+[6SD
M]KK>@(6,0"^7$X4E* ^!Y\93FFNK120J..;-TAO&EYF8)[G]9;Q(J\[!,(:#
M\9F!I#_\E-)P7TMMH<%G6DK#9-*WS^>\&89C!VV-1E-#H^*&%H$PX40+4""$
M53EC!.<*>90KXS15QEAL4O56L0RX,T=&S+0W27YY09Z6%E$+\A,)\G6U(@2*
M!9,Q=]13$&3K<JT(S1'VRL3@HA%NZ0T7RX0\6JVHO1$/E\6D7G?3P=WEK!N&
M6>V'> H_1#GA $ U\DP->4YOJ!!>1ZVL(;F)2.>,2I+;*'#N')$!L$<ARI?>
MX&6&]!S9,[4?8DXUB%IN9R2WUS4&!8J_TYKDG(>0,\E]K@CR.0T:!40D<]:4
M<LOQ',GM+^.'^- /1Z;PYWE$+V<2N1*Y5'LG9JU*C$FQ45%BM>NW$AFJ^+_:
MMIDR4FW=# 8!V\8S['$>A :DBESE&CF<&\J%A[7%&&67WNAEB=4<F3:UCV).
M-8Q:G)]6G*\K'AJ06-'(<F^=33Y'DUL79.Z(\5I;PKW1*7)B&8M':QY/YZIX
M7$G-9RC3N?@1W*U>2ADS!6UH//!['P1Y>=@ZM8V<&D5G@:*-UFI"T%(Q:IXU
M4./0?1',*\>DRQ6U/F<4M")E/,F1""QJJ31V8+\1I98UHU.RX!YR5&I1W#*_
ML-1/;=>GEOJ92?WI5:FW:9L'191C*5G.N!2YB4KEW'MCC9!"H"3UA"QC]>@=
MVZ>2^A=T5O N9TZ5C+"J^G%4)E K\[7TXO#8]$.Y*50[<F;OR*G(\*%MND,P
M_#8FQ*A]S5.%K8T;R@H)WC-L92XB MB2R.4:>Y%+1:+$AAOA,,"66);JT;I*
M[<.97TF>G@^GEN0GDN1K"HBCC!AB9"Z]=V!V$)2K* EP%M7&1Q2L9"#)>IE+
M/D>2_.*=(5OGM8S;P0Q"5LY)WHMY64#VT;Z1EPU+TU(PSHGP/M%@.W5F*WX:
MA-) JG%I>KBT>4/#H$%0X1')F:$Q9P[ "0PBG"LL,,'<1"E5J6%0_>CC>'4<
MROR*\K0TC%J4GTZ4KZD8. 3&A&>YI4;G3#"=6Z9P;H((2$8LJ24@RG*9TD>K
M&/,7FC+'*D89?0*374>@/+5><;%#W>QU7>UHG38(-6[H$Q([;IS%N;16Y@R(
ME@+J3>ZHL\@2*SU)N]3+5-9!)R]8@J>F3M02/',)OJ9&:&XX,USD7((&P0+V
M8!%(E O';/ <(Z?-_$GPBW=45%$;MVL.L]VK7>"D2 \>_XL!X.E&IM2(.SW$
M_7C3!^,4Y5CZ7# .B*N0SY4*,A>26(J]#32ZI3>4T66F'XVY"Q:24D-;#6TS
M#;^IH6VJT'9]VTOHR"B6N54& ;39F&L@78XP"TX:&85*[F6%EIE8&&@;ZYJ3
MCDSXN*R']1R)J"\-F,*0?&^4LK=]-\WX8O3R!2GUMR=#?U]<KQ'?<U\/>FV8
MJ,%_ET%/P],ZP_:B.GXGJ=+;%U3^N7SIOU#B^_D_87J>Z>K(G-Z6YNK1^XB+
MKY2^3+USVEF[/E3\4\=_3UT/W;]I8H,)35GT.9+!Y4PXG%NB32ZP()@A0[VS
M8&(O2_X"LVW4B/1"$6G:Z<=J1)HA(EVSC /F0#/B<L&=S)D1::/4HQR%J!"R
M7F#DEMZP9:7G"9%^F3PB(!+]4?AN'I%+:GT=RO$$2E.BQR6#N4:IJ:/4UQMZ
M$S,28XEH[E*R968-S4UD/A=62F,#B0&EL'6UC-4\[0;7\1SSJVG48OP$8GQ-
MV1#.":&)SA60+V>!B%1U!8,L6R8UQ1:S6(JQ?OP&X_P%=<R_MK$>8@ Q\%D_
M? O=T<^E3O\EXM2G5JL.&DVO^UP,#]9& QA[Z$]0Z;3&I&ECTN'-1!R*>0O
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MBZ'6H"RJ]O0N@3)BX"M>"T^ T00=1-+4)0NO)(IU36,>F\:,/+H<L^8$&Q3
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MADE#B39.TQ\G8IY:#G8KK*PEX9Z2$+WVB7F-@HRYQ;!UR#COD0N:@V/@#*?
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M>'?XY][NSM'+W<:[(_BU__+@Z%WC\%7CQ<Z[_VF\^O/PP[NE?XI?AAT[#$U
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MB9WAW3(MJ^O^/$D8HWW<^?8[+$"N?WQ;3?_;:O9KT)D#=*XY"I!2<%L2D0B
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MSVF#,31"=YA/^UC6H^1N-<0U\B.N[[_U;GAV5FTYM*U&<2I>M;I?&WN="HE
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MY34*68Y"R,TRX=K1BQ=MB?/MN[W/Y>BE*H)=?6=.)/=R9+,%UF%J<>*WZ(?
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M>K" W9PT+(-?RES<XW/Y\W^2Q982*I#W(B(N54 Z^(BH]E)XK90S9M4S:T0
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M,&>#/2XJF"FFRJ$Y39<NY#IA_/8GGR _ZP0->?JH+,S=KUOC6<QATQ*.N5R
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M*@A5N:66BLTM[]^YJ_3G:.85>":4<*%3K)$FQD,6<XQ41BVXTZG%QFJ395G
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M#EU;W[;X97@)#\?[GYD:PQH&_N4F_<G6*K&J/-;DY,HM]8]3]G0VB8B.X7=
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M&G2&%#;-,,Y!S<>8(Z6W!4][[[A=/X J]=L-B17KA\0^M'FO5U>[; @F(J_
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MBF&/OW4O=XYXEC+GA$".2X=8!L:LYHE!6%HC.$XUN!Z^MV<]OVZO<X5+EO&
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MO2O2;KY,+B[ZUR\R;>R(C3,-KV7?E#Y6PTW0)#';M2151?$Z$#>=2P6CG21
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M6[):0%;7O;W]$^)2GPG;-TG(@*QD0\4X$*#M$B<.(N%Q%F)T9$Z1=X.LFEX
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ML/?\6QR9ZU0]E<IY #J/X ?#.7QU$]-^'YMJL3L"<%<$Y'(C-S&MQ+5 /L?
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MIMUM=O&B"TP&D]=Q3X8<F")R1JEC[K#7\IY;/U.#U9@Q,7[+@.GC$WN@*X/
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MTS'^!$K)EYR7OUG>Q^+84WE(4-H54U/R",5';NQ\_O)G_AIY@M!'#RP _,V
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MB:A1W%LJ9!K3;1OQ]$2M1U)M#6;FW>!Z0V5S3X9T@-82&L;H(Y>]%I3K37>
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MIT,Z9&M@!MN+\@-_KLP--D_3>>:;A,D3MO/KTVW3BS'2S^CP5*"S0IKK,J\
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M>M:0+0 5Y8XX0*1I1N_I'R)O<X5DX$MF 9_1;K]LC4?M)2:.P_YBM;^KE2%
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M&V,A+KD?< U%_E,@N<90DS6G">U6#//=T!TMX-<TF-G__#]02P,$%     @
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M6[Q]V.([\5\U *A14T_=+;+\[=!U($C\D[],AU+D++GO(]GX A A'>>'=$2
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M:-Q-6QA@_(,4/!!ERN4-O!R8K!0O;2$.O5%R3E6_,?X^,/V<_W_7J$4P2?,
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M4 $#7';5[WRZ&\DJD9+Z!K"XT.=T\Q<_+U^"[^#WG_X/4$L#!!0    ( )J
MJ5:+HMDB0T8  -$? P 5    ;6=N>"TR,#(S,#,S,5]D968N>&UL[;W9DILY
MDBYXWT^1D^=VO!/[4M;5QY1:LF4G4Z&1E%7GS W-L4F<BB!5)$,E]=./@T'&
MSHB?)'Z2L;19JV)+XH/[!\ =\.4__N?WD^.?ON7)=#@>_?5G_N_LYY_R*([3
M</3YKS__^>D-N)__YW_^V[_]Q_\%\+]__?#[3Z_&\?0DCV8_O9QDG.7TT[^&
MLR\__3WEZ3]^*I/QR4]_'T_^,?R& /\Y_X]>CK_^F P_?YG]))B0UW\[^8N*
MWFA,"0+C#)01"@):#<&[XI)1J'7^OS__Q6J7@PX1+(\(RD4.#IV!DD-2LJ#*
MB<\_]'@X^L=?ZC\!I_DGFMQH.O_VKS]_F<V^_N677_[UKW_]^_<P.?[W\>3S
M+X(Q^<ORKW]>_/GW&W__+SG_:^Z]_V7^V_,_G0YO^T/Z6/[+__[C]X_Q2SY!
M&(ZF,QS%BP%H^#0[_P\OH]&_G/V2_G0Z_,MT_M__/HXXFZOGWBG\M/(OZG>P
M_#.H/P(N0/)__SY-/__GO_WTTYGD<!(GX^/\(9>?%E_^^>'M3:3#T>R7-#SY
M9?$WO^#Q,2&>?\+LQ]?\UY^GPY.OQWGYLR^37%:B7TZY@M(5SO^HG_;+UIB^
M$)!)/ T9Z*=Y5 G>$.-MG[X]YO//@I0+GA[/&B*^^=E-\8Y/<-A2P#<^N@':
M^0?!23X)>=(2ZI7/O81S"?(ZPA,D0)_S:!BG_Q[')[_,T;T\>O?QZ/>WKUY\
M>OWJXR?Z]X_7[SY]/'IS]/[UAQ>?WM)O7[Q[]?+HC_<?7O_7ZW<?W_[M]>]'
M'S_>/XV3SZ/O4#=?)L^6^__8<*1+$R,&#4?#NBG]3M\NAJNSZ'^*^?LLCU).
M/_\T3'_]>:BYDRP)RW0]+(IR3#$KI>&!68."#S8<L\YU.=OC<;P"X;ANR.-S
M!AUCR,?SGPY.I_ 9\>O@XXS.QGI,DGCR6_IR.A"<:^-<!.9\!E5,@1 -!R^]
M83*$PC#<Y-]TR>>"TS!GX&((8J(0O^3CV73YDZIC,=?O:A1G.MQ\7A_RMSPZ
MS=,783J;8)P-9)%&2V0@C4^@!&;P& ID5Y+C.BJTOO&LKF.X.J<+9KZ8+&>W
M6/\;;A#5JFFJW=FXH5#/-$<3^/FG\23ER5]_9JV4/%#&1LS2T2R< A41(1CG
MP;@B0]9)1RE[4N[NE;J=%E:H="T1WE0EWU:5+\?3V?3%*+W^_I4.TTN3TPQ3
M9+% XFA!)6T!M?> A6/DF2OI6ZMV%98'OWZ;"+DGY1^5W\;C5-%]S)-OPYBG
M'\?':<"E]B9F#YS% "JP2 X7]R""2\)9*YG%'M1_.YK=$Z"-QFZA00-Q-R1"
MM?P6L/[ T6FA&9Y.R+%?8ALDY3F/E@&7UM-TO82@BX1H<S'.L,A1W&=,WC?(
M ]=N4QG>U*W8_K">9OK +S3?5W3H'(^_UHUM,?6!--:JG"QD(S4H'B,@4PHL
MS37'F+(MMS@]6Y[@=P!ZX&1H+_2;C)#;,N*W/,H3/"9L+]()R;?.=S;\EI?P
M,%BCHK*04# ZZH0%EU,"CJ@9\]B#(W(/I$?"BI:"O\D+U=H6''B>?&3: 1I!
MIY(Q'@(79/AD5K1RJ)BV/=N CT3S6XGVIJKUMJH^^IHK]4:?WX[B^"3_/IY.
M![0I.<5Y G)>"))5"%X)#<DZ-(J;HD-JK.U;8#P2A6\KX)LZ-UOK?/8E3]Z-
M1^.KT ;"!L,9YR!<(<_&6G)J4A3@8W(VJVAEBJWU?CN4QZ+[!H*^J7_;7/_+
M8X>,$)]]02 ?%T%Y%0!Y"""+9<YH5TSS*[I56!XK S81]4T*N&TI\"[/+NU'
MGDX=FJ( S9,B/A9!9U DQT1*HZQ0P;+6"_\*@$>B[,V%>E/#OLDB?SD^^3K)
M7^KKV+=\@8V 'I5/^/W]>#(7\VPV&8;3&8;C_&G\'B?DH9P+) <=BY0$7K)J
MBM:S2M?;+[)7N#7,)MG:+VP$_<'?%NY#A3W<.]PUC1??<'A<0;\93S[B<?Z8
MX^F$M$0K,OU_I]-9%>9RJ@/%0Y0N>% QDK=L5*9Y> .Z>%1!A!AY+_9) ^R[
MY^)>R+,&@7O3?"_7XS>F< ZM))$*MP[(3W.@5'$0M&; R8;GCG[)7>L[DCO@
M//@]KY6H>[@M>XV3$5EPT_=Y\O$++9)?<3J, V=-$B@D,*L$3381*"\X'?@A
MB*2]=5(WUO^M0!Z\YK<7;P\W8==!O1H>G\YR&@3GHY?10PC<@.)U?^2.0RS6
M98=16,9[UOH"RJ/3^R8B[N%B[.^YAJ+F].(;>6Z?\[O3*I2C,H<X/3J=U3C-
M&OIZ1E.KZN8C"Z")9.QG1,"</1A>E""2YJA$8SZL!?#!LZ0_=?1PP;8"[(+9
M-S /3/0B2V?!%DSD=*( ;P0#JPJ+64@97.L+US4A/E;^-%%)#U=TY[/_5$WD
M06!&D^6KP&A#,U<B 28?B-0F:J:C$,V/FZL(&NK_4@!X[UK?0HRWN1$_G87S
M_B4>CZ<Y_?7GV>0T7_QP/)KE[[/7Q_,!__KS-'^N7VS*A.ED-G@_&:?3.#N:
M+$((7GP?3@<YZARLT\"R)U_("W+(BA8@I2?#2%G%$^O"!1K@$@_HNPL.K!J[
M(0ON"+F_@Q4;J''<4)P-7<M+>"[' +V:;XZ=0 VNQ?UOK^N;0%IN^ZOR%2[4
MW49'-Q7>2, [TSZ2,RM#4A"-0E R!7"26RC.UJL/);+KY%(>EM:O9'WL1>GK
MR+5U;-TBS/<-S?OE^)A^.SZ+^'CQ>9+G6]OTC[E!-(B")UMG[ M&4*:Z/<E(
M$%HF5UB(/%^S!5<$VG4=<7>F74/MC/L6;0_!\HNI+\"PXJUTRH'QDH/"X@$Y
MS9EA#L*G6+AL?6]X!<!#5OOV$NUQ>?\V)A=C5'EW@X N)31DKD(,6H**M+F%
M*!G0MN:80.<=NG77]NKA'K*&>Q)JP]>M1;3O:/Y*<B7>=X%+!A9*B@$TID+G
M%XOD048%EKP6+;,@)R9T4O8=@SQX%;<28,/K_NO4^S#^@<?#V8_KQ%N@M *9
MR#(3WTS-_:']A_S4 $*E%%C1VJ!9=TW?/>2#5WH_PEUY^_\?OUP3U._T;>/,
MVX^?CE[^K_\Z^OW5ZP\?7_\_?[[]]'^NPMHNV_:63^\OP_:^J5S+JF5&^I0]
MRS$953(&K;,ID;%"N*0I*[-J;QFG>29M,"I:$\F'L/7QF-5+ J<*(-D$12FG
MU/6LE0/,I'T[BI.,T_PJG_WOV]''V3C^X\OXF%@^??W/4UH_'\CP?3.>_ LG
M:< U-\D'"Q&E Y5< H=2@LM:::W1,=,Z6'M-B =QF[P.-ZX;GGVJI ?/X^QZ
M^^UT>IK3P&4Z/6G?A#2_V18YTYZ:/)20K"A&NZ2:9Y=?&G_WNN]56=<OG#>5
M= ]1*S=G29(X/JW/&[<&_KP;C^H=-HGV>!ZJ/,LTE=D@&K*U#-+)B\: *I&3
MUQPTZ&*E538DQEOG_[9!_LB9MGOM]A ;>!'K-?TT?I'27$%X_!Z'Z>WH)7X=
MSO!XOJ9J+:)4@X/R:#HO<?0ATZ2GPUE>6*7O\V0X3A]R''\^4_/?\/@T#TSB
M.7DE0'O'0&59XPF\!5:"CN@,S]@ZI+WO.3UN7A\4(WJ((EO&-EW%_F(RP='G
MN87RZX^+/WF//^9W'E6J1U_K'TY_HS^<3=^.SF8W8%[Y(ET&XQ,Y81@S!"G(
M8?+!!ZEK+;36_&X[@\?-YCUJNV$TW-QKGPOIS+)Y-;^F.<-T9O',?_G^&$<O
MXFSXC00X((3626,! Z%4VM+!@E&0C:V=4$P6\NL[W8NL-^[CI%/?"F@8/W<7
MU/D&?!,I*T(F:Q@4R<@&D4R!,UZ1G2P\<^2>.=_M6GRM89\>4QJ(OX=@N3MI
M_2[_:_ZKZ2#*J&,T&A(C/TIALD# 2!A%286&"]?^H.N$[''RJ$?M]!(NMYKP
M%R"-*W0^F@RV* [*!=H,DR;/G FG2[*%V]9AEIV /4D&;:&;'O)A_QR1'(Z'
M_YW3;R2_FI]T-'H[^I87GLA ^I)YC3H,OE9XD[7L,.<<LDLE">6SQ-:7(/=
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M O(*BZU<11#%!>F+3#9W.X7O'>K1:;^M<%NW*'Y'U@).ORRF>[XA"14][4B
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M*MQG&.R8">L(NY=V)Q>7M<O@DY2X+.2(IY) 1:/ )Y_ VX0Q"O+.3>MZ&3=
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M-:&9_7TX^_+R=#H;G^3)>8[80'"#WG,'15ND TPB.,D1:O598JU'+]K[.W<
M>L*$::>H'D*$[@3W\G0RJ>4[>(F1%2DAF%"[[#@/P=?9)W+Q>"R*Z]:5[+O@
M>N94.[7U$E-T!\8JK05,5Y(H)2-XJQ@=IVCH*V_ >%N82!RY;]]]MA.T9X(U
M55[K(@+OQS.",,3C>BF5)[6XX1_#XTQ@1WEIK/TYHH'.\]X&$@.SG&00L<9\
MFR+ 2X4@E1:EUC%QO%L,[/IC/T$R[4)+-TEEVY#J5>T'-_Y: >$H?<B?:V.0
M\>3'?>"+2IE)0SXC1P*OZ!^?9 ',7NMLDBFE6VV2;9$\><+M0H,WZ>>V2U:^
MP/QB#<RU#_GG4>U4,\A1<BF9IK.^IMG:6M:%?%0P63LLTD;1\;)P:RA/E8"[
MU>%-!OK^:B,650+C7-7:3^3SDK\+2,* 8B,=^XX'I[J1ZS!J(QX6;YI)_I:K
MR.VNI*_*9TG82].?9]8-7!(H'4I019,O:TU-B>(,A"^2&&UEZ%BPJ=MX3Y4G
M/6CC%L9L=WN]N"7[XY1(_+7V63LFK)/ZS')9;*_R+$].AJ/Y:^11^9B/CVN&
M3(5_EETU**EPG7P&RUF]:RT,@C6,+$,CA,"0A B=*-4(T%/EW#[T>0LIMRL%
MN\P)ISVUC"<G-57O*!P//\_A3@?!H%62G TIZH5N=AE<#&3\.>==D3GC]:R$
M5<^L=X[S5"G44/JW,*-A-[P&XCH+N@R813$ET4F-#%30&0*W'E!+3#E$]*YU
MGXKVL]A9/M6^27H@1-AW]E8M&466:#J-LZ/)66^1LRIA3FHA:C)S\-4MSK7*
M($L.$G,NQB"+<9T:/]Y3.^VVL?<?4;T?*HP;JJ1QS;T%GHL&-'G93J8+J(85
M&5<"V7T%QNUU=%/AC02\,^VCQ<P86D@FU3KA/((3BKX-2C"9'(NI15G6'6O]
MCHJ*.U+Z.G)M'8JT#'FHU>%_)TRC2Z4$EZV>)%KM57UL%+J&2J$"#+2O15G0
M)5.\+'8=1^VNP79;/[&13F[QIIH)M'4(XF5\+_\XNHYM@5 $B<Y+#R(&FCY6
M8YTI#B(PZZ)@SOAN_E*GX1Z5TML(M<]U7A$2NC2_Q5Y"738')-,Z^&0@N2!!
M^5332E4B$3BODPU*74^XZZCX%0,^.M6W$&S#R,)YE=AJLIZE"ANKF$@%/!H$
M%9% :",J(15YY.0^N4[IE/?52%X.^&S<;RC\/ABP(&(7&"VKJE\,O7NK?4/A
M7U??%I)K70[]$AS#!>.<&&E,K2L512)#5 L@*L:4I,VY-%O,?2KP#@.\K?[6
M$5ACO?U!DCHY/5D 83YIC:(6 \/: @0-."]J#RZ4UENF8NR4"76/YJX,NN/"
MY)N*?=Q"9@UMYCF0LZ* "R#:VY!382 YLZ",]A"4"?0M,N81G58MEMV501^@
M\C:66>.5=VM7A$1L43Y:,)(94"K0OE*#_#4Y]MX9C#QUBGI^  UF#M DVEHE
M#5,NUNNBT 7D$^Y(LY8.-VHVLHD"]M:1AGFA19$,HBD1%-,%@I3D]!OZ4@FC
MA6$/GR7K=J3IGR3KR+WU/<N-1/S%"9B\\#YY!CS*VH=',3I'100D(5CC12@=
M[U!7#'"H?6?6TL6XL2!;WYV^_0/#K\/QUR\X.<$%'L>\TUPK8%(3G1.K%;E\
M@<24-\('B;Q;MNXM'_[XE+JE 'NH)_,A3S-]X!<R?BX']U[8/<MTF4_C173+
MF_'D:/8E3Z:__OA$@\PW-1:]*B(Y,,621#P) XLPP'DDM\4GAJ)U.$@3X$_<
M&MT?"7K(]]QB$G4*R[7=81(]E5=K,H']E&/; X':47A+[1_6IGQI,L:$J##4
M!,;:HL'J2*:"K/:"C1AMDDFT[K9SP!2^IXS<8V'P.DKOQ_C_X[<7C(OK[W_D
M]&BIE(."GA,N.B<]'4V@8K$A>*[)J%K# ;AUD-V''^]!9S>=A.T%WMQ1N W7
M2_K38<3C%V2U?!O6!*!E7(#TP9=@(4:/H,R\>Z85('/RNB!Y-*5;\:>UAMT=
M6=JJZE[]-Y%SGUO#$N R!&$!+SM30E$11!2T"A 3.50N@2C".1E2,4&N38/;
MQWK2&T4#\3=GQV6_^))'1!H9I>M19,N7F41\125!U)HR2D9)>+F!)(+DVGN:
MA>E&E_4'?WK\Z5E!*^,]>JB>^MOP.&/Z&(?YK)_9]L535WUBL]JIG2!?*YV:
M(Z-UJZ4WFBO+K;>>):=SUJE$)<O@GL\^H,JIL7 =7,J@_3SEI4@(P0BPG&?+
MC=<TI\:.S.%73O6N9AO: $R5#//T,E>R >L]5T+,+WPZ[7^/M'+J.J3I5CEU
M'8GWT"GBO#I?%"$E3A!B4@E481F"XA%80JE)O48DU=RO?Q3%$3?AQ%;B[Z4
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MMN(<Q(*(76"T/.HOAM[]8;ZA\*^K;PO)M3ZC+\&AHR8;1 ;!VAH#HVL,C/>
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M-APIP)Z)1E5;YP4^5#8&WQBF(OXA=/4$P6\?14&^BG=K[3J_EZ_FB[7Z;:W
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M9WA3QKALZABWI;")Y"E!60)S1+BR/82$>8(2R E*1,2D# *C;D!VTT[M&-,
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M'_AU<5N>$J8,*'%U9-<WU;B';@9"/SLV,_G.T&)(RH=4#U!9S_&^J#MC+NM
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M'^:-9[;I$S4+4BK"E&NS!V&(<ETQ.98,8IZ0+(DS%LITMA1?227XY_%2_8Y
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M;S<8-,#%><]'ZPA^%&55S%DE> WG=LD/?O-E.:_*=H=ZJ@WH[44ZRG*21U1
MF44,(IE3B"7E,..!C D6.0GC@8G3SL%.;<O9/3#Y^.E+E]KR-#C?VOWRVIYU
M7'?1KGWDL96JS0C71Q_/?JF%O=DL=GL,XB<L8XR%<9]X[A[JM3+7O9'>D_KN
M;\YAV\\K0:M/@JV+VKW9W=\^$37+OKZ)PSQ-]$X2!5B[(VD(<XDS&*K?Q4%
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MI-O!K]/R=B?QZA]B_O5;)?CMHRC(5_'ZNRC8O!1U X&/RK-6 N@OSBC.U$[
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MU"Q ),QI&D.<!%27PP\A)0&#B%."$)?*0(EG#W6LPZ>*%)69^IJ":#;O_*&
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MU1>7:JF?E,L\$RD5-"491#3$$$4L@)BG"0R#E!+"\U RJX"#W<&GIHXVV&[
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M:A;(2IDX,9.=G$DE:, 9^@4T/:Y!],=H8$LR(#P!]P+ZPS3287XX7&%G[NU
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M)BOY8>UGK*(A.+!Q.@#O0-*!<@>\0(E]N_1L7[>Y(MJF]L5[GJTO=3,F30Y
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MI! <*T&D]MI(\>UP<M.S%CEQ,B>UT/OJ@"$7HGS@]@BJ(H,XS@E-F[21(H$
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M\&PG;4EB%Q!VMV/KL3<2#;&AS5N;G)&B5R\L6@/1]A;&BRF]-#D*#_W>Z.B
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M7R0);WVI@W?6U#/]H-<VJ'YTT?5[L9A_+E><S2S+-56<I4! 9(T&8A!0FBF
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M2<"AE@ 3DB%J<H:H/[-X2T=3LPA.TL2*FMA^]E4V0LC$VU#UL :1L!K8#ER
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MAXPTX=$G?\/3VFF'L.C3"):GD?![F*EIQ]?/R/2':QSSTLB9_-1(^C=W0_Y
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M]4;'MD>DY^BG_3&%1\^V+JU6AP/]SO[T[__2_,;^X>B1__U?_C]02P,$%
M  @ FX"I5D2MO-2_;   T0X% !4   !M9VYX+3(P,C,P,S,Q7W!R92YX;6SL
MO5ES6TF2)OK>OR)OW=?KE;$O;5T]QJ2D+-DH)8VD[)J>%UBL$FZ!@!H E6+_
M^O$ P)T@#X X.$%5E5DI28I"^/*%AWN$+__V/[Z?37[ZEN:+\6SZES_1/Y,_
M_92F81;'T\]_^=/OGUZ!^=/_^/=_^9=_^W\ _O<O'][\]&(6SL_2=/G3Z3RY
M98H__3%>?OGI;S$M_OY3GL_.?OK;;/[W\3<'\.^K?W0Z^WHQ'W_^LOR)$<;O
M_NW\7T6P2KH8P1-*0"@FP#LMP5N3353"29G^O\__JJ5)7OH F@8'P@0*QAD%
M.?DH>'8B1;KZT,EX^O=_+7]XMT@_(7/3Q>K;O_SIRW+Y]5]__OF//_[X\W<_
MG_QY-O_\,R.$_WSYVW_:_/KW>[__!U_]-K76_KSZVZM?78P?^D7\6/KS__[M
MS<?P)9TY&$\72S<-98'%^%\7JQ^^F06W7,G\2;I^VOH;Y3NX_#4H/P+*@-,_
M?U_$/_W[O_STTUH<\]DD?4CYI_+?WS^\OEKRS(7Y['.:CL/BSV%V]G/Y^Y]/
M9XB&]^YSH7;UKY<77]-?_K08GWV=7/WLRSSEO_SI[//T.Q2U$KY>\_^]_L<_
M7R__=9X6B)@5NV_P!YO/**OM14KZODS3F-8<7BXRF85;OS0I\IW-+__EQ/DT
M6?UT%--XM/KD$[]8SEU8CD1VC F"N(K) L+)@Z&>@28^$L:<S)+>YKQ0O4"R
M5^I8I/#GS[-O/^,'HUH8*U\4L;"52.XMMQ;-?G1?[KY/^+NC8%)63EB(SAL0
MB6=P4@C0RMDD5!)&^8/(OKG:;:IOJO1D'GZ:S6.:H_FX7,[-PRWUWH?NYC=^
M_NKF^$$0OHPG\?)?%SM20U?+607)K=6"Y/[I)^0ZI_D\Q3=KK6QE;L79$HUJ
M6OUF#8W_KW,WQT^<7'Q(7V?SY2B(@!Q$ ]1F!L(2-(B$H 6UGDM-#'?15E'^
MG84[X8"UCX-#Y-D()-ZG^7@67T[C"SR(1SYG;HEQ8%5&3 NBP4ME@:H4&<(Z
M69ZJ .+6LIW@P-N'P_ZR; 0,G^9NNA@7P6\ S11-(=L,-*<,0OL,/@0)1EJ6
MN-4:36"=T^'.RIT@(=J'Q$$2'1@5+Z?+\?+BU7B2WIZ?^30?46:U$R0"83GB
MB1<S&"T\2,J\=5Z$(/A!:+B[8B<4R'91<) $F]#^A_1Y7(0P7;YU9VE$2$C.
M8Y3D:-"(7L+P*X7TZ\@SL5DZ6@,!MU?MA +5.@H.D&032'B- ?T<3=A*\!]1
M_NET=CY=SB].9Q$/.\4SLR&#I3R!0#F!S5Z C%'0R'5T+E8 QJ-$=,*);ATG
M]>3<!&P^N>^O(XIOG,?KNXJ-)226YZ@"RL<S/ >SY2BD*,%K%!43G O+*@!F
MR_*=H&):ATH-V38!DI,8406+S7_>C*>)CKB2@@F,IRTU"IEP'+R3%G*0Q%O#
M3=*'W:=L7;H3.&SKX#A4IBT!XQ2_?#?_-/MC.@HYFE3N6I!Z#T)1"=8' CD%
MH80,R1M1#Q;7"W>[NB+/!!5["K0E3*R.QG?S]_/9M_$TI)'@-$?)/22&_C4Z
M5'A&*I; .,<HRYZG;.H!X\[JW=#1\,UF-=&V!)'WL\723?[/^.O*=:+2.F&1
M=I<#1[1+@[&75F"\9=(H:CP[[+)S^]K=X-'PA6<EL0X,CF+U3N;)K>C6Z HI
MCM;.&8&@-L7N<9> 1A&T%L8H=MC5ULW5N@&@X2O.O44WL,K+"^GD_9?9]/(&
MAD<E/1YK@'8KE(MY#^CX( -2*JYYU,Z&@]1^=\5NJF_X*O,@$0ZL_H\IG,\1
MNI3Y3^/E)(V,U^CH6@F,9HWQ48Q(>Q)0,@BTXAQ]H<-V_=T5NZF_X3O,@T0X
ML/H_S5W)0?EX<>9GDU&(QI#BQE D$P3-!/!\HF"=-2)0@T$S.4CWMY;KIOB&
MKRWW%UXCF_[E]_#%33^GU7TK@A*AJ10H81@()Q6&.<0 TTDXRB/&PH?=-SVT
M:C<,-'PE>; HFP@'3L_G15SK%[@":=3!^6*D"0]4>@61<82TX0*\B0+/L4A#
M0LDHJP^"Q&.K=X-&\U>0%43;!$1>3_'34!SC;^F%6[H-6Z-,-3$.J0^J\,%,
M!A,B@RQ8SACX).2ORK/&0ZMW@TCS%Y$51-L$1,HS[OS4+=/GV?QBI 2)CE$+
M(=E0LCL8GH<1C6 *3."1R 2M83QN+=HM;:KY.\C]!=D$#CZ>N<GDE_/%>)H6
M"PR&HI'>92!.H#>L% -G!4'G."5*8THQUK 0MQ;MAH/F;QOW%V03.'AYEN:?
M\<C[=3[[8_GE=';VU4TO1H$JA<X1<I"T1[.F*#A.!/#LT*29+*B4%?#PX.+=
M<-'\->/A@FT"'Q^_I,GDDOI<WNN9M^!<,.5)%B,G+3!RCMD[CK$U]34NGV^N
MV0T-#=\Y'BC&)D" A)^5-(Y9^/O'+RBWQ;OS9:GC*)'U*/M@@F04C) 82%&T
M=K8\QRIFB5#2$T(.NXQZFH9N(&GX=K*RF <&S<E9FL:2-_IJX@KAAC-'%&@E
M,MH]I-XP'H%;H4T.1&I[F-&XM5PW*#1\4[F_\!I)OWXU7@0W^<_DYJ_P)XN1
MQ'C(&J:1<X728$&#<38"M=0K(53" _ @_6]9N!L2&KZZK"'0IC"QKBQ8,^&5
MEP&]82 &;9HP+(+'\P\BE0&Y4X0=F#FW=>ENN&CX.K..4-MP+)"-N9N\GL;T
M_7^FBY'P/+ D)#I%',-H2DK=B5$0M.'>6>]9=C5\B=O+=D-$^[>8!PASZ)R&
M]77:M:6[+#]R)C*DDP+)I3R11X).,]?@6)26NQ )/>RA>]O*W3#1\+5E%9%6
M@\6__7Q/CF_P!_L69K][^_'=F]<O3CZ]?/'+R9N3MZ<O/_[UY<M/'V_3W;%0
M>^N'52G<[D;J@87<YPOX[-S7T2KGK9P-[_*K\=1-PQ@/B-FZ=.L*43(YI2.J
MG3F!D40("4QBIA3-:\>CS$H]5AZ9W<*OM+U9=+VQTF2YN/S)]0[;A:Y][<?E
M&B>+15HNKKBDV@8FR_T*\6@"%3?@L_9 O<Q49<ORHX\>^W!YFX)ARL1[0\*E
M;:D@[@$/F]O4;VSD%1-$!!6,86!)N9@)+H#1DH!DBD7.I9;ZL?J?_3%SAY!A
MH7.(9A\$R2%B;@ KIV[QY60:RW]>_M?Y^)N;(#.+D^6IF\\OQM//_^$FYVFD
M:-2>8V@NC<)(G4H)E@4*C%.B>58LB\>N.?;!3B?"6L#200"8]:V-!B#V>OHM
M+9;%7"]&*)L<2F2/V\NC<&0&IY,#%X/G0H?,W6.U(?L Z<;RPS2UZ \N^TJV
M 5"<A%!J)A<?4DB(<S]);]/R,O' T:!(DAZ(#Q&$B X,1X903C;(R!)R5ONH
M>H2>89I?] >;:K)O $=E"TSQ5RZ0A5%F*5FIRQE.%!I&-)'>1(L>H-1.!\ZR
MK.WBW%Q_F(X8_9J7O63; "[>S]-7-XXOOW]-TT7",_7=\DN:WY+1R BTB0:#
M@^A+HP\2-5@;""3$O\H$@P5=VZOI0-8P'37Z0U%M330 KMO$9V("14& 2$0@
M\9R"IRBF:!--C#+B^6-OQ <'5L,TW^CQ>-I;NOM#8[9TDTIV9_8US9<7[R<.
MQ3&-Q8W_6CRT8D.%C#E8+H"H\LS-243Y" TQ$AE,U%+*QS(2]S,XV^EIP1VN
M$HE7$WH#MN4=<N)*GO:;Y!;I0VFI^B[_CH:SB&LDHLH,#]NR$2R(*#EXXE9O
M'UPKD;)3M>.G1PEJP36N J%Z8F\!0]<G[-O9-%P>LDSSR&T K5-)LM&R5(41
M,,3IG!QGPC_VW+07=AXBI 4WN0YF#A9S UA9TS\BEC@>T2Q2ILLQ&Y!J(3@H
M+9F6SFIJ'DM9V-^):<'=K7@=O),@&_!7WHR='T_&RW%:X,&Y2L_[,IN@T!?E
M$%U>7(DFZVA0'AJDR1R=,9'11<_HC)G,G%%94%,[6.I*V[!^3.^/4;VHJ '+
M<X.ON^$#]9[34 Y8R4BYA$)Q1>5!2"IC,BSA<=P?V)IZL.I'^]LA=H@J&@#5
MY=WF>W=1+C8OH\AH9<#CEP W,H'(%!TXGBW8DG^:C*.153_>'J2D&3 =I.<M
M%\H'"+T-Z,S/<=5[,AIE[E0HK<*YH*N.P!*\XQQ2PBA &6KCHRTI]D3/P\0,
M>]CU!Z *HF\ 0Z>SZ4H:?QLOOYR>+Y:SLS2_Y.KBZK8S998(C;@;4%R"4 9&
M<C3<2EA7+K>"JPVG+G0-&\OWA*SJ"MD;9-_2W,]ZN22ZQX^P :UM<A"MML7;
M]&!$Y&7X!8F:.\W58XWV#K\EV@M:O87\/4&KHA(:L%P/V%[CJ:%E*((P$6VO
MC!&%8R($K[@6V4?DHW<O?-C[@9Z@<Z"P![PW*"G&5^1??$B3,ASLT^S5^?)\
MGC[,+MRD,#5*-!H>T(YZQ]"B9F-+'&*!464R<=Q3>Z<U\/W<Y6Y+#?OZ51D?
M/4BW =/RZ!E\X^942TJ(U:24CH>R!0SX2"UP:[TG0A#R: 5V=;]HQROK8SC=
M_5T!]*&D!K"WY9"^P1">T[AE2NUI\*59'G[EA3' :19)^ABBJ?XL\A11S;CB
M_>&MKF):0%IY#;HANAN<$$5Y#"2 (:61DJ0!,':-H$+"#1-54ORQCB-[O[P]
M2$TSOGB/V*JCB@9 =8.)D::1E/P98(*DTN,;'0KN!7@J0PI),Q(>&[=PH#O>
MC!]^E%OPG83=P#/>(Q)A,:-';1Q@'.'7\VB<-!RHE=(P(TG]MY0#G^J.X:WW
MAZ)*JFC ^-QHV;(N/$%O3V;E UA## C+%1BK(V2OF2(J,$H?JV#?ST&_3</0
MA8=U='O/]SY T T Y23&U7.WF[QWX_AZ>NJ^CM&RW6!KI%R(@D@+,=G5'0>&
MK&7H)J%1Y*B9$+;Z$\J35 V=.- +F"HKHP5XA7!^=KZZ"UEY=J75V#Q]2=/%
M^%LJP]C.TIO98G'RS8TGY?WQU6S^T4W2IC-R,?;Q_S]?UTF]3<MW^9/[CA+6
MM!1% 3-.E!;ILF3T4<"-1U(R4CKYV%#M/9_T:K,Q;)S8%X '5G<3+SP?TM*-
MIRF^=/,I!LF+&T)YD?(XC)<C3S6WNM3AB-+KPI6O:$DYQ/_ES%6@CT[^W0?"
M3U,U;'39$R(K*Z,!DWI?4".%4;')*""7I$(!H90<51D("VG5VC7HVI<4]ZD8
M-LKL"3X'"KN!\/*IP&FDDE$^B@A:H%LA"-%@96GEQU3 X-DJ5CVEX2F:AIDU
M.]2%Q>%JJ0:S([5#>K_2PY>T' <WN<W$@;V1;G]RKXV2'F'BF%V3G%1!4V<@
MTS+TG%,.EB0'(2!<)%,ZRMI7B\?HFM1Y$RJ.VRT1Y#HK"D)*"<8K"31+E82(
M@<3:#0>J)K</VVEI%_3LG=R^BXJ:=+"N.$D\,JV3AD"\*.-<&9C$"4K/)2$)
MP7"DL0O9X9/;=])^]PO97531 *ANW.'@P?%NOMJ=<75E^#[-5VVU1THR%Q6Z
MIXFM2NF]!Q.RA^2%S,HA3_:QCL0'WM%N(VMH*U8' =NO;:NHHRV$K;NTGYPO
MO\SFX_].$<V\)UGF$J24]W@2,D8OG $1PM%H WJ7]=.6MY+3[-UM)40=)/X6
MD72SWW^)/32:= BZC L1D8 QMA15FQ ,LS+'VF7L!X]8&.(:M2J6]E7 ,^B3
M^_$3_OG;R[>?/KY[]>[]RP\GGU[CWYZ\?7'Z[K?W'U[^]>7;CZ__X^6;=Q\/
M;J*[PTJU \=]F:P42*YOWJ\"@NL>SBE2II0'J4R9#L8,>&4].*&L\BHH%6O'
MCEM(.=QGWWS@I_*L,/)$R1"D (4^9F$L@HN%L:2")#(P1GH+BE<4#.LTU=#W
M?5=\;PD/>*0MYLO28B:>AR4Z>6G^;1S2R??Q8I2"3%X;">C%21"6.8Q/) /.
MK654:$$?'5=\A1!<X 8Z\+MK9&Q;>VB'>G\]SBH*M0U0K&+7-0>+%[,S-YZ.
M'#61^UA&9PI7^M"CV\^IAFRT4"()AB=W/63<)V 8>-31Z7V '"C@ 5&R*NCX
MD+ZEZ7EZA7(ZG4WP;V<E\_E;.OD\3ZM=M/@MG?DT'P5&HRX2LMF%TGZ$@8^*
M Y,\FDQ\H"D^Y:SLM.+@,#E4L[.^Q=Q )+41U89XDM%Q-\* LIR"<-D"AG\>
MB$N>V1@RY;435VX1,$S<71\RATNW(;/R:YFJ,EVY:7?!;F)TBC@/P4L.(J 1
M]J&$D)(9PIRQQIE=;<KVY8:)I/LW*)4$/#1D+HN\?G/3<[1]R_/Y>/IYPP?W
MQ.<8T*]WI0#5D@!6!0%:$2[+2,^@?">@/++(,-E!/<&CEC"'!L4-F*]*3,L%
MU!V0;[C2S!&6>$)LJPB"H9TT-GE@(L9R.2G5W2R/IVW)XTL.DP_4OSVI*.@&
M/)2K</#->)I>XY>+$:-4*F,"$"0<1%89K:*B8+G%+>!]1HO9U^7)%15#OQ$<
M'"17$G #$-E@_[K5(L]<2>X(<&4+Q%T"ZWR&9'(T5 ;AJC=?OTM#(W<H>^KT
M7H[J 0)N"" CH71PB1ODVHC2.MR!5\:",IG[)*,,O/9LL\NUAP7$81K< H>=
MQ-D #$YGB]69NQD7<"T,25RIVRWS7ITN+9@U.&DQ/,O48<!.!;>U8;&-ED:.
ME3IVHXK &P'.N_SK;!9ONFP?9Y,XHERB\YTL4((>N?#HC'M++3!O(C-:<Z+K
MERUNHV98&U-'VP] J(+HAXZ#UFS<BN8N>1E%82D-F@#EI9E7+$_E,G,(.F5E
M% G4W<G9VQH<;UUD6+-2%1E5Y=F <?F ND "RFR^%WBP3F:KZ1(;48VXTEJD
MJ*$TCP!!0P!'! ;[*)L40DPZU\X>?I2@8=-9>C$Q]130 )I^3=,T=Q/DY22>
MC:?C(I_R4'')CO-:B5!&E+C2.2PS#:8,OJ?.24*LZR%V?H*D8:OZ>D%4324T
M@*F[,AK954Z@-. 4PY-7*0N>,G0,$\E2&"=(]5E#=VD8MIBO-U=G;S$W4,AW
MU77KNHYZA,;3"$HC8%")+&CAP HF(6KCE* J2U][:N(#9 S;&:87L!PJ[!;P
M4@KPW\ZFL]NLC)CVBA)*@9E<VB-I##9C8&!#-#J)H'GL99;0?5*&+?/L!S<5
MA-[ D72/C<NC%9TTFVQV4-K8@+"B%#][#SQK8I0T656_^MU&2R?TF.>-GGW$
MOCM\[!H^T_1YU;.V&HK>IN4-\VGQ@$7),) T"MP"F95ID!@W<JZ$9L)K4MON
MW"*@$U[LL\++_@)NY7S:TB#FLOG+^]E\I:#E<C[VY\OR&/=IMBZ\OBZT\#)D
M7A+!."G>?CF69;E01;>.:D5TY+5#^$JD#UV[4O4R>@AUMG)2UFAS)*@/W/C5
MN($ROTXDY-LJD-DZX9D/@?;BEAVKE55O]^*# &\'\/>&@@;0_P#+5ZSDR&*F
MV@ IH^>%R :\E 0HADG4X%]24_LJ[!%RAFYN5?GAKX[8&_ "+OMR759=_^(6
MXS R6D7F& >BR\S%7#K56T;+$"G/HK3:5.^Z_2 A0_>TJHJ:PT7=@,6YR\2+
M\>0<@Y:1-S98'BQX3Q4(6NPX-11"UB89%YBN7O&WA91A;\-ZQLP^XFX -7]+
M92IXBB??,+#^G-Z>EU3-=_E><?5Z2VA1C"3/X$K>KTBN]'I+%A3-@N&&2$'4
M[O*R$X'#WIM51EA_JFD7=YM==+^V7P7+4NDHI[.+(*)C8!4CH$4F(3'.O:E]
MG[\CB</>NAT'>U74\\Q:+WS\].[T?_[UW9L7+S]\?/F_?G_]Z3]O,W)8NX4'
M/KW/%@M/,5._/]]CC4"4])*JDB!C. CK-1@>.;#('4\D,%=]HF,GPBJW7,@I
M:&6UP(U'BD>0-/@D\"L;,HTF<%?]T;JEE@OUL?!$ X9=Y-W 27A%_5HB)8*=
M34OQS*K(G&:2E),1",FDM-H2X%60JSX54=!@C:B=(?PH08U@:0]-;P/-P6)O
M $-W>-C4="'MU$2/)[["V%4H3<OT363'N2S1*Y1:U[:O#Q+2"&8.5_3=$/!@
MJ3< G1L=M2[+/!-73#L"493$PYA]&2%M@*&@%&XK05WM*Z9[1 P+F0J*W=ZW
M; \I-P"3+0-8-LQDYFABI3*8:PPUB K@N(]XF&<51;9<W>WQ<?C@D<<(&C;K
MO#Y\ZDF_ 2C='3RQX0(9P%.;)<B)EF$3&+@:Y3U0RP172F3/:[O)#U,R[.-S
M??!4D'<#J#F9A?'K:9B<E_N&!U\MRT#,TKU@-IFLTLMP[;2X[(%B+ W!V@2!
M<0N"!P=.9@O>)D,$RUY5'_M^&,7#/LOU8,*.I[\&T/K =9Q7 J,5="V)+J_8
MI%3)&Y'!$9>R$$:(N]56/WKS@"KAVWX";@ BN!GF94KTB[3^[^OI_>N1#[@7
M7LWF?[AY'%%)52SW(L%QW'S11#".<S!)EM;QSA!5VX+M2&(C<=Z>B)@=3ST-
MH&]]A?]ZL3A/<602EQS##HBKVWN6$A@;+60?-<M*FBBJ]S6YL?[@+6'[4_1=
MJ[6OU/=&S-<T'\\B[HWYLM+!=E<V^QSJHZ!X8@K#7>,4&OP<*/CH)<BLN1;:
M1T+K7VO6H'S8 _2H6#V^IIM!^77^X>+3;$OPO=K+'I40BYN<IHL5"CXD%-5B
MO$R;JO#W*\H^I##[/%U]RGH6LHHT12L82%O\Y\1+OHC50+*7P1E%DZM=+=(W
M3\.&S<?<&4VAHQ5?XI>[O)[,YV[Z>>61_7)Q_2OOW<6JXV31PKNOY1<7O^(O
M+A>OIVMIC(@5-G.30-GH,+8,"3PO]Q366\^E-,G7WAMU.1@V=#^Z/S.,YH=N
MK+(2ZMJ3>[%J [+F8>WAK<<G3=ST)"S'WU9#*VW4ABL-SB-70FH\!EU@&(](
MPP3AF:4[#L^67BN[K3MLFNXQH-BW,AK%V>J@N,\9R8Q'K0CDU94*)P*,L@)C
M"F:)P3#8V&Z-D7=:=MC$WJ%15D$5+1SBCVVAM^F/U5\M1H$'&8*2$ G&J\)%
M#;[,6#)9<.$49:;^X=R)LF%3?X\>F-75U-[X^Y;F?M8O E?;ZYHM93)Z 2J!
MSH*",![-=I01!&%&YJ@SU;6?FCL1-FSZ;P/X.T!/#9B_WZ<HMTF92?BK&T]+
M=>*[Z>OIM[2)\T;<YD1+]K2WI6TIUQ(\I122B3DR81-WM2^LGB!IV*K]8P*N
MIFX:@-KMW@3"\"2L,Q!]N1^+'@5C5EV7,L==DP@WM9\%=V_^0,F/@*/]!=\
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MA$ 80<=%BK(](E KM<<P2*I<.W%B-PJ'-7S]8>M>FGU_>FO4K'7+;NP_57.
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M=;#1Q&ZWW%N7&!@>E14YJR[5%BP/ZF/U K,^W4]G9U]GT]+^8K6/DM*,:^,
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M3U<'%/X\\9%5ZGQV(;M&6<_I;((_VJQR,HUOT$N?WFC"L[C1M-('0Z(%KJ3
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MC)51>R'NOAUV!,V6!8=YO#D2;&H(>>@NSL6C6R<X*RT(BQFL4PY$<$BT5*R
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M]>ELNGIO_31[G^9Y-C][-9N_6WY! GZY^(2+K(PO"59D%@VHK%&"%H7G,E-
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MXG(7@RIB *LYE8S03.X>2(\G=S^^W.  .52G#Z1@5Q1P U>A57/F6 DDN?!
MDD+1$MR*3GD"E 7.HM)$=\N-^&<3V.$?!@8#QM!V=&L;TI1#UOK_MO=M36[=
M.M;O\U]0Q?OE9:J<D^24JTX2E^.3J>^I"R1!6S4=R9_4G8GGUP\H]<WMONA"
M:>^M) ^==K>M30 +)+ )+%0#E=JDC& :FZY-@,KYY+(+T6[WVNDO0 *[D\&W
M(H'=1?M#0^AP<C(58I"Y%F"Q.)21M54:5(1,.G,JQ.>4SUMA[31D<]-HDMX;
ME*>UY]#HO2V;GK<WQFM+_WM%Y</BS6I%J]5ON)PUW_R*F^6FN<Q4RR$X.O;1
MK, 8+2$$2J"+\J@RGT*TW5#1O9=P1J2S>Z/U-/8;&J5?7SC<*_.7.7V8_4[_
MX.7,KMJ4AEN"/I%D2B4+J%(G=D&A(5H3P8L4C(@RU+I=)=RN3SXCKMF],7E4
M:XT@C;IC4+.Q;>@H@*0DUE PK"&.NXW2RK0R?)EZDXSM1&8WC3;I?7!VD"E&
M *&7R1V-DE1]],#8YU1.8@;,H8*LE!)Q2,R:Z9Y:'\K(.8W>YD/ UL]H8T?@
M;:,V*XJL\@E\(ZTW!C6D@A(*>1^RH:Q3[\:M;LWVT^AF/AH>]S'AV&'YH$-;
M65:<L &D\Q&,0X+8^""MJR[$E)SSO>N1>_;:3Z,M^FC@W-.00Z<A-P'L3[/+
MR_6;@$TD>Y%=K093 (K6\<X?$N?[.@-E3O1KQ62*VBK9>/KSSX@J=N^4HH/F
MQ]UF__/;-V^_O_69P]OLG_RXCFWVKR_WM&WV*4MO@ZJ@=2D<]!<&@DP>7,JN
M.-7&7F\W%F'*;?8R%3[?.8UVQ0@PD3/H4 E!A^!BIA(L]>Y1^(NVV>\"MQ.T
MV>]B^''4MWQ=RU%3<15M!&^]:'2VZVMTRYE4J=6Y9)S:BCCI6(534VJSWPD+
MKQ5.[6*8<0#KB1H0#BZC#(9#RNHUF"(MI%P5!*2BG8ONFUE.9UTXM9--MRJ<
MVD7!0X?P#^MZ_LG.<UO0<U&=#"I5A!1::.J]@Z0H\Y<:(V:5@MQN6.)S3Q@<
M!H=:[KGRJ+W5.$;&%\_I0U+9<1**" 8]:Z1-V"G:5HTQ">MZU/#NS?@RI5;E
M?8^B@PTS=!O(UMP$H<1:@O2 M3$.4XKL?T)!534D::O+L4M[T4097W:R^5Z,
M+[L88.BCZ^>U(?#R[7QU-;NZOF)7?7-Y2<N/7]@QW\XK-=^[7GT_6Q%+?KLA
MHZY.L;* !:R-:Y6=, 0)4IJ43/9*U^T(GO=Z_!188W;"P.*D!AEZ([OKZR)G
M, 13@820K",K ;4HH'TPT2861;D>&]79]D'N>Q;N9X(QX.8&[I%D<5(54"D2
MF!HXNJ1DP0LO=?5%I,<$\^?0![F3L9[I@]Q%<Z/J@T2#R<80(&KI&.ND&E$;
M@71(UOF0M.W1J33"/LB=3/9L'^0N^AO%E6W'&R*ABC4E"<#4F)B=-Y"\K5 2
M8:7BL)2M\J\Q=Y5,J0]SGW-K<& ,'JE?-S_^I?[$GYG9'JL/B^_HIJZ<"DM_
M/P&I%8P_&GJDK6!Y&C-'-KR)&!$@6=)-Y=:Z5@OYF ;TN8C]D&6<47_*3M!9
M#&+'H1'[87&%EW<#NM9<]H^D<<*YG#A/B;+-7@VI );,)Y-&Y:B8DO-V10ZO
M/NJ,FE#V1EY?>XP@2+@KU%7%U"RI<C3C$A@K'"#F J+JC,I+\I$Z'_ [U4Q/
MHU]D'V =9(IQ5\^\6R[^:*ZRF!]>.O/M9W6LFWEEH0<6S3RR\+IW_8DRO+LR
MAN*E(N4D^,JIJDG(>TA,""&S4JJV2OK>L[2V7-H(JVMTDD459!]).;6^@LRY
MG6C5M"&AJ8(3^]X;U[E4UQP3ER<HK]G%\F.\T]36)F%$ F$;?WELZN0U@RDF
M!B)1?-G*S?^>8K$C%EZ[T]S%,$._TMWZ.B53JBX$%H5*9E&RAU@,@A-KRAZE
M4NXQ,V6J=YH[V7RO.\U=##!TWGD?#WTW6]R2ZACMA*3F4\6W<0L!(F_YD$64
MJ)+CP/?56.ZY#Y_"?>1.]EMT5.8HTL0>A.&^1+*NLM"BC7S(T0"RZ.!3BBI4
MH]G3NL>U?P\KZ'-:#@>%:>/_ <MS+5%2,!*231P_FY@@H"5 68+,*K8IE>/!
M_WD-*]@)<$<95K"+]<=S_K][_YM6/MY>I.J2,<D,5:  $[2%:)P"7Z34,97J
MW7:#BYYYP&21MJ^=GXX3]E?ZJ( CM+PE(DY1BXP5:K7KZTH'410#*61CI"K.
MZ.WZP)[^_',8 = '-ONI? 0G;-/$+_6!TM:[MN)01)O@0:C<[NJDA6 3 L;*
M>[EPP9JMZMMV.#&?7,C9U;T=$@$>;JH1X.U;Y>'3^KIQ)]72-8X10*6@.'Y(
MC?I06<B9-#5B]&!ZOY/?<8G#GIT=0+$XG87&<TP^,TS(9VTY7I5 IK'6M)@U
M>JL@>Y2UH@K%B1T/S#&.>3JJC9\^)#LH?&CT-!+!JW>/7UO=52D6@ZWLH)H4
MP5B-K"+>V5WP'&!(J\)C!I9GD//24X8-N$Z&FFZ*'D<3[M<-IR4EX5/Q@!DU
M&&D*H*@$-5%!EL&5L!4MP=]C,?:_?CK8,., UA,MK)11)*\=9&'9.T(0[!UH
MH)CLR'FJ)?2X;II*=_=.-MUN+,8."A[ZP'K8EOP->\?M^$2.%%&P<K+1+$_V
M"B*V.2+&A2P(=:[;%3)N\;#!P7&H/9_K^>ZAW!$D9UUK\I*N!3$@>*]*JUKA
M;5FV^[;D190F"_1;=3J-N75A2@,Q#GGU,!@PAMY!OQ;\_J;Z 7_X>\K$OUP7
MOR_FOUXM\G__USHNOOKASU8,OZ)W2]X>WM'RUT]L^XM<HK6YD?NET*Z@XWH&
M3P;E3$H:-6\,.W-Q=UK;&34Y[ 2R9]BZA[#XT("_*[)_\$H==YC[<$&J^!BL
M!R53N_!S@16/A86-T>HL5+1;7E4=N)(SZIO8&\PGM>9HH'O?AO2:>-)[BQR%
M010<\IF( H+E,U&U(U%Z/AGK=BQ'NS_[C+HO#H?G<2PV-" [C,[A'%4*/BI8
M.,?)B?(05?:-8K'1O1C!,=U6^#S-**1I#/+8&ZZGM>?0Z+USSL?B?5A\^#1;
MEG>XO)IQ^KM8OIU?T>4EY:MKO.1$^S,MK[X\<ELO458J 8AS:C!6I=;-3R#8
M%CFKZFK>\EZEXZK.:&C(X5OPJ:T\-+R?CO,?:'<=PU\88US&I,'ZS(K5U0 J
M&4&QKSHT.2BYW<S8[9YW1J-%.F=@!UEFG&#;,JE<W?;=K[/)U85 0F.%8G&I
ML;PG#XCL:CEDGT0FTKA=T-IS56<T@V285P>'6'D$KX[ONZAU(?2D(#1G-*PL
M"(V\QRI;C"0;<W?6]9T:VJ<Q:F0?#!YDBJ%WR(UCM!?5FW;8!]3S+029T_*"
ME*Q:*@TB2 1C2 "*+$&0<"P;1];*;K7OO?ZL,YHQLO=NUMDB(V5,6&_!W^%J
MO25_)E9@^\"G?_K#G^U;.H!3X8"G]6!=Z"5L)UZ&[V>K?+E872_7UUSWCWY/
MG%>WU:RN5NO3,+7%W2;7=VWQ2E+Q67, J&H%0Z:T(L<,TI(F4:I7J7=IZ&$K
M[L?BL'[&-R9[N%5\]^7^[]RLX\W_X++<W 5F+"8Y"Y5$ZZFT!$$0)VK)ERJM
MS0%[T\IU6_RPEU0GQ.SS5 ZG-/\(8LMWESB_:QC/V<DH@H.4D->><@0,'!?[
MJ(+UJBKAL3-T'SY_+ P.)X7 HI,]1H2EF^J?E!PJ;P2HJ&R;4FH!-?\QMBHQ
MLCI5W7MD\=<K&!9/^UOR&4CLH=:A,X\/_[/X\&EQO<)Y^77&@0W-?^!0;O&%
M:!T8W98A-PEOJ[J\$E(X"2%%5I3R!*G=C,H:5".D-4ILQTBY\Z/'@99]C+PX
MF<:'QM.;]HEK0=[.VSAW3M(>2&)9,9AX_45$M9GM'J2O4#U5J9+FB&"[^0,O
M/F;8VH=>..FGR:$Q\:T0C&=](XC6GB._V @K8WN1W<J#T$3(C&L9%?*YO-W=
MV$M/&;;<H!<BNNEQ!)'(JQ'<<P'<_;N=G!GUGL_IZ&-MI*?(WR4/29B@@G/\
M@]ZQ\.&K'@NKRY 1](EM/V6T?WTM\N;ZZM-BN:FE*+DJC 3*4J-K+0A8@VG4
MB*:&@HC;=;J< OS/"3%P-GEB%/9R@BZ0&#HD>#[DW0R_>#.?7[?"N/G5<I:N
MUR_UW]'R]E_QM^T0O,BZ9F&$ 2M;@TGE[Y)ME?W!>%,*?U';A9-=EC/PUCX,
MG >RYM#XW5O;OU1>[&S^D86>+4J;61^B3 EBX_@SIE3^+@>HN1H7^""M9KL2
MQTX+&IAR9$ ,#V'1L40FZ76QTV.Q[]R\E2.M;P-N2SIN_=F97-HX/<Y#BF%-
M9+:"9'N8Z'Q*0E&,W2?0'TV:@9O'1Q"K# ^2L;C+/H;81&MO5ZMK*F_G-WN%
MU$4$80W46MKT[<K6$9H#.$[<#:(5(?<FFNHJP,!=HB-PBD&@,&4_^.7S.OS[
MY?IJU7JQ^-S<Y#,7D:77TJ3-'F""UIM12222H4Q29MG]4KZW$,/6+T_5'[I
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MY<.(TV]/22:B IEL 4,:(6@BSJMJK:24LF>2?H^/PG&\#G,83 Y,OW^8C^6
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M86-T961A9W)E92YH=&U02P$"% ,4    " ":@*E6-V G$S\'  !7(P  %0
M            @ $!J0  97AH:6)I=#,Q+3%Q,3(P,C,N:'1M4$L! A0#%
M  @ FH"I5K<I.U4V!P  62,  !4              ( !<[   &5X:&EB:70S
M,2TR<3$R,#(S+FAT;5!+ 0(4 Q0    ( )J J59"" A%[@,  (D/   5
M          "  =RW  !E>&AI8FET,S(M,7$Q,C R,RYH=&U02P$"% ,4
M" ":@*E67"7[@-T#  #D#@  %0              @ ']NP  97AH:6)I=#,R
M+3)Q,3(P,C,N:'1M4$L! A0#%     @ FH"I5D/K<K*58@$ #.X- !$
M         ( !#<   &UG;G@M,C R,S S,S$N:'1M4$L! A0#%     @ FH"I
M5OGS^&N;#P  **(  !$              ( !T2(" &UG;G@M,C R,S S,S$N
M>'-D4$L! A0#%     @ FH"I5DHEMU-6$P  -:P  !4              ( !
MFS(" &UG;G@M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( )J J5:+HMDB
M0T8  -$? P 5              "  21& @!M9VYX+3(P,C,P,S,Q7V1E9BYX
M;6Q02P$"% ,4    " ":@*E6"R/V1#2D  #G*@< %0              @ &:
MC ( ;6=N>"TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ FX"I5D2MO-2_
M;   T0X% !4              ( ! 3$# &UG;G@M,C R,S S,S%?<')E+GAM
7;%!+!08     "P + .("  #SG0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
